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Background: Schizophrenia is a devastating disorder, treated with antipsychotics 
acting via dopaminergic D2 blockade, and significant comorbidity impacting through 
social dysfunction. The neural mechanisms underlying the processing of socially salient 
material and the dopaminergic networks posited to be central to this social decision 
making remain unclear. These mechanisms are explored in this thesis. 
Methods: fMRI was performed on 20 healthy controls (HC) treated with single dose of 
a dopamine agonist, ropinirole (0.25mg); dopamine antagonist, amisulpride (400mg), 
and placebo. fMRI was also performed in 42 patients with schizophrenia (SZ); and a 
subsample of 20 patients after treatment with oxytocin (40IU) or placebo nasal spray. 
Participants performed a decision-making task incorporating stochastically rewarded 
faces of varied social valence during the fMRI.  
Results: The normal bias towards selecting a happy face was attenuated by all 
pharmacological agents (ropinirole, amisulpride and oxytocin). In HC, attenuation of 
bias after ropinirole administration was accompanied by an increase in neural activity 
within the dorsal anterior cingulate and dorsomedial prefrontal cortex and attenuation 
in the amygdala. In SZ, attenuation of bias after oxytocin administration was 
accompanied by attenuation of neural activity in the temporoparietal junction and 
amygdala. When looking between groups, SZ showed attenuated neural activity in the 
thalamus, cerebellum and medial prefrontal cortex (mPFC). HC on amisulpride showed 
similar attenuation in the cerebellum to SZ. 
Discussion: Modulation of processing of socially salient stimuli was evident during the 
perturbation of the dopaminergic system, impacting both behaviour and neural 
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processing. The key regions demonstrating change between HC and SZ were the 
thalamus, cerebellum and mPFC; supporting a deficit in the coordination and 
integration of decision-making following the cognitive dysmetria model. Oxytocin 
demonstrated prosocial effects in SZ, through modulation of amygdala activation; and 
showed some overlap with dopaminergic responsive regions, lending support to a 
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CHAPTER 1 -  INTRODUCTION 
1.1 SCHIZOPHRENIA 
Schizophrenia is a very debilitating illness which has a lifetime prevalence between 
0.3% to 0.66% (McGrath et al., 2008). It remains one of the costliest disorders in terms 
of both social and economic costs (Knapp et al., 2004). Schizophrenia is characterised 
by the presence of positive and negative symptoms as well as altered 
pathophysiological processes, such as aberrant neurochemical pathways. Positive 
symptoms are the core symptoms presented in schizophrenia. These positive 
symptoms are symptoms that most people do not normally experience but are 
manifested in schizophrenia. They include delusions (i.e. fixed false beliefs that are 
firmly held despite being bizarre or implausible, for example the belief that one’s 
thoughts are being broadcast; or the feeling of being controlled by external forces) as 
well as hallucinations (e.g. the perception of voices that no one else can hear which 
may comment on one’s actions or give their own commands). Negative symptoms, on 
the other hand, refer to experiences that are absent in individuals with schizophrenia 
as compared to the healthy population. These include stunted emotional responses, 
the inability to experience pleasure (i.e. anhedonia), a decreased desire to seek 
meaningful relationships with others, decreased speech, and a general lack of 
motivation. Additionally, although not an official diagnostic criteria, patients with 
schizophrenia also exhibit impairments in almost all cognitive domains (Carroll, 2000; 
Kraus and Keefe, 2007), including decision-making tasks (Heerey et al., 2008; Hutton et 
al., 2002; Larquet et al., 2010) and tasks that require social cognition (Couture et al., 
2006; Fett et al., 2011; Lee et al., 2004). Generalised cognitive impairment, indexed by 
IQ, precedes the onset of psychosis and is detectable as far back as infancy (Khandaker 
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et al., 2012). In addition, the severity of impairment is linearly related to the risk of 
developing psychosis and predicts functional outcome following illness onset 
(Khandaker et al., 2012; Leeson et al., 2009). Most importantly, cognitive impairments 
have been closely linked to one of the most debilitating issues in schizophrenia: the 
impairment in everyday life functioning (Green, 1996; Green et al., 2000; Kraus and 
Keefe, 2007). Further to cognitive deficits, deficits in social functioning are a defining 
characteristic of schizophrenia; and a marked impairment in social or occupational 
competency is a requirement for diagnosis (DSM-IV, 2000). Social dysfunction is 
evident in the premorbid phase of the illness (Davidson et al., 1999), and in first-
degree relatives (Glatt et al., 2006), confirming its status as a trait marker for the 
disorder. Furthermore, impaired social cognition predicts functional outcome in 
schizophrenia, impacts affect quality of life (Couture et al., 2006; Penn et al., 1997) and 
has been more strongly associated with community functioning than other cognitive 
variables (Fett et al., 2011). Social and cognitive impairments significantly impact the 
way in which patients with schizophrenia process beliefs about the (social) world 
around them and social cognition deficiencies in schizophrenia impair the formation 
and maintenance of social relationships which may contribute to the instantiation and 
perseverance of some symptoms observed in schizophrenia. Cognitive and social 
impairment are thus core features of schizophrenia that significantly impact on the 
course of illness; warranting a more detailed understanding of its generalised nature 
and neurobiological basis (Roiser et al., 2013). 
1.1.1 AETIOLOGY OF SCHIZOPHRENIA 
Although schizophrenia has been the subject of much research since its recognition as 
a disorder over 100 years ago (Bleuler, 1908), its exact aetiology is still unclear. A 
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number of theories have been posited to explain how the symptoms of schizophrenia 
arise. One of these theories is the glutamate hypothesis, or the idea that aberrant 
levels of glutamate due to aberrant functioning of N-methyl-D-aspartate (NMDA) 
receptors (Coyle, 2006; Stephan et al., 2009; Stone et al., 2007). Support has been 
garnered for this theory by the observation that NMDA receptor antagonists, such as 
ketamine, have the ability to induce both the positive and negative symptoms 
associated with schizophrenia as well as research showing NMDA receptor gene 
expression abnormalities in schizophrenia (Moghaddam and Javitt, 2012). A follow up 
hypothesis to abnormalities induced by aberrant NMDA functioning is the concept of 
dysconnectivity or the idea that aberrant NMDA receptor mediated synaptic plasticity 
leads to abnormal functional connectivity between different areas of the brain due to 
abnormal regulation of NMDA receptors by neuromodulatory transmitters such as 
dopamine, serotonin or acetylcholine (Pettersson-Yeo et al., 2011; Stephan et al., 
2006; Stephan et al., 2009). Andreasen and colleagues specified that they believe 
many of these symptoms arise through specific dysconnectivity between the mPFC, 
thalamus and cerebellum, a theory which they refer to collectively as cognitive 
dysmetria (Andreasen et al., 1999; Andreasen et al., 1996; Andreasen et al., 1998). 
However, there are two main hypotheses that have been developed over the years 
which are proposed to explain the genesis and neurological underpinnings of 
schizophrenia: the neurodevelopmental hypothesis and the dopamine hypothesis. 
1.1.1.1 NEURODEVELOPMENTAL HYPOTHESIS OF SCHIZOPHRENIA 
The neurodevelopmental hypothesis posits that schizophrenia arises due to a 
disruption in brain development during earlier stages of life which later leads to the 
emergence of symptoms observed in schizophrenia (McGrath et al., 2003; Owen et al., 
2011). This theory has been supported by studies demonstrating that early life 
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exposure to risk factors such as birth complications, influenza epidemics and stress can 
significantly increase the risk of developing schizophrenia; as well as longitudinal 
studies showing that those who go on to develop schizophrenia tend to have poorer 
motor skills and language difficulties (Cotter and Pariante, 2002; McGrath et al., 2003). 
Furthermore, patients with schizophrenia tend to show neuropathological differences 
in the brain such as ventricular enlargement and decreased cortical and hippocampal 
volume, which are common across all subtypes including first-episode, medicated and 
unmedicated patients with schizophrenia (Harrison, 1999). The neurodevelopmental 
theory accounts for a gradual development of schizophrenia over time due to 
disruptions in early brain development, yet it does not fully explain what neural 
processes cause the symptoms of schizophrenia due to these disruptions. Many 
observations have led to the theory that an aberrant dopaminergic system may be 
responsible for some of the symptoms observed in schizophrenia. 
1.1.1.2 DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA 
1.1.1.2.1 DOPAMINE 
The neurotransmitter dopamine has long been viewed as a key player in reward 
related processes to have an effect on motivation, incentive salience, conditioned 
reinforcement, memory consolidation as well as addiction (Wise, 2004). It has been 
implicated in a wide range of neurological processes including reward prediction, 
reinforcement learning, executive function; motor control and working memory. It has 
been implicated in a range of disorders next to schizophrenia, for example substance 
abuse or Parkinson’s disease. It is one of the most studied neurochemicals in 
neuroscience and, due to its role in learning mechanisms, has recently become heavily 
modelled in the field computational neuroscience. It is believed that dopamine models 
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prediction errors (i.e. the difference between the predicted value and the actual 
value).  
When presented with a reward, dopamine will spike in the brain (Glimcher, 2011). If an 
action is paired with this reward, it is possible to create a learned effect, due to the 
association between the action and the reward. This association is known as 
conditional learning. Repeating this association over time leads to a “stamping-in” of 
this association referred to as reinforcement learning (Wise, 2004). By aiding in 
learning between an action and a reward, dopamine plays a role in memory 
consolidation and encoding. The desire to keep repeating this action for a reward is 
how dopamine is associated with motivation. For example, when given dopamine 
antagonists, rats will show a decrease in their initiation and perseverance of this 
reward seeking behaviour (Bardgett et al., 2009; Wise, 2004). Furthermore, rats 
treated with dopamine antagonists will show deficits in learning to associate actions 
such as lever pressing with rewards (Parkinson et al., 2002; Wise, 2004).  
1.1.1.2.1.1 DOPAMINE PROPERTIES 
Dopamine is comprised of two different families of G-protein coupled dopamine 
receptors, each with different pharmacological properties mainly derived from their 
interaction with adenyl cyclase (AC), D1 family receptors and D2 family receptors. D1 
family receptors are comprised of D1 and D5 while D2 family receptors are comprised of 
D2, D3 and D4 receptors. From this point onward, I will refer only to these families of 
receptors unless otherwise specified. D1 receptors are coupled with the Gs protein and 
act by stimulating AC thus increasing intracellular concentrations of cAMP (Williams 
and Castner, 2006). D2 receptors act in the opposite direction; they are coupled with 
the Gi protein and directly inhibit the formation of the AC enzyme which, in turn, 
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inhibits the formation of cAMP (Williams and Castner, 2006). Both families of receptors 
act along four major pathways in the brain, the mesolimbic, mesocortical, nigrostriatal 
and tuberoinfundibular dopaminergic pathways. Of these, the mesolimbic and 
mesocortical are believed to be the most influential in the instantiation and 
perseverance of schizophrenia. The mesolimbic pathway projects from the ventral 
tegmental area (VTA) to areas of the limbic system and plays a role in motivation and 
pleasurable sensations (Arias-Carrion et al., 2010).  
Hyperactivation of the mesolimbic pathway is believed to be responsible for the 
formation of delusions and hallucinations in schizophrenia possibly through the 
attribution of aberrant salience, where seemingly innocuous events are imbued with 
increased salience due to a hyperdopaminergic state (Kapur, 2003). The mesocortical 
pathway, which projects from the VTA to regions of the prefrontal cortex (PFC), is 
believed to play a role in cognition and affective symptoms. Hypoactivation of this 
pathway is thought to lead to cognitive deficits via the dorsolateral PFC (dlPFC) and 
affective or negative symptoms observed in schizophrenia via the ventromedial PFC 
(vmPFC). The nigrostriatal pathway projects from the substantia nigra (SN) to the basal 
ganglia or striatum and is part of the extrapyramidal nervous system which controls 
motor function and movement. This pathway is believed to be normal in schizophrenia 
although antipsychotics sometimes cause hypoactivation of this pathway leading to 




FIGURE 1.1 - Figure showing the main dopaminergic pathways involved in the actions 
of antipsychotic drugs. Taken from: (Bethopedia, 2012) 
The original dopamine hypothesis posited that schizophrenia arises due to hyperactive 
dopaminergic systems in schizophrenia (van Rossum, 1966). A variety of evidence has 
accumulated in support for this hyperactive dopaminergic system in schizophrenia. 
However, a hyperactive system only accounts for the positive symptoms observed with 
schizophrenia, whereby increased dopamine leads to psychosis. A revised theory 
posited that hyperactivity in D2, mainly within the mesolimbic pathway, was 
responsible for the positive symptoms while hypoactive D1 receptors, mainly those in 
the frontal brain areas, were responsible for the negative and cognitive deficits also 
observed in schizophrenia. Although it is currently unable to explain all of the 
symptoms of schizophrenia, the dopamine hypothesis does offer a direct line of 
evidence between many of the symptoms of schizophrenia and their cessation with 
treatment. Initial support came from studies showing that neuroleptic drugs interfered 
with brain dopamine function (Baumeister and Francis, 2002; Carlsson and Lindqvist, 
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1963). Initial links of neuroleptics to dopamine showed that nonreserpine neuroleptics 
were dopamine antagonists as they were able to activate dopamine receptors and 
block stimulus induced movement as well as studies which implicated dopamine in 
neuroleptic-induced extrapyramidal motor symptoms (Carlsson and Lindqvist, 1963) 
(for a review see (Baumeister and Francis, 2002)). Research also found that high doses 
of psychostimulants, mainly amphetamine, induced paranoid psychosis in those that 
had not been previously diagnosed with psychosis (Angrist and Gershon, 1970; Griffith, 
1968). However, these early studies only reported on the positive symptoms which 
they observed with only anecdotal references to negative symptoms as these were not 
classically recognised as a class of symptoms of schizophrenia until (Crow, 1980). In 
further accordance with these observations, it was demonstrated that, in patients with 
schizophrenia, low doses of psychostimulants that did not induce psychosis in healthy 
subjects could exacerbate or induce psychosis in patients with schizophrenia 
(Lieberman et al., 1987; Ujike, 2002). However, this response also appears to be state 
dependent and does not occur when a patient is in remission. One of the most 
convincing pieces of evidence came with the observation that the clinical efficacy of an 
antipsychotic drug is directly proportional to its affinity for dopamine receptors 
(Creese et al., 1976; Ginovart and Kapur, 2012; Seeman and Lee, 1975). Furthermore, 
to this day, all antipsychotics used clinically bind to D2 receptors. However, none of 
these studies adequately explained how dopamine affected negative and cognitive 
symptoms. Additionally, post-mortem studies did not reveal consistent elevation in 
dopamine throughout the brain nor could these studies exclude the effects of prior 
antipsychotic use (Bacopoulos et al., 1979; Bird et al., 1977; Crow et al., 1979; 
Reynolds, 1983; Toru et al., 1982). A revised hypothesis (Davis et al., 1991) posited a 
more regional specificity of dopamine in schizophrenia. Evidence from further studies 
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showed reduced cerebral blood flow to the frontal cortex (Davis et al., 1991; 
Weinberger et al., 1986) and that hypofrontality correlated with low dopamine 
metabolite levels in the cerebrospinal fluid (CSF) (Doran et al., 1987). Doran and 
colleagues proposed that schizophrenia was caused by hypodopaminergia in the 
prefrontal cortex as well as by hyperdopaminergia in the subcortical regions. They also 
hypothesised that this hypodopaminergia was responsible for the negative symptoms 
observed in schizophrenia. Further to this, a “final common pathway” was proposed by 
Howes and Kapur (2009), stating that the dopamine dysregulation is caused by 
multiple direct and indirect environmental and genetic factors and that this 
dysregulation is caused at the presynaptic level. Furthermore, they hypothesised that 
dopamine dysregulation results in the faulty appraisal of stimuli resulting in the 
attribution of aberrant salience such that seemingly innocuous stimuli are accorded 
much higher salience (Kapur, 2003). This is important in schizophrenia as it shows how 
patients with schizophrenia may place increased importance on stimuli that would not 
hold value for others thus leading to the formation of delusions. 
In line with these theories around dopaminergic involvement in schizophrenia, all 
current antipsychotic drugs which are prescribed act as D2 antagonists. While these 
drugs are effective in the treatment of positive symptoms of schizophrenia, they still 
have limited efficacy on the negative symptoms and social functioning deficits 
observed in schizophrenia (Gray and Roth, 2007; Penn et al., 2009; Sergi et al., 2007). 
The need to find newer drugs which can alleviate these distressful symptoms is 





4.1.1.1.1.1 OTHER NEUROCHEMICALS 
Two other neurochemicals which also may contribute to the pathology of 
schizophrenia are serotonin (5-hydroxytryptamine, 5-HT) and glutamate. Glutamate is 
the most prevalent neurotransmitter in the human brain, representing about half of 
the neurotransmitters in the brain and can be found throughout the brain. Serotonin is 
primarily produced in the raphe nuclei which are located in the brain stem. These 
nuclei then project to regions of the gastrointestinal tract as well as the CNS. Axons 
from the raphe nuclei project to the spinal cord and cerebellum as well as to the 
thalamus, nucleus accumbens, hypothalamus, hippocampus, amygdala, cingulate 
cortex, including the cingulum and the neocortex (Berger et al., 2009). Both 
neurochemicals are fairly ubiquitous in their projections within the brain, extending 
throughout most regions of the brain. 
1.2 OXYTOCIN 
One neurochemical that has been posited to have a beneficial effect on the social 
functioning deficits observed in schizophrenia is oxytocin. The role of oxytocin in social 
behaviour has been well established. It plays an important role in parturition, milk 
ejection, sexual function, attachment and parenting behaviour (Insel and Young, 
2001a; Meyer-Lindenberg et al., 2011). In experimental studies, oxytocin has been 
linked to the facilitation of social behaviours such as trust (Baumgartner et al., 2008; 
Kosfeld et al., 2005) and parental bonding (Galbally et al., 2011). It has also been 
shown to increase the ability to identify emotions, increase empathy toward others, 
and to attenuate aversion to angry faces (Bartz et al., 2011; Evans et al., 2010; McCall 
and Singer, 2012). Additionally, it also helps regulate intergroup conflict by enhancing 
intergroup trust and cooperation while at the same time increasing defensive 
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aggression toward out groups (De Dreu, 2012; De Dreu et al., 2011). Furthermore, its 
role in facilitating social interactions by ameliorating social bias and response to 
emotional faces has led it to be considered as a possible drug to use in disorders with 
severe social deficits such as autism and schizophrenia (Evans et al., 2010; Guastella et 
al., 2013).  
1.2.1 OXYTOCIN PROPERTIES 
Oxytocin is synthesised in the hypothalamic paraventricular parvocellular neurons 
(PVN) and the supraoptic nuclei (SON) and is then secreted by the posterior pituitary. 
Neurons from the PVN project to various areas in the limbic system (hippocampus, 
amygdala, striatum, hypothalamus and nucleus accumbens), brain areas which are also 
heavily involved in social cognitive processing (Gimpl and Fahrenholz, 2001).  
4.1.2 OXYTOCIN AND SCHIZOPHRENIA SYMPTOMATOLOGY 
When directly measuring oxytocin levels in the CSF and plasma, no differences have 
been found between healthy controls and patients with schizophrenia (Beckmann et 
al., 1985; Gattaz et al., 1985; Glovinsky et al., 1994; Sasayama et al., 2012b; Walss-Bass 
et al., 2013). However, numerous studies looking at oxytocin levels within both the CSF 
and plasma have found that in both healthy controls and patients with schizophrenia 
measures associated with the symptomatology of schizophrenia (e.g. positive and 
negative symptom scores, and delusions) and prosociality correlated with oxytocin 
levels. Within the CSF, oxytocin levels in patients with schizophrenia correlated with 
negative symptoms (Sasayama et al., 2012b). In the plasma, higher levels of oxytocin 
were associated with greater prosocial behaviours (Rubin et al., 2010) and predicted 
the ability of patients with schizophrenia to identify facial expressions correctly 
(Goldman et al., 2008). Additionally, plasma oxytocin levels were found to correlate 
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with negative, but not positive symptoms, depression, anxiety and neuropsychological 
functioning (Keri et al., 2009). Furthermore, in both patients with schizophrenia and 
healthy controls, plasma oxytocin levels were found to correlate with delusional 
thought content, where lower oxytocin levels predicted more delusional thoughts 
(Walss-Bass et al., 2013). Together, these findings show that oxytocin levels within the 
body offer putative correlations to symptomatology measures which affect sociality in 
both healthy controls and patients with schizophrenia. 
1.2.2 OXYTOCIN AS A THERAPY 
Although dopaminergic medications are currently able to treat the positive symptoms 
of schizophrenia quite well, the social deficits of schizophrenia currently remain 
untreated. Oxytocin provides a putative mechanism for treating these social deficits. In 
patient groups, preliminary work has proved encouraging in schizophrenia, as well as 
in other disorders that have been associated with profound social dysfunctions such as 
autism and social anxiety disorders. In subjects diagnosed with autism, oxytocin has 
been shown to improve comprehension of affect information in speech (Hollander et 
al., 2007) and promote emotion recognition (Guastella et al., 2010); in social anxiety 
disorder, oxytocin alleviates negative self-perception following exposure therapy 
(Guastella et al., 2009). Clinical trials of oxytocin in patients with schizophrenia offer 
preliminary support for its efficacy. All studies but one which looked at the effect of 
oxytocin administration on the outcome of the positive and negative symptom scale 
(PANSS), have found a significant reduction in various symptom scores after patients 
with schizophrenia had taken oxytocin compared to a placebo after two to eight weeks 
of oxytocin administration (Feifel et al., 2010a; Gibson et al., 2014; Modabbernia et al., 
2013; Pedersen et al., 2011a). A meta-analysis of these studies (with the exception of 
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(Gibson et al., 2014)) found a modest effect size of treatment across positive, negative 
and general symptoms (Gumley et al., 2014). However, only two of these studies 
addressed the effects of repeated oxytocin administration on social cognition. One 
study showed an improvement in Theory of Mind tasks patients with schizophrenia 
given oxytocin versus placebo (Pedersen et al., 2011a), while another suggested 
improvements in verbal memory function post oxytocin treatment (Feifel et al., 
2012b). Overall, these studies suggest that oxytocin administration may offer potential 
benefits for patients with schizophrenia across symptom scores and social domains but 
further research needs to be done to highlight the specificity for these effects and 
what factors may contribute to how oxytocin differentially affects patients with 
schizophrenia and who may benefit the most from treatment.  
While these studies suggest that, over time, oxytocin may have an effect on 
symptomatology in schizophrenia; other studies have also explored the acute effects 
of oxytocin administration on general social cognition. Given that studies in healthy 
controls have shown changes in behavioural and neural activity after oxytocin 
administration (Wigton et al.), ranging from tasks looking at trust (Baumgartner et al., 
2008) to exploring ingroup outgroup dynamics (De Dreu, 2012; De Dreu et al., 2011), a 
few studies in patients with schizophrenia have been conducted to see if these findings 
could be replicated to improve social cognition in patients. These studies have shown 
that oxytocin administration is capable of increasing the ability of patients with 
schizophrenia to accurately identify emotions (Averbeck et al., 2012) as well as 
increasing the degree of empathy that patients with schizophrenia show toward an in-
group (Abu-Akel et al., 2014) compared to a placebo. Acute oxytocin administration 
has also been shown to significantly improve “controlled social cognition,” or how 
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indirectly expressed social stimuli such as emotions, thoughts, intentions and complex 
deliberations are understood over longer periods of time, similar to theory of mind 
tasks, but not “automatic social cognition,” or how social cues from the voice, face and 
body are interpreted, for example, explicit emotion recognition (Woolley et al., 2014). 
Together, these studies suggest that, even with an acute dose, oxytocin administration 
offers potential benefit to patients with schizophrenia in interpreting social cue and in 
increasing more complex social processing such as empathy and theory of mind. 
Although oxytocin seems to have promising potential for enhancing social cognition, 
fundamental questions regarding the mechanism underpinning the oxytocin effects on 
social processing need to be addressed to establish its therapeutic potential in clinical 
practice. In healthy controls, oxytocin administration appears to influence behaviour 
through an attenuation of neural activity in social regions such as the amygdala, at 
least in male participants. This attenuation has resulted in the facilitation of prosocial 
behaviours such as increased trust (Baumgartner et al., 2008) and emotion recognition 
(Gamer et al., 2010a) in healthy controls but has yet to be explored in patients with 
schizophrenia. 
1.2.3 DOPAMINE AND OXYTOCIN 
Recent evidence has emerged showing a possible relationship between oxytocin and 
dopamine. There is research linking midbrain and mesolimbic dopamine with the 
effects of oxytocin on the processing of social stimuli. A few studies have shown that 
dopamine is involved in mediating some of the same maternal (Shahrokh et al., 2010) 
and pair bonding (Wang and Aragona, 2004) behaviours that are exhibited under the 
influence of oxytocin. In rabbits, some of the same disturbances seen in the 
hippocampal EEG and behaviour under oxytocin are also observed under dopamine 
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agonists (Maurelli et al., 1988). In humans, oxytocin has been implicated in helping to 
mediate addiction and withdrawal in the mesolimbic dopaminergic pathways 
(Baskerville and Douglas, 2010b). Furthermore, differences in peripheral and central 
levels of oxytocin have been found in patients with disorders with potential dopamine 
abnormalities such as autism (Al-Ayadhi, 2005; Anderson et al., 2008; Hamilton et al., 
2013; Previc, 2007), schizophrenia (Howes et al., 2012; Howes and Kapur, 2009; 
Laruelle and Abi-Dargham, 1999; Sasayama et al., 2012a) and social anxiety disorder 
(Bell et al., 2013; Fink et al., 2009; Hoge et al., 2008; Schneier et al., 2009). Preclinical 
studies have shown that dopaminergic fibres may regulate oxytocin release (Lindvall et 
al., 1984; Melis and Argiolas, 2011) and that the receptor binding sites and neuronal 
fibres of both of these neurochemicals reside in the same regions of the CNS and are 
often next to each other (Baskerville and Douglas, 2010b; Schwartz et al., 1994; 
Smeltzer et al., 2006a). Further evidence suggests that, at least in the ventral and 
dorsal striatum, D2 dopamine receptors and oxytocin are heteromers with facilitatory 
receptor to receptor interactions (Romero-Fernandez et al., 2012). Evidence from 
these studies leads to the proposal that dopamine and oxytocin may work together to 
regulate behavioural responses to social stimuli, such that dopamine affects the 
assignment of emotional salience (Laviolette, 2007) while oxytocin modulates 
amygdala tone (Rosenfeld et al., 2011). 
1.3 MODELLING DECISION-MAKING AND DOPAMINE 
Decision-making is comprised of a series of cognitive processes with the intention of 
selecting the best action from a competing set of beliefs or possibilities. The formation 
of beliefs and their subsequent integration into views of the world and actions is what 
drives decision-making. This is important because it determines how actions are 
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executed and, in turn, how the results of those actions are interpreted. In 
schizophrenia, this process has been shown to be impaired during the formation of 
preference, execution and outcome evaluation (Ernst and Paulus, 2005b). 
In a Bayesian sense, the actions of others can be interpreted on the basis of 
probabilistic inference by which a new model of the world is derived from old evidence 
(priors) and new experiences or evidence (likelihoods). These types of models base 
their outcomes on how well one is able to integrate both old and new evidence to 
generate a belief about the world and what level of pertinence is allocated to each 
piece of evidence. A common way to assess neural correlates from these types of tasks 
has been to use prediction errors, conventionally conceptualized in terms of the 
difference between predicted and actual reward outcome, to determine the effects on 
cognition (Montague and Berns, 2002; Pessiglione et al., 2006). These signals predict 
activity in structures with strong dopaminergic connections such as the ventral 
striatum (O'Doherty et al., 2003; Pessiglione et al., 2006; Wittmann et al., 2008), or, 
more generally, the caudate and putamen (Gradin et al., 2011; Sanfey, 2007; Waltz et 
al., 2011), which makes this modelling extremely useful to assess the influence of 
dopamine on reward processing during decision-making. Furthermore, it is thought 
that functional or structural damage to the neural mechanisms controlling these areas 
may be a fundamental pathophysiology leading to disorders such as schizophrenia 
(Brune, 2005a, b) and that this pathophysiology may be brought about due to a 
dysregulation of dopamine from its integral role in reward learning (Berridge and 
Robinson, 1998; Kapur et al., 2005). In this regard, deficits have been consistently 
observed over all subtypes of the illness, including in unmedicated patients (Andreasen 
et al., 2008) and remitted patients (Marjoram et al., 2006). With this in mind, using 
probabilistic models, it has been possible to assess computational aberrance in 
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dopaminergic systems in schizophrenia (Gradin et al., 2011; Morris et al., 2012; Murray 
et al., 2008; Waltz et al., 2011). However, this approach still insufficiently explains the 
more complex processes underlying decision-making, its neural correlates, and related 
dysfunction in schizophrenia.  
1.4 USE OF DOPAMINE AGONISTS AND ANTAGONISTS TO PROBE BRAIN 
FUNCTION 
The use of dopamine agonists and antagonists to probe neural function is not in itself a 
new idea. Previous studies that have used both drugs were mainly done in rats to show 
that dopaminergic manipulation has a significant effect on impulsive decision-making, 
Specifically, increases in dopamine have been shown to increase impulsive decision-
making (e.g. rats choose a lower immediate reward more often than waiting for a 
larger delayed reward (van Gaalen et al., 2006)); and dopamine antagonists have been 
found to decrease the rats’ motivation for pursuing any reward (Franklin and McCoy, 
1979) (for a review see (Wise, 2004)).  
Only a handful of studies have looked at the effect of dopamine agonists and 
antagonists in human healthy participants using neuroimaging. Most studies have used 
a decision-making paradigm in which subjects are asked to determine through trial and 
error which of two probabilistically rewarded stimuli has the highest probability of 
being rewarded in each trial. These studies have shown how dopaminergic 
manipulation allows for the modulation of both behaviour and neural activity in 
humans. In Pessiglione et al. (2006), subjects had a higher tendency towards picking 
the more rewarding option than after receiving a dopamine agonist (L-DOPA) 
compared to a dopamine antagonist (haloperidol). This study also showed that 
dopaminergic drugs modulate reward prediction error signals in the striatum and that 
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the magnitude of this modulation could be modelled by how the drugs affected 
behavioural choices, such that L-DOPA increased neural activity correlating with RPE in 
the striatum and increased the tendency to choose the more highly rewarded stimuli 
while haloperidol had the opposite effect (Pessiglione et al., 2006). However, another 
study by Bernacer et al. (2013), showed that dopamine agonists actually may disrupt 
decision-making. The authors used methamphetamines as a dopamine agonist, 
together with methamphetamines combined with a dopamine antagonist 
(amisulpride) and a placebo condition. They found that methamphetamine attenuated 
the amount of activity in correlating with the encoding of incentive values, or RPE, in 
the limbic striatum, as well as attenuating the amount of neural activity in the 
ventromedial prefrontal cortex (vmPFC) correlating with incentive value. Thus 
methamphetamines were found to disrupt neural activity associated with learning 
signals in the brain. Pretreatment with amisulpride did not alter the effects of 
methamphetamines in the striatum or in the vmPFC suggesting that, in this study, 
effects may have also been driven by something other than dopamine D2 receptors 
such as norepinerphrine or dopamine D1 receptors. Another study that looked at how 
dopamine antagonists modify value based decision-making, found that the dopamine 
antagonist (amisulpride) improved the ability of participants to learn better reward 
contingencies between two highly rewarding stimuli, but that it had no effect on 
learning rates when stimuli were poorly rewarded. Furthermore, during this task 
reward prediction error signals in the striatum were enhanced by amisulpride (Jocham 
et al., 2011) suggesting that some dopamine antagonists are actually able to enhance 
behavioural performance and neural activity.  
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During non-classical decision-making tasks, the dopamine agonist (L-DOPA), an 
antagonist (haloperidol) and a placebo modulated behavioural and neural effects of 
sensory decision-making (involving discriminating the speed or rhythm of a “tickling 
sensation” on their finger occurred) (Pleger et al., 2009). In this study, L-DOPA 
enhanced neural activity within the primary sensory cortex and haloperidol attenuated 
neural activity within this area. Interestingly, this study did not find a significant drug 
effect within the striatum, but they did find a modulatory effect of reward value within 
the primary sensory cortex. The second study also used L-DOPA, haloperidol and a 
placebo but in this study, subjects were presented with subliminal sexual images that 
required no decision-making. They found that neural activity within the dorsal anterior 
cingulate (dACC) and nucleus accumbens was enhanced by L-DOPA and attenuated by 
haloperidol, suggesting that these regions also respond to subconscious sexual reward 
which is modulated by dopamine (Oei et al., 2012). It is important to note that drug 
pharmacodynamics can vary with dose, though this differs between compounds and 
individuals, the specifics of how each drug interacts with different neural systems are 
commonly not well circumscribed. Collectively, these studies show that dopaminergic 
manipulation produces changes in neural activity - where dopamine agonists (or at 
least L-DOPA) typically increase neural activity in reward related regions with high 
dopamine receptor densities, while dopamine antagonists (at least haloperidol) 
typically attenuate neural activity within these regions but that these findings are 
discordant when using other dopaminergic compounds.  
1.5 AIMS OF THIS THESIS 
In this thesis, I aim to use functional magnetic resonance imaging (fMRI) to explore 
neural activity after the administration of pharmacological probes during an 
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associative learning decision-making task which incorporates emotionally valenced and 
neutral faces as social variables. I propose to explore how dopamine, oxytocin and the 
processing of socially salient affective stimuli influences decision-making in patients 
with schizophrenia through assessing neural activity compared to healthy controls in 
the core regions associated with decision-making and social processing. 
I will assess changes in hemodynamic activity in the brain using functional magnetic 
resonance imaging (fMRI) after the administration of oxytocin and dopamine upon the 
networks and regions that contribute to associative learning and decision-making in 
healthy controls and patients with schizophrenia. The same task is used across all the 
studies in this thesis to allow for a more direct comparison of drug and group effects.  
The purpose of the first part of this study was to explore the effects of dopaminergic 
manipulation in healthy controls and compare these perturbations to patients with 
schizophrenia. The rationale behind this was to observe similarities and differences 
between dopaminergic activity in patients and manipulated levels in controls. Given 
that dopamine appears to play a large role in the substantiation of psychosis, mainly in 
the realm of positive symptomatology, dopaminergic binding within the brain was 
manipulated in healthy controls using a dopamine agonist (ropinirole), antagonist 
(amisulpride) and placebo. The idea behind this manipulation was to give a clearer 
picture of how the changes from dopamine perturbation could relate to changes 
observed in patients with schizophrenia during decision-making with an element of 
implicit social processing. In the second part of the study, the aim of the study was to 
explore the effects of oxytocin administration using the same task in patients with 
schizophrenia. Given oxytocin’s recent popularity as potential treatment alternative for 
the deficits in social cognition observed in schizophrenia, as well as its putative links 
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with the dopaminergic system; this second study looked to see how neural activity 
would be affected by oxytocin administration in schizophrenia and see if there were 
any commonalities with changes in neural activity after dopaminergic perturbation.  
Part 1: The effect of dopamine on decision-making and its relation to schizophrenia 
Chapter 3 will explore how dopaminergic perturbations using the dopamine agonist, 
ropinirole, and the dopamine antagonist, amisulpride, affects neural activity and 
performance compared to a placebo when deciding which of two faces has a higher 
probability of being rewarded out of two emotionally valenced faces (i.e. an angry or 
happy face) or two neutral faces of different identites. Chapter 4 will explore the task 
in patients with schizophrenia compared with data from healthy controls. 
Part 2: The effect of oxytocin on decision-making in schizophrenia 
As the main focus of the first two chapters is in regard to dopamine, Chapter 5 will give 
an overview of oxytocin and its use in neuroimaging studies as well as providing a brief 
overview of how oxytocin may be related to the dopaminergic system and how it may 
benefit disorders with social impairment such as schizophrenia. 
Chapter 6 will use the same task as in Chapters 3 and 4 but will explore how the 
administration of oxytocin to patients with schizophrenia affects neural activity and 
performance.  
Chapter 7 will provide a general discussion of the findings from Chapters 3 to 6. 
Hypotheses: 
In general, I hypothesise that both patients with schizophrenia and healthy controls 
who have taken a placebo will be biased toward choosing a happy face even when the 
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evidence supports the angry face as a better choice. This bias will be attenuated by 
ropinirole, amisulpride and oxytocin. Furthermore, this attenuation in bias will be 
accompanied by changes in neural activity where ropinirole will act to augment neural 
activity in regions associated with decision-making, reward and social processing which 
have dopaminergic ties and amisulpride will act to attenuate neural activity in these 
regions. As the majority of the patients with schizophrenia in this study were 
medicated using dopamine antagonists, changes in neural activity in the patients will 
most closely resemble healthy controls who were administered amisulpride and will 
demonstrate an attenuation of neural activity in regions associated with decision-
making, reward and social-processing. Additionally, attenuation of bias toward 
choosing the happy face after oxytocin administration in patients with schizophrenia 
will be accompanied by the attenuation of neural activity in regions associated with 
social processing.  
Furthermore, as emotionally valenced faces are through to be more salient than 
neutral faces, it is thought that, in general, more changes will be seen when deciding 
between emotionally valenced faces than neutral faces and that this will be the most 
evident in regions associated with social processing such as the amygdala. 
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CHAPTER 2 -  METHODS AND MATERIALS 
2.1 PARTICIPANTS 
2.1.1 STUDY USING DOPAMINERGIC MANIPULATION 
Forty-eight right-handed patients diagnosed with schizophrenia and schizoaffective 
disorder as categorised by the International Classification of Diseases -10 (ICD-10, 
1992) (33 males) and twenty-seven matched healthy controls (22 males) were 
recruited for the main study exploring how dopamine affects decision-making. Of the 
27 healthy controls, 14 participants did not complete all three scanning sessions 
leaving a final sample of 20 healthy controls (17 males) and 42 patients with 
schizophrenia (39 males). Healthy controls and patients with schizophrenia were 
matched in terms of age, gender, handedness and socioeconomic background as 
determined using parental occupation in the National Statistics Socio-Economic 
Classification (Rose, 2001). Intelligence quotient (IQ) was measured in all participants 
using the two-item Wechsler Abbreviated Scale of Intelligence (WASI) consisting of the 
vocabulary and matrix reasoning subtests (Wechsler, 1999). IQ was lower in the 
patients with schizophrenia than in the healthy controls (t(60) = 2.548, p = 0.013). 
Further demographics are listed in Table 2.1.  
Diagnosis of the patients with schizophrenia was confirmed by assessment of case 
notes and by correspondence with each individual’s consultant psychiatrist. To assess 
symptom severity, patients with schizophrenia were also assessed using the Positive 
and Negative Syndrome Scale (PANSS) (Kay et al., 1987). Duration of illness for the 
patients with schizophrenia was 13.5 ± 8.8 (mean ± standard deviation).  
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Forty patients with schizophrenia were taking anti-psychotic medication throughout 
the course of the study and two patients with schizophrenia were stable off of their 
medication for a duration of over six weeks [olanzapine (n =11), quetiapine (n = 2), 
haloperidol (n = 1), aripiprozole (n = 4), amisulpride (n = 2), risperidone (n = 3), 
modecate (n = 1), risperidol consta (n = 2), clopixol (n = 3), clozapine (n = 14), piportil 
(n = 1)]. Chlorpromazine equivalents were calculated for all patients with schizophrenia 
using conversion tables (Chue et al., 2005; Lehman et al., 2004; Nayak et al., 1987; 
Schooler and Levine, 1976; Woods, 2003). Patients with schizophrenia were recruited 
though local national health trusts. Healthy controls were recruited using local 
advertising. 
Healthy controls were excluded if they: had any previous history of mental or 
neurological illness or if any first degree relatives suffered from any previous psychotic 
illness. Participants from both groups were excluded if they: exhibited any significant 
visual or hearing impairments; suffered from any neurological disorders; reported any 
drug dependencies over the last 6 months. Patients with schizophrenia were all stable 
on their current medication. Healthy individuals also provided urine samples on each 
day of testing to screen for the use of cannabis, cocaine, opiates, amphetamines and 
benzodiazapines. All urine samples were negative for those included in the study. 
Female participants were also required to provide a negative pregnancy test prior to 
being administered fMRI scanning. 
Ethics were obtained from the Central London Research and Ethics Committee 1. All 




2.1.2 STUDY USING OXYTOCIN 
In our second experiment, 20 right-handed, male patients with schizophrenia and 
schizoaffective disorder as categorised by the (ICD-10, 1992), taken from the first 
study, were included in a double blind crossover study using oxytocin and a placebo. 
The mean age was 37.9 ± 7.4 (mean ± standard deviation). The patients with 
schizophrenia included in this study did not significantly differ from the patients in the 
previous study in any categories aside from gender as no females were included in this 
study. Further demographic details can be found in Table 2.1. 
Nineteen patients with schizophrenia were taking anti-psychotic medication 
throughout the course of the study [olanzapine (n = 10), risperidone (n = 2), modecate 
(n = 1), clopixol (n = 1), clozapine (n = 3), haloperidol (n = 1)]. Chlorpromazine 
equivalents were calculated for all patients with schizophrenia using conversion tables 
(Chue et al., 2005; Lehman et al., 2004; Nayak et al., 1987; Schooler and Levine, 1976; 
Woods, 2003). 
Ethics approvals were obtained from the Camberwell and St Giles Research Ethics 
Committee. All participants gave informed written consent and were compensated for 
their time and travel. 
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TABLE 2.1 - Demographics and clinical sample characteristics 
 













groups for dopamine 
study   (N=20) (mean (SD)) (N=42) (mean (SD)) (N=20) (mean (SD)) 
  
Age (years) 36.25 (9.41) 37.36 (8.82) 37.90 (7.43) t(60) = 0.238, p = 0.813 t(60) = 0.452, p = 0.653 
WASI IQ 107.30 (14.42) 97.10 (14.89) 98.85 (13.24) t(60) = 0.449, p = 0.655 t(60) = 2.548, p = 0.013* 
Parental occupation  
(NS – SeC) 
2.35 (1.60) 2.79 (1.63) 2.80 (1.70) t(60) = 0.032, p = 0.975 t(60) = 0.989, p = 0.326 
Gender 18M, 2F 33M, 9F 20M χ
2
(1)  = 5.013, p = 0.025* χ
2
(1)  = 0.359, p = 0.735 
Age at onset (years) - 23.76 (5.80) 24.50 (6.48) t(60) = 0.452, p = 0.653 
 Duration of illness (years) - 13.54 (8.76) 13.40 (6.53) t(60) = 0.062, p = 0.951 
 CPZ equivalents (mg/day) - 473.93 (393.15) 430.05 (236.27) t(60) = 0.460, p= 0.647 
 PANSS - 
 Positive Symptoms - 16.18 (4.37) 14.95 (4.97) t(60) = 0.977, p = 0.332 
 Negative Symptoms - 18.28 (5.48) 18.30 (4.99) t(60) = 0.017, p = 0.986 
 General Symptoms - 31.13 (6.95) 30.70 (7.10) t(60) = 0.222, p = 0.825 
 Total - 65.58 (13.89) 63.95(14.65) t(60) = 0.419, p = 0.676 
   
SD = Standard deviation 
IQ = Intelligence quotient; M = Male; F = Female. 
 WASI = Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999) 
 NS - SeC = National Statistics Socio-economic Classification (Rose, 2001) 
 CPZ = Chlorpromazine equivalent (Woods, 2003)  
 PANSS = Positive and Negative Symptom Scale (Kay et al., 1987) 




2.2 PHARMACOLOGICAL PROBES 
2.2.1 DOPAMINERGIC PROBES IN HEALTHY CONTROLS 
Healthy controls were administered a dopamine agonist (ropinirole (0.25mg)), 
dopamine antagonist (amisulpride (400 mg)) or a placebo (ascorbic acid) in a double-
blind crossover design. The order of each drug administration was counterbalanced 
across testing days. All drugs were encapsulated and packaged by the South London 
and Maudsley (SLaM) pharmacy and administered on the same day.  
Patients with schizophrenia were not given any medication supplement to any that 
they were currently taking. It was decided not to dose them with a placebo as this 
would introduce potential confounders secondary to the medication that they were 
already taking. As this study included patients under many varieties of medications, it 
was deemed too difficult to separate out effects from taking a placebo in addition to 
parsing out any effects of long term-medication. Furthermore, even the subjective 
experience of being told they are receiving a placebo is capable of introducing 
differences in performance and neural activity (de la Fuente-Fernández et al., 2001; 
Moerman and Jonas, 2002). 
2.2.1.1 AMISULPRIDE PHARMACOKINETICS 
Amisulpride was used as a dopamine antagonist in this study. It was chosen due to its 
high affinity for dopamine D2/D3 receptors (Green, 2002) as well as its efficacy in 
treating the negative symptoms of schizophrenia (Boyer et al., 1999). At low doses (50-
100 mg), amisulpride is disinhibitory and preferentially blocks presynaptic dopamine 
synthesis. At higher doses (>200 mg) amisulpride has a higher D2-receptor postsynaptic 
occupancy and antagonism (Green, 2002). There are two distinct absorption peaks 
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occurring at approximately 1 and 4-5 hours (Tmax) after administration (Kudris et al., 
2011) (Figure 2.1).  
 
FIGURE 2.1 - Pharmacokinetic profile of amisulpride showing the test solution 
concentration in the plasma with a peak at 1 and 4-5 hours post administration 
(Kudris et al., 2011) 
2.2.1.2 ROPINIROLE PHARMACOKINETICS  
Ropinirole is an indole (or non-ergot) derived dopamine agonist whose chemical name 
is 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one. It was chosen for this study due 
to its high affinity for D2/D3 receptors. It is most commonly used for the treatment of 
Parkinson’s which is a disorder caused by a deficiency in dopamine (Alonso Cánovas et 
al., 2014). It is rapidly absorbed and reaches its maximum concentration in 1 to 2 hours 
which is increased by 1 to 2 hours if taken with food. However, greater increases in 





FIGURE 2.2 - Pharmacokinetic profile of ropinirole showing the concentration in the 
plasma with a peak at 1-2 hours (black dots) the white dots represent plasma 
concentration after receiving a meal with an extremely high fat content (64g of fat) 
(BREFEL ET AL., 1998). 
2.2.2 OXYTOCIN IN PATIENTS WITH SCHIZOPHRENIA 
In our second experiment, patients with schizophrenia were administered an oxytocin 
nasal spray (Syntocinon, Switzerland, 40 IU) or a matched nasal spray containing all the 
same inert ingredients as the oxytocin spray. All sprays were purchased through 
Mawdsley Brooks & Co. and manufactured by Delpharm. Both the oxytocin and 
placebo spray contained glycerol, sorbitol, sodium chloride, citric acid, chlorobutanol 
hemihydrate, disodium phosphate, methyl parahydroxybenzoate, propyl 
parahydroxybenzoate and water.  
The pharmacokinetics of intranasal oxytocin have yet to be fully established. Currently 
only one study to date has explored how intranasal oxytocin administration affects 
oxytocin levels within the cerebrospinal fluid (CSF) over time in order to determine its 
peak effects within the CSF and plasma (Striepens et al., 2013). They found that 
although oxytocin levels in the plasma increased after only 15 minutes, no significant 
increases in CSF oxytocin levels were observed until 75 minutes post administration. 
However, the sample size was extremely small (1 on placebo and 3 on oxytocin) and no 
further time points were recorded so it hard to draw conclusions on whether these 
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findings would extend to a greater population and how long oxytocin in the CSF would 
remain elevated. A similar study in humans using a related neuropeptide, vasopressin, 
has formed the basis for current timings in many oxytocin studies and have shown that 
levels were increased in the CSF compared to a placebo were significantly increased as 
soon as 10 minutes post–administration up to at least 2 hours after administration 
(Born et al., 2002) suggesting that the effects of oxytocin in the CSF may also be longer 
lasting. Furthermore, even though plasma levels of oxytocin have not been found to 
correlate with levels in the CSF (Kagerbauer et al., 2013; Striepens et al., 2013), the 
literature suggests that oxytocin administration can result in elevated levels of plasma 
oxytocin for up to 7 hours, with oxytocin levels up to 10 times greater than in the 
placebo condition (van Ijzendoorn et al., 2012) and that, in rodents, CSF oxytocin levels 
are almost immediately elevated following intranasal administration and can remain 
elevated for up to 90 minutes in the amygdala and hippocampus (Neumann et al., 
2013).  
Current fMRI challenge studies, beginning with the paper by Kirsch et al. (2005) have 
been primarily based on the earlier findings from Born et al. (2002) looking at how 
plasma levels and CSF levels of the neuropeptide vasopressin are elevated at earlier 
time points than in the study by Striepens et al. (2013) and scanning times have 
accordingly generally begun 30 to 45 minutes post- oxytocin administration (Domes et 
al., 2007b; Kirsch et al., 2005; Kosfeld et al., 2005; Wittfoth-Schardt et al., 2012). Given 
that these studies using this timeframe have shown an effect of oxytocin 
administration on neural activity, oxytocin administration in this study was timed to be 
30 minutes before participants were put in the MRI scanner and 45 minutes before the 
start of the first task within the scanner. However, the first task administered in the 
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scanner does not form part of this thesis. The task used here was performed second 
after approximately 45 minutes performing the other task at a time of approximately 
90 minutes post-administration. 
2.3 DRUG ADMINISTRATION 
2.3.1 DOPAMINERGIC PROBES 
For the double-blind dosing of our participants, ropinirole (0.25 mg), amisulpride (400 
mg) and the placebo (ascorbic acid) were all self-administered orally by our 
participants. For each session, each dose was placed in a plastic cup in front of the 
participant alongside a cup of water. They were asked to swallow the pill and follow 
this with a drink of water. We ensured that the participants did not touch the pills so 
that they could not distinguish between any of the medications encapsulated within. 
Additionally, the pharmacy took great care to ensure that each capsule appeared 
qualitatively similar to also keep the capsules from being visually discriminated. This 
procedure was repeated twice each day with one capsule corresponding with the time 
frame for either amisulpride or ropinirole to reach Tmax at scanning time such that the 
first administration was timed four hours before the scan (to coincide with the Tmax of 
amisulpride) and the second administration was timed two hours before the scan (to 
coincide with the Tmax of ropinirole). Additionally, as fatty acids can affect the Tmax of 
ropinirole, fatty acid intake was restricted for all participants on the day of the scan. 
2.3.2 OXYTOCIN NASAL SPRAY 
In our second experiment, both the oxytocin (40 IU) and placebo nasal sprays were 
self-administered by our participants. Each spray was manufactured to appear 
qualitatively similar so that neither the participant nor tester had any knowledge which 
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spray was being administered. Nasal sprays were administered following the guidance 
outlined by Guastella et al. (2013). First each spray was primed so that it was spraying 
full sprays each time it was pumped. Each participant was told to tilt their head back at 
a slight angle and insert the nasal spray into one of their nostrils while trying to keep 
the spray bottle as upright as possible. They were then told to push down on the pump 
action while simultaneously inhaling through their nostrils as deep as possible while 
also blocking the opposing nostril with their other hand. They were then asked to 
switch nostrils and repeat this administration. A break of 45 seconds was given 
between each administration to allow for the nasal spray to allow the nasal spray to be 
absorbed by the nasal cavities. Proper administration was demonstrated to each 
participant before self-administration albeit without the actual insertion and spraying 
of the agent. Each spray was acquired on the day of administration from the South 
London and Maudsley pharmacy, approximately one hour before being administered 
to ensure an adequate storage temperature was not been breached before 
administration. 
2.4 TASK 
The task used was a forced-choice, stochastically rewarded decision-making task 
incorporating elements of social valence. This task has been developed and tested 
extensively by ourselves over the last few years, and we have used it to show how 
social information (provided by different facial expressions taken from the Ekman 
series (Ekman and Friesen, 1971)) can guide decision making processes (Averbeck et 
al., 2012; Averbeck and Duchaine, 2009; Evans et al., 2011a; Evans et al., 2010; Evans 




“The next task is the task we practiced outside the scanner with the 
two different faces. 
You will be presented with two faces on each side of the screen, each 
with a different probability of winning. Your job is to work out during 
each block which face has the highest chance of winning and to 
continue to pick the face that you think is winning the most often. 
Remember, if the face you pick loses, the other face would have won. 
Also, keep in mind that at the beginning of each block, the chances of 
each face winning will be reset. You will be told each time a new 
block will begin. 
The faces are positioned side by side so to select the face on the left 
press with your index finger. Can you do that now please? To pick the 
face on your right, press with your middle finger. Can you do that for 
me now please? 
Great, any questions before we begin the task?.” 
 
Thus, their aim is to try and determine through trial and error which face has the 
highest probability of winning on any given trial and to pick that face, so as to 
maximize their reward (number of wins). In each trial two faces were presented to the 
left and the right of the screen. Pairs consisted of either: a happy face and an angry 
face of the same identity, or of two neutral faces of differing identities see Figure 2.4 
for examples of each stimulus pair. Stimulus pairs were alternated so that one block 
consisting of pairs of emotionally valenced stimuli (i.e. happy and angry faces) was 
alternated with a block consisting of pairs of neutrally valenced stimuli (i.e. neutral 
faces). Each visit consisted of two scanning sessions comprised of four blocks of stimuli 
each presented in the counterbalanced manner described above. Each block consisted 
of 30 trials with the presentation of each face counterbalanced across the left and 
right sides. Participants selected a face using the button box and were then told 
whether they had won or lost on that trial. A ‘win’ corresponded to 10p being added to 
the total winnings, a ‘loss’ meant that nothing was added. Participants were told that 
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they would all receive a fixed amount and that the money they “earned” in the task is 
fictitious. Although the money did not affect the overall earnings of the participants, 
the financial incentive still helped to ensure that participants engage with the task. 
Over each block, each face is rewarded according to a predetermined probability. 
Unbeknownst to the participants, one face is rewarded 40% of the time, the other 
60%. Reward probabilities remained constant for each block of 30 trials and were then 
reassigned. The probabilities of each face winning was counterbalanced across blocks 
such that the angry face won more in half of the blocks and the happy face won more 
in the other half, and that identity one won more over identity two for half of the 
blocks. The order of these wins was counterbalanced across the participants and visits. 
Timings and presentation of the stimuli presented are listed in Figure 2.3. The different 
facial stimuli used are presented in Figure 2.4. This task was run immediately after the 
structural and localiser scans were complete in Chapters 3 and 4 and after another task 
not described in this thesis in Chapter 6. 
 




FIGURE 2.4 - Facial stimuli used for decision-making task in the scanner 
 
FIGURE 2.5 - Example of a session layout for the decision-making task in the scanner 
 
Other tasks were also run in the scanner for both experiments but will not be 
discussed in this thesis. We expect to publish these results elsewhere. 
2.5 BEHAVIOURAL DATA ANALYSIS 
2.5.1 ASSESSING THE PROBABILITY EACH FACE WILL BE REWARDED 
Participants were told that they needed to pick which face was winning the most often 
from a set of two faces either both a happy and an angry face of the same identity, or 
from two neutral faces of different identities. Participants were not given any prior 
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information on which face would likely win any given trial, from a purely probabilistic 
standpoint, participants should view both faces in the first instance with an equal 
probability of winning. This represents a flat prior for the start of each trial centred at 
0.5 or (50%). For any proceeding trials, participants should be able to work out the 
relative probability of a win based on previous feedback. Overall, the probability of 
each face winning will represent a split of 0.6 to 0.4 (i.e. 60% to 40%); however, due to 
the nature of the game, the probability that any one face may be winning at any point 
in time may be different to the overall probability. Thus, in the short term, the face 
that is least probable to win over the whole block may have a higher probability of 
winning at an earlier trial. To take this into account, an ideal observer was calculated 
to determine the optimal face to pick on a trial by trial basis based on current 
feedback. Performance of each individual was referenced to this observer to 
determine if they were picking the optimal face, in terms of which had the highest 
probability of being rewarded, as well as to determine if they were biased toward 










 ,  j=angry face or neutral identity 2 
Where Өi represents the probability that either the happy face or neutral face with 
identity 1 (i) will be rewarded and Өj represents the probability that the angry face or 
identity 2 (j) will be rewarded; qi represents the number of times a face has been 
chosen and has been rewarded (i.e. the happy or angry face or either of the neutral 
face identities); zi represents the number of times the chosen face would have won but 
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the other face was chosen and lost; ntrials is the number of current valid trials. Both 
probabilities were summative to 1 such that probability for the angry face, or neutral 
identity 2, could also be calculated as 1 – p(Өi). Performance was deemed optimal if 
the face picked had a probability of winning greater than or equal to 0.5 such that the 
choice of the ideal observer (f(Ө)): 
p(Өi > Өj) > 0.5, f(Ө) = i 
p(Өj > Өi) > 0.5, f(Ө) = j 
2.5.2 ASSESSING REWARD PREDICTION ERROR (RPE) 
From these estimates a reward prediction error (RPE) was also determined. RPE 
measures the difference between the actual reward and the probability of being 
rewarded as calculated by the model. It is calculated as follows: 
RPE(t) = r(t) - p(r(t)) 
Where r(t) represents the reward received on trial t of either 1 (yes rewarded) or 0 
(not rewarded) and p(r(t)) represents the probability of being rewarded for whichever 
face was chosen on trial t and was determined using the probabilities listed in the 
previous section. This can also be thought of as the reward received (0 or 1) minus the 
probability of the reward predicted.  
2.5.3 ASSESSING BIAS TOWARD ONE OF THE FACES 
Bias was looked at by measuring the number of times each participant picked the face 
that was not currently supported by the ideal observer. Thus, to assess how facial 
expression, or identity, biased decision-making, all trials were separated into when 
participants agreed with the ideal observer and when they disagreed with the ideal 
observer for each facial valence as well as for the two neutral face identities. A 2x2 
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contingency table was calculated for each block type (i.e. emotionally valenced and 
neutral) representing choices by the ideal observer and choices by the participant. 
When the probability for each face winning was ambiguous (i.e. equal probabilities for 
both faces), the contingency count for each face (HH, AA) was increased by 0.5.  
TABLE 2.2 - Contingency table example for emotionally valenced faces 
  
Ideal Observer choice 
  
happy face angry face 
Participant 
choice 
happy face HH HA 
angry face AH AA 
 
Using this table it was possible to calculate the conditional probability of each 
participant choosing the happy face when they should have chosen the angry face 
given the current evidence for the angry face p(happy|angry) as well as when they 
chose the angry face when they should have chosen the happy face given the current 
evidence for the happy face p(angry|happy). For the happy faces, this was calculated 
as the times they chose the happy face when they should have chosen the angry face 





And for the angry face this was calculated as the times they chose the angry face when 
they should have chosen the happy face over the total number of times the angry face 





It is important to note these measures are not calculated in the same way as talked 
about in section 2.5.1 assessing the general probabilities of being associated with a 
reward. The difference between these two measures looking at bias was calculated to 
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represent the degree of bias toward picking the happy face p(happy|angry) - 
p(angry|happy). This is a measure of conditional probability given both the observed 
and expected choice. This measure indicates how often participants ignore the 
evidence that has accumulated for the negatively valenced face and chose the 
positively valenced face compared to how often they ignored evidence that had 
accrued for the positively valenced face and chose the negatively valenced face. This 
bias distribution was examined across all participants and entered into a one sample t-
test to see if it significantly differed from 0. This process has been replicated in 
multiple studies to represent the degree of bias (Averbeck and Duchaine, 2009; Evans 
et al., 2011a; Evans et al., 2010; Evans et al., 2011b; Furl et al., 2012). This process was 
also repeated for the two neutral face identities to see if participants favoured either 
of these faces. 
 FUNCTIONAL MAGNETIC RESONANCE IMAGING (FMRI)  4.2
Functional Magnetic Resonance Imaging (fMRI) was used in this study as an indirect 
measure of neural activity in each of our participants. It is generally accepted that 
increased neural demand causes an increase in blood flow to regions of the brain 
which are neurally active. fMRI works by measuring small signal changes in the brain 
due to increased blood flow to different regions of the brain. In the late 1990’s, it was 
observed that deoxygenated haemoglobin (molecules in the blood which carry oxygen) 
was affected differently in a magnetic field than oxygenated haemoglobin (Ogawa et 
al., 1990). They observed that haemoglobin becomes strongly paramagnetic in a 
deoxygenated state and thus, when introduced to a radiomagnetic pulse, the signal 
decays more rapidly than oxygenated haemoglobin causing areas with oxygenated 
blood to appear “brighter”. Thus oxygenated blood works as a natural contrast agent 
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to regions of the brain with increased localized blood flow and is referred to as the 
blood oxygenation level-dependent (BOLD) signal (Logothetis, 2008).  
2.6 IMAGE ACQUISITION 
Functional magnetic resonance imaging (fMRI) data for both experiments were 
acquired on a Discovery MR750 3T scanner at the Centre for Neuroimaging Sciences, 
London (T2* weighted gradient-echo echo-planar images (EPIs), repetition time (TR) = 
2000 ms, echo time (TE) = 35 ms, flip angle = 75°, 64 x 64 matrix, 24cm field of view). A 
12-phase head coil array was used over the whole head for RF transmission and 
reception. Each whole-brain image contained 38 3-mm axial slices separated by a 
distance of 0.3 mm with in-plane isotropic voxel resolution of 3.75 x 3.75 mm. For each 
session, 430 scans were acquired and two sessions were recorded for each participant.  
Before the behavioural portion of the experiment, a T1-weighted structural scan using 
a fast-spoiled gradient-echo pulse sequence (TR = 9.356 ms, TE = 3.828 ms, flip angle = 
12°, time to inversion = 450 ms) was acquired for reference purposes. The first four 
volumes were discarded to allow for transient effects.  
For the study looking at dopaminergic manipulation in healthy controls and the 
differences to patients with schizophrenia, participants made their responses using a 
two buttons on a three button-box in the index and middle fingers of their right hand. 
The third button was for an additional task which will not be analysed in this thesis. For 
the study using oxytocin administration, only a two button-box was used. Participants 
also made their choices with the index and middle fingers of their right hand. Head 
movement was minimised using headphones and additional padding around the head 
and ears as well as around the arms and legs. 
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2.7 IMAGE ANALYSIS 
All data were preprocessed and analyzed using Statistical Parametric Mapping 12 
(SPM12) (Wellcome Department of Imaging Neuroscience, London, 
UK. www.fil.ion.ucl.ac.uk/spm) and MATLAB R2014a (MathWorks Inc. Sherbon, MA, 
USA). First, each structural image was reoriented to set the point of origin at the 
anterior commissure and the degree of rotation was set to match the posterior 
commissure. Each structural image from the first visit of each subject was segmented 
into various tissue classifications and then smoothed slightly. Segmentation allows for 
each subject’s brain to be spatially normalised to a standard space and allows grey 
matter to be matched between subjects and reduces non-brain structural variability on 
the registration. Further preprocessing comprised spatial realignment to the first 
image of the first session where each image is realigned using a least squares approach 
and a six parameter (rigid body) spatial transformation (Friston et al., 1995) which 
helps with the removal of movement artefacts by realigning each image to the same 
native space. Next each image was resliced to match the first image voxel-for-voxel. 
Then each session was coregistered to the mean image of each session and the T1-
weighted structural image, forward deformations from the segmentation process were 
used to normalise the images to a standard template of the Montreal Neurological 
Institute (MNI) brain, finally all the images were smoothed using an 8-mm full-width at 
half-maximum Gaussian kernel to reduce noise and residual differences in functional 
and gyral anatomy between subjects. Images were analysed using an event-related 
general linear model (GLM). Onsets were modelled at each task event using a delta 
(stick) function.  
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Events of interest in the GLM included the presentation of the faces, a decision-making 
regressor indicating when the decision was made for which face the subject believed 
would be rewarded (determined by a button press), and the feedback presentation of 
whether the subject received a reward or not within each trial. Also modelled were 
regressors to represent the motion parameters as well as parametric modulators on 
the decision-making and feedback regressors. The decision-making regressor was 
parametrically modulated by the probability that the face they picked would win. The 
calculations used to determine this probability are outlined on page 47. The feedback 
regressor was parametrically modulated by the reward prediction error (RPE) 
determined by subtracting the actual reward from the predicted probability the face 
the participant chose would win, as detailed on page 49. Each regressor, except for the 
motion parameters, was convolved with a canonical hemodynamic response function 
and its temporal derivative. 
The contrasts for each chapter focussed on outputs from the decision-making and RPE 
regressors for between group and drug analyses. Further details on the contrasts for 
each chapter are outlined in each chapter. 
Contrasts were whole brain cluster-level family wise error (FWE) corrected at p<.05 
with a height threshold of p < .005, uncorrected, and an extent threshold of 100 
contiguous voxels. Voxels which survived peak level family wise error correction at 
p<.05 are also reported. When looking at the main effect of task and emotion in the 
placebo condition, cluster level results are reported at a more stringent height 
threshold of p < .001. Reported voxels coordinates were converted from Montreal 
Neurological Institute (mni) coordinates into Talairach coordinates using the function 
icbm_spm2tal (Laird et al., 2010; Lancaster et al., 2007a) and were entered into 
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Talairach Daemon to confirm their location in gray matter (Lancaster et al., 1997; 
Lancaster et al., 2000). Questionable results were further visualised by entering the 
original mni coordinates into xjview (http://www.alivelearn.net/xjview). Results are 
reported as their original mni coordinates as output by SPM12.  
Region of interest analyses were also carried out within regions with an a priori 
interest to the study. Volumes of interest were defined using WFU PickAtlas Tool 
(Maldjian et al., 2003) for the amygdala and striatum and the ventral striatum was 
taken from Mawlawi et al. (2001).  
Effect sizes were also calculated for all two-sample and paired t-tests to assess the 
strength of each finding. The effect size is a dimensionless number which facilitates the 
integration of findings across studies that used different types of measurements. The 
choice of effect size estimator is a much debated and still unresolved issue (Hunter and 
Schmidt, 1990) and is related to the choice of whether or not greater reliance should 
be laid on studies carried out on larger samples when the effect size is to be 
computed. We chose to use an effect size estimator corrected for the number of 
subjects included in each study using Cohen's d statistic (Cohen, 1992). Guidelines for 
calculations were followed using Thalheimer and Cook (2002)’s method. By examining 
effect sizes rather than statistical significance, we can better understand what 
differences exist in the general population and whether these differences might merit 
further study. Effect size (d) is taken to mean “the degree to which a phenomenon is 
present in the population” (Cohen, 1988); d was indexed according to Cohen's scheme 
(Cohen, 1992). Cohen placed the value of d for small effects at 0.2, for medium effects 
at 0.5, and for large effects at 0.8.  
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CHAPTER 3 -  THE NEURAL CORRELATES OF DECISION-
MAKING DURING AN ASSOCIATIVE LEARNING TASK WITH A 
SOCIAL COMPONENT – THE EFFECTS OF DOPAMINERGIC 
MANIPULATION IN HEALTHY PARTICIPANTS 
3.1 BACKGROUND 
Decision-making results from a complex interplay between our internal thoughts and 
preferences and their interactions with the world around us. Differences in the 
evaluation of the world lead to the differences in decisions an individual makes. An 
important aspect of this evaluation is determining the potential outcomes of any 
actions and, specifically, the value that these outcomes hold. For example, when trying 
to determine what to order on a menu, generally a person will evaluate each option 
and assign it with an implicit value. The option a person will pick from the menu is the 
one that holds the highest implicit value to them. One person may value price over 
taste and thus will pick the cheapest item while another may value quantity and will 
pick the greatest serving size and yet another may value taste and pick the item they 
deem the tastiest. How we assign these values to particular items internally and 
subsequently interpret them to generate an action is driven by an important 
neurotransmitter called dopamine (Schultz, 2006, 2007; Smith and Huettel, 2010; Wise 
and Rompre, 1989). It has been suggested that, dopamine aids in both the formation, 
or the conceptualisation of value in terms of the costs and benefits of a given option or 
set of options, and updating, or re-evaluation, of predictions about rewards (Schultz, 
2006), for example, how much value we could expect from picking from a set of 
options like a menu. By altering the incentive salience, or the implicit degree of 
desirability, or “wanting,” of an object (Berridge, 2007), and updating how future 
rewards are represented internally (Schultz, 2013), dopamine is believed to contribute 
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to value formation and motivational behaviour. Incentive salience spurs behaviour by 
attributing a higher value to certain salient stimuli that stick out amongst competing 
stimuli, and in turn also contributes to determining which events are important 
enough to be encoded in memory. An example could be the marketing of a new menu 
item through flashy advertising designed to make it look like it tastes better and/or 
substantially discounting the price to make it a more salient option. The degree to 
which these stimuli are more salient than other stimuli in the environment and the 
relative rewards received from picking these stimuli are thought to be updated based 
on dopaminergic outputs. Both negative feedback, in the form of punishments or less 
desirable outcomes, and positive feedback, or rewards from more desirable outcomes, 
help to update relative values of stimuli. Negative feedback induces a reduction in 
dopaminergic firing and positive feedback induces increased dopaminergic firing 
(Schultz et al., 1997) (Figure 3.1). The degree to which dopamine neurons fire in 
response to feedback is mediated by the anticipated reward amount combined with 
the feedback received. If a high reward is expected and a high reward is received there 
will be little dopaminergic activity because the difference between the actual reward 
and the anticipated reward is negligible. However, if a high reward is expected and no 
reward is received, this negative feedback should induce a greater reduction in 
dopaminergic firing than if no reward had been expected (Schultz, 1998; Schultz et al., 
1997). This firing in relation to the difference between reward received and anticipated 
reward is known as the reward prediction error (RPE) signal and has been well 
established (Berridge, 2012; Colombo, 2014; Glimcher, 2011; Hart et al., 2014; 
Hollerman and Schultz, 1998; Lak et al., 2014; Murray et al., 2008; Philiastides et al., 
2010; Poore et al., 2012) and can even encode the variance in the signal as well 
(Friston et al., 2012). In behavioural terms, positive outcomes, or rewards would be 
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encoded as events which would lead to reward in the future whereas aversive 
outcomes, or those which do not fulfil our expectations would be encoded as events to 
avoid in the future. Given the high concentration of dopamine neurons in the striatum, 
these signals have generally been found in the ventral striatum close to the substantia 
nigra and ventral tegmental area. Further encoding of incentive salience and overall 
value of a choice generally correlates with signals in a network of areas including the 
anterior cingulate cortex (ACC) and medial prefrontal cortex (mPFC) (Botvinick, 2007; 
Devinsky et al., 1995; Matsumoto et al., 2007). 
 
FIGURE 3.1(a-c) - Examples of neural response to reward in the striatum, where CS 
represents a conditioned stimulus and R represents where a reward was given or not given. 
Taken from (Schultz, 1998). a) The higher concentration of dots after the reward stimulus are 
indicative of greater firing of dopaminergic neurons in the striatum after receiving a reward 
with no conditioned stimulus. b) Dopamine neurons fire after the conditioned stimulus 
associated with a reward but when no reward is given, this is also accompanied by a reduction 
of dopaminergic neurons firing in response to the conditioned stimulus and lack of the 
associated reward. c) Once the dopaminergic neurons are conditioned to expect a reward and 
a reward is given, dopaminergic neurons only fire in response to the stimulus which indicates a 
reward will be given. 
However, given that incentive salience also affects dopaminergic signalling, the 
predicted reward can be altered by the incentive salience determined by behavioural 
or social biases. This is notable in social situations where the same face may take on a 
higher social salience based on its emotional valence, known as affective priming 
(Murphy and Zajonc, 1993). A smiling face is more likely to be regarded as salient 
amongst a series of neutral faces as would be an angry face amongst neutral faces. The 
difference is that the smiling face will generally be associated with a more positive 
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value and it is more likely that viewing a happy, or smiling, face will facilitate 
cooperation (Mussel et al., 2013; Scharlemann et al., 2001). In fact, people are even 
willing to forego the chance of a monetary reward just to see a genuine smile (Shore 
and Heerey, 2011); whereas prior experience will bias most people to associate angry 
faces with more negative interactions and has been shown to decrease cooperative 
interactions (Mussel et al., 2013). Furthermore, in a task which presented different 
emotionally valenced faces to people before asking them to pour and consume a drink, 
people who viewed happy faces first increased the amount of a beverage poured and 
consumed and made participants more willing to pay for their drink while viewing 
angry faces first had the opposite effect (Winkielman et al., 2005). This shows that 
emotionally valenced faces can also have an unconscious effect on our actions.  
The use of dopamine agonists and antagonists offers a way of manipulating 
dopaminergic binding in the brain and to examine the association between 
dopaminergic activity and neural activity during cognitive tasks. Previous studies using 
dopaminergic manipulation in healthy controls have generally modelled the response 
to reward related stimuli using prediction errors (RPEs) and value related functions of 
processing decisions. These studies used similar decision-making paradigms during 
which subjects were presented with two choices with varying probabilities of being 
rewarded. They were then asked to pick the option that they believed was more likely 
to be rewarded. The first study by Pessiglione et al. (2006) found that giving L-DOPA, a 
dopamine agonist, made subjects more likely to choose the more rewarding option 
compared to subjects who received the dopamine antagonist, haloperidol. 
Additionally, these choices were accompanied by modulation of neural activity within 
the striatum where L-DOPA administration enhanced neural activity, correlating with 
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RPE in the striatum relative to haloperidol. Additionally, two further studies that used 
L-DOPA and haloperidol, albeit without the same reward-based probabilistic decision-
making paradigm, found that, during somatosensory decision-making L-DOPA, 
haloperidol and a placebo modulated behavioural and neural effects L-DOPA enhanced 
neural activity within the primary sensory cortex and haloperidol attenuated neural 
activity within this region (Pleger et al., 2009). Interestingly, this study did not find a 
significant drug effect within the striatum. The other study also used an L-DOPA, 
haloperidol and a placebo but presented their subjects with subliminal sexual images 
which required no decision-making. They found that neural activity within the dorsal 
anterior cingulate (dACC) and nucleus accumbens was enhanced by L-DOPA and 
attenuated by haloperidol, suggesting that these regions also respond to subconscious 
sexual reward which is modulated by dopaminergic binding (Oei et al., 2012). 
Together, these three studies show that the dopamine agonist L-DOPA appears to 
increase neural activity in areas related to reward, which are have high dopaminergic 
receptor densities and decrease neural activity with the dopamine antagonist 
haloperidol in these same regions. 
However, in another study run by Bernacer et al. (2013) dopamine agonists were 
found to  disrupt decision-making. They used methamphetamines as a dopamine 
agonist, methamphetamines combined with a dopamine antagonist (amisulpride) and 
a placebo and found that methamphetamine attenuated the amount of activity 
correlating with the encoding of incentive values, or RPE, in the limbic striatum, and 
attenuated neural activity in the ventromedial prefrontal cortex (vmPFC) correlating 
with the encoding of incentive value. Pretreatment with amisulpride did not influence 
the effects of methamphetamines in the striatum or in the vmPFC, suggesting that, in 
61 
 
this study, effects may have also been driven by something other than D2 dopamine 
receptors such as norepinephrine or D1 dopamine receptors. Jocham et al. (2011) 
looked at the effects of amisulpride on a very similar decision-making task and found 
that a low dose of amisulpride increased the amount of activity in the striatum, 
correlating with RPEs, as well as enhancing neural activity in the vmPFC which was 
correlating with tracking learned value. Obviously, drug pharmacodynamics can vary 
with dose, though this differs between compounds and individuals. Unfortunately, the 
specifics of these interactions within the brain are commonly not well circumscribed. 
In the study by Jocham and colleagues the dose of amisulpride was lower than the 
dose usually administered in clinical settings, and there are data to support it having 
greater effects on presynaptic dopaminergic receptors at this dose (Green, 2002). 
Additionally, even animal studies have shown that low does dopamine antagonists can 
potentiate conditioned reinforcement opposite to larger doses (Smith et al., 1997) 
suggesting that this low dose of amisulpride may have acted on behaviour and neural 
activity in the opposite direction as if a larger dose had been administered. Together 
these studies show that dopaminergic manipulation has an effect on neural activity 
during decision-making, but the direction of this effect sometimes shows enhanced 
and other times shows attenuated activation. While a vast amount of animal literature 
suggests that dopamine agonists have a reinforcing effect on reward related learning, 
while dopamine antagonists impair reward related learning (Wise, 2004), the 
contradicting results in humans shows that a lot of work still needs to be done to 
explore dopamine perturbation in humans.  
Additionally, most of these studies used only simple decision-making tasks. This study 
proposes to expand on these previous studies by incorporating social cues to standard 
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utilitarian decision-making factors while exploring the effects of dopaminergic 
perturbation on neural activity. Previous studies have already shown that 
incorporating social cues into a simple associative learning decision-making task can 
affect how participants make decisions by biasing their choices toward picking a happy 
face even when the evidence for reward supports choosing an angry face (Averbeck 
and Duchaine, 2009; Evans et al., 2011a; Furl et al., 2012). This study incorporated 
another element by also incorporating dopaminergic manipulation while undergoing 
fMRI during the same value-based decision-making task using facial expressions to 
explore social bias in decision-making during an associative learning task. Additionally, 
the task explored in this study incorporated a choice condition between two neutral 
faces in order to investigate non-socially salient task effects.  
In light of current research, I hypothesise that: 
1. Healthy controls will show the same bias as previously shown toward choosing the 
happy face in lieu of an angry face when given a placebo (Averbeck and Duchaine, 
2009; Evans et al., 2011a; Evans et al., 2011b; Furl et al., 2012) but that when given 
ropinirole and amisulpride, healthy controls will learn better reward contingency 
associations with the faces and learn to pick the more highly rewarding face regardless 
of social salience such that bias toward the happy face will be attenuated in both drug 
conditions.  
2. On account of its shared pharmacology with L-DOPA, it is hypothesised that when 
deciding which face is more likely to be rewarded, dopaminergic perturbation by 
ropinirole, relative to placebo administration, will increase neural activity in regions 
along the mesolimbic dopamine pathway, particularly in regions subserving reward 
learning (such as the ACC) and emotion (such as the amygdala). By contrast, using a 
63 
 
higher dose of amisulpride, than previously explored with fMRI, will attenuate neural 
activity in these regions. Furthermore, these effects will be greater when making 
decisions between two emotionally valenced faces on account of their enhanced social 
salience compared with neutral faces. In addition, the change in neural activity in these 
regions will correlate with the degree of change in bias. 
3. As previously demonstrated by Pessiglione et al. (2006), RPE will be modulated by 
dopamine perturbation such that ropinirole administration will act to increase neural 
activity in dopamine rich reward areas (such as the striatum, and specifically the 
ventral striatum), relative to placebo administration and amisulpride administration 
will act to attenuate neural activity in these regions relative to placebo administration 
when processing both emotionally valenced faces as well as neutral faces.  
3.2 METHODS 
3.2.1 PARTICIPANTS 
Twenty seven healthy controls (22 males) were recruited for this study. Of these 
twenty-seven, seven participants did not complete all three scanning sessions leaving a 
final sample of 20 healthy controls (17 males). Intelligence quotient (IQ) was measured 
in all participants using the two-item Wechsler Abbreviated Scale of Intelligence 
(WASI) consisting of the vocabulary and matrix reasoning subtests (Wechsler 1999). 
Demographic information can be found below in Table 3.1. All participants signed 
informed consent and were compensated for their participation in the study. Ethical 
approval was obtained from the Central London Research and Ethics Committee 3. 
Further details of recruitment and inclusion and exclusion criteria can be found in 
Chapter 2 (page 35).  
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TABLE 3.1 - Demographics for healthy participants 
Healthy Participants 
  (N=20) (mean (SD)) 
Age (years) 36.25 (9.41) 
WASI IQ 107.30 (14.42) 
Parental Occupation (NS-SeC) 2.35 (1.60) 
Gender 18M, 2F 
IQ = Intelligence quotient; M = Male; F = Female. 
WASI = Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999) 
NS - SeC = National Statistics Socio-economic Classification (Rose, 2001) 
3.2.2 TASK 
The task used was a forced-choice, stochastically rewarded decision-making task 
incorporating faces of varying social valence. In each trial two faces were presented to 
the left and the right of the screen. Pairs consisted of either: a happy face and an angry 
face of the same identity, or of two neutral faces of differing identities. Each visit 
consisted of two scanning sessions comprised of four counterbalanced blocks of 30 
trials each (Figure 2.5, page 47). Pairs of emotionally valenced stimuli (i.e. happy and 
angry faces) were alternated with pairs of neutrally valenced stimuli (i.e. neutral faces). 
Within each emotionally valenced block, the identities of each face were kept 
consistent but the order of presentation of each identity was counterbalanced across 
sessions. Each block consisted of 30 trials with the presentation of each face 
counterbalanced across the left and right sides. Probability estimates were assigned to 
the faces at the beginning of each trial such that on 60% of the trials one face would 
win and 40% of trials the other face would win. The probability distribution of each 
face winning was counterbalanced across blocks such that the angry face won more in 
half of the blocks and the happy face won more in the other half, and that identity one 
won more over identity two for half of the blocks and vice versa for both the 
emotionally valenced and neutral faces. The order of these wins was counterbalanced 
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across the participants and visits. In each trial, participants were instructed to pick the 
face which, at that time, they believed was the most likely to win. They were told that 
after making this decision they would be told whether or not they had won where a 
win would show that they had won 10 pence along with their current winnings total 
and a loss was associated with no change in winnings and only the message “You lose.” 
The presentation of stimuli is shown below in Figure 3.2. Further details, including the 
task instructions, can be found in Chapter 2 (page 44). 
 
FIGURE 3.2 - Presentation of stimuli in the scanner in each trial 
3.2.3 PHARMACOLOGICAL PROBES 
Healthy controls were administered a dopamine agonist (Ropinirole (0.25mg)), 
dopamine antagonist (Amisulpride (400 mg)) or a Placebo consisting of ascorbic acid in 
a double-blind crossover design. Drug order was counterbalanced across days to 
balance the order in which participants received the drugs such that: on the first day 6 
received placebo, 7 received amisulpride and 7 received ropinirole; on the second day 
8 received placebo, 7 received amisulpride and 5 received ropinirole; on the third day 
6 received placebo, 6 received amisulpride and 8 received ropinirole. All drug 
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conditions were counterbalanced so that each drug was administered at 
approximately equal amount of times across each testing day. All drugs were 
encapsulated and packaged by the South London and Maudsley (SLaM) pharmacy and 
were administered on the same day. Each drug was administered at a time to 
maximise its concentration in the plasma levels (Tmax) at the time of the scan such that 
the first administration was timed four hours before the scan (to coincide with the Tmax 
of amisulpride) and the second administration was timed two hours before the scan 
(to coincide with the Tmax of ropinirole). A placebo was administered at each time slot 
where a drug was not administered. Scans were scheduled a minimum of one week 
apart to allow for an adequate washout period of each drug administered. Further 
details of each of the drugs used can be found in Chapter 2 (page 39). 
3.2.4 FMRI DATA ACQUISITION 
Functional magnetic resonance imaging (fMRI) data were acquired on a Discovery 
MR750 3T scanner at the Centre for Neuroimaging Sciences, London (T2* weighted 
gradient-echo echo-planar images (EPIs), repetition time (TR) = 2000 ms, echo time 
(TE) = 35 ms, flip angle = 75°, 64 x 64 matrix, 24cm field of view). A 12-phase head coil 
array was used over the whole head for RF transmission and reception. Each whole-
brain image contained 38 3-mm axial slices separated by a distance of 0.3 mm with in-
plane isotropic voxel resolution of 3.75 x 3.75 mm. For each block, 430 scans were 
acquired and two sessions were recorded for each participant.  
Before the experimental portion of the experiment, a T1-weighted structural scan 
using a fast-spoiled gradient-echo pulse sequence (TR = 9.356 ms, TE = 3.828 ms, flip 
angle = 12°, time to inversion = 450 ms) was acquired for reference purposes. The first 
four volumes were discarded to allow for transient effects.  
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Participants made their responses using a two buttons on a three button-box with 
their index and middle fingers of their right hand. Head movement was minimised 
using headphones and additional padding around the head and ears as well as around 
the arms and legs. 
3.2.5 ANALYSIS 
All data were preprocessed and analysed using Statistical Parametric Mapping 12 
(SPM12) (Wellcome Department of Imaging Neuroscience, London, 
UK. www.fil.ion.ucl.ac.uk/spm) and MATLAB R2014a (MathWorks Inc. Sherbon, MA, 
USA). Further details of these steps can be found in Chapter 2 (page 53). 
A general linear model (GLM) was constructed in SPM12 to analyse the images with 
each event modelled as a delta (stick) function. Each block, consisting of 30 trials, was 
modelled independently and was defined as being either a block using emotionally 
valenced faces (e.g. happy and angry faces) or neutral faces (e.g. two faces of different 
identities). Events of interest within each block included the presentation of the faces, 
a decision-making regressor indicating when the decision was made for which face the 
subject believed would be rewarded (determined by a button press), and the feedback 
presentation within each trial. Also modelled were regressors to represent the motion 
parameters as well as parametric modulators on the decision-making regressor for the 
probability of each face chosen being associated with a win and feedback regressors. 
The probability that the face they picked would win was calculated using an ideal 
observer. The calculations used to determine this probability are outlined in depth in 
Chapter 2 (page 47). The feedback regressor, associated with when they were given 
feedback about whether or not the face they had chosen was associated with a 
reward, was parametrically modulated by the reward prediction error (RPE) 
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determined by subtracting the actual reward (i.e. 1 for a win and 0 for a loss) from the 
predicted probability that the chosen face would win as detailed in Chapter 2 (page 
49). Each regressor, except for the motion parameters, was convolved with a canonical 
hemodynamic response function and its temporal derivative. Missed trials were not 
modelled as events. Blocks where subjects failed to respond for greater than 50% of 
the trials were excluded from analysis as they were deemed to be insufficiently 
attending to the task. Furthermore, without feedback from all trials, it would have 
been more difficult for subjects to accurately assess which face was winning more 
often throughout the block. These excluded blocks accounted for 2 blocks across 2 
subjects, both in the amisulpride condition (both blocks were when making decisions 
between two neutral faces). 
Performance estimates were calculated across all trials by comparing the face the 
subject picked to the face the ideal observer assigned the highest probability of 
winning. In the case that both faces had equal probability of winning (i.e. at 50% 
probability) either face picked was deemed optimal. Overall performance estimates 
were calculated across all trials as the number of times the participant picked the face 
deemed optimal over the number of valid trials (i.e. 30 – any misses). These estimates 
were then averaged across all blocks which were not excluded to get an overall 
performance estimate for all blocks using emotionally valenced and neutral faces. 
To assess how facial expression biased decision-making, all trials were separated into 
when participants agreed with the ideal observer and when they disagreed with the 
ideal observer for each facial valence as well as for the two neutral face identities. A 
2x2 contingency table was calculated for each block type (i.e. emotionally valenced 
and neutral) representing choices by the ideal observer and choices by the participant. 
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When the probability for each face winning was ambiguous (i.e. equal probabilities for 
both faces), the contingency count for each face was increased by 0.5. Using this table 
it was possible to calculate the conditional probability of each participant choosing the 
happy face when they should have chosen the angry face given the current evidence 
for the angry face p(happy|angry) as well as when they chose the angry face when 
they should have chosen the happy face given the current evidence for the happy face 
p(angry|happy). The difference between these two measures was calculated to 
represent the degree of bias toward picking the happy face (p(happy|angry) – 
p(angry|happy)). This measure indicates how often participants ignore the evidence 
that has accumulated for the negatively valenced face and chose the positively 
valenced face compared to how often they ignored evidence that had accrued for the 
positively valenced face and chose the negatively valenced face. This bias distribution 
was examined across all participants and entered into a one sample t-test to see if it 
significantly differed from 0. It is important to note these conditional probabilities 
were calculated separately to the probability that each face would win. A more 
comprehensive overview with equations is provided in Chapter 2 (page 49). This 
process has been replicated in multiple studies to represent the degree of bias 
(Averbeck and Duchaine, 2009; Evans et al., 2011a; Evans et al., 2010; Evans et al., 
2011b; Furl et al., 2012). 
The main focus of this study was to look at how decision-making and RPE affected 
neural activity so contrasts were looked at representing neural activity when a button 
was pressed to indicate which face the participant had chosen on a given trial, here 
after referred to as the decision-making condition as well as contrasts representing 
neural activity correlating with RPE given by the parametric modulator on reward 
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feedback. Second-level contrasts between drug conditions were assessed using paired 
sample t-tests and overall effects of task were assessed using a one sample t-test in 
the placebo condition. Within each drug comparison (i.e. amisulpride versus placebo 
and ropinirole versus placebo), the main effect of task was analysed looking at by 
combining the blocks for emotionally valenced and neutral faces. Then contrasts were 
also created for blocks looking at only decision-making between the emotionally 
valenced faces to assess differences in decision-making with emotionally salient stimuli 
as well as within only the blocks looking at decision-making between neutral faces to 
assess differences in decision-making between general social stimuli with no emotional 
salience. Interaction effects between the emotion and drug were also analysed to see 
if there was any interaction between the emotionally valenced face condition and the 
neutral face condition and the drug they were administered.  
To look at interaction effects between drugs and emotion an overall examination of 
blocks looking at the effects of drug (i.e. ropinirole versus placebo and amisulpride 
versus placebo) and emotion (i.e. emotionally valenced versus neutral faces) were 
entered into 2x2 full factorial in SPM12 with drug and emotion as conditions. 
Contrasts were whole brain cluster-level family wise error (FWE) corrected at p<.05 
with a height threshold of p < .005, uncorrected, and an extent threshold of 100 
contiguous voxels. Voxels which survived peak level FWE correction at p<.05 are also 
reported. When looking at the main effect of task and emotion in the placebo 
condition, cluster level results are reported at a more stringent height threshold of p < 
.001. Reported voxels coordinates were converted from Montreal Neurological 
Institute (mni) coordinates into Talairach coordinates using the function icbm_spm2tal 
(Laird et al., 2010; Lancaster et al., 2007a) and were entered into Talairach Daemon to 
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confirm their location in gray matter (Lancaster et al., 1997; Lancaster et al., 2000). 
Questionable results were further visualised by entering the original mni coordinates 
into xjview (http://www.alivelearn.net/xjview). Results are reported as their original 
mni coordinates as output by SPM12. If more than one voxel was found to be 
significant within a region without a priori interest, only the peak voxel is reported. 
Additionally, the contrast estimates from each image were analysed at the peak voxels 
to determine the direction of change between each condition analysed as significant 
decreases under one condition could still appear as increases in another condition 
even if no change in neural activity was present. 
Region of interest analyses were also carried out within regions with an a priori 
interest to our study using small volume correction (SVC) within SPM12. Volumes of 
interest were defined using WFU PickAtlas Tool (Maldjian et al., 2003) for the 
amygdala and striatum and the ventral striatum was taken from Mawlawi et al. (2001). 
Only voxels which survived FWE correction at a peak level of p <.05 are reported. 
3.3 RESULTS 
3.3.1 BEHAVIOURAL ANALYSIS 
3.3.1.1 PERFORMANCE 
On average, all subjects were able to perform the task at above chance levels (mean 
performance estimates across all trial types 0.71 ± 0.15, see Table 3.2 for estimates for 
each trial type). To assess performance, the face picked by the subject on each trial 
was compared to an ideal observer calculated based on the number of times a face 
won or would have won over the number of valid trials. Performance estimates were 
averaged separately across all neutral face trials and emotionally valenced face trials 
for each subject and are shown in Figure 3.3 and Figure 3.4.  
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TABLE 3.2 - Performance estimates across drug conditions referenced to an ideal 
observer in terms of percentage agreement 
  Emotional faces Neutral faces 
 
Difference from Chance (50%) 
   mean (SD) mean (SD) 
 
Emotional faces Neutral faces 
 Placebo 70.9% (15.7%) 68.9% (17.5%)   p>.05 p>.05   
Amisulpride 71.1% (15.1%) 67.7% (16.4%) 
 
p>.05 p>.05 
 Ropinirole 72.3% (13.5%) 67.3% (12.4%)   p>.05 p>.05   
Total 71.4% (14.6%) 67.9% (15.3%) 
           
SD = Standard deviation     
Performance is measured in terms of percentage accordance to an ideal observer. This is looked at 
separately across all blocks using emotionally valenced faces and neutral faces  and t value were 
calculated to show significant difference from chance 
 
  
FIGURE 3.3 - Performance estimates compared to an ideal observer across drug 
conditions in healthy participants when deciding between emotionally valenced faces 
where performance is compared to an ideal observer on a trial by trial basis. Each cross 





FIGURE 3.4 - Performance estimates compared to an ideal observer across drug 
conditions in healthy participants when deciding between neutral faces where 
performance is compared to an ideal observer on a trial by trial basis. Each cross 
represents the performance of a single individual and the line represents the mean 
across all subjects 
3.3.1.2 BIAS MEASURES 
The distribution of bias toward picking the happy face was found to be significantly 
different from 0 only after receiving a placebo and at a trend level after being 
administered amisulpride. No bias was observed after subjects were administered 
ropinirole however, this attenuation of bias was not significantly different from after 
receiving a placebo (t(19) = 0.828, p = 0.418). No significant biases were observed in 
the neutral condition, but, after being administered placebo, healthy controls show a 
trend level bias toward picking one of the neutral faces. 






   mean (SD) mean (SD) 
 
Emotional faces Neutral faces 
 Placebo 0.08 (0.11) -0.07 (0.18)  t(19) = 3.11, p=0.006* t(19) = 1.82, p=0.085†   
Amisulpride 0.06 (0.14) 0.05 (0.23)  t(19) = 1.94, p=0.068† t(19) = 0.867, p=0.397  
Ropinirole 0.07 (0.19) -0.02 (0.16)  t(19) = 1.59, p=0.128 t(19) = 0.60, p=0.556   
* significant at p<0.05, 
†
 trend level significance at p<0.1, SD = Standard deviation 
 
Bias estimates are estimated as the degree of bias toward picking one of the faces when the ideal 
observer supports the other face as the better option using a contingency table described on page 49. 




3.3.2 FMRI ANALYSIS 
3.3.2.1 DECISION-MAKING 
Neural activity was analysed when each of the participants made a button press to indicate 
their decision about which face they believed would be rewarded. 
3.3.2.1.1 MAIN EFFECT OF DECISION-MAKING (PLACEBO) 
Neural activity in healthy participants after taking a placebo during decision-making 
across both emotionally valenced and neutral face conditions affected a range of 
regions throughout the brain ranging from the medial frontal gyrus to the cerebellum. 
The list of regions within each decision-making condition for this task can be found in 
Table 3.4 and is pictured in Figure 3.5. 
 
FIGURE 3.5 - Neural activity for decision-making across both emotionally valenced 
and neutral faces after taking a placebo.This shows the main effect of decision-making 
within healthy participants after taking a placebo. This image is shown at an uncorrected 
height threshold of p < 0.001 with an extent threshold of 100 and only clusters surviving FWE 









3.3.2.1.2 DIFFERENCE IN NEURAL ACTIVITY BETWEEN EMOTIONALLY VALENCED 
FACES AND NEUTRAL FACES (PLACEBO) 
Neural activity in healthy participants who have taken a placebo when deciding 
between neutral faces was greater than when deciding between emotionally valenced 
faces within the right cingulate gyrus extending into the bilateral anterior cingulate, 
cuneus, the left middle occipital lobe, the right dorsolateral prefrontal cortex (dlPFC) as 
well as the right cerebellum extending through the tentorium into the fusiform and 
parahippocampal gyrus (Figure 3.6 and Table 3.4). 
 
FIGURE 3.6 - The difference in neural activity between deciding between neutral 
faces and emotionally valenced faces.Showing greater neural activity in the right cingulate 
gyrus extending into the bilateral anterior cingulate, cuneus, the left middle occipital lobe, the 
right dorsolateral prefrontal cortex (dlPFC) as well as the right cerebellum extending through 
the tentorium into the fusiform and parahippocampal gyrus for decision-making between 
neutral faces over emotionally valenced faces. This image is shown at an uncorrected height 
threshold of p < 0.001 with an extent threshold of 100 and only clusters surviving FWE cluster-











TABLE 3.4 - Neural activity during decision-making after taking a placebo 











              
 Decision (Emotional and Neutral faces) 
            
 
R Medial Frontal Gyrus* 9 
 
11 36 26 
 
9.39 <.001 <.001 42733 
  
 
L Superior Frontal Gyrus* 6 
 
1 20 56 
 
8.55 <.001 <.001 42733 
  
 
R Cingulate Gyrus* 32 
 
7 34 26 
 
9.22 <.001 <.001 42733 
  
 
L Cingulate Gyrus* 32 
 
-1 34 22 
 
8.89 <.001 <.001 42733 
  
 
R Anterior Cingulate* 24 
 
3 38 12 
 
8.54 <.001 <.001 42733 
  
 
L Precentral Gyrus* 6 
 
-31 -10 64 
 
8.96 <.001 <.001 42733 
  
 
R Precentral Gyrus* 9 
 
43 30 34 
 
8.23 <.001 <.001 42733 
  
 
L Inferior Parietal Lobule* 40 
 
-43 -36 60 
 
8.84 <.001 <.001 42733 
  
 
R Inferior Parietal Lobule* 40 
 
47 -44 54 
 
6.63 <.001 <.001 42734 
  
 
L Thalamus (LPN)* 
  
-19 -18 16 
 
8.48 <.001 <.001 42733 
  
 
R Thalamus (VLN)* 
  
19 -12 16 
 
7.16 <.001 <.001 42733 
  
 
L Lingual Gyrus* 18 
 
-7 -92 -2 
 
8.35 <.001 <.001 42733 
  
 
R Lingual Gyrus* 
  
7 -72 -12 
 
8.43 <.001 <.001 42733 
  
 
R Supramarginal Gyrus (TPJ)* 40 
 
53 -42 38 
 
7.83 <.001 <.001 42733 
  
 
L Supramarginal Gyrus (TPJ)* 40 
 
-45 -48 38 
 
6.61 <.001 <.001 42733 
  
 
R Middle Temporal Gyrus* 20 
 
57 -44 -12 
 
7.45 <.001 <.001 42733 
  
 
L Middle Temporal Gyrus* 39 
 
-27 -54 26 
 
6.89 <.001 <.001 42733 
  
 
R Lateral Globus Pallidus* 
  
29 -10 -6 
 





-27 -24 0 
 
6.90 <.001 <.001 42733 
  
 
R Precuneus* 7 
 
17 -68 54 
 
6.87 <.001 <.001 42733 
  
 
R Fusiform Gyrus 
 
 
27 -66 -14 
 
4.68 <.001 <.001 42734 
  
 
L Cerebellum (Pyramis)* 
  
-19 -80 -30 
 
















R Cerebellum (Declive)* 
  
13 -76 -18 
 
8.64 <.001 <.001 42733 
  Decision (Emotional and Neutral faces deactivation) 
      
  
   
 
R Postcentral Gyrus  3 
 
57 -10 44 
 
6.01 <.001 <.001 923 
  
 
R Precentral Gyrus  6 
 
61 2 36 
 
5.9 <.001 <.001 923 
  
 
R Postcentral Gyrus 40 
 
41 -30 54 
 
5.42 <.001 <.001 923 
  
 
R Postcentral Gyrus  2 
 
37 -24 46 
 
5.01 <.001 <.001 923 
  
 
R Postcentral Gyrus  3 
 
49 -14 56 
 
4.91 <.001 <.001 923 
  
          
 
  Decision (Neutral faces > Emotional faces) 
   
 
     
 
R Cingulate Gyrus 32 
 
5 30 28 
 
6.07 <.001 0.021 259 
  
 
L Anterior Cingulate 32 
 
-5 40 18 
 
4.73 <.001 0.021 259 
  
 
R Anterior Cingulate 32 
 
11 40 14 
 
4.09 <.001 0.021 259 
  
 
L Cuneus 18 
 
1 -82 24 
 
5.25 <.001 0.013 290 
  
 
L Cuneus 17 
 
-13 -82 16 
 
4.63 <.001 0.013 290 
  
 
L Cuneus 18 
 
-13 -88 20 
 
4.35 <.001 0.013 290 
  
 
R Cuneus 18 
 
7 -88 20 
 
4.11 <.001 0.013 290 
  
 
R Cuneus 17 
 
11 -92 16 
 
3.82 0.001 0.013 290 
  
 
L Middle Occipital Gyrus 18 
 
-9 -94 18 
 
4.83 <.001 0.013 290 
  
 
L Middle Occipital Gyrus 18 
 
-19 -94 20 
 
4.81 <.001 0.013 290 
  
 
L Middle Occipital Gyrus 18 
 
-25 -90 20 
 
4.72 <.001 0.013 290 
  
 
R Middle Frontal Gyrus (dlPFC) 9 
 
45 32 20 
 
4.72 <.001 0.038 222 
  
 
R Middle Frontal Gyrus (dlPFC) 9 
 
53 34 26 
 
3.95 <.001 0.038 222 
  
 
R Fusiform Gyrus/Parahippocampal Gyrus 37 
 
27 -46 -14 
 
3.59 0.001 0.021 261 
  
 
R Cerebellum (Culmen) 
  
25 -44 -24 
 
4.51 <.001 0.021 261 
  
 
R Cerebellum (Declive) 
  
41 -64 -24 
 
















R Cerebellum (Uvula) 
  
37 -72 -24 
 
4.03 <.001 0.021 261 
  
     
   
 
    
  
Corresponding coordinates for each brain region listed represent the peak voxels for each corresponding region within each significant cluster. All 
areas reported were found to be significant at a family wise error (FWE) cluster level corrected threshold of <.05 after running a whole brain analysis 





3.3.2.1.3 DECISION-MAKING IN PLACEBO VERSUS ROPINIROLE 
3.3.2.1.3.1 MAIN EFFECT OF DECISION-MAKING ACROSS EMOTIONALLY VALENCED 
AND NEUTRAL FACES (ROPINIROLE VERSUS PLACEBO) 
When deciding which face is most likely to be rewarded between two emotionally 
valenced faces and two neutral faces, healthy controls show no differences in neural 
activity between when they have taken a placebo versus after they have taken 
ropinirole.  
3.3.2.1.3.2 DECISION-MAKING BETWEEN EMOTIONALLY VALENCED FACES 
(ROPINIROLE VERSUS PLACEBO) 
When deciding which of two emotionally valenced faces was most likely to be 
rewarded, healthy controls showed greater neural activity after being administered 
ropinirole versus a placebo in the left dorsal anterior cingulate (dACC) extending into 
the bilateral cingulate gyrus and left dorsomedial prefrontal cortex (dmPFC) (Figure 3.7 
and Table 3.5).  
 
FIGURE 3.7 - Neural activity after being administered ropinirole over a placebo when 
deciding between two emotionally valenced facesThis image is shown at an uncorrected 
height threshold of p < 0.005 with an extent threshold of 100 and only clusters surviving FWE 









Furthermore, as the amygdala is an area often implicated in emotional processing 
(Adolphs, 2010; Dyck et al., 2011), a region of interest (ROI) analysis using small 
volume correction (SVC) was performed within a mask for the right and left amygdala. 
Neural activity was significantly attenuated after ropinirole administration over 
placebo administration in the right amygdala (peak, x = 33, y = 0, z = -28), t(19) = 4.02, 
p = 0.014, k = 32, with p representing the significance at FWE peak level correction, 
when looking at neural activity during decision-making between two emotionally 
valenced (Figure 3.8 and Table 3.5). 
 
FIGURE 3.8 - Neural activity after being administered ropinirole over a placebo when 
deciding between two emotionally valenced facesThis image is shown at an uncorrected 
height threshold of p < 0.005 with all peaks surviving FWE cluster-level correction of p < 0.05 
As bias was also attenuated after the administration of ropinirole, mean values from 
within the cluster found in the dmPFC and dACC were extracted using 
spm_summarise() to see if attenuation was driven by the changes in neural activity 
within these regions. Although the change in bias measures did not correlate with the 








administration for each participant (r = 0.34, p = 0.133 (two-tailed)). However, the bias 
measurements after placebo administration were strongly negatively correlated with 
the change in neural activity between the two drug conditions (r = -0.71, p < 0.001), 
suggesting that initial bias measures may have influenced how much each participant 
was influenced by ropinirole in this region. Furthermore, bias measures after receiving 
placebo also correlated with neural activity after receiving a placebo in this region (r = 
0.45, p = 0.047) suggesting that the mean neural activity was increased across all 
subjects regardless of their original bias measures after being administered ropinirole 
compared to a placebo and that those with stronger biases exhibited generally higher 
levels of neural activity in this region after placebo administration.  
3.3.2.1.3.3 DECISION-MAKING BETWEEN NEUTRAL FACES (ROPINIROLE VERSUS 
PLACEBO) 
When deciding which face is most likely to be rewarded between two neutral faces, 
healthy controls show no differences in neural activity between when they have taken 
a placebo versus after they have taken ropinirole. 
3.3.2.1.3.4 INTERACTION EFFECTS FOR DECISION-MAKING BETWEEN EMOTIONALLY 
VALENCED AND NEUTRAL FACES (ROPINIROLE VERSUS PLACEBO) 
When looking for any interaction effects between decision-making in the emotionally 
valenced faces compared to the neutral faces after receiving placebo and ropinirole, 
no significant differences were found in neural activity at a whole brain level. However 
after a region of interest (ROI) analysis using small volume correction (SVC) was 
performed within a mask for the left and right amygdala. There was a significant 
interaction effect in the right amygdala (x = 33, y = 2, z = -26), t(76) = 3.63, p = 0.008, k 
= 26, and a trend toward significance in the left amygdala (x = -27, y = 2, z = -24), t(76) 
= 2.66, p = 0.082, k = 1, with p representing the significance at FWE peak level 
correction, when comparing the interaction between drug (placebo versus ropinirole) 
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and emotion (emotionally valenced versus neutral faces) (Figure 3.9 and Table 3.5). 
This effect was found to be driven by a stronger decrease in neural activity within the 
amygdala after being administered ropinirole than placebo (Figure 3.10) and was 
mainly driven by a difference in neural activity when deciding between emotionally 
valenced faces as demonstrated on page 79. 
 
FIGURE 3.9 - Neural activity for interaction effects between drug conditions (placebo 
versus ropinirole) and emotion (emotionally valenced versus neutral faces) This image 
is shown at an uncorrected height threshold of p < 0.005 with all peaks surviving FWE cluster-
level correction of p < 0.05 
 
FIGURE 3.10 - Contrast estimates within the right amygdala showing interaction 
effects for drug (placebo versus ropinirole) by emotion (emotionally valenced versus 
neutral faces). This image shows that there is a significant attenuation of neural activity in 
the amygdala by ropinirole when processing emotional faces which is slightly greater than 












Side Brain Regions BA 
 
















(Emotional faces)  
L Cingulate Gyrus 32 
 
-11 24 30 
 
5.80 <.001 0.004 887 1.88 
 
  
R Cingulate Gyrus 32 
 
5 32 24 
 
5.14 <.001 0.004 887 1.67 
 
  
R Cingulate Gyrus 24 
 
7 16 28 
 
4.54 <.001 0.004 887 1.47 
 
   
L Anterior Cingulate 32 
 
-3 36 20 
 
3.76 0.001 0.004 887 1.22 
 
   
L Anterior Cingulate 33 
 
1 16 20 
 
3.67 0.001 0.004 887 1.19 
 
   
L Medial Frontal Gyrus (dmPFC) 32 
 
-9 20 42 
 
3.80 0.001 0.004 887 1.23 
 
   
L Medial Frontal Gyrus (dmPFC) 6 
 
-19 36 32 
 
3.38 0.002 0.004 887 1.10 
 
   
L Medial Frontal Gyrus 6 
 
-13 14 50 
 
3.11 0.003 0.004 887 1.01 
 









33 0 -28 
 
4.02 <.001 0.014* 32 1.30 
 





33 -2 -24 
 
3.88 0.001 0.018* 32 1.26 
 





29 -4 -20 
 
3.47 0.001 0.038* 32 1.13 
 
                 
Drug (Ropinirole x Placebo) x 







33 2 -26 
 







-27 2 -24 
 
2.66 0.005 0.082* 1 0.86 
 
                 
Corresponding coordinates for each brain region listed represent the peak voxels for each corresponding region within each significant cluster. All areas reported were found 
to be significant at a family wise error cluster level corrected threshold of <.05 after running a whole brain analysis at an uncorrected threshold of p<.005. *values for peak 
level FWE correction using small volume correction 
a
areas looked at using small volume correction; k = cluster size BA  = Brodmann’s Area 





3.3.2.1.4 DECISION-MAKING IN PLACEBO VERSUS AMISULPRIDE 
3.3.2.1.4.1 MAIN EFFECT OF DECISION-MAKING ACROSS EMOTIONALLY VALENCED 
AND NEUTRAL FACES (AMISULPRIDE VERSUS PLACEBO) 
When deciding which face is most likely to be rewarded between two emotionally 
valenced faces and two neutral faces, healthy controls showed no differences in neural 
activity between when they have taken a placebo versus after they have taken 
amisulpride. 
3.3.2.1.4.2 DECISION-MAKING BETWEEN EMOTIONALLY VALENCED FACES 
(AMISULPRIDE VERSUS PLACEBO) 
When deciding which face is most likely to be rewarded between two emotionally 
valenced faces, healthy controls showed no differences in neural activity between 
when they have taken a placebo versus after they have taken amisulpride.  
3.3.2.1.4.3 DECISION-MAKING BETWEEN NEUTRAL FACES (AMISULPRIDE VERSUS 
PLACEBO) 
When deciding which face is most likely to be rewarded between two neutral faces, 
healthy controls showed greater neural activity in the bilateral cerebellum extending 
through the tentorium into the right parahippocampal gyrus, lingual gyrus and 
fusiform gyrus for placebo administration relative to amisulpride administration (Table 




FIGURE 3.11 - Neural activity for placebo versus amisulpride when choosing between 
neutral faces showing attenuated neural activity in the bilateral cerebellum and through the 
tentorium into the right fusiform gyrus after amisulpride administration. This image is shown 
at an uncorrected height threshold of p < 0.005 with all peaks surviving FWE cluster-level 
correction of p < 0.05 and an extent threshold of k = 100. 
3.3.2.1.4.4 INTERACTION EFFECTS FOR DECISION-MAKING BETWEEN EMOTIONALLY 
VALENCED AND NEUTRAL FACES (AMISULPRIDE VERSUS PLACEBO) 
When looking for any interaction effects between decision-making for drug 
(amisulpride versus placebo) by emotion (emotionally valenced versus neutral faces), 
no significant differences were found in neural activity at a whole brain level. An ROI 
analysis using SVC was carried out in the left and right amygdala however, only a trend 
toward significance was found in the left amygdala at (x = -27, y = 2, z = -24), t(76) = 
2.72, p = 0.071, k = 2, with p representing the significance at FWE peak level correction, 
when comparing the interaction between emotional and neutral stimuli between 




FIGURE 3.12 - Contrast estimates within the left amygdala showing interaction effects 
for (placebo versus amisulpride) by emotion (emotionally valenced versus neutral 
faces). This image shows that there is a trend toward a significant interaction effect of drug by 
emotion on neural activity in the amygdala for amisulpride when processing emotional faces 
which is slightly greater than activity compared to the placebo condition when deciding 





TABLE 3.6 - Difference in neural activity for placebo versus amisulpride administration during decision-making 











               
Placebo > Amisulpride Decision 
(Neutral faces) 
R Parahippocampal Gyrus 37 
 
29 -50 -12 
 
3.85 0.001 <.001 1656 1.25 
R Lingual Gyrus 18 
 
5 -74 -4 
 
3.86 0.001 <.001 1656 1.25 
R Fusiform/Lingual Gyrus 
  
21 -70 -12 
 
3.43 0.001 <.001 1656 1.11 
  
R Fusiform Gyrus 37 
 
47 -58 -22 
 




-15 -44 -26 
 




-13 -60 -22 
 
5.16 <.001 <.001 1656 1.67 
  
L Cerebellum (Cerebellar Tonsil) 
  
-19 -38 -36 
 
4.10 <.001 <.001 1656 1.33 
  
L Cerebellum (Culmen) 
  
-21 -32 -26 
 
3.58 0.001 <.001 1656 1.16 
  
R Cerebellum (Culmen) 
  
21 -46 -24 
 
5.66 <.001 <.001 1656 1.84 
  
R Cerebellum (Culmen) 
  
3 -54 -24 
 
3.77 0.001 <.001 1656 1.22 
  
R Cerebellum (Pyramis) 
  
31 -78 -28 
 
4.43 <.001 <.001 1656 1.44 
  
R Cerebellum (Pyramis) 
  
11 -82 -24 
 
3.56 0.001 <.001 1656 1.16 
  
R Cerebellum (Uvula) 
  
37 -72 -24 
 
4.05 <.001 <.001 1656 1.31 
  
R Cerebellum (Declive) 
  
7 -80 -22 
 
3.65 0.001 <.001 1656 1.18 
  
R Cerebellum (Declive) 
  
15 -68 -18 
 
3.59 0.001 <.001 1656 1.16 
  
R Cerebellum (Declive) 
  
7 -70 -12 
 
3.56 0.001 <.001 1656 1.16 
   
            
Drug (Amisulpride x Placebo) x Emotion 









 2 0.88 
             
               Corresponding coordinates for each brain region listed for peak voxels for each corresponding region within each significant cluster. All areas reported were found to be significant at 
a family wise error cluster level corrected threshold of <.05 after running a whole brain analysis at an uncorrected threshold of p<.005; k = cluster size BA  = Brodmann’s Area 
*values for peak level FWE correction using small volume correction; 
a
areas looked at using small volume correction; 





3.3.2.2 REWARD PREDICTION ERROR (RPE) 
3.3.2.2.1 MAIN EFFECT OF RPE (PLACEBO) 
Neural activity after being given a placebo correlating with RPE activated two 
significant clusters bilaterally in occipital cortex extending into the bilateral fusiform 
gyrus, left cuneus, right precuneus, and bilateral cerebellum (Figure 3.13 and Table 
3.7).  
As previous studies have shown RPE to correlate with neural activity in the striatum 
and ventral striatum (Jocham et al., 2011; Pessiglione et al., 2006), an ROI analysis 
using SVC was carried out in these regions however, no significant neural activity was 
found. 
  
FIGURE 3.13 - Neural activity after receiving placebo correlating with RPE. showing 
increased neural activity in the bilateral occipital cortex extending through the tentorium into 
the fusiform gyrus, cerebellum, left cuneus and right precuneus. This image is shown at an 
uncorrected height threshold of p < 0.001 with an extent threshold of 100 showing only 
clusters surviving FWE cluster-level correction of p < 0.05 
3.3.2.2.2 EFFECT OF EMOTION ON RPE (PLACEBO) 
When looking at the differences in neural activity for RPE between when deciding 
between emotionally valenced faces versus neutral faces, healthy controls who have 
taken a placebo show no differences in neural activity even after SVC in the striatum 







TABLE 3.7 - Neural activation correlating with RPE after receiving placebo 





k effect size 
  
               RPE (Emotional and Neutral faces) 
           
 
L Cuneus* 17 
 
-13 -100 2 
 
7.91 <.001 <.001 2604 2.57 
 
 
L Middle Occipital Gyrus* 
  
-29 -94 6 
 
7.79 <.001 <.001 2604 2.53 
 
 
L Middle Occipital Gyrus* 18 
 
-27 -88 14 
 
6.96 <.001 <.001 2604 2.26 
 
 
R Middle Occipital Gyrus* 19 
 
29 -90 12 
 
6.44 <.001 <.001 2660 2.09 
 
 
R Middle Occipital Gyrus 18 
 
37 -90 2 
 
5.59 <.001 <.001 2660 1.81 
 
 
R Inferior Occipital Gyrus* 17 
 
15 -92 -2 
 
7.78 <.001 <.001 2660 2.52 
 
 
R Inferior Occipital Gyrus 18 
 
35 -92 -2 
 
5.67 <.001 <.001 2660 1.84 
 
 
L Fusiform Gyrus* 37 
 
-49 -60 -12 
 
7.18 <.001 <.001 2604 2.33 
 
 
R Fusiform Gyrus 19 
 
39 -82 -8 
 
5.20 <.001 <.001 2660 1.69 
 
 
R Fusiform Gyrus 37 
 
43 -62 -14 
 
5.07 <.001 <.001 2660 1.64 
 
 
R Fusiform Gyrus 37 
 
55 -48 -14 
 
3.91 <.001 <.001 2660 1.27 
 
 
R Superior Parietal Lobule 7 
 
27 -60 50 
 
5.35 <.001 <.001 2660 1.74 
 
 
R Precuneus 7 
 
29 -64 44 
 
4.93 <.001 <.001 2660 1.60 
 
 
R Precuneus 31 
 
29 -72 22 
 
4.27 <.001 <.001 2660 1.39 
 
 
R Precuneus 31 
 
29 -68 30 
 
4.22 <.001 <.001 2660 1.37 
 
 
L Cerebellum (Declive)* 
  
-21 -86 -14 
 
7.15 <.001 <.001 2604 2.32 
 
 
L Cerebellum (Declive) 
  
-39 -72 -14 
 
5.36 <.001 <.001 2604 1.74 
 
 
R Cerebellum (Declive) 
  
25 -78 -12 
 
5.83 <.001 <.001 2660 1.89 
 
 
R Cerebellum (Declive) 
  
19 -80 -14 
 
5.76 <.001 <.001 2660 1.87 
 
 
   
 
   
 
    
  RPE (Emotional > Neutral faces) 
 
 
   
 
    
  
 
no significant voxels 
 
 
   
 









k effect size 
  
   
 
 
   
 
    
                 
RPE (Emotional < Neutral faces) 
 
 
   
 
    
  
 
no significant voxels 
 
 
   
 
    
                                
Corresponding coordinates for each brain region listed represent the peak voxels for each corresponding region within each significant cluster. 
All areas reported were found to be significant at a family wise error cluster level corrected threshold of <.05 after running a whole brain 
analysis at an uncorrected threshold of p<.001; k = cluster size; BA = Brodmann’s Area 




3.3.2.2.3 RPE FOR ROPINIROLE VERSUS PLACEBO 
3.3.2.2.3.1 RPE FOR EMOTIONALLY VALENCED AND NEUTRAL FACES (ROPINIROLE 
VERSUS PLACEBO) 
When looking at differences in neural activity correlating with RPE after placebo versus 
ropinirole administration across both blocks including both emotionally valenced faces 
and neutral faces, no differences in neural activity were observed even after using SVC 
within the striatum and ventral striatum.  
3.3.2.2.3.2  RPE FOR EMOTIONALLY VALENCED FACES (ROPINIROLE VERSUS PLACEBO) 
When looking at differences in neural activity correlating with RPE after placebo versus 
ropinirole administration across blocks including emotionally valenced faces, no 
differences in neural activity were observed even after using SVC within the striatum 
and ventral striatum.  
3.3.2.2.3.3  RPE FOR NEUTRAL FACES (ROPINIROLE VERSUS PLACEBO) 
When looking at differences in neural activity correlating with RPE after placebo versus 
ropinirole administration across blocks including neutral faces, no differences in neural 
activity were observed even after using SVC within the striatum and ventral striatum.  
3.3.2.2.3.4 RPE FOR INTERACTION BETWEEN EMOTIONALLY VALENCED AND NEUTRAL 
FACES AND DRUG (ROPINIROLE VERSUS PLACEBO) 
When looking at interaction effects for neural activity correlating with RPE between 
blocks including emotionally valenced faces and neutral faces after placebo 
administration and ropinirole administration, no differences in neural activity were 
observed even after using SVC within the striatum and ventral striatum.  
3.3.2.2.4 RPE FOR AMISULPRIDE VERSUS PLACEBO 
3.3.2.2.4.1 RPE FOR EMOTIONALLY VALENCED AND NEUTRAL FACES (AMISULPRIDE 
VERSUS PLACEBO) 
When looking at differences in neural activity correlating with RPE after placebo versus 
amisulpride administration across both blocks including both emotionally valenced 
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faces and neutral faces, no differences in neural activity were observed even after 
using SVC within the striatum and ventral striatum.  
3.3.2.2.4.2  RPE FOR EMOTIONALLY VALENCED FACES (AMISULPRIDE VERSUS 
PLACEBO) 
When looking at differences in neural activity correlating with RPE across blocks 
including emotionally valenced faces after placebo and amisulpride administration, no 
differences in neural activity were observed even after using SVC within the striatum 
and ventral striatum.  
3.3.2.2.4.3  RPE FOR NEUTRAL FACES (AMISULPRIDE VERSUS PLACEBO) 
When looking at differences in neural activity correlating with RPE across blocks 
including neutral faces after placebo administration versus amisulpride administration, 
an increase in neural activity after amisulpride administration relative to placebo 
administration is observed in the bilateral vmPFC extending to dmPFC (Figure 3.14 and 
TABLE 3.8). An ROI analysis using SVC was also carried out in the striatum and ventral 
striatum however, however, no significant neural activity was found. 
 
FIGURE 3.14 - Neural activity correlating with RPE when looking at amisulpride versus 
placebo administration when deciding between two neutral faces This image is shown 
at an uncorrected height threshold of p < 0.001 with an extent threshold of 100 and only 








3.3.2.2.4.4 RPE FOR INTERACTION BETWEEN EMOTIONALLY VALENCED AND NEUTRAL 
FACES AND DRUG (AMISULPRIDE VERSUS PLACEBO) 
When looking at differences in neural activity correlating with RPE between blocks 
including emotionally valenced faces and neutral faces after placebo administration 
and amisulpride administration, no differences in neural activity were observed even 
after using SVC within the striatum and ventral striatum.  
TABLE 3.8 - Neural activity correlating with RPE for amisulpride versus placebo 













              RPE (Neutral faces) 
           Placebo < Amisulpride 
         
 
L SFG (vmPFC) 10 
 
-21 58 20 
 
4.91 <.001 0.041 909 1.59 
 
L SFG (vmPFC) 10 
 
-13 66 14 
 
3.33 0.002 0.041 909 1.08 
 
R SFG 6 
 
13 42 50 
 
3.77 0.001 0.041 909 1.22 
 
R SFG (dmPFC) 8 
 
11 48 46 
 
3.18 0.002 0.041 909 1.03 
 
L MFG (dmPFC) 9 
 
-3 56 20 
 
4.53 <.001 0.041 909 1.47 
 
L MFG (dmPFC) 9 
 
1 52 24 
 
4.40 <.001 0.041 909 1.43 
 
R MFG (dmPFC) 8 
 
11 48 36 
 
4.50 <.001 0.041 909 1.46 
              Corresponding coordinates for each brain region listed represent the peak voxels for each 
corresponding region within each significant cluster. All areas reported were found to be significant at 
a family wise error cluster level corrected threshold of <.05 after running a whole brain analysis at an 
uncorrected threshold of p<.005. SFG = Superior Frontal Gyrus; MFG  = Medial Frontal Gyrus; vmPFC = 
ventral medial prefrontal cortex; dmPFC = dorsomedial prefrontal cortex; BA = Brodmann’s Area; k = 
cluster size 
Effect size is calculated using Cohen’s d 
3.4 DISCUSSION  
This chapter explores the effect of dopaminergic manipulation on decision-making in 
an associative learning task in healthy individuals using emotionally valenced and 
neutral faces as social variables. Our findings demonstrate that the bias toward 
selecting the positively valenced emotional faces (i.e. happy faces) can be attenuated 
using dopamine perturbation by both ropinirole and amisulpride and that, after 
receiving ropinirole, this attenuation is accompanied by increased neural activity 
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within the dmPFC and dACC, areas suggested to be involved in appraisal (Maier et al., 
2012) and emotional processing (Phan et al., 2002a) as well as being a target of D2 
binding during executive decision-making (Ko et al., 2009; Lumme et al., 2006). There is 
also an attenuation of neural activity within the amygdala, a region associated with 
emotional processing (Costafreda et al., 2008; Pessoa and Adolphs, 2010; Sergerie et 
al., 2008) and part of the mesolimbic dopamine pathway (Koob and Swerdlow, 1988). 
This suggests that dopamine may act to attenuate bias by increasing conflict 
monitoring while attenuating the biological significance of emotional stimuli.  
As predicted, healthy individuals were able to perform this task significantly above 
chance across all drug conditions and, after being administered a placebo, subjects 
demonstrated the same bias as previously shown toward picking the happy face even 
when evidence supported the angry face as the more optimal choice (Averbeck and 
Duchaine, 2009; Evans et al., 2011a; Furl et al., 2012). As expected, dopamine 
perturbation had a mitigating effect on the degree of bias exhibited toward the happy 
face such that, after being administered amisulpride, this bias was attenuated to only 
trend level significance and, after receiving ropinirole, this bias was completely 
attenuated so that subjects demonstrated no preference for choosing either the happy 
or angry face. Although performance was not significantly enhanced by either drug 
relative to a placebo, the attenuation of a significant bias toward either face 
demonstrates that both drugs were able to aid subjects to perform more in line with 
an ideal observer without being biased by emotionally valence suggesting that 
dopaminergic perturbation may affect behaviour by potentially reducing the social 
salience of emotionally valenced faces. 
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This is further supported by the finding that, while deciding between emotional faces, 
ropinirole attenuated neural activity in the amygdala, an area shown to be involved in 
emotional processing, especially in regard to facial expression (Costafreda et al., 2008; 
Pessoa and Adolphs, 2010; Sergerie et al., 2008) and is also considered a major target 
of midbrain dopaminergic neurons (Fried et al., 2001). One suggestion for the 
amygdala’s involvement in emotional processing is that it is involved in determining 
the biological significance of emotional stimuli such that more behaviourally relevant 
stimuli increase the neural response of the amygdala (Pessoa and Adolphs, 2010). 
Attenuation of the amygdala in this task may show that subjects are able to recognise 
that the stimuli are not behaviourally relevant and are able to dissociate the 
probabilities of each face being associated with a win during decision-making from the 
social and emotional valence of each image.  
Furthermore, this attenuation of bias after receiving ropinirole was accompanied by an 
increase in neural activity within the dmPFC and dACC. In addition to being a target of 
dopamine (Paus, 2001), the ACC has been shown to help track reward and choice 
outcome (Holroyd and Coles, 2002), is important in conflict monitoring (Botvinick, 
2007) and, along with the dmPFC, aids in action and outcome monitoring (Matsumoto 
et al., 2007; Walton et al., 2004), appraisal (Maier et al., 2012) and emotional 
processing (Phan et al., 2002a). Additionally, the dACC has been shown to be a target 
of D2 binding during executive decision-making (Ko et al., 2009; Lumme et al.) as an 
area of output from the mesolimbic dopamine pathway (Vogt and Gabriel, 1993). As 
dopamine, the dACC and the dmPFC are related to reward related learning, 
dopaminergic manipulation may affect reward related behaviour and reinforcement 
learning through increasing neural activity in these regions. Increases in D2 dopamine 
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should lead to higher performance on reinforcement learning tasks where more action 
contingencies are recognised and reinforced by dopamine while decreases in 
dopamine should have a negative effect on learning action contingencies through 
depleted neural activity. This has been demonstrated in rats where, after being given 
dopamine antagonists, they have difficulty linking rewards to certain behaviours 
(Parkinson et al., 2002) while dopamine agonists help in the “stamping in” of reward 
contingencies (Wise, 2004). In this task, augmented activity in the dACC and dmPFC 
after ropinirole administration compared to placebo administration when deciding 
which was the most rewarding face between two emotional faces may be indicative 
that increases in dopamine also increases sensitivity to reward contingencies without 
regard to emotional salience and enhances conflict monitoring coupled with these 
associations.  
To test the association between bias and neural activity, mean neural activity within 
the dACC and dmPFC which showed significantly greater neural activity after ropinirole 
administration compared to a placebo was extracted and compared to the bias 
measures. Change in bias was not found to correlate with the change in neural activity 
within this region, however, baseline bias, measured as bias without dopaminergic 
perturbation (i.e. after placebo administration), was found to positively correlate with 
baseline neural activity when deciding between two emotionally valenced faces as well 
as negatively correlating with the change in neural activity after ropinirole 
administration. This suggests that those with greater degrees of baseline bias exhibit 
higher levels of neural activity within the dACC/dmPFC and that they also show less 
change in neural activity after ropinirole administration. Meaning, those with less 
baseline bias exhibit higher neural activity after ropinirole administration albeit 
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without an accompanying change in bias. It is also possible that no change in neural 
activity was seen in some participants after taking ropinirole as those with already high 
levels of neural activity in the placebo condition had already reached a peak in their 
neural activity so that no amount of perturbation could cause an increase in neural 
activity. Interestingly, bias measures in the ropinirole condition did not correlate with 
neural activity suggesting that this increase in neural activity happened independent of 
bias and change in bias and suggests a general increase in conflict monitoring and 
appraisal after ropinirole administration.  
Another interesting finding in this study was that when deciding between two neutral 
faces amisulpride attenuated activity in the bilateral cerebellum extending through the 
tentorium into the right fusiform gyrus and right parahippocampal gyrus compared to 
a placebo when deciding which face is more likely to be rewarded between two 
neutral faces. The fusiform gyrus has been shown to be an important area in the 
implicit processing and identification of faces (Fairhall and Ishai, 2007; Grill-Spector et 
al., 2004; Haxby et al., 2000; McCarthy et al., 1997c), and the cerebellum has also been 
found to be involved in social processing (Van Overwalle et al., 2014). Greater 
activation of these regions when deciding between two neutral faces but not when 
deciding between two emotional faces in the placebo condition may be indicative of 
participants recruiting areas more selective to the identification of the face rather than 
its emotion or either a decrease in attention toward emotionally valenced faces. This is 
further supported by the fact that when just looking within the placebo condition 
during decision-making between neutral faces, the right fusiform gyrus is also more 
active than when deciding between emotionally valenced faces and, in our previous 
study looking at only emotional faces, this area was not significantly activated (Evans 
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et al., 2011a), thus supporting a role more closely tied to facial identification than 
emotional processing.  
Although our study did not find any correlation between neural activity and RPE within 
the ventral striatum based on an ideal observer, this may be because our models did 
not incorporate values that take into account inherent behavioural biases such as the 
social salience of faces and the natural discounting of trials further in the past. The 
model used only looked at optimal performance that would only have been feasible 
with perfect memory retention and no bias toward emotionally valenced faces. 
Meaning, this model did not take into account behaviourally mitigating factors such as 
how choosing a happy face may have provided its own implicit reward as suggested by 
previous studies (Averbeck and Duchaine, 2009; Evans et al., 2011a). The ideal 
observer implemented in this study assumes that participants will learn from positive 
feedback and negative feedback equally to adjust their decisions. Although the 
difference between feedback and expected reward seem to affect areas tied to 
dopamine (Glimcher, 2011), learning from positive and negative feedback appears to 
take place in disparate areas of the brain (Zanolie et al., 2008) and subjects are not 
able to integrate negative feedback as well as positive feedback (Pessiglione et al., 
2006). All other studies exploring the neural effects of dopaminergic manipulation so 
far have made use of more sophisticated models of behaviour using algorithms such as 
Q-learning. Despite the ability of our participants to correspond with the ideal 
observer over a substantial number of trials, to confirm if reward had similar effects as 
other studies in our experiment, it may be helpful to explore different ways to model 
how subjects made their decisions. However, the goal of this work was to show how 
general reward associations may affect neural activity so the RPE calculations were 
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designed to be simple reward associations. Additionally, as a fairly strict preprocessing 
routine was implemented, small dropout within regions of the ventral striatum were 
observed outside of the final mask thus we cannot rule out that perhaps the signal of 
those regions most affected by our RPE were not picked up by the imaging paradigm 
implemented. 
Although it was hypothesised that ropinirole and amisulpride would act on neural 
activity in opposing directions especially within the ACC during decision-making and 
the striatum when processing reward, only ropinirole showed a significant difference 
to placebo in a region of the ACC when deciding between two emotionally valenced 
faces. Unexpectedly, neither drug appeared to have an effect on RPE compared to a 
placebo. In previous studies, dopamine has also been shown to have differential 
effects on a variety of subjects based on their baseline levels of performance where 
dopamine has an inverted U effect on cognition (Cools and D'Esposito, 2011; Gjedde et 
al., 2010; Monte-Silva et al., 2009). Participants who perform well at baseline will 
perform worse if dopamine is altered too much in either direction while participants 
who perform poorly at baseline will improve with dopamine agonists. However, if 
dopamine is increased too much, this performance will degrade once again. It is 
possible that manipulating dopamine in our subjects had differential effects on their 
location in this inverted U curve, such that, for some participants, dopamine 
antagonists had beneficial effects over performance while, for others, dopamine 
agonists enhanced performance. Thus the lack of significant findings may be explained 




This study was limited by the fact that the concentration of dopamine was not 
standardised to each person. Dopamine agonists and antagonists were given as fixed 
doses at fixed intervals to all individuals in the study but, due to individual variances in 
size age and metabolism, each drug may have affected some more than others. 
Furthermore levels within the bloodstream have also been shown to be affected by fat 
content consumed throughout the day. Although care was taken to provide our 
subjects with qualitatively similar low-fat meals while they were at the institute and 
instructions were given for appropriate meals on the testing day, it was not possible to 
control what they had eaten before they attended the testing session. Therefore some 
of the peak concentrations of some individuals may have been different than for 
others. Additionally, plasma levels were not recorded so it is impossible to tell how 
affected each individual was by the dopamine perturbation. Future work could benefit 
from recording individual plasma concentrations throughout the day and dosing each 
participant accordingly to ensure that each participant received a standardised dose of 
medication dependent on their weight. 
In theory, administering dopamine agonists should increase the amount of dopamine 
available in the synapses and thus increase sensitivity to reward, however this is not 
what all studies have shown. An increasing number of studies report conflicting 
findings for the mediating effects of dopaminergic manipulation on neural activity. 
Where some studies report increases in RPE responses in the striatum after 
administering dopamine agonists and a decrease from dopamine antagonists 
(Pessiglione et al., 2006), others report increases in the striatum correlating with RPE 
after giving a dopamine antagonist (Jocham et al., 2011). Furthermore, in one study, 
treatment with an antagonist in addition to an agonist, did not change the effect of the 
101 
 
dopamine agonist on RPE (Bernacer et al., 2013). These studies show that the effects 
of dopaminergic manipulation on neural activity is still not well understood and can 
have a range of effects. Two lines of reasoning prevail when looking at why differential 
effects may be observed when administering dopamine agonists and antagonists in 
different studies. The first complication arises from the presence of autoreceptors or 
receptors which are capable of providing their own negative feedback without further 
neurochemical perturbation along the neuron and act to control the synthesis and 
release of neurotransmitters, such as dopamine, mainly in the nigrostriatal and 
mesolimbic systems (Meltzer, 1980). Autoreceptors are capable of reducing phasic 
dopamine release through inhibitory feedback (Fasano et al., 2010; Grace, 1991) and 
are aided by dopamine’s increased affinity for presynaptic receptors over postsynaptic 
receptors (Nemeroff, 2004). In line with this, previous studies have demonstrated how 
low doses of dopamine agonists can inhibit reinforcement learning (Pizzagalli et al., 
2008; Santesso et al., 2009) and reduce phasic dopamine release (Schmitz et al., 2003; 
Tissari et al., 1983). Although autoreceptors are mainly reported to be affected by 
dopamine agonists, studies using dopamine antagonists have also reported that they 
had an effect on neural activity. This was demonstrated by one study using low doses 
of amisulpride also purported that the presence of autoreceptors acted to augment 
neural activity in the striatum in response to reward prediction error (Jocham et al., 
2011). The second line of reasoning is that dopamine has differential effects on 
individuals based on their baseline levels of dopamine availability such that the 
administration of dopamine agonists and antagonists creates an inverted U effect on 
cognition (Cools and D'Esposito, 2011; Monte-Silva et al., 2009) where alterations in 
dopamine that oversaturate the system lead to similar deficits observed when 
dopamine is under-saturated in the synapses. Therefore, administration of dopamine 
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agonists may increase the presence of autoreceptors which act to attenuate the 
dopaminergic response or dopamine agonists could be oversaturating dopamine 
release in the synapses leading to similar performance and neural activation as seen 
with dopamine antagonists and the inverse could be true for dopamine antagonists. 
Overall, this study showed that healthy participants who have been administered both 
ropinirole and amisulpride show changes in both behaviour and neural activity 
reflected by an attenuation of bias toward choosing a happy face. This was 
accompanied by an increase in neural activity within the dACC/dmPFC after ropinirole 
administration indicative of an increase in conflict monitoring and a decrease in neural 
activity in the amygdala indicative of a decrease in the attribution of biological 
significance toward the emotional faces. After amisulpride administration, healthy 
participants demonstrate an attenuation of neural activity in the cerebellum extending 
through the tentorium into the right fusiform gyrus but only when deciding between 




CHAPTER 4 -  THE NEURAL CORRELATES OF DECISION-
MAKING DURING AN ASSOCIATIVE LEARNING TASK WITH A 
SOCIAL COMPONENT –  IN PATIENTS WITH SCHIZOPHRENIA 
 BACKGROUND 4.1
Patients with schizophrenia show aberrant patterns of neural activation across a range 
of cognitive tasks from executive functioning (Minzenberg et al., 2009), decision-
making (Paulus et al., 2002; Rausch et al., 2014), processing of emotional faces (Gur et 
al., 2002; Takahashi et al., 2004) to viewing and encoding reward (Gradin et al., 2011; 
Murray et al., 2008; Nielsen et al., 2012), compared to healthy controls. These 
differences are apparent even when controlling for medication effects (Sugranyes et 
al., 2011). Although most of these tasks show diminished neural activity, a number of 
studies in patients with schizophrenia also show increased neural activity in neural 
areas relating to decision-making, emotional and reward processing (Dyck et al., 2014; 
Thormodsen et al., 2011). Furthermore, aberrant neural activity in patients with 
schizophrenia, both as increases and decreases, has been found despite similar 
behavioural task performance as controls, particularly in tasks looking at associative 
learning (Murray et al., 2010) suggesting that patients with schizophrenia may recruit 
compensatory networks to make up for aberrant processing in other neural areas. 
Together, both decreased and increased neural activity in patients with schizophrenia 
demonstrate wide-spread differences (Ernst and Paulus, 2005a), which may be 
mediated through aberrant dopaminergic processing in schizophrenia (Howes and 
Kapur, 2009; Rolls et al., 2008). Various lines of research, which are outlined in more 
detail in Chapter 1 (page 16), have shown that that higher presynaptic dopamine levels 
in the mesolimbic dopaminergic system - involving more striatal and limbic areas - may 
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lead to psychotic symptoms and decreased levels of dopamine in the mesocortical 
system - involving more prefrontal areas - are believed to lead to negative and 
affective symptoms (Howes and Kapur, 2009; Kapur, 2003). As dopamine plays a 
significant role in decision-making, by aiding in both value formation, or the 
conceptualisation of value in terms of the costs and benefits of a given option or set of 
options, and updating of predictions about rewards to inform decisions (Schultz, 2006), 
disruption to this system in schizophrenia may also lead to aberrant decision-making 
by altering the salience of informational stimuli (Berridge, 2012; Kapur, 2003). This 
means that, in schizophrenia, abnormal dopamine responses to stimuli, which would 
otherwise be innocuous, may lead to the incorrect assertion that these stimuli are 
more important than they actually are. This, in turn, may lead to the aberrant 
encoding, or classification, of stimuli and consequently to the formation of false 
beliefs. For example, a patient with schizophrenia might falsely perceive that what a 
character is saying in a television series is a personal message to them due to them 
attributing aberrant salience to the stimuli. In this case, the increased salience given to 
otherwise innocuous speech is interpreted with higher personal meaning as it is 
perceived as holding greater importance. This affects how patients with schizophrenia 
interact with the environment by impacting on how they weigh information in order to 
make decisions. As described in chapter 3 (page 56), the salience of stimuli can help 
guide decisions by coding their importance (Berridge, 2012) thus, aberrant attribution 
of salience to certain stimuli can lead to aberrant decision-making.  
In schizophrenia, the altered attribution of salience to stimuli means that the affective 
appraisal of social stimuli is often different to that of healthy controls and thus may 
lead to altered decision-making. This is particularly important when faced with social, 
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or interpersonal, stimuli, such as discerning the emotion of another person or 
interpreting the meaning of what another person is saying; decision-making requires 
the affective, or emotional, appraisal of options to evaluate the respective value of 
different stimuli which is governed by both automatic and conscious processes (Ernst 
and Paulus, 2005a). Currently, most paradigms addressing salience during decision-
making tasks incorporate non-social elements to determine general decision-making 
biases. 
One such method of assessing the salience of stimuli is by determining the expected 
value of a reward for a given specific stimuli. The higher the magnitude of the expected 
value, the more salient the stimuli should become. Using the magnitude of the 
expected value and the resulting reward gained from picking a certain stimulus, it is 
possible to calculate the difference between the expected value of a stimulus and the 
actual value after picking it. This difference between actual reward and expected 
reward is known as the reward prediction error and has been used with increasing 
frequency in studies looking at how dopamine affects decision making. As 
dopaminergic activity is dependent on both reward and reward expectancy, the 
reward prediction signal has been shown to correlate with neural activity in dopamine 
rich areas, such as the striatum (Glimcher, 2011; Schultz, 1998). In schizophrenia, 
neural prediction error responses have been generally found to be reduced compared 
to healthy controls, in areas such as the striatum, suggesting that, in schizophrenia, 
abnormal dopaminergic processing disturbs the encoding and reward processing 
stages of decision-making (Gradin et al., 2011; Morris et al., 2012; Murray et al., 2008). 
However, patients with schizophrenia also show exaggerated neural activity within the 
ventral striatum in response to expected rewards but diminished responses in the 
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ventral striatum associated with unexpected rewards (Morris et al., 2012). This 
suggests that patients may disproportionately weight positive reward which may affect 
how they make decisions. 
As social information plays an important role in making decisions when interacting 
with others, this current study aims to expand on previous work which explored how 
facial valence affected decision-making in the same associative learning task described 
in chapter 3 (page 64) where subjects were presented with two faces, either a happy 
face and an angry face of the same identity or two neutral faces of different identities. 
They were then asked to determine through trial and error which of the two faces was 
being financially rewarded the most often.  
Using this task previously showed that, when deciding which face was most likely to be 
rewarded between a happy and angry face, both healthy controls and patients with 
schizophrenia were biased toward picking a happy face even when evidence supported 
the angry face as the better option (Averbeck and Duchaine, 2009; Evans et al., 2011a; 
Evans et al., 2011b; Furl et al., 2012). Furthermore, when evidence strongly favoured 
the angry face, patients with schizophrenia showed greater aversion toward picking 
the angry face than healthy controls (Evans et al., 2011b). This implies that positive 
social cues are valued to a greater extent in patients with schizophrenia and that both 
groups are more averse toward picking the angry face.  
This current study aims to expand on this previous work using fMRI by examining the 
differences in neural activity in patients with schizophrenia versus healthy controls in 
this same task (Averbeck and Duchaine, 2009; Evans et al., 2011a; Evans et al., 2011b) 
as well as incorporating in a condition looking at decision-making between two neutral 
faces in order to explore the effects of decision-making on social stimuli without 
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varying social salience. The main analyses will investigate the differences in neural 
activity during decision-making and the processing of RPE between patients with 
schizophrenia and healthy controls who have taken a placebo. Furthermore, as 
dopamine is considered an important aetiological factor in the manifestation and 
treatment of schizophrenia, this study will also explore how changes in neural activity 
due to dopaminergic perturbation in healthy controls using a dopamine agonist, 
ropinirole, antagonist, amisulpride, evaluated against a placebo compares to changes 
in neural activity in patients with schizophrenia. 
In light of previous research, I hypothesise that: 
1. In line with Evans et al. (2011b), patients with schizophrenia will demonstrate the 
same bias as previously shown toward picking the more positively valenced happy face 
even when evidence supports the more negatively valenced angry face as the most 
likely to be rewarded. Patients with schizophrenia will not be biased toward either of 
the neutral identities. Furthermore, any decision-making bias will not be due to poor 
task performance as patients will perform this task significantly above chance and will 
not significantly differ in performance to healthy controls, as previously shown (Evans 
et al., 2011b). 
2. When compared to healthy controls who have taken a placebo, patients with 
schizophrenia will show decreased neural activity during decision-making, which will 
be apparent within various regions associated with decision-making and emotional 
processing such as the medial prefrontal cortex (mPFC), anterior cingulate cortex 
(ACC), thalamus, posterior cingulate cortex (PCC), and amygdala as well as reward 
related decision-making regions such as the caudate and putamen.  
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3. When processing RPE related to their decisions (i.e. the difference between 
expected reward and actual reward), patients with schizophrenia will also show some 
activation of the ventral striatum, a region high number in dopamine receptors, in 
response to RPE albeit to a significantly lesser extent than healthy controls as 
demonstrated in other decision-making studies (Gradin et al., 2011; Morris et al., 2012; 
Murray et al., 2008).  
4. Within the regions shown to be perturbed by dopaminergic manipulation in Chapter 
3, in comparison to healthy controls who have received a placebo, patients with 
schizophrenia will show similar patterns of neural activity as healthy controls who had 
received amisulpride as both groups will have been under the influence of dopamine 
antagonists. Following this, patients with schizophrenia will show the opposite pattern 
of neural activity as healthy controls who had been administered ropinirole such that 
where ropinirole increased neural activity in healthy controls, patients will show 
decreased neural activity. 
5. Further to the previous hypothesis, looking within regions which show altered 
neural activity between patients with schizophrenia and healthy controls who have 
taken a placebo, when looking in healthy participants only, these same regions will 
show increases in neural activity after ropinirole administration and decreases in 
neural activity after amisulpride administration. 
 METHODS 4.2
4.2.1 PARTICIPANTS 
In addition to the 20 right-handed healthy controls (17 males) which were described in 
chapter 3 (page 63), 48 right-handed patients with schizophrenia and schizoaffective 
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disorder (39 males), diagnosed according to ICD-10 (Organization, 1992), comprised 
the current sample. Seven of the patients with schizophrenia dropped out of the study 
before completing scanning, leaving a final sample of 42 patients with schizophrenia 
(33 males). Intelligence quotient (IQ) was estimated in all participants using the two-
item Wechsler Abbreviated Scale of Intelligence (WASI) consisting of the vocabulary 
and matrix reasoning subtests (Wechsler, 1999). Demographic information can be 
found below in Table 4.1. All participants signed informed consent and were 
compensated for their participation in the study on completion of the testing. Ethical 
approval was obtained from the Central London Research and Ethics Committee 3. 
Further details of recruitment and inclusion and exclusion criteria can be found in 
Chapter 2 (page 35). 
TABLE 4.1 - Demographic and clinical sample characteristics 
  
Patients with 
schizophrenia Healthy Controls Statistics 
  (N=42) (mean (SD)) (N=20) (mean (SD))   
Age (years) 37.36 (8.82) 36.25 (9.41) t(60) = 0.45, p > 0.1 
WASI IQ 97.10 (14.89) 107.30 (14.42) t(60) = 2.55, p = 0.013 
NS-SeC 2.79 (1.63) 2.35 (1.60) χ
2
(4)  = 5.79, p >0.1 
Gender 33M, 9F 18M, 2F χ
2
(1)  = 0.36, p > 0.1 
Age at onset (years) 23.76 (5.80) - 








 Positive Symptoms 16.18 (4.37) - 
 Negative Symptoms 18.28 (5.48) - 
 General Symptoms 31.13 (6.95) - 
 Total 65.58 (13.89) - 
         
IQ = Intelligence quotient; M = Male; F = Female. 
WASI = Wechsler Abbreviated Scale of Intelligence  
ns-sec = National Statistics Socio-economic Classification 
CPZ = Chlorpromazine equivalent (Woods, 2003; Bazire, 2005).  




The task used was a forced-choice, stochastically rewarded decision-making task 
incorporating faces of varying social valence. In each trial two faces were presented to 
the left and the right of the screen. Pairs consisted of either: a happy face and an angry 
face of the same identity, or of two neutral faces of differing identities. Each visit 
consisted of two scanning sessions comprised of four counterbalanced blocks of 30 
trials each (Figure 2.5, page 47). Pairs of emotionally valenced stimuli (i.e. happy and 
angry faces) were alternated with pairs of neutrally valenced stimuli (i.e. neutral faces). 
Within each emotionally valenced block, the identities of each face were kept 
consistent but the order of presentation of each identity was counterbalanced across 
sessions. Each block consisted of 30 trials with the presentation of each face 
counterbalanced across the left and right sides. Probability estimates were assigned to 
the faces at the beginning of each trial such that on 60% of the trials one face would 
win and 40% of trials the other face would win. The probability distribution of each 
face winning was counterbalanced across blocks such that the angry face won more in 
half of the blocks and the happy face won more in the other half, and that identity one 
won more over identity two for half of the blocks and vice versa for both the 
emotionally valenced and neutral faces. The order of these wins was counterbalanced 
across the participants and visits. In each trial, participants were instructed to pick the 
face which, at that time, they believed was the most likely to win. They were told that 
after making this decision they would be told whether or not they had won where a 
win would show that they had won 10 pence along with their current winnings total 
and a loss was associated with no change in winnings and only the message “You lose.” 
The presentation of stimuli is shown below in Figure 4.1. Further details, including the 




FIGURE 4.1 - Presentation of stimuli in the scanner for each trial 
4.2.3 FMRI DATA ACQUISITION 
Functional magnetic resonance imaging (fMRI) data were acquired on a Discovery 
MR750 3T scanner at the Centre for Neuroimaging Sciences, London (T2* weighted 
gradient-echo echo-planar images (EPIs), repetition time (TR) = 2000 ms, echo time 
(TE) = 35 ms, flip angle = 75°, 64 x 64 matrix, 24cm field of view). A 12-phase head coil 
array was used over the whole head for RF transmission and reception. Each whole-
brain image contained 38 3-mm axial slices separated by a distance of 0.3 mm with in-
plane isotropic voxel resolution of 3.75 x 3.75 mm. For each block, 430 scans were 
acquired and two sessions were recorded for each participant.  
Before the experimental portion of the experiment, a T1-weighted structural scan 
using a fast-spoiled gradient-echo pulse sequence (TR = 9.356 ms, TE = 3.828 ms, flip 
angle = 12°, time to inversion = 450 ms) was acquired for reference purposes. The first 
four volumes were discarded to allow for transient effects.  
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Participants made their responses using a two buttons on a three button-box with 
their index and middle fingers of their right hand. Head movement was minimised 
using headphones and additional padding around the head and ears as well as around 
the arms and legs.  
4.2.4 ANALYSIS 
All data were preprocessed and analysed using Statistical Parametric Mapping 12 
(SPM12) (Wellcome Department of Imaging Neuroscience, London, 
UK. www.fil.ion.ucl.ac.uk/spm) and MATLAB R2014a (MathWorks Inc. Sherbon, MA, 
USA). Further details of these steps can be found in Chapter 2 (page 53). 
A general linear model (GLM) was constructed in SPM12 to analyse the images with 
each event modelled as a delta (stick) function. Each block, consisting of 30 trials, was 
modelled independently and was defined as being either a block using emotionally 
valenced faces (e.g. happy and angry faces) or neutral faces (e.g. two faces of different 
identities). Events of interest within each block included the presentation of the faces, 
a decision-making regressor indicating when the decision was made for which face the 
subject believed would be rewarded (determined by a button press), and the feedback 
presentation within each trial. Also modelled were regressors to represent the motion 
parameters as well as parametric modulators on the decision-making regressor for the 
probability of each face chosen being associated with a win and feedback regressors. 
The probability that the face they picked would win was calculated using an ideal 
observer. The calculations used to determine this probability are outlined in depth in 
Chapter 2 (page 47). The feedback regressor, associated with when they were given 
feedback about whether or not the face they had chosen was associated with a 
reward, was parametrically modulated by the reward prediction error (RPE) 
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determined by subtracting the actual reward (i.e. 1 for a win and 0 for a loss) from the 
predicted probability that the chosen face would win as detailed in Chapter 2 (page 
49). Each regressor, except for the motion parameters, was convolved with a canonical 
hemodynamic response function and its temporal derivative. Missed trials were not 
modelled as events. Blocks where subjects failed to respond for greater than 50% of 
the trials were excluded from analysis as they were deemed to be insufficiently 
attending to the task. Furthermore, without feedback from all trials, it would have 
been more difficult for subjects to accurately assess which face was winning more 
often throughout the block. Excluded blocks accounted for 1 block across 1 subject 
(one block when making decisions between two emotionally valenced faces). 
Performance estimates were calculated across all trials by comparing the face the 
subject picked to the face the ideal observer assigned the highest probability of 
winning. In the case that both faces had equal probability of winning (i.e. at 50% 
probability) either face picked was deemed optimal. Overall performance estimates 
were calculated across all trials as the number of times the participant picked the face 
deemed optimal over the number of valid trials (i.e. 30 – any misses). These estimates 
were then averaged across all blocks which were not excluded to get an overall 
performance estimate for all blocks using emotionally valenced and neutral faces. 
To assess how facial expression biased decision-making, all trials were separated into 
when participants agreed with the ideal observer and when they disagreed with the 
ideal observer for each facial valence as well as for the two neutral face identities. A 
2x2 contingency table was calculated for each block type (i.e. emotionally valenced 
and neutral) representing choices by the ideal observer and choices by the participant. 
When the probability for each face winning was ambiguous (i.e. equal probabilities for 
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both faces), the contingency count for each face was increased by 0.5. Using this table 
it was possible to calculate the conditional probability of each participant choosing the 
happy face when they should have chosen the angry face given the current evidence 
for the angry face p(happy|angry) as well as when they chose the angry face when 
they should have chosen the happy face given the current evidence for the happy face 
p(angry|happy). The difference between these two measures was calculated to 
represent the degree of bias toward picking the happy face (p(happy|angry) – 
p(angry|happy)). This measure indicates how often participants ignore the evidence 
that has accumulated for the negatively valenced face and chose the positively 
valenced face compared to how often they ignored evidence that had accrued for the 
positively valenced face and chose the negatively valenced face. This bias distribution 
was examined across all participants and entered into a one sample t-test to see if it 
significantly differed from 0. It is important to note these conditional probabilities 
were calculated separately to the probability that each face would win. A more 
comprehensive overview with equations is provided in Chapter 2 (page 49). This 
process has been replicated in multiple studies to represent the degree of bias 
(Averbeck and Duchaine, 2009; Evans et al., 2011a; Evans et al., 2010; Evans et al., 
2011b; Furl et al., 2012). 
The main focus of this study was to look at how decision-making and RPE affected 
neural activity so contrasts were looked at representing neural activity when a button 
was pressed to indicate which face the participant had chosen on a given trial, here 
after referred to as the decision-making condition as well as contrasts representing 
neural activity correlating with RPE given by the parametric modulator on reward 
feedback. Second-level contrasts between groups were assessed using two sample t-
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tests. Within each group comparison (i.e. patients with schizophrenia versus healthy 
controls), the main effect of task was analysed looking at by combining the blocks for 
emotionally valenced and neutral faces. Then contrasts were also created for blocks 
looking at only decision-making between the emotionally valenced faces to assess 
differences in decision-making with emotionally salient stimuli as well as within only 
the blocks looking at decision-making between neutral faces to assess differences in 
decision-making between general social stimuli with no emotional salience. Interaction 
effects between the emotion and group were also analysed to see if there was any 
interaction between the emotionally valenced face condition and the neutral face 
condition and group.  
To look at interaction effects between group and emotion an overall examination of 
blocks looking at the effects of group (i.e. patients with schizophrenia versus healthy 
controls) and emotion (i.e. emotionally valenced versus neutral faces) were entered 
into 2x2 full factorial in SPM12 with group and emotion as conditions. 
Contrasts were whole brain cluster-level family wise error (FWE) corrected at p<.05 
with a height threshold of p < .005, uncorrected, and an extent threshold of 100 
contiguous voxels. Voxels which survived peak level FWE correction at p<.05 are also 
reported. Reported voxels coordinates were converted from Montreal Neurological 
Institute (mni) coordinates into Talairach coordinates using the function icbm_spm2tal 
(Laird et al., 2010; Lancaster et al., 2007a) and were entered into Talairach Daemon to 
confirm their location in gray matter (Lancaster et al., 1997; Lancaster et al., 2000). 
Questionable results were further visualised by entering the original mni coordinates 
into xjview (http://www.alivelearn.net/xjview). Results are reported as their original 
mni coordinates as output by SPM12. If more than one voxel was found to be 
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significant within a region without a priori interest, only the peak voxel is reported. 
Additionally, the contrast estimates from each image were analysed at the peak voxels 
to determine the direction of change between each condition analysed as significant 
decreases under one condition could still appear as increases in another condition 
even if no change in neural activity was present. 
Region of interest analyses were also carried out within regions with an a priori 
interest to our study using small volume correction (SVC) within SPM12. Volumes of 
interest were defined using WFU PickAtlas Tool (Maldjian et al., 2003) for the 
amygdala and striatum and the ventral striatum was taken from Mawlawi et al. (2001). 
Only voxels which survived FWE correction at a peak level of p <.05 are reported. 
Additionally, in order to compare neural activity in the patients with schizophrenia to 
regional changes in neural activity from dopaminergic perturbation in healthy controls, 
Volumes of interest were also defined by creating masks around the clusters which 
survived FWE cluster level correction in Chapter 3 (pages 79 and 84) within SPM12. 
These regions were the bilateral dACC/dmPFC from the contrast between ropinirole 
and placebo administration when deciding between two emotional faces (page 79), 
and the right cerebellum/fusiform gyrus in the contrast between amisulpride and 
placebo administration when deciding between two neutral faces (page 84). These 
masks were used to see if between group effects between patients with schizophrenia 
and healthy controls could be observed within the same regions after SVC. 
Inversely, for all clusters which showed differences between patients with 
schizophrenia and healthy controls, masks around these volumes of interest were 
defined using SPM12. These masks were then used in the same contrasts for healthy 
participants after dopaminergic perturbation to see if similar effects from between 
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patients with schizophrenia and healthy controls could be observed after SVC within 
healthy participants who had received ropinirole or amisulpride versus a placebo. 
 RESULTS 4.3
4.3.1 BEHAVIOURAL ANALYSIS 
4.3.1.1 PERFORMANCE DURING DECISION-MAKING 
To assess performance in terms of the percentage accordance to an ideal observer, the 
face picked by the subject on each trial was compared to an ideal observer calculated 
based on the number of times a face won or would have won over the number of valid 
trials. Performance estimates across subjects averaged separately across all trials when 
deciding between two emotionally valenced faces and two neutral faces as well as 
across each group are shown in Table 4.2, Figure 4.2 and Figure 4.3. On average, both 
healthy controls and patients with schizophrenia performed above chance levels (p > 
0.1). Furthermore, when individual choices were compared to an ideal observer, 
patients with schizophrenia did not differ significantly in performance from the 
placebo condition in healthy controls (p > 0.05), when deciding between both 
emotionally valenced faces and neutral faces Table 4.2. Albeit they did differ from the 
healthy controls at a trend level significance (p < 0.1) when deciding between two 
emotionally valenced faces. 
TABLE 4.2 - Performance estimates for each group 
 
Emotional faces Neutral faces  Statistics between groups 
 









t(60) = 1.46, 
p=0.149 Healthy Controls (Placebo) 70.9% (15.7%) 68.9% (17.5%) 
SD = Standard devia_on; * = p < 0.05, † = p < 0.1 
Performance is measured in terms of percentage accordance to an ideal observer. This is looked at 
separately across all blocks using emotionally valenced faces and neutral faces; t-values were calculated 





FIGURE 4.2 - Performance estimates across drug conditions when deciding between 
emotionally valenced faces for healthy controls who have taken a placebo (black) and 
patients with schizophrenia (blue) where performance is compared to an ideal observer on 
a trial by trial basis. Each cross represents the performance of a single individual and the line 
represents the mean across all subjects. Although both groups did not significantly differ in 
performance, patients performed slightly worse than healthy controls at a trend level. 
 
FIGURE 4.3 - Performance estimates across drug conditions when deciding between 
two neutral faces for healthy controls (black) and patients with schizophrenia (blue) 
where performance is compared to an ideal observer on a trial by trial basis. Each cross 
represents the performance of a single individual and the line represents the mean across all 
subjects. Neither group significantly differed in peformance. 
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4.3.1.2 BIAS MEASURES 
When deciding between two emotionally valenced faces, the distribution of bias 
toward picking the happy face when evidence supported the angry face as the best 
choice was found to be significantly different from 0 in the patients with schizophrenia. 
When deciding between two neutral faces, there was no significant bias toward picking 
either of the neutral identities in patients with schizophrenia (Table 4.3). No significant 
differences were found between bias estimates observed in the patients with 
schizophrenia and the healthy controls who had taken a placebo for either condition (p 
> .05). 




faces Statistics for bias toward 
  







0.08 (0.11) -0.07 (0.18) 
t(19) = 3.11, 
p=0.006* 




0.12 (0.22) -0.03 (0.18) 
t(41) = 3.63, 
p=0.001* 
t(41) = 1.06, 
p=0.296 
* signiﬁcant at p<0.05, † trend level signiﬁcance at p<0.1, SD = Standard devia_on 
Bias estimates are estimated as the degree of bias toward picking one of the faces when the ideal 
observer supports the other face as the better option using a contingency table described in the methods. 
Bias significance was calculated as the difference from 0 
4.3.2 FMRI ANALYSIS 
4.3.2.1 HEALTHY CONTROLS VERSUS PATIENTS WITH SCHIZOPHRENIA DURING 
DECISION-MAKING 
4.3.2.1.1 DECISION-MAKING ACROSS EMOTIONALLY VALENCED FACES AND 
NEUTRAL FACES 
When deciding which face has a higher probability of being rewarded between two 
emotionally valenced faces and two neutral faces, patients with schizophrenia showed 
attenuated neural activity compared to healthy controls in the bilateral thalamus 
extending into the caudate and posterior cingulate (Table 4.4, page 128, Figure 4.4, 
Figure 4.5) with a peak in the thalamus within the medial dorsal nucleus (MDN) at (x = 
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5, y = -12, z = 6). Furthermore, even after applying a more stringent height threshold of 
p < .05 FWE corrected, significant peaks remained within the thalamus, posterior 
cingulate and cerebellum and a cluster of 370 voxels within the thalamus survived 
cluster level correction at this stringent threshold. 
 
FIGURE 4.4 - Neural activation during decision-making across emotionally valenced 
and neutral faces for controls (placebo) versus patients with schizophrenia. Peak 
differences showing greater attenuation of neural activity in patients with schizophrenia than 
healthy controls were found with a peak in the thalamus (medial dorsal nucleus) at (x = 5, y = -
12, z = 6). Results are shown for clusters which survive FWE cluster level correction at p<.05 
with an uncorrected height threshold of p<.005 and an extent threshold of 100. 
 
FIGURE 4.5 - Contrast estimates with standard error bars for differences in neural 
activity in the thalamus for healthy controls and patients with schizophrenia during 
decision-making across both emotionally valenced and neutral faces. The thalamus is 
shown here as it represents the peak difference in neural activity between patients with 
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schizophrenia did not show any significant changes where healthy controls who had taken a 
placebo showed robust changes in neural activity while deciding which face was most likely to 
be rewarded across emotionally valenced faces and neutral faces. 
Patients with schizophrenia also showed greater neural activity than healthy controls 
in the right post- and precentral gyrus (Table 4.4, page 128). However, these effects 
were not as robust as the findings for attenuated neural activity in patients with 
schizophrenia compared to healthy controls. Furthermore, this effect was found to be 
driven by a stronger attenuation of neural activity in the right post- and precentral 
gyrus in the healthy controls while patients with schizophrenia appeared to show no 
changes in neural activity within this region. 
4.3.2.1.2 DECISION-MAKING BETWEEN EMOTIONALLY VALENCED FACES 
When looking at the effect of neural activity when deciding which face has a higher 
probability of being rewarded between two emotionally valenced faces, patients with 
schizophrenia showed attenuation of neural activity compared to healthy controls in 
the bilateral thalamus (Figure 4.6, Figure 4.7, and Table 4.4, page 128). However, the 
differences between groups were not as significant or as widespread as when 




FIGURE 4.6 - Neural activation during decision-making across emotionally valenced 
faces for controls (placebo) versus patients with schizophrenia. Peak differences were 
found within the thalamus at (x = 7, y = -16, z = 14) and extended into further regions of the 
thalamus. Results are shown for clusters which survive FWE cluster level correction at p<.05 
with an uncorrected height threshold of p<.005 and an extent threshold of 100. 
 
FIGURE 4.7 - Contrast estimates with standard error bars for differences in neural 
activity in the thalamus for healthy controls and patients with schizophrenia during 
decision-making across emotionally valenced faces The thalamus is shown here as it 
represents the peak difference in neural activity between patients with schizophrenia and 
healthy controls and demonstrates that, neural activity in patients with schizophrenia did not 
show any significant changes where healthy controls who had taken a placebo showed robust 
changes in neural activity while deciding which face was most likely to be rewarded between 
two emotionally valenced faces. 
Healthy controls also showed significantly decreased neural activation compared to  
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the areas seen in the combined contrast comparing neural activation during decision 
making between groups across emotionally valenced and neutral stimuli (Table 4.4, 
page 128). This difference was also driven by a stronger decrease in healthy controls 
with no significant changes in neural activity in patients with schizophrenia. 
An ROI analysis using SVC was also performed within the left and right amygdala to see 
if patients with schizophrenia showed altered neural activity to healthy controls in this 
region involved in emotional processing when deciding which face was most likely to 
be rewarded between two emotionally valenced faces. However, no differences were 
observed. 
4.3.2.1.3 DECISION-MAKING BETWEEN NEUTRAL FACES 
When looking at the effect of deciding which face has a higher probability of being 
rewarded between two neutral faces between patients with schizophrenia and healthy 
controls who have taken a placebo, patients with schizophrenia showed greater 
attenuation of neural activity than healthy controls in the bilateral thalamus, posterior 
cingulate cortex (PCC), cuneus, caudate, lingual gyrus and extending through the 
tentorium into the cerebellum with a peak in the left PCC at (x = -1, y = -36, z = 22) and 
the right thalamus at (x = 5, y = -12, z = 6). These areas are consistent with the areas 
showing greater activation in the combined contrast looking at the effect of 
emotionally valenced and neutral faces only with the addition of the lingual gyrus and 
extending through the tentorium to show more extensive activation differences in the 
cerebellum (Table 4.4, page 128 and Figure 4.8). Further analysis revealed that these 
effects were due to increases in neural activity within the healthy controls with no 




FIGURE 4.8 - Neural activity when deciding between two neutral faces in patients 
with schizophrenia versus healthy controls on placebo in the thalamus extending into 
the PCC and through the tentorium into the cerebellum where neural activity is 
greater in the healthy controls than the patients with schizophrenia. This image is 
shown at an uncorrected height threshold of p < 0.005 with an extent threshold of 
100 and only clusters surviving FWE cluster-level correction of p < 0.05 
 
FIGURE 4.9 - Contrast estimates with standard error bars for differences in neural 
activity in the thalamus for healthy controls and patients with schizophrenia during 
decision-making across neutral faces The thalamus is shown here as it represents the 
peak difference in neural activity between patients with schizophrenia and healthy 
controls and demonstrates that, neural activity in patients with schizophrenia did not 
show any significant changes where healthy controls who had taken a placebo 
showed robust changes in neural activity while deciding which face was most likely to 
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4.3.2.1.4 INTERACTION BETWEEN THE EMOTIONALLY VALENCED AND NEUTRAL 
FACES DURING DECISION-MAKING 
When looking at the interaction effects between decision-making in using emotion 
(emotionally valenced versus neutral faces) and group (healthy controls who have 
taken a placebo versus patients with schizophrenia) there was an interaction effect in 
the right cuneus and left middle occipital gyrus and lingual gyrus (Table 4.4 and Figure 
4.10). Further examination of the changes in neural activity revealed that this effect 
was driven by an increase in neural activity in the healthy controls between 
emotionally valenced and neutral faces and an attenuation of neural activity in 
patients with schizophrenia between emotionally valenced and neutral faces (Figure 
4.11). 
 
FIGURE 4.10- Neural activity for interaction effects between group (patients with 
schizophrenia versus healthy controls on placebo) and emotion (emotionally 
valenced faces versus neutral faces) where neural activity is greater in the healthy controls 
than the patients with schizophrenia in the right cuneus, left middle occipital gyrus and lingual 
gyrus. This image is shown at an uncorrected height threshold of p < 0.005 with an extent 










FIGURE 4.11 – Contrast estimates showing a significant interaction effect for neural 
activity between group and emotion within the peak voxel within the right cuneus 
The right cuneus was chosen for further analysis as this represented the peak voxel showing 
differences in neural activity during this interaction analysis. In this region, patients with 
schizophrenia showed greater neural activity when deciding between two emotionally 
valenced faced which was attenuated when deciding between two neutral faces and healthy 
controls showed the opposite pattern of neural activity. 
 
As the amygdala is an important region for emotional processing and decision-making, 
a region of interest (ROI) analysis using small volume correction (SVC) was performed 
within a mask for the left and right amygdala. There was a significant interaction effect 
between group and emotional condition in the right amygdala (x = 33, y = 2, z = -26), 
t(120) = 3.74, p = 0.005, k = 20, with p representing the significance at FWE peak level 




FIGURE 4.12 - Neural activity for interaction effects between group (patients with 
schizophrenia versus healthy controls on placebo) and emotion (emotionally 
valenced faces versus neutral faces) using SVC within the amygdala. Neural activity is 
greater in the healthy controls than the patients with schizophrenia in the right amygdala. This 
image is shown at an uncorrected height threshold of p < 0.005 with any peaks surviving FWE 
peak-level correction of p < 0.05 after SVC. 
 
 
FIGURE 4.13 - Contrast estimates showing an interaction effect for neural activity 
between group and emotion in the right amygdala. This analysis reveals that patients 
with schizophrenia demonstrate attenuated levels of neural activity in the right amygdala 
when deciding between two emotionally valenced faces but show exaggerated levels of neural 
activity in this region when deciding between two neutral faces compared to healthy controls 











TABLE 4.4- Neural activity in patients with schizophrenia versus healthy controls on placebo when deciding between two faces 











               
Healthy Controls 





R Thalamus (MDN)* 
  
5 -12 6 
 
5.95 <.001 <.001 12103 1.64 
R Thalamus (AN)* 
  
13 -10 14 
 
5.92 <.001 <.001 12103 1.63 
L Thalamus* 
  
-3 -22 6 
 
5.21 <.001 <.001 12103 1.44 
  
L Posterior Cingulate* 29 
 
1 -38 22 
 
5.26 <.001 <.001 12103 1.45 
  
R Supramarginal Gyrus 40 
 
59 -44 38 
 
4.86 <.001 <.001 12103 1.34 
  
L Cingulate Gyrus 23 
 
1 -28 26 
 
4.64 <.001 <.001 12103 1.28 
  
L Cingulate Gyrus 23 
 
3 -20 34 
 
4.63 <.001 <.001 12103 1.28 
  
R Cingulate Gyrus 24 
 
23 -12 34 
 
4.43 <.001 <.001 12103 1.22 
  
R Cingulate Gyrus 31 
 
9 -38 38 
 
4.26 <.001 <.001 12103 1.18 
  
R Cingulate Gyrus 31 
 
5 -36 40 
 
4.24 <.001 <.001 12103 1.17 
  
L Anterior Cingulate 32 
 
-15 30 12 
 
4.53 <.001 <.001 12103 1.25 
  
R Precuneus 7 
 
5 -72 44 
 
4.51 <.001 <.001 12103 1.25 
  
R Precuneus 31 
 
13 -64 34 
 




37 -44 8 
 
4.01 <.001 <.001 12103 1.11 
  
L Lingual Gyrus 18 
 
1 -80 4 
 
3.61 <.001 <.001 2112 1.00 
  
R Lingual Gyrus 18 
 
9 -80 2 
 
3.33 0.001 <.001 2112 0.92 
  
L Cerebellum (Culmen)* 
  
1 -36 2 
 
5.26 <.001 <.001 12103 1.45 
  
L Cerebellum (Culmen) 
  
-37 -56 -28 
 
3.35 0.001 <.001 2112 0.93 
  
R Cerebellum (Culmen) 
  
45 -56 -26 
 
4.00 <.001 <.001 2112 1.10 
  
L Cerebellum (Declive)* 
  
-15 -82 -20 
 
5.90 <.001 <.001 2112 1.63 
  
R Cerebellum (Declive) 
  
11 -78 -18 
 
4.79 <.001 <.001 2112 1.32 
  
R Cerebellum (Declive) 
  
41 -68 -20 
 
3.84 <.001 <.001 2112 1.06 
  
R Cerebellum (Declive of Vermis) 5 -80 -14 
 
4.62 <.001 <.001 2112 1.28 
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L Cerebellum (Tuber)* 
  
-33 -78 -30 
 
5.01 <.001 <.001 2112 1.38 
  
L Cerebellum (Tuber) 
  
-43 -70 -28 
 
4.50 <.001 <.001 2112 1.24 
  
L Cerebellum (Uvula) 
  
-39 -74 -24 
 
4.30 <.001 <.001 2112 1.19 
  
R Cerebellum (Uvula) 
  
29 -72 -24 
 
4.10 <.001 <.001 2112 1.13 
  
R Cerebellum (Uvula) 
  
25 -80 -24 
 
3.91 <.001 <.001 2112 1.08 









R Postcentral Gyrus 3 
 
37 -28 52 
 
4.73 <.001 0.004 1431 1.31 
R Postcentral Gyrus 3 
 
49 -16 50 
 
4.41 <.001 0.004 1431 1.22 
R Postcentral Gyrus 3 
 
57 -8 44 
 
4.25 <.001 0.004 1431 1.17 
 
R Postcentral Gyrus 3 
 
45 -24 52 
 
4.17 <.001 0.004 1431 1.15 
  
R Postcentral Gyrus 3 
 
55 -12 48 
 
4.14 <.001 0.004 1431 1.14 
  
R Precentral Gyrus 4 
 
35 -24 48 
 
4.68 <.001 0.004 1431 1.29 
  
R Precentral Gyrus 4 
 
59 -4 38 
 
4.28 <.001 0.004 1431 1.18 
  
R Precentral Gyrus 4 
 
57 -4 42 
 
4.23 <.001 0.004 1431 1.17 
  
R Precentral Gyrus 6 
 
63 0 24 
 
4.15 <.001 0.004 1431 1.15 
  
R Precentral Gyrus 6 
 
61 -2 34 
 
4.04 <.001 0.004 1431 1.12 
  
R Precentral Gyrus 4 
 
65 -6 26 
 
3.89 <.001 0.004 1431 1.07 
              
 
Healthy Controls 






7 -16 14 
 
3.94 <.001 0.003 1374 1.09 
L Thalamus 
  
-5 -14 14 
 
3.94 <.001 0.003 1374 1.09 
 L Thalamus 
  
-5 -6 2 
 




-3 -24 8 
 
3.29 0.001 0.003 1374 0.91 
  
L Thalamus (VLN) 
  
-17 -8 4 
 
3.30 0.001 0.003 1374 0.91 
  
L Thalamus (VLN) 
  
-13 -8 6 
 




-27 4 -2 
 
3.21 0.001 0.003 1374 0.89 
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L Lateral Globus Pallidus 
  
-19 -4 2 
 
3.14 0.001 0.003 1374 0.87 
  
L Cerebellum (Culmen) 
  
1 -42 6 
 
3.34 0.001 0.003 1374 0.92 








R Precentral Gyrus 6 
 
63 -4 32 
 
4.72 <.001 0.002 1461 1.30 
R Postcentral Gyrus 3 
 
47 -16 52 
 
4.36 <.001 0.002 1461 1.20 
 R Postcentral Gyrus 3 
 
37 -22 48 
 
3.88 <.001 0.002 1461 1.07 
 
R Postcentral Gyrus 3 
 
35 -26 52 
 
3.82 <.001 0.002 1461 1.05 
  
R Precentral Gyrus 4 
 
55 -6 46 
 
3.71 <.001 0.002 1461 1.02 
  
R Postcentral Gyrus 3 
 
57 -12 38 
 
3.66 <.001 0.002 1461 1.01 
  
R Postcentral Gyrus 40 
 
37 -30 60 
 
3.59 <.001 0.002 1461 0.99 
  
R Precentral Gyrus 4 
 
43 -12 36 
 
3.42 0.001 0.002 1461 0.94 
              
 
Healthy Controls 




L Posterior Cingulate* 23 
 
-1 -36 22 
 
6.72 <.001 <.001 19617 1.86 
R Thalamus (MDN)* 
  
5 -12 6 
 
6.60 <.001 <.001 19617 1.82 
 
R Thalamus (AN)* 
  
13 -8 14 
 
6.36 <.001 <.001 19617 1.76 
  
L Thalamus (MDN)* 
  
-5 -10 6 
 




-3 -20 6 
 
5.80 <.001 <.001 19617 1.60 
  
L Thalamus (VLN)* 
  
-17 -16 16 
 
5.36 <.001 <.001 19617 1.48 
  
R Precuneus* 31 
 
15 -62 30 
 
5.39 <.001 <.001 19617 1.49 
  
L Lingual Gyrus* 18 
 
1 -80 2 
 
5.35 <.001 <.001 19617 1.48 
  
R Middle Frontal Gyrus* 9 
 
53 22 28 
 
4.98 <.001 <.001 19617 1.38 
  
L Cerebellum (Declive)* 
  
-19 -80 -22 
 
6.58 <.001 <.001 19617 1.82 
  
R Cerebellum (Declive)* 
  
13 -76 -18 
 
5.86 <.001 <.001 19617 1.62 
  
R Cerebellum (Declive)* 
  
29 -70 -22 
 
5.86 <.001 <.001 19617 1.62 
  
L Cerebellum (Tuber)* 
  
-35 -76 -30 
 
6.16 <.001 <.001 19617 1.70 
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L Cerebellum (Tuber)* 
  
-41 -72 -28 
 
5.57 <.001 <.001 19617 1.54 
  
R Cerebellum (Culmen)* 
  
3 -36 2 
 
5.25 <.001 <.001 19617 1.45 
              
 
Group x Emotion Interaction R Cuneus 18 
 
11 -90 20 
 
4.54 <.001 0.046 682 1.25 
  
R Cuneus 17 
 
5 -78 18 
 
3.35 0.001 0.046 682 0.93 
  
R Cuneus 30 
 
5 -76 14 
 
3.32 0.001 0.046 682 0.92 
  
L Middle Occipital Gyrus 18 
 
-13 -90 20 
 
4.42 <.001 0.046 682 1.22 
  
L Middle Occipital Gyrus 19 
 
-31 -80 30 
 
3.85 <.001 0.046 682 1.06 
  
L Middle Occipital Gyrus 19 
 
-27 -90 20 
 
3.01 0.002 0.046 682 0.83 
  
L Lingual Gyrus 18 
 
-7 -72 10 
 
3.33 0.001 0.046 682 0.92 
  
L Lingual Gyrus 18 
 
-11 -80 10 
 










 20 1.03 
               Corresponding coordinates for each brain region listed represent the peak voxels for each corresponding region within each significant cluster. All areas reported were found to be 
significant at a family wise error cluster level corrected threshold of <.05 after running a whole brain analysis at an uncorrected threshold of p<.005. *p < .05 FWE peak level 
correction; k = cluster size BA  = Brodmann’s Area 
a Regions which were found to be significant using small volume correction. FWE values are reported at peak level significance after correction 




4.3.2.2 HEALTHY CONTROLS VERSUS PATIENTS WITH SCHIZOPHRENIA FOR 
REWARD PREDICTION ERROR (RPE) 
When looking at the differences in neural activity correlating with reward 
prediction error when receiving feedback about their decision for both emotionally 
valenced and neutral faces no whole brain differences are observed between 
patients with schizophrenia and healthy controls. However, given that the ventral 
striatum has been a region previously shown to be activated by RPE, small volume 
correction was performed around this region. Patients with schizophrenia 
demonstrated greater bilateral neural activation in the putamen than healthy 
controls (peak coordinates: (x = -13, y = 6 z = -6), t(60) = 4.04, p = 0.004, k =14, (x = 
13, y = 12, z = -4), t(60) = 3.28, p = 0.029, k = 24, where p represents the significance 
at FWE peak level when using SVC around the ventral striatum) (Figure 4.14). 
Looking at contrast estimates within the peak coordinate with the greatest 
difference in neural activity showed that these differences were due to a significant 
increase in neural activity in patients with schizophrenia while healthy controls 
showed relatively no changes in neural activity (Figure 4.15). 
No interaction effects were found for differences in neural activity from group 
(patients with schizophrenia versus healthy controls who have taken a placebo) by 
emotion (emotionally valenced versus neutral faces), even when applying SVC in 
the ventral striatum, suggesting that these differences in neural activity are a 
general effect of RPE across conditions and not specific to processing emotionally 




FIGURE 4.14 – Neural activity within a region of interest analysis around the 
ventral striatum for reward prediction error showing greater neural activity within the 
patients with schizophrenia in the bilateral ventral striatum compared to healthy controls. 
 
FIGURE 4.15 - Contrast estimates and 90% confidence intervals for RPE in the peak 
coordinate in the ventral striatum for healthy controls on placebo and patients with 
schizophrenia across both emotionally valenced and neutral faces. This shows that patients 
with schizophrenia have greater neural activation in the ventral striatum while healthy 
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4.3.2.3 GROUP DIFFERENCES IN NEURAL ACTIVITY DURING DECISION-
MAKING USING SMALL VOLUME CORRECTION FROM AREAS 
AFFECTED BY DOPAMINERGIC PERTURBATION 
To assess whether group differences in neural activity between patients with 
schizophrenia and healthy controls were reflective of changes in neural activity 
observed after dopaminergic perturbation in healthy participants, masks were 
taken from regions showing changes in neural activity from Chapter 3 and were 
used to assess if between group differences in neural activity existed after small 
volume correction (SVC). 
4.3.2.3.1 DIFFERENCE TO ROPINIROLE INCREASES IN NEURAL ACTIVITY IN THE 
DACC/DMPFC IN HEALTHY CONTROLS WHEN DECIDING BETWEEN TWO 
EMOTIONALLY VALENCED FACES 
When using an SVC analysis in the contrast between healthy controls and patients 
with schizophrenia during decision-making between two emotional faces taken 
from the same contrast between ropinirole and placebo administration in healthy 
participants found in Chapter 3 (page 79), no differences were observed in neural 
activity. Thus patients with schizophrenia do not show similar or opposing patterns 
of neural activity perturbation as healthy controls who have been administered 
ropinirole. 
4.3.2.3.2 DIFFERENCE TO AMISULPRIDE DECREASES IN THE CEREBELLUM/ 
FUSIFORM GYRUS IN THE HEALTHY CONTROLS WHEN DECIDING 
BETWEEN TWO NEUTRAL FACES 
When using an SVC analysis in the contrast between healthy controls and patients 
with schizophrenia during decision-making between two neutral faces taken from 
the same contrast but between amisulpride and placebo administration in healthy 
participants found in Chapter 3 (page 84), significant differences in neural activity 
were observed in the same regions seen in Chapter 3, within the right cerebellum 
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extending through the tentorium into the lingual and fusiform gyrus. Thus patients 
with schizophrenia appear to show similar patterns of attenuation in neural activity 
as healthy controls who have been administered amisulpride. 
 
FIGURE 4.16 - Neural activity between healthy controls and patients with 
schizophrenia within a mask taken from between healthy particpants who have 
taken a placebo versus those who have taken amisulpride. Results are shown at a 
height threshold of p<.005 with an extent threshold of k = 100. As SVC was performed 
within this region, only voxels which survive FWE correction are shown. 
 
FIGURE 4.17 - Contrast estimates and standard error bars for neural activity within 
the cerebellum showing that neural activity is greater in the healthy controls than 
the patients with schizophrenia within the same region that shows an attenuation 
by amisulpride in healthy participants.  
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4.3.2.4  EFFECTS OF DOPAMINERGIC PERTURBATION ON NEURAL ACTIVITY 
DURING DECISION-MAKING IN HEALTHY CONTROLS USING SMALL 
VOLUME CORRECTION FROM BETWEEN GROUP DIFFERENCES 
To assess whether group differences in neural activity between patients with 
schizophrenia and healthy controls were reflected in differences between healthy 
participants after dopaminergic perturbation, masks were created around regions 
which showed significant differences between patients with schizophrenia and 
healthy controls and were applied to a within group analysis in healthy controls 
after dopaminergic perturbation using SVC. 
4.3.2.4.1 DIFFERENCES WITHIN THE REGIONS FOUND TO SHOW ABERRANT 
NEURAL ACTIVITY IN PATIENTS WITH SCHIZOPHRENIA 
4.3.2.4.1.1 AMISULPRIDE VERSUS PLACEBO 
When looking at differences in neural activity in healthy controls within the mask 
created for clusters which showed a significant difference in neural activity 
between patients with schizophrenia and healthy controls during decision-making 
in the combined emotionally valenced and neutral condition, no differences were 
found in healthy controls between the amisulpride and placebo condition.  
No differences in neural activity were observed for the differences for decision-
making in the emotionally valenced face condition either. However, when looking 
at differences within healthy controls taken from a mask around changes observed 
during decision-making between two neutral faces between the healthy controls 
and patients with schizophrenia, an attenuation of neural activity by amisulpride 
was observed in the left ACC (x = -17, y = 32, z = 14, t(19) = 5.60, p = 0.041 FWE 
peak level corrected) and a cluster in the precuneus (peak voxel, x = 3, y = -68, z = 
48, t(19) = 3.49, p = 0.037, k = 471 FWE cluster level corrected). Interestingly, 
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although the right cerebellum and fusiform gyrus showed up within the mask, this 
cluster extending through the tentorium was only significant at a trend level (p = 
0.063, k = 395). 
4.3.2.4.1.2 ROPINIROLE VERSUS PLACEBO 
No significant differences in neural activity were found within the masks taken from 
the group contrasts between healthy controls and patients with schizophrenia for 
any of the conditions looking at decision-making between emotionally valenced and 
neutral faces, both combined and separately, when using SVC between ropinirole 
and placebo. 
 DISCUSSION 4.4
This chapter explored the effect of dopaminergic manipulation on decision-making 
in an associative learning task in patients with schizophrenia using emotionally 
valenced and neutral faces as social variables. As hypothesised, patients with 
schizophrenia demonstrated the same bias toward choosing the happy face even 
when evidence supported the angry face as the better option. This bias in decision-
making between two emotionally valenced faces was also accompanied by a 
change in neural activity within the bilateral thalamus, an area mainly known for 
relaying information between subcortical areas the cerebral cortex but which also 
aids in the planning and processing of decision-making by filtering and forwarding 
information (Buchsbaum et al., 2006; Haber and Calzavara, 2009). Furthermore, 
when looking at the general effect of decision-making across both emotionally 
valenced and neutral faces, attenuation of neural activity within the patients with 
schizophrenia was found to be the greatest in the medial dorsal nucleus (MDN) of 
the thalamus – a region known to be abnormal in patients with schizophrenia 
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(Andrews et al., 2006; Byne et al., 2001; Chana et al., 2008; Mitelman et al., 2005; 
Pakkenberg, 1990) – and extended to a further network including the cerebellum, a 
region involved in coordinating and connecting information, and processing social 
information and also known to show decreased neural activity in patients with 
schizophrenia (Andreasen and Pierson, 2008; Van Overwalle et al., 2014), and the 
dACC and mPFC, regions involved in decision-making through interpreting 
information and initiating responses (Asplund et al., 2010; Botvinick, 2007; Maier et 
al., 2012). When looking at similarities in the changes in neural activity between 
patients with schizophrenia and healthy controls and previous changes 
demonstrated by dopaminergic perturbation within healthy participants, patients 
with schizophrenia only showed similar patterns in neural activity to healthy 
controls who had received amisulpride compared to healthy controls who had 
taken a placebo. These changes in neural activity were apparent in the cerebellum 
and fusiform gyrus when both groups were deciding which face had a higher 
probability of being rewarded between two neutral faces. Conversely, when only 
looking at differences in the healthy participants within the networks listed above 
which showed differences in neural activity between patients with schizophrenia 
and healthy controls, similarities were only found for healthy participants who had 
taken amisulpride compared to a placebo when looking at neural activity when 
deciding between two neutral faces in the left ACC and right precuneus, also 
regions involved in decision-making (Botvinick, 2007; Cavanna and Trimble, 2006; 
Paulus et al., 2002). Together, these findings demonstrate that patients with 
schizophrenia show attenuated neural activity during this task within regions of the 
brain involved in the integration and coordination of decision-making. Although 
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these deficits were not all found to coincide with dopaminergic perturbation, they 
indicate that despite being able to perform the task with a similar degree of 
accuracy as healthy controls, patients with schizophrenia demonstrate a systematic 
deficiency in areas which are involved in integrating and coordinating information 
to form decisions.  
When looking at differences in neural activity during decision-making, the strongest 
finding between groups was a significant attenuation in neural activity in the 
patients with schizophrenia in the thalamus compared to the healthy controls. The 
thalamus is known for being an area of integration where information is relayed 
between subcortical areas and the cerebral cortex and plays an important role in 
mediating motivation and emotional drive, as well as in planning and cognitive 
processes that guide decision-making (Buchsbaum et al., 2006; Haber and 
Calzavara, 2009). It is well connected to extensive regions of the frontal cortex 
which are involved in the formation of preference as well as planning and cognition 
(Cummings, 1993); the basal ganglia, which play a large role in processing reward 
information (Smith et al., 2004) and also the limbic system, including the amygdala, 
which helps processing emotional stimuli (Taber et al., 2004). The thalamus is 
subdivided into several specific regions with unique sets of afferent and efferent 
projections. One of these subdivisions, the MDN, an area known to be abnormal in 
patients with schizophrenia (Andrews et al., 2006; Byne et al., 2001; Chana et al., 
2008; Pakkenberg, 1990) was found to be significantly attenuated in patients with 
schizophrenia compared to healthy controls in this study. Other studies looking at 
the size of the MDN in patients with schizophrenia have found an overall reduction 
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in volume and number of neurons in the MDN compared to healthy controls (Byne 
et al., 2001; Chana et al., 2008; Pakkenberg, 1990). Studies have also found a 
metabolic disconnection between the MDN and left lateralised fronto-temporal 
regions in patients with schizophrenia compared to healthy controls (Mitelman et 
al., 2005) which demonstrates that this area exhibits both structural and functional 
deficits in schizophrenia. One theory for the role of the thalamus in schizophrenia 
postulates that a defect in circuitry between the thalamus, frontal cortex and 
cerebellum accounts for how certain symptoms arise and is known as “cognitive 
dysmetria,” or poor mental coordination (Andreasen, 1997; Andreasen et al., 1996; 
Andreasen et al., 1998). In a functioning network, the thalamus should act to filter 
and forward on stimuli while the cerebellum should coordinate and connect 
information and the frontal cortex should interpret information and initiate 
responses, however, deficits within this network in patients with schizophrenia are 
believed to undermine these functions. The attenuated neural activity within this 
network in our study further supports this model of cognitive dysmetria. 
Further to these findings in the thalamus, and in further support of a deficit within 
this circuit, patients with schizophrenia showed a pattern of attenuated neural 
activity in the cerebellum compared to healthy controls after taking a placebo. 
Interestingly, this effect was also found in the cerebellum extending through the 
tentorium into the fusiform gyrus when looking at the effects of dopaminergic 
perturbation via amisulpride; healthy controls showed attenuated neural activity 
within this region after taking amisulpride compared to taking a placebo when 
deciding which face had a higher probability of being rewarded between two 
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neutral faces. This suggests that, at least within the cerebellum, some of these 
changes in neural activity observed in patients with schizophrenia may be driven by 
dopaminergic antagonists.  
Although the cerebellum is mainly thought of as an area which is primarily 
dedication to the coordination of motor activity, recent evidence has emerged 
demonstrating the cerebellum’s role in cognition and social processing as well as 
suggesting that its functioning is impaired in schizophrenia (Andreasen and Pierson, 
2008; Van Overwalle et al., 2014). Furthermore, there is also evidence that some 
dopamine binding occurs in the cerebellum which can be influenced by 
antipsychotics (Hurley et al., 2003; Melchitzky and Lewis, 2000; Narendran et al., 
2011). As both patients with schizophrenia and healthy controls who have received 
amisulpride showed attenuated neural activity in this area when deciding between 
two neutral faces, this suggests a tentative role for aberrant dopamine in the 
disruption of the coordination of information processing during this task in the 
cerebellum. 
As all three areas of this purported network, the thalamus, cerebellum and mPFC 
were found to be attenuated in patients with schizophrenia, these findings appear 
to support aberrant processing within this network in patients with schizophrenia. 
Overall, studies support that there exist both structural and functional 
abnormalities with the thalamus in patients with schizophrenia which affects neural 
processing most likely by disrupting the integration of information is receives in 
conjunction with the cerebellum and mPFC. This study showed that patients with 
schizophrenia functionally mirror these deficits through attenuation of neural 
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activity when deciding which face they believe has a higher probability of winning. 
Even though this attenuation did not translate into significant deficits behaviourally, 
this showed that patients with schizophrenia do not recruit the same networks to 
the same degree as healthy controls. Furthermore, the lack of significant 
differences in neural activity within all of these regions in healthy controls after 
dopaminergic perturbation points to these deficits extending beyond dopaminergic 
differences in patients with schizophrenia but with some potential ties to 
dopaminergic aberrance in the cerebellum.  
Further to this point, although this study did not explicitly measure connectivity, 
previous studies have shown dysconnectivity in patients with schizophrenia in the 
network presented here of the thalamus, cerebellum and mPFC, which provides 
some evidence that these areas are not communicating with each other as 
efficiently in healthy controls (Andreasen et al., 1996; Andreasen et al., 1998; Wiser 
et al., 1998). Regarding possible pathophysiological mechanisms underlying 
schizophrenia, the “dysconnection” hypothesis has garnered a significant amount of 
interest (Friston, 1998; Pettersson-Yeo et al., 2011; Stephan et al., 2006; Stephan et 
al., 2009). The principal behind this model is that the symptoms of schizophrenia 
arise due to aberrant effective connectivity between neural systems, or the 
influence that one system has over another (Kiebel et al., 2008), due to abnormal 
synaptic efficacy from neuromodulatory transmitters such as dopamine and 
glutamate (Stephan et al., 2009). It is also important to note that dysconnectivity is 
an overarching term for aberrant connectivity and does not only refer to diminished 
connectivity between regions but also to hyperconnectivity between regions. 
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Ineffective communication from one neural area to another is thought to be 
responsible for the emergence of symptoms such as the perception of internally 
generated speech as a voice from a separate entity and is evident even in tasks as 
simple as a visual attention task requiring no decisions (Roiser et al., 2013). Given 
that the regions in which patients with schizophrenia demonstrate the greatest 
attenuation of neural activity in this study are known to be regions highly 
interconnected regions within the brain, it is likely that these deficits in neural 
activity have arisen due to dysconnectivity between these regions. However, 
further exploration of these findings in regard to their functional connectivity will 
be necessary to confirm this theory. 
Additionally, a region of interest analysis when looking at decision-making between 
two emotionally valenced faces versus two neutral faces between groups within the 
amygdala showed an interaction effect between healthy controls and patients with 
schizophrenia when deciding between emotional and neutral faces where healthy 
controls taking placebo recruited the amygdala more in the emotional condition 
than patients with schizophrenia and patients with schizophrenia showed greater 
activation of the right amygdala when deciding between neutral faces. However, 
differences in amygdalar activity were only apparent in an interaction analysis 
suggesting that within each condition, for emotionally valenced and neutral faces, 
patients with schizophrenia do not demonstrate aberrant levels of neural activity; 
however, they do appear to attribute aberrant patterns of neural activity to each of 
these conditions in comparison to healthy controls. 
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Unexpectedly, when looking at the association between neural activity and RPE, 
patients with schizophrenia showed greater bilateral neural activity in the striatum 
than healthy controls who had taken a placebo. This finding is surprising in light of 
the few current studies which have shown relative decreases in RPE in patients with 
schizophrenia compared to healthy controls (Gradin et al., 2011; Murray et al., 
2008; Rausch et al., 2014). However, it is also important to note that these studies 
did still find systematic increases in neural activity within the striatum in patients 
with schizophrenia, albeit to a lower extent than healthy controls. Furthermore, 
one study even found that when only looking at the effects of expected reward, 
patients with schizophrenia showed elevated neural activity in the ventral striatum 
compared to healthy controls (Morris et al., 2012). Chapter 3 provided surprising 
results as well showing that healthy controls did not display the robust increase in 
neural activity in the striatum correlating with RPE as expected. As the model 
adapted for this study was designed to be simplistic in its nature, it is possible that 
this model tracked neural activity in patients with schizophrenia with greater 
accuracy than healthy controls or the reward stimuli used in this study had a 
greater effect on patients with schizophrenia than healthy controls. As explored in 
Chapter 3 (page 56), studies looking at RPE and dopamine have not always provided 
consistent results in terms of increased or decreased neural activity as a result of 
dopaminergic perturbation (Jocham et al., 2011; Murray et al., 2008; Pessiglione et 
al., 2006). Therefore it is not entirely surprising that this study also found different 
effects for RPE than previously observed in patients with schizophrenia. 
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Overall, these findings suggest that patients with schizophrenia show differential 
patterns of neural activity in areas of connectivity such as the thalamus and 
cerebellum indicative of “cognitive dysmetria” or dysconnectivity within this group. 
Although these findings did not all coincide with changes in neural activity observed 
after dopaminergic perturbation, patients with schizophrenia do show some similar 
patterns in neural activity particularly within the cerebellum and fusiform gyrus to 
healthy controls who have taken amisulpride suggesting that this region may be 
influenced by dopaminergic antagonist medication.  
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CHAPTER 5 - NEUROPYHSIOLOGICAL EFFECTS OF ACUTE 
OXYTOCIN ADMINISTRATION: A SYSTEMATIC REVIEW AND 
META-ANALYSIS OF PLACEBO-CONTROLLED IMAGING 
STUDIES 
5.1 INTRODUCTION 
The role of oxytocin in influencing social behaviour has been well established in animal 
research(Insel and Young, 2001a; McCall and Singer, 2012) but over the past decade 
has been increasingly shown to be relevant in humans(Meyer-Lindenberg et al., 2011). 
Early research focussed on its core role in parturition, milk ejection, sexual function 
and parenting but recent studies have focussed on  its effects on social behaviour(Insel 
and Young, 2001a). The use of evolving technologies in animal models such as oxytocin 
receptor agonists and antagonists, receptor knockouts and autoradiography have all 
helped to identify analogous areas of interest for examination in human 
research(McCall and Singer, 2012; Neumann and Landgraf, 2008) and have contributed  
the basis of further investigation of the effects of OXT on human behaviour and social 
cognition (Gimpl and Fahrenholz, 2001). 
In behavioural studies oxytocin has been linked to social behaviours such as trust and 
parental bonding. It has also been shown to increase the ability to identify emotions, 
increase empathy toward others, and attenuate aversion to angry faces (Bartz et al., 
2011; McCall and Singer, 2012). Furthermore, its role in facilitating social interactions 
by ameliorating social bias and response to emotional faces has led it to be considered 
as a possible drug to use in disorders with severe social deficits such as autism and 
schizophrenia (Evans et al., 2010; Guastella and MacLeod, 2012).  
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The neurophysiological effects of oxytocin were initially investigated in animal models 
before testing in humans. Although oxytocin is produced and secreted in the same 
areas in both humans and animals, the receptor distribution can vary in a species 
specific manner (Gimpl and Fahrenholz, 2001; Loup et al., 1991). Much of this variation 
may be due to species specific differences in the way social stimuli are perceived and 
processed - with subsequent reorganisation of neural connections in favour of more 
developed areas in each species. For example, in rats, the primary source of social 
input is through odour, whereas in humans it is based on visual and auditory cues, and 
relies heavily on facial cues(McCall and Singer, 2012). oxytocin is synthesised in the 
hypothalamic paraventricular parvocellular neurons (PVN) and the supraoptic nuclei 
(SON) and is then secreted by the posterior pituitary. Neurons from the PVN project to 
various areas in the limbic system (hippocampus, amygdala, striatum, hypothalamus 
and nucleus accumbens) which are involved in social cognition (Gimpl and Fahrenholz, 
2001). With this in mind, recent neuroimaging techniques have allowed scientists to 
investigate in vivo the neurophysiological correlates of the effect of oxytocin. By 
examining fluctuations in the hemodynamic activity in the brain using functional 
magnetic resonance imaging (fMRI) after the administration of oxytocin compared to 
the administration of a placebo, the network and regions that contribute to oxytocin’s 
influence over brain activity have become clearer.  
This systematic review and meta-analysis aims to provide an integrative and 
comprehensive review of placebo-controlled neuroimaging studies of oxytocin. We will 
also report the magnitude of change in activation of various brain regions as a result of 
oxytocin administration versus a placebo during tasks related to social behaviour by 
computing its effect sizes in the limbic system – including the amygdala -, the reward 
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system, the frontal lobe, and the temporal lobe. Finally, we will look at a voxel-based 
meta-analysis of the effect of oxytocin administration on the human brain as 
addressed by various fMRI studies. An examination of animal studies has also been 
performed and is presented in the Supplementary Materials of the published paper 
but will not be presented in this thesis (Wigton et al., in press). 
5.2 METHODS 
5.2.1 SEARCH STRATEGIES 
A systematic search strategy following the PRISMA guidelines for systematic reviews 
(Liberati et al., 2009) was used to identify relevant studies for this review. Initially, the 
search used Embase, Medline and PsychInfo to identify relevant studies (published 
from 1806 up to 7 February 2013). To be included, each study had to be an original 
study using oxytocin as a pharmacological manipulator of brain activity. Since this 
review aims to cover all types of brain imaging, search parameters were expanded to 
include different brain imaging techniques. Search terms included “oxytocin”, 
“magnetic resonance imaging,” “MRI”, “fMRI”, “magnetoencephalography”, “MEG”, 
“electroencephalography”, “EEG”, “positron emission tomography”, “PET.”  
The bibliographies in the retrieved articles were also hand searched to uncover 
relevant papers that may have been missed in the search. Although no limits were 
placed on the language for an article, all articles found that fit our selection criteria 
were in English. No articles were found for MEG or PET research using oxytocin as a 
pharmacological probe. Studies were only included if they were an original publication 




5.2.2 SELECTION CRITERIA 
We included only studies that fit all of the following criteria: (i) explored the effects of 
intranasal administration of oxytocin in a placebo-controlled double-blind design, (ii) 
used functional neuroimaging or electrophysiological techniques. Studies which used a 
patient population but also reported findings for healthy controls were included if they 
satisfied all other criteria. Exclusion criteria were post-mortem studies, structural 
imaging techniques, studies only looking at endogenous oxytocin and studies on 
vasopressin or oxytocin antagonists as these studies did not look at how oxytocin 
administration affected brain activity. Only intranasal administration in humans was 
explored as this is the most common method of administering oxytocin in current 
imaging studies and there is a body of research supporting its influence over brain 
regions by potentially increasing its concentration in the CSF (Born et al., 2002; van 
Ijzendoorn et al., 2012).  
For the whole brain fMRI voxel-based meta-analysis, further criteria were applied. Only 
studies using emotional stimuli in healthy controls and that reported the peak 
coordinates of homogenously-thresholded oxytocin effects at the whole-brain level 
were included as there were not enough studies using social interactions alone to 
allow for an additional comparison. A total of 11 studies fit all the criteria and were 




FIGURE 5.1 - PRISMA flow diagram for all human studies included in the review 
5.2.3 SYSTEMATIC REVIEW 
For each retrieved study we recorded the following variables: number of subjects, 
study design, gender, dosage of oxytocin, the tasks implemented, major findings, areas 
attenuated or activated by oxytocin administration and their corresponding 
coordinates, contrasts and statistical value. 
Results were comprehensively reported in tables to assist the reader in forming an 
independent view on the following discussion. In particular, we decided to discuss the 
core findings with respect to different brain areas of interest: Basal ganglia, Insula, 
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Thalamus, Temporal lobes, Prefrontal cortex (PFC) and Amygdala as these are the 
areas most commonly reported in studies using oxytocin. 
5.2.4 EFFECT SIZES  
We analysed the magnitude of the oxytocin effects (effect sizes) on the regions of 
interest outlined in Table 5.3. Where sufficient information was provided in a study to 
assess the significance of the results (eg presence t value, p-value, F value, or means 
and standard deviations), we calculated the effect size.  
Studies which fit the criteria for effect size analysis accounted for 11 of the 15 studies 
reporting modulation from oxytocin aside from connectivity measures. The effect size 
is a dimensionless number which facilitates the integration of findings across studies 
that used different types of measurements. The choice of effect size estimator is a 
much debated and still unresolved issue (Hunter and Schmidt, 1990) and is related to 
the choice of whether or not greater reliance should be laid on studies carried out on 
larger samples when the effect size is to be computed. We chose to use an effect size 
estimator corrected for the number of subjects included in each study using Cohen's d 
statistic (Cohen, 1992) generated by the SPSS program. We calculated these values 
because most studies included fairly small numbers of subjects. When the power of a 
study is insufficient to show statistically significant differences between or within 
groups, even when such is the case in the population, type II errors occur. By 
examining effect sizes rather than statistical significance, we can better understand 
what differences exist in the general population and whether these differences might 
merit further study. Effect size (d) is taken to mean 'the degree to which a 
phenomenon is present in the population' (Cohen, 1988, p. 9); we indexed d according 
to Cohen's scheme (Cohen, 1992). Cohen placed the value of d for small effects at 0.2, 
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for medium effects at 0.5, and for large effects at 0.8.  
5.2.5 VOXEL-BASED META-ANALYSIS 
Meta-analysis of the oxytocin effects at the whole-brain level was conducted with the 
effect-size version of Signed Differential Mapping (ES-SDM, 
http://www.sdmproject.com/) (Radua and Mataix-Cols, 2012; Radua et al., 2012b), a 
technique that has already been applied to the study of both healthy controls (Peters 
et al., 2012) and many neuropsychiatric disorders such as ADHD (Hart et al., 2013), 
anxiety (Radua et al., 2010), autism (Radua et al., 2011) and schizophrenia (Fusar-Poli 
et al., 2012; Radua et al., 2012a). 
Briefly, ES-SDM used the information reported in the papers about the brain peaks of 
maximum oxytocin effects to recreate a statistical parametric map for each study, and 
then conducted a standard meta-analysis to obtain a meta-analytic brain map of 
oxytocin’s effects. First, peak coordinates were converted to Talairach space and their 
t-values were converted into effect sizes and their standard errors – i.e. accounting for 
study precision and sample size. It must be noted that SDM software was modified in 
order to account for the fact that some of the studies had conducted one-sample tests 
while others had conducted two-sample tests. Second, each peak was used to recreate 
a cluster of voxels with significant oxytocin effects by assigning an effect-size to the 
voxels close to the peak, taking the distance of each voxel to the different close peaks 
into account. Finally, the different recreated maps were voxel-wise combined by fitting 
random-effects models and p-values were derived from a permutation test. Results 
were thresholded with voxel p ≤ 0.005, peak z ≥ 2, and cluster extent ≥ 10 voxels. 
Please see (Radua and Mataix-Cols, 2012) for further details. 
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This analysis was complemented with two other analyses to assess the robustness of 
the meta-analytic findings. First, we conducted a jack-knife test which consisted in 
repeating the meta-analysis many times, with each time including all the studies but 
one, in order to infer the replicability of the findings. Second, funnel plots were drawn 
from the meta-analytic peaks in order to discard publication bias and gross 
abnormalities. Potential publication biases were further assessed with Egger tests 
(Figure 5.2b). 
5.3 RESULTS  
5.3.1 DATABASE 
Our literature search uncovered 21 full papers which met our inclusion criteria. Details 
of the retrieved studies are given in Table 5.1.  
To make the anatomical labelling of the relevant areas reported more consistent, all 
coordinates from each study were converted to Talairach coordinates using icbm2tal 
for the appropriate template (i.e. SPM, FSL etc) (Lancaster et al., 2007b). These 
coordinates were then entered into Talairach client (Lancaster et al., 2000) to create a 
standardised list of areas reported by each study. When different to the areas reported 
by the study, this was noted as shown in Table 5.2 and is referenced throughout the 
systematic review. 
In the studies, 16 used fMRI and 5 used EEG to explore the effects of oxytocin. The 
voxel based meta-analysis in fMRI studies included a total of 11 studies. Details of the 
literature search are described in the PRISMA flowchart in Figure 5.1 
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Task used Brain areas analysed Effects of oxytocin  
Baumgartner et 
al, 2008 
49 between M fMRI 24 IU Trust game 
Amygdala, Brainstem, 
Caudate, Putamen, Insula, 
Thalamus 
Increased trust in partner after trust had 
been violated 
Domes et al, 
2007 
13 within M fMRI 24 IU 
Implicit facial emotion processing 
by identifying gender of fearful, 
angry and happy faces 
Amygdala, Temporal Pole, 
TPJ, Thalamus, PFC 
Increased ability to identify emotions 
Domes et al, 
2010 
16 within F fMRI 24 IU 
Explicit facial emotion processing 
by rating arousal of fearful, angry 
and happy faces 
Amygdala, Brainstem, 
Temporal pole, Superior 
Temporal Gyrus, Fusiform 
gyrus, Insula, PFC, Thalamus 
Greater arousal in rating facial emotions 
Gamer et al, 
2010 
46 between M fMRI 24 IU 
Explicit facial emotion processing 
by classifying emotion of fearful 
and happy faces 
Amygdala, Superior Colliculus 
Increased ability to identify emotions, gaze 
starts at mouth and is redirected to eyes for 
longer 
Kirsch et al, 
2005 
15 within M fMRI 27 IU 
Implicit facial emotion processing 
by matching fearful and angry faces 
Amygdala, Brainstem Increased ability to identify emotion 
Labuschagne et 
al, 2010*† 
18 within M fMRI 24 IU 
Implicit facial processing by 
matching angry, fearful, happy and 
neutral faces 
Amygdala Insignificant decreases in amygdala activity 
Labuschagne et 
al, 2012* 
18 within M fMRI 24 IU 
Explicit facial processing using 
emotional classification of sad, 
happy and neutral faces 
mPFC, ACC, Thalamus, STG 
General attenuation in areas associated 
with processing social stimuli, cognitive 
control, and emotion regulation 
Lischke et al, 
2012 
14 within F fMRI 24 IU 
Explicit processing by rating 
emotional arousal of negative, 
positive and neutral scenes 
Amygdala, Temporal Pole, 
Fusiform gyrus 
Increased threat-sensitivity in amygdala to 
scenes depicting social and non-social 











Task used Brain areas analysed Effects of oxytocin  
Petrovic et al, 
2008 
27 between M fMRI 32 IU 
Aversely conditioned face 
processing by rating likeability of 
faces that were previously paired 
with a negative experience 
Amygdala, Anterior cingulate, 
vlPFC, fusiform area 
Increased likeability of faces even after 
being linked to aversive stimuli 
Pincus et al, 
2010** 
9 within 1M/8F fMRI 40 IU 
Explicit emotional processing using 
Reading of the Mind's Eye Test 
(RMET) by emotional classification 
Caudate, Amygdala, ACC, 
STG, GP 
Oxytocin increased activity in areas 
associated with reward and processing of 
social stimuli 
Riem et al, 2011 42 between F fMRI 24 IU Auditory exposure to babies crying Amygdala, Insula 
decrease in amygdala to sound clips of 
crying babies 
Riem et al, 2012 42 between F fMRI 16 IU
‡
 
Auditory exposure to infant 
laughter 
Connectivity between the 
Amygdala and the OFC, ACC, 
hippocampus, precuneus, 
supramarginal gyri and MTG 
Increased functional connectivity between 
the amygdala and other areas involved in 
regulating emotion and decrease in 
amygdala when listening to laughter over 
control noise 
Rilling et al, 
2012 
60 between M fMRI 24 IU Altruistic interaction 
Amygdala, Caudate, ventral 
PFC, Insula, Putamen 
Differences in activity in reciprocated and 
unreciprocated cooperativity, increase in 
Amygdala only in reciprocated interaction 
Singer et al, 
2008 
20 between M fMRI 32 IU 
Empathy for pain and experience of 
pain 
PFC, OFC, Amygdala 
no significant observations in response to 
viewing their partner in pain, reduced 
amygdala activation when receiving painful 
stimulation 
Sripada et al, 
2012 
15 within M fMRI 24 IU Resting state connectivity Amygdala to ACC/rmFC Increased connectivity during resting state 
Striepens et al, 
2012 
70 between M fMRI 24 IU 
Implicit processing of social scenes 
using a memory task with negative 
and neutral pictures paired with 
nouns 
Insula, Amygdala 
Increased memory for negative pictures at 
the expense of neutral stimuli which was 
accompanied by an increase  in the left 
insula and changes in connectivity between 











Task used Brain areas analysed Effects of oxytocin  
Wittfoth-
Schardt et al, 
2012 
21 within M fMRI 24 IU 
Implicit facial processing of familiar 
and unfamiliar faces 
Globus Pallidus, MTG, 
Caudate 
Reduced activity and functional connectivity 
to the GP from reward related regions to 
pictures of own child and unknown child 
         
Born et al, 1987 17 within M EEG 40 IU Auditory mismatch paradigm N2 and P3 no effect of oxytocin 
Fehm-
Wolfsdorf, 1988 
30 between M EEG 20 IU 
memory recall of 25 nouns, tone 
counting  
auditory evoked potentials 
no effect of oxytocin on memory or auditory 
stimuli 
Huffmeijer et al, 
2012 
47 between F EEG 
15.6 
IU 
Altruistic interaction frontal asymmetry 
increased donations from oxytocin 
corresponded with decrease in left/increase 
in right frontal activity 
Huffmeijer et al, 
2012 
48 within F EEG 16 IU 
combination of feedback 
processing and facial processing 
vertex positive potential 
(VPP) and late positive 
potential (LPP) 
more positive VPP and LPP after oxytocin 
which was heightened more for those 
experiencing less love withdrawal 
Perry et al, 2010 24 within M EEG 24 IU 
point-light experiment to mimic 
biological and non-biological 
motion 
mu rhythms 
better able to identify biological movement 
which corresponded to mu suppression 
across the whole scalp 
         
nr = not reported; OXT = oxytocin; IU = International Units;  M = male; F= female; ACC = Anterior cingulate cortex, PFC = Prefrontal cortex, mPFC = medial prefrontal cortex, vlPFC = ventro lateral prefrontal cortex, rmFC= 
rostro-medial frontal cortex GP =  Globus pallidum, STG = superior temporal gyrus, TPJ = temporo-parietal junction, VTA = ventral tegmental area 
sample size only incudes subjects used in the oxytocin and placebo samples. Other subjects may have also done the study under other arms 
 *also included 18 patients with generalised anxiety disorder but only results from healthy controls reported.  
 **also included patients with depression but only results from healthy controls are reported. 
†Excluded from analysis other than that of the amygdala because no direc_on of eﬀects were reported ‡ reported as 20 IU but later wrote an erratum to show that it was really 16 IU  
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5.3.2 SYSTEMATIC REVIEW 
The present systematic review aims to elucidate the role/effect of oxytocin in various 
regions of the brain and their corresponding networks. The specific brain areas 
modulated by oxytocin in each study are detailed in Table 5.2 and further details on 
the differences between oxytocin receptors and its administration between humans 
and animals can be found in the Supplementary Materials which are presented in the 
published paper.  
We have also assessed the magnitude of oxytocin effects by providing the Cohen’s d 
for specific brain areas in the complementary Table 5.3.  











et al., 2008 
49 between M 
Trust interaction as trustee with 





placebo   
Trust feedback ↓L/R Amygdala wb 
  
26 
oxytocin   
 
↓L Brainstem wb 
  
   
 
↓L/R Caudate wb 
  
   
 
↓L Postcentral gyrus 
(Superior parietal lobe) 
wb 
  
   
 
↓L Putamen/Insula wb 
  
   
     
   
Trust prefeedback ↑R Thalamus/pulvinar wb 
  
   
 
↓R ACC wb 
             
Domes et al., 
2007 
13 within M 
Implicit facial processing by 
indicating gender of happy, 
angry, fearful and neutral faces 
  
  
   
Implicit facial processing 
(fearful > neutral) 
↓L Paracentral gyrus wb 
  
   
 




   
 
↓L Medulla wb 
  






   
 




   
 
↓L MTG wb 
  
   













   
Implicit facial processing (angry 
> neutral) 
↓L Thalamus/Pulvinar wb 
  
   
 




   
 




   
     
   
Implicit facial processing (happy 
> neutral) 




   
 
↓L Paracentral gyrus wb 
  
   
 
↓L MTG wb 
             
Domes et al., 
2010 
16 within F 
Explicit facial processing by 
rating emotional arousal of 




   
Explicit facial processing (fearful 
> neutral) 










   
 






   
 
↑L STG wb 
  
   
 
↑L Insula wb 
  
   
 
↑R Cerebellum wb 
  
   
 
↑R Brainstem (SN) wb 
  
   
 
↓R dlPFC (SFG) wb 
  
   
     
   
Explicit facial processing (angry 
> neutral ) 




   
 




   
 
↑R dlPFC (MFG) wb 
  
   
 
↑L/R vlPFC (MFG) wb 
  
   
     
   
Explicit facial processing 
(happy > neutral) 
↑L MTG (Temporal Pole) wb 
  
   
 
↑R Hippocampus (Amygdala) wb 
  
   
 




   
 
↑L Fusiform gyrus (cerebellum) wb 
  
   
 
↑L Insula (postcentral gyrus) wb 
  
   
 




   
 
↑R Cerebellum wb 
  
   
 
↓R dlPFC (SFG) wb 
             
Gamer et al., 
2010 
46 between M 
Explicit facial processing 
by emotional 
classification of fearful, 





placebo   
Explicit facial processing 
(fearful > neutral) 
↓L/R Amygdala ROI 
  
23 
oxytocin   









Gender Task (contrast) Effect of oxytocin  
wb/ 
ROI 
    
  
Gazing toward eyes ↑R posterior Amygdala ROI 
  
   
     
   
Gazing toward mouth 
↑L/R Superior Colliculus 
(cerebellum) 
wb 
              
Kirsch et al., 
2005 
14 within M 
Implicit  emotional 
processing by matching 
fearful/threatening 
scenes and 




   
All social stimuli, but 
greater for faces 
↓L Amygdala ROI 
  




   





   
   
Labuschagne 
et al., 2012** 
18 within M 
Explicit facial processing 
using emotional 
classification of sad, 
happy and neutral faces 
    
  
   
Explicit facial processing 
(sad > neutral) 
↓R ACC wb 
  
   
 
↓R MFG wb 
  
   
 




   
 




   
 
↑L Thalamus wb 
  
   
     
   
Explicit facial processing 
(happy > neutral) 
↓L Cerebellum wb 
  
   
 
↓L Cerebellum/fusiform wb 
  
   
 
↓L Calcarine ﬁssure/cerebellum wb 
  
   
 
↓R mPFC (MFG) wb 
  
   
 
↓L MFG wb 
  
   
 
↓L Precuneus (cuneus) wb 
  
   
 
↑R STG (IFG) wb 
  
   
   
Lischke et al., 
2012 
14 within F 
Explicit processing by 
rating emotional arousal 
of negative, positive and 
neutral social scenes 
    
  
   
Explicit social processing 
(negative > neutral 
scenes) 
↑L/R Amygdala (/R Putamen) ROI 
  
   
↑L MTG wb 
  
   
 




   
 
↑L temporal pole: STG wb 
  
   
 
↑L postcentral gyrus wb 
  
   
   
  
   
Explicit social processing 
(positive > neutral 
scenes) 
↓R Supplementary motor cortex 
(SFG) wb 
  
   














27 between M 
Conditioned neutral 
faces with direct and 
indirect gaze to aversive 
stimuli (Implicit 
processing) 
    
  
12 
placebo   
Fear conditioning (main 
effect) 
↓R anterior MTL (MFG) ROI 
  
15 
oxytocin   
 
↓R vmPFC (ACC) wb 
  
   
 
↓L lateral OFC (IFG) wb 
  
   
 
↓R ACC wb 
  
   
 
↓R rostral ACC (MFG) wb 
  
   
 
↓L vlPFC (IFG) wb 
  
   
     
   
Fear conditioning for 
direct gaze 
↓R Amygdala (subcallosal gyrus) ROI 
  
   
 
↓L/R caudal ACC wb 
  
   
 
↓R subgenual ACC wb 
  
   
 
↑L vlPFC (MFG) wb 
  
   
 
↓R vlPFC (MFG) wb 
  
   
 
↓R fusiform face area wb 
             
Pincus et al., 
2010* 
9 within M/F 
Explicit facial processing 
using Reading of the 





(1M/8F) All stimuli ↑ L Caudate wb 
  
   
 
↑R Parahippocampal gyrus wb 
  
   
 
↑R Amygdala wb 
  
   
 
↑R Inferior frontal gyrus (MFG) wb 
  
   
 
↑L Len_form nucleus (GP) wb 
  
   
 
↑L Anterior cingulate wb 
  
   
 
↑R Parahippocampal gyrus wb 
  
   
 




   
 
↑L STG (MTG) wb 
  
   
 
↑L STG (MTG) wb 
  
   
 
↑L ACC (subcallosal gyrus) wb 
  
   
 
↑L ACC (MFG) wb 
  
   
   Riem et al., 
2011 
42 between F 
Auditory exposure to 
babies crying 
    
  
21 
placebo   
Implicit emotional 
processing (Infant's cry 
> control noise) 
↓R Amygdala (GP) ROI 
  
21 
oxytocin   
↑L Planum polare (STG) wb 
  
   
 
↑R IFG (Insula) wb 
             
Riem et al, 
2012 
42 between F 





placebo   
Implicit emotional 
processing (Infant's 
laughter > control noise) 




oxytocin   









Gender Task (contrast) Effect of oxytocin  
wb/ 
ROI 
    
  
Connectivity (laughter > 
control noise) 




   
 




   
 




   
 





   
 




   
 




   
 




   
 





   
 




   
 





   
   Rilling et al., 
2012 
60 between M 
Altruistic interaction 
using the prisoner's 
dilemma  
    
  
34 
placebo   
Reciprocated 
cooperation 





oxytocin   
 




   
 
↑R Putamen/Insula wb 
  
   
     
   
Unreciprocated 
cooperation 
↑L vlPFC (MFG) wb 
  
   
 
↑L vmPFC (MFG) wb 
  
   
     
   




   
 




   
 





   
 





   
 





   
 




   
 




   
 





   
 




   
 




   
 
↓R Amygdala - L MFG 
ROI
/wb 
             
Singer et al., 
2008 
20 within M 
Empathetic responses 




   
Pain inflicted in self ↑R mOFC (IFG) wb 
  
   
 













   
 
↓R Amygdala/Striatum (GP) ROI 
  
   
     
   
Pain inflicted in self 
(prosocial>selfish) 
↓L fronto-insular PFC (MFG) wb 
  
   
 
↓L mPFC (MFG) wb 
  
   
Pain inflicted in self 
(selfish>prosocial) 
↓L Amygdala wb 
  
   
 




   
     
   
Pain inflicted in other ↓R OFC (IFG) wb 
              
Sripada et 
al., 2012 
15 within M 
Resting state 
connectivity 
↑R Amygdala - ACC/rmFC 
ROI
/wb 
              
Striepens et 
al., 2012 
70 between M 
Implicit processing of 
social scenes using a 
memory task with 
negative and neutral 
pictures paired with 
nouns 
  
  35 placebo 
 
Later remembered 
negative > later 
forgotten neutral 
↑L anterior insula (IFG) wb 
  35 oxytocin 
 
Negative and neutral > 
baseline 
↑R Amygdala ROI 
  
   
Negative > baseline ↑R Amygdala ROI 
  
   
Neutral > baseline ↑R Amygdala ROI 
  
   
     
   




   
Connectivity (negative > 
neutral stimuli) 




   
 




   
 





   




21 within M 
Implicit facial processing 
where fathers viewed 
pictures of their own 
child, a familiar and 
unfamiliar child 
    
  
   
Implicit facial processing 
(own child > familiar 
child) 
↓L Globus Pallidus ROI 
  
   
     
   
Implicit facial processing 
(unfamiliar child > 
familiar child) 
↓L Globus Pallidus (Putamen) ROI 
  
   
↓L precentral gyrus wb 
  
   
 
↓L Hippocampus (Amygdala) ROI 
  
   
 
↓L/R MTG (L STG/ R ITG) wb 
  
   
 
↓L STG wb 
  
   
 




   
   
  
   
Implicit facial processing 
(own child > unfamiliar 
child) 













   
     
   
Connectivity (own child 
> familiar child) 




    




    




    
↓L GP - R superior parietal lobe 
ROI
/wb 
             
        
ROI - Region of interest, wb - whole brain analysis;  M = male; F= female; IU – International Units; ACC - Anterior Cingulate Cortex, MFG 
- Medial Frontal Gyrus, MTG - Medial Temporal Gyrus, STG - Superior Temporal Gyrus, ITG - Inferior Temporal Gyrus, SN -  Substantia 
Nigra, PFC -  Prefrontal Cortex, dlPFC - dorsolateral Prefrontal cortex, vlPFC - ventrolateral prefrontal cortex, mPFC - medial Prefrontal 
Cortex, rmPFC - rostral medial Prefrontal Cortex, IFG - Inferior Frontal Gyrus, OFC - Orbitofrontal  Cortex, lOFC - lateral Orbitofrontal 
Cortex, mOFC - medial Orbitofrontal cortex, GP - Globus Pallidus 
* also used patients with depression but only results for healthy controls are reported here **also used patients with social 
anxiety but only results for healthy controls are reported here 
 
Areas in italics represent areas that were different when the coordinates were entered into Talairach client, all other areas are those 
reported by the studies listed 
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TABLE 5.3 – Overview of neural effects of oxytocin on different brain areas 
Table 3a Effect of OXT on the Insula 
 







al. (2010) 24 M Trust interaction trust game postfeedback  0.92  -  
Domes et al. 
(2010) 








        happy > neutral†     - 
 
Riem et al. 
(2011) 24 F listening to infant crying infant cry > control noise*  -     
Rilling et al 
(2012) 24 M Trust interaction reciprocated cooperation  -  0.91  
Striepens et al. 
(2012) 24 M Implicit processing of social scenes 
later remembered negative > later 
forgotten neutral† 
 1.47  - 
 
 
    
        
 
Table 3b Effect of OXT on the Thalamus 
 







al. (2008) 24 M Trust interaction trust game prefeedback  -  1.03  
Domes et al. 
(2007) 24 M Implicit facial processing fearful > neutral  1.69  -  
Domes et al. 
(2010) 24 F Explicit facial processing angry > neutral*     -  
Labuschagne et 
al. (2012) 
24 M Explicit facial processing sad > neutral  1.27  - 
 
 







Table 3c Effect of OXT on the Basal Ganglia   










24 M Trust interaction trust game postfeedback  0.81  0.9 Caudate 
  
   
 -  0.84 Caudate 
   
   
 -  0.84 Caudate 
   
   
 0.92  - Putamen 
Domes et al. 
(2010) 24 F Explicit facial processing fearful > neutral*  -    Brainstem (SN) 
Lischke et al. 
(2012) 24 M Emotion arousal rating task negative > neutral scenes
†  -    Putamen (ROI) 
Pincus et al. 
(2010) 
40 M/F Explicit facial processing across all facial valances  1.97  - Caudate 
  
  
across all facial valances†  2.12  - Caudate 
   
   
 1.86  - Globus Pallidus 
Rilling et al. 
(2012) 
24 M Trust interaction reciprocated cooperation  1.03  - Caudate  
    
 -  0.91 Putamen 
Wittfoth-Schardt 
et al. (2012) 
24 M 
Viewing familiar or unfamiliar child 
own child > unfamiliar child     - Caudate 
  
 
own child > familiar child  
 
 - Globus Pallidus 
  
  





          Table 3d Effect of OXT on the Temporal Lobes   








Domes et al. 
(2007) 





 1.38  - MTG 
   
 
  happy > neutral  1.45  1.44 STG 
           1.38  - MTG 
Domes et al. 
(2010) 
24 F Explicit facial processing fearful > neutral     - MTG (Temporal pole) 
  
     
 
 - STG 
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Table 3d Effect of OXT on the Temporal Lobes    










  happy > neutral  
 
 - MTG (Temporal pole) 
 
  
     
 
 - STG 
 
  
        - fusiform gyrus 
Labuschagne et 
al. (2012) 24 M Explicit facial processing happy > neutral  -  1.67 STG 
Lischke et al. 
(2012) 
24 F Emotional arousal rating task negative > neutral scenes     - STG (temporal pole) 
  
 
     
 
 - MTG 
  
            - 
inferior temporal 
gyrus (fusiform gyrus) 
Petrovic et al. 
(2008) 
32 M Fear conditioning to faces main effect  1.49  - MTG 
      fear conditioning with direct gaze  -  1.49 Fusiform gyrus 
Pincus et al. 
(2010) 
40 M/F Explicit facial processing    1.97  - STG (MTG) 
         1.85  - STG (MTG) 
Riem et al. 
(2011) 24 F Listening to infant crying infant cry > control noise     - planum polare (STG) 
Wittfoth-Schardt 
et al. (2012) 
24 M 
Viewing familiar or unfamiliar child 
(implicit facial processing) 
unfamiliar child > familiar child       MTG 
  
   
 
 
 - STG 
         
Table 3e Effect of OXT on the PFC   








Domes et al. 
(2007) 24 M Implicit facial processing fearful > neutral  1.38  - MFG (dlPFC) 
Domes et al. 
(2010) 
24 F Explicit facial processing fearful > neutral  -    dlPFC 
  
 






    




   
happy > neutral  -    dlPFC 
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Table 3e Effect of OXT on the PFC 
Author (year) 








   
happy > neutral  1.39  - MFG 
 
    
 -  1.29 mPFC 
           -  1.21 mPFC 
Petrovic et al. 
(2008) 
32 M Fear conditioning main effect  -  1.66 vlPFC 
        direct gaze  1.9  2.02 vlPFC 
Pincus et al. 
(2010) 
40 M/F Explicit facial processing    -  1.87 Inferior frontal gyrus 
Rilling et al. 
(2012) 
24 M Trust interaction unreciprocated cooperation  0.92  - vlPFC 
  
  
   0.92  - vmPFC 
Singer et al. 
(2008) 
32 M Observing pain inflicted in self and 
others 
pain in self  -    mOFC 
  
  
 -  
 
lOFC 
   
  




 - fronto-insular PFC 
   
   
 
 
 - mPFC 
   
  




         
Table 3f Effect of OXT on the Amygdala   








al. (2008) 24 M Trust interaction trust game postfeedback  -  - wb 
Domes et al. 
(2007) 
24 M Implicit facial processing fearful > neutral  -  0.91 ROI 
  angry > neutral  -  1.05 ROI 
        happy > neutral  -  0.91 ROI 
Domes et al. 
(2010) 
24 F Explicit facial processing fearful > neutral  0.79  - wb 
  happy > neutral*  -  0.39 wb 
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Table 3f Effect of OXT on the Amygdala  
Author (year) 









   -  - ROI 
      Gaze at faces gaze preference to eyes  0.99  - ROI 
Kirsch et al. 
(2005) 
27 M 
Implicit facial and scene processing 
main effect for faces and scenes  1.02  - ROI 
  main effect for faces  0.83  - ROI 




Implicit facial processing 
angry > neutral  -  - ROI 
  fearful > neutral  -  - ROI 
   happy > neutral  -  - ROI 
Petrovic et al. 
(2008) 
32 M Fear conditioning (direct gaze) gaze to negative stimulus > neutral  -  0.96 ROI 
main effect  -  - ROI 
Pincus et al. 
(2010) 40 M/F Explicit facial processing reading of the mind's eye task  -  1.33 wb 
Riem et al. 
(2011) 24 F Listening to crying babies cry > control noise  -  0.43 ROI 
Riem et al. 
(2012) 16 F Listening to laughing babies laughter > control noise       
ROI 
Rilling et al. 
(2012) 
24 M Trust interaction reciprocated cooperation  0.47  - wb 
  
[(reciprocated cooperation human > 
computer) OXT > (reciprocated 
cooperation human > computer) 
Placebo] 
 1.03  - wb 
Singer et al. 
(2008) 
32 M Empathy for pain pain in self  -  0.64 ROI 
  
self, placebo > oxytocin, selfish > 
prosocial  
 0.64  
 
wb 
       0.75 ROI 
Striepens et al. 
(2012) 
24 M Implicit scene processing and 
subsequent memory test 
negative and neutral > baseline  -    ROI 
  negative > baseline  -  ROI 
   neutral > baseline  -    ROI 
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Table 3f Effect of OXT on the Amygdala    








et al. (2012) 
24 M Viewing familiar or unfamiliar child 
viewing own child, familiar child, 
unknown child 
 -  - ROI 
                  
the arrows indicate the direction of differences in BOLD response during the selected contrast (significant differences are highlighted in bold: p<0.05); studies that did not provide enough information to 
calculate effect size were left blank; all doses are in IU, intranasal units; OXT = oxytocin; M = male; F= female; ROI = region of interest; wb = whole brain; MFG = Medial Frontal Gyrus; MTG = Medial 
Temporal Gyrus; STG = Superior Temporal Gyrus; SN =  Substantia Nigra; PFC =  Prefrontal Cortex; dlPFC = dorsolateral Prefrontal cortex; vlPFC = ventrolateral prefrontal cortex; mPFC = medial Prefrontal 




5.3.3 FMRI STUDIES IN HUMANS 
5.3.3.1 REWARD SYSTEM  
Social learning is largely influenced by how reward is processed in the reward system 
and can be modulated by oxytocin manipulation. The reward system is influential in 
social behaviour by driving the evaluation and interpretation of choices and their 
associated values (Adolphs, 2003). It also houses a large proportion of the oxytocin 
receptors in the human brain, the highest concentration of which is located in the 
substantia nigra (SN) (Loup et al., 1991; Loup et al., 1989), an area heavily implicated in 
reward processing and prediction error and dopamine signalling (Gimpl and 
Fahrenholz, 2001; Loup et al., 1991; Loup et al., 1989). However, this area is very small, 
and its between subjects variability makes it difficult to show robust activation in 
human imaging studies. Thus, its relative omission from the current human imaging 
studies in oxytocin is not surprising. However, the SN still plays a role in reward 
mediated social behaviours due to its influence over other areas of the basal ganglia, 
such as the caudate and putamen, the limbic system, and other areas of the brain that 
have shown consistent changes in brain activity after oxytocin administration. After 
correcting for location by standardising to Talaraich coordinates, one study that had 
originally reported finding activation after oxytocin administration in the brainstem 
showed that oxytocin elicited increased activation in the right SN while explicitly 
processing fearful faces over neutral faces (Domes et al., 2010). 
We examined six studies addressing the reward system after oxytocin administration 
(Baumgartner et al., 2008; Domes et al., 2010; Lischke et al., 2012; Pincus et al., 2010; 
Rilling et al., 2012; Wittfoth-Schardt et al., 2012), and we review the available evidence 
in each of the above areas of interest (Basal Ganglia: comprised of Caudate, Putamen, 
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and Globus Pallidum(GP)). We found that oxytocin administration has an effect over 
reward related learning in that it seems to increase activation associated with reward 
related learning in the Caudate while decreasing learning effects. It has a similar 
influence on activation in the Putamen but is specific to learning during social 
interactions. How oxytocin affects neural activity during social tasks in the GP is less 
clear but it appears to play a role in attachment. We review the available evidence in 
each of the above areas of interest below.  
5.3.3.1.1 BASAL GANGLIA 
We identified six studies addressing oxytocin effects on the activation within the basal 
ganglia (five using whole brain analysis) (Baumgartner et al., 2008; Domes et al., 2010; 
Lischke et al., 2012; Pincus et al., 2010; Rilling et al., 2012; Wittfoth-Schardt et al., 
2012), see Table 5.3. The basal ganglia are important areas for reward processing in 
the brain and are comprised of: (i) the globus pallidum (GP) (Pincus et al., 2010; 
Wittfoth-Schardt et al., 2012), (ii) the substantia nigra (SN) (Domes et al., 2010), (iii) 
putamen (Baumgartner et al., 2008; Lischke et al., 2012; Rilling et al., 2012), (iv) 
caudate (Baumgartner et al., 2008; Pincus et al., 2010; Rilling et al., 2012; Wittfoth-
Schardt et al., 2012) and (v) ventral striatum. Some of these areas, such as the ventral 
striatum, show strong connections to the amygdala (Adolphs, 2003) and are important 
in reward based learning, by interpreting actions and their corresponding outcomes to 
make future decisions (Adolphs, 2003).  
5.3.3.1.1.1 CAUDATE 
The caudate plays a role in feedback processing when there exists a perception of 
contingency between the action and outcome, especially when the task incorporates 
an element of trust (Gromann et al., 2013; King-Casas et al., 2005; Montague et al., 
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2006; O'Doherty, 2004; Tricomi et al., 2004), therefore the caudate is an important 
region to address when exploring the effects of oxytocin administration as it may help 
modulate how decisions are made based on preconceptions of trust. Four studies have 
addressed the role of the caudate after oxytocin administration (Baumgartner et al., 
2008; Pincus et al., 2010; Rilling et al., 2012; Wittfoth-Schardt et al., 2012). The 
correlation between action and outcome in terms of action contingency appears to be 
activated exclusively within the left caudate and activation correlates with prediction 
error during instrumental conditioning (O'Doherty, 2004; Tricomi et al., 2004). On the 
other hand, bilateral activation of the caudate is observed in games involving trust 
where increased activity was related to an “intention to trust” (King-Casas et al., 2005; 
Montague et al., 2006). Furthermore, increased activation within the caudate has been 
shown to correlate with more benevolent partners (Delgado et al., 2005a; King-Casas 
et al., 2005) by reinforcing actions which could potentially lead to further rewards 
(Tricomi et al., 2004). In a task using a simple trust interaction involving money 
between two parties, Baumgartner et al. (2008) found that activation in the bilateral 
caudate was attenuated by oxytocin administration after receiving feedback about the 
trustworthiness of a supposed human partner they had just interacted with. In 
contrast, using a standard Prisoner’s Dilemma paradigm to explore trust, Rilling et al. 
(2012) found that the left caudate was significantly activated after oxytocin 
administration in response to trustworthiness in the form of reciprocated cooperation 
in human opponents but there was no change in activation in the caudate after 
unreciprocated cooperation thus reinforcing its role in action contingency. It is 
important to note that the differences between these findings may be attributed to 
the fact that Baumgartner et al. (2008) did not distinguish between trust affirming and 
trust negating trials or reciprocated and unreciprocated trust and, as such, the 
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difference in caudate activity may be due to differences in trial types between the 
studies. Another explanation for the diminished activity may be that caudate activation 
diminished as learning progressed or that they believed their partner to be morally 
“good” (Delgado et al., 2005a; Delgado et al., 2005b; King-Casas et al., 2005). 
Furthermore, the increased activation in the caudate after oxytocin administration 
may have predicted their belief in the likelihood of future cooperation (King-Casas et 
al., 2005).  
The caudate is also of interest in other studies incorporating the processing of social 
stimuli such as novel and familiar faces. A study by Wittfoth-Schardt et al. (2012) had 
fathers view pictures of their own child, a familiar child and an unfamiliar child after 
being administered oxytocin. They reported that oxytocin administration increased 
activation in the left caudate when men viewed their own child versus an unfamiliar 
child. This may reflect the enhanced rewarding effects of parental attachment with 
one’s own child - which is augmented by oxytocin administration. A study by Pincus et 
al. (2010) also showed an increase the neural activation in the left caudate after being 
administered oxytocin while assessing social stimuli during a reading of the mind’s 
eyes task. Furthermore, Labuschagne et al. (2010) showed a main effect of oxytocin in 
the activation within the left caudate while explicitly processing emotional faces by 
matching angry, happy and fearful faces. These interactions may potentially reflect the 
neural effects of learning, attachment and evaluating novelty in terms of learning 
reward contingencies when combined with oxytocin administration, showing that 






The putamen is adjacent to the caudate and plays a role in associative learning 
(Haruno and Kawato, 2006). It has been demonstrated to show greater activation, 
relative to the caudate, during performance of actions associated with reward but 
shows similar levels of activation, relative to the caudate, when still learning the 
optimal action associated with a reward (Hikosaka et al., 2002). Three studies have 
addressed the changes in the activation of the putamen after being administered 
oxytocin (Baumgartner et al., 2008; Lischke et al., 2012; Rilling et al., 2012). Two 
studies included in the systematic review used trust interactions to demonstrate 
greater activation in the putamen extending into the insula after being given oxytocin 
and having received feedback about their partner (Baumgartner et al., 2008; Rilling et 
al., 2012). One study by Rilling et al. (2012) used a Prisoner’s dilemma game to 
demonstrate greater activation in the right putamen as a response to reciprocated 
cooperation after oxytocin was administered. Another study used a trust game (King-
Casas et al., 2005) to demonstrate an attenuation in the activation within the left 
putamen following feedback on a partner’s trustworthiness after oxytocin 
administration (Baumgartner et al., 2008). A study in females by Lischke et al. (2012) 
showed that the right putamen was more active after receiving oxytocin when rating 
negative scenes over neutral scenes. However, the activation observed in the putamen 
was part of a region of interest analysis centred around the amygdala and activation in 
these regions was not evident during whole brain analysis. Overall, the putamen only 
showed reliable changes in activation after oxytocin administration during games 
involving trust manipulations and when there was concurrent activation within the 
caudate. Therefore, the putamen may play a role, alongside the caudate, during the 
processing of rewards related to interactions with other people.  
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5.3.3.1.1.3 GLOBUS PALLIDUS (GP) 
Another area of the reward system that has been implicated in oxytocin studies, albeit 
to a lesser extent, is the GP, which has been associated with general reward signal 
processing (Hong and Hikosaka, 2008) as well as maternal attachment (Bartels and 
Zeki, 2004; Leibenluft et al., 2004). Although we recognise that the GPe and GPi have 
different functions, restrictions in the number of studies involving the GP made it 
difficult to draw further conclusions on subsections. Two studies have addressed 
oxytocin administration on activation within the GP (Pincus et al., 2010; Wittfoth-
Schardt et al., 2012). A recent study by Wittfoth-Schardt et al. (2012) showed that 
oxytocin administration attenuated activity in the GP when viewing one’s own child 
versus viewing a familiar child as well as viewing an unfamiliar child versus a familiar 
child. This suggests a role for oxytocin administration in attenuating activation in the 
GP related to reward and novelty and also coincides with areas associated with 
maternal attachment (Bartels and Zeki, 2004; Leibenluft et al., 2004).. The earlier study 
by Pincus et al. (2010) also showed an effect of oxytocin administration in the 
activation within the left GP during a reading of the mind’s eye task. However, these 
findings in the GP after oxytocin administration have not been robustly replicated. 
5.3.3.2 TEMPORAL LOBES 
Although primarily known for their role in auditory processing (Simons et al., 2010) and 
vision, the temporal lobes also play an important role in memory and the 
interpretation of social cues through visual processing and spatial recognition to help 
determine socially relevant information (Adolphs, 2001; Allison et al., 2000). The 
temporal lobes are also known to be a target of output from the basal ganglia 
(Middleton and Strick, 1996) which may show how oxytocin administration influences 
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neural processes in this area through learning and reward processing of social stimuli. 
Of the areas in the temporal lobe, the middle and superior temporal gyrus (MTG and 
STG) have been shown to be consistently activated in studies involving human 
emotional face processing (Fusar-Poli et al., 2009) and during mentalising, or theory of 
mind (Fett et al., 2013; Frith and Frith, 2005; Hampton et al., 2008). Eight of the twelve 
studies reporting whole brain findings found differential activation in the temporal 
lobe after oxytocin administration, most of which used faces as social stimuli (Domes 
et al., 2007a; Domes et al., 2010; Labuschagne et al., 2011; Lischke et al., 2012; 
Petrovic et al., 2008; Pincus et al., 2010; Riem et al., 2011; Wittfoth-Schardt et al., 
2012), see Table 5.3. Additionally, another study found that connectivity to the 
temporal lobe from the amygdala was increased after oxytocin administration (Rilling 
et al., 2012). This consistency of activation made this the most robust region showing 
activation after oxytocin administration.  
Domes et al. (2007a) used implicit facial processing in men to demonstrate  decreases 
in the activation within the left MTG and bilateral STG after oxytocin administration in 
response to happy facial stimuli; as well as increased activation within the left inferior 
temporal lobe and MTG in response to fearful facial stimuli. On the other hand, Domes 
et al. (2010) used an explicit facial processing task in women to show increased 
activation in the left MTG and STG after oxytocin administration in response to happy 
and fearful facial stimuli. Labuschagne et al. (2010) used explicit and implicit 
processing tasks in males to show a main effect of oxytocin administration on the 
activation within the left MTG and bilateral STG when implicitly processing a range of 
emotional faces, although the direction of this effect was not reported. In a follow-up 
report, Labuschagne et al. (2011) showed increased activation within the right STG 
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after oxytocin administration while explicitly processing happy faces. Wittfoth-Schardt 
et al. (2012) also showed that, in men, activation is attenuated in the bilateral MTG 
and left STG after oxytocin administration when implicitly processing the faces of an 
unfamiliar child versus a familiar child. This effect of oxytocin administration on neural 
attenuation associated with facial valence is not just limited to the processing of faces 
but extends to influencing activity where negative stimuli have been paired with faces. 
In a task pairing a shock with different faces to condition for fear, Petrovic et al. (2008) 
showed attenuation in the activation within the right anterior MTG after being 
administered oxytocin across all fear conditioning trials. However, increased activity 
when viewing faces appears to be mainly evident in women as Lischke et al. (2012) 
asked women to rate the emotional arousal from a series of faces, and demonstrated 
greater activation in the STG and inferior temporal gyrus (ITG) after being 
administered oxytocin. Furthermore, a study by Pincus et al. (2010) using mainly 
women (8 out of 9 subjects) showed greater activation in the STG after being 
administered oxytocin during the reading of the mind’s eye task. A similar increase in 
activation within the STG activation was reported in women administered oxytocin 
before auditory stimuli of crying infants by Riem et al. (2011). It is important to note 
that all of these studies in women used explicit emotional processing - except for the 
study by Riem et al. (2011) - while the studies in the men used tasks with implicit facial 
processing  - except the study by Labuschagne et al. (2011) who also showed increased 
activation in the temporal lobes after oxytocin administration, contrary to other 
studies in males. Thus, task type, as well as gender, may play a large role in how 
oxytocin administration affects neural activity in the temporal lobes. 
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Of the areas in the temporal lobes associated with social processing, the fusiform gyrus 
has been the area most consistently activated in response to tasks incorporating facial 
stimuli (McCarthy et al., 1997a) and is known to be modulated by facial valence (Pujol 
et al., 2009). Neural activity in this area has also been shown to be modulated by 
oxytocin administration. In women, Domes et al (2010) (Domes et al., 2010) showed an 
increase in activation across various regions of the temporal lobes after being 
administered oxytocin when viewing fearful and happy faces but not angry faces. 
However, in men, Petrovic et al. (2008) showed a decrease in activation in the left MTG 
and right fusiform gyrus following oxytocin administration after fear conditioning using 
faces with direct gaze. Overall, oxytocin administration appears to play a role in the 
increase and decrease of activity in the temporal lobes with gender specific effects; 
where oxytocin administration increases activation in the temporal lobes in women 
and generally attenuates activation in the temporal lobes in males. However, this 
difference in activation by gender within the temporal lobes may also be due to the 
variability in task types; oxytocin administration may attenuate activation in the 
temporal lobes during implicit facial processing but may increase activation in the 
temporal lobes during explicit facial processing.  
5.3.3.3 INSULA 
The activation of the insula after oxytocin administration may reflect neural processing 
to minimise risk prediction errors (Preuschoff et al., 2008) and reward anticipation in a 
social context (Villafuerte et al., 2012; Wittmann et al., 2010). Activity in the insula may 
also be associated with emotion regulation(Phan et al., 2002b) and facilitating a sense 
of emotional involvement when interacting with others in a trust game (Singer et al., 
2004). Its activation during trust games implicates it in making decisions about the risk 
179 
 
of trusting another person during social interactions. Five studies in our review have 
investigated neural activity in this area (Baumgartner et al., 2008; Domes et al., 2010; 
Riem et al., 2011; Rilling et al., 2012; Striepens et al., 2012). Overall, activity in the 
insula is generally augmented after oxytocin administration, suggesting a heightened 
role in modulating risk prediction and reward anticipation in a social context. There 
does not appear to be a significant effect by gender in this area. Furthermore, our 
meta-analysis of all whole brain imaging data found the left insula to be the most 
robustly activated area between all the studies included in the meta-analysis (Figure 
5.2).  
In a trust game, Baumgartner et al. (2008) showed attenuation of activation within the 
left putamen and insula after oxytocin administration in response to all feedback about 
their partner’s trustworthiness while Rilling et al. (2012) demonstrated an increased 
activation in the right putamen and insula after oxytocin administration following 
reciprocated cooperation but not unreciprocated cooperation. This may show a 
lateralisation of oxytocin’s effect on the processing of trust related stimuli in the 
putamen and insula or may reflect a difference caused by cooperation bias that was 
not explicitly established by Baumgartner et al. (2008) as they did not differentiate 
between cooperative and uncooperative trials.  
The insula is also important in evaluating tasks with an element of emotional 
processing. Domes et al. (2010) found that, in women only, oxytocin administration 
intensified activation in the insula in  response to fearful and happy emotional faces 
compared to neutral faces when asked to identify gender. Another study in women by 
Riem et al. (2011) also demonstrated a greater activation within the insula after being 
administered oxytocin and listening to a crying infant. This effect may reflect an 
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implicit empathising that is intensified by oxytocin administration in women but not 
men. However, using men, Striepens et al. (2012) also showed an increase in activation 
within the left anterior insula after being given oxytocin when viewing negative social 
scenes that were later remembered over neutral social scenes that were later 
forgotten. This may reflect the role of the insula in the recall of emotional information. 
They went on to show that the connections between the insula and other regions were 
also important in determining which negative social scenes were remembered over 
neutral social scenes after being administered oxytocin. Furthermore, functional 
connectivity increased between the left anterior insula and the left inferior frontal 
gyrus (IFG) as well as the left basolateral amygdala after being administered oxytocin. 
However, connectivity between the right amygdala and left insula was attenuated 
after receiving oxytocin. Of these areas, the basolateral amygdala was shown to be the 
major projection area of oxytocin-related sharing of information between the left 
insula and the left amygdala, suggesting that the insula may have been using some of 
the modulatory functions of the amygdala to bias emotional processing (Striepens et 
al., 2012).  
5.3.3.4 LIMBIC AND PARALIMBIC SYSTEM 
The limbic system is important in the regulation of autonomic and endocrine 
functioning as well as the processing and response to emotional stimuli (for a review 
see (Phan et al., 2002b)). 
All of the fMRI studies presented in this review have investigated some aspect of the 
limbic system (Baumgartner et al., 2008; Domes et al., 2007a; Domes et al., 2010; 
Gamer et al., 2010a; Kirsch et al., 2005; Labuschagne et al., 2010, 2011; Lischke et al., 
2012; Petrovic et al., 2008; Pincus et al., 2010; Riem et al., 2011; Rilling et al., 2012; 
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Singer et al., 2008; Sripada et al., 2012; Striepens et al., 2012; Wittfoth-Schardt et al., 
2012). Its role has been one of the focuses of neuroendocrine research, most notably 
oxytocin, and has mainly revolved around the role of the amygdala, which is explored 
in greater detail below. This systematic review explores the role of other areas in the 
limbic system in addition to the amygdala and their contribution and importance for 
this neuropeptide.  
5.3.3.4.1 AMYGDALA 
In all the fMRI studies involving oxytocin administration retrieved in the present 
systematic review, aside from one (Wittfoth-Schardt et al., 2012), one of the main 
regions of interest was the amygdala, see Table 5.3. Its involvement in numerous 
animal studies have implicated it as an important area for oxytocin binding and release 
(Gimpl and Fahrenholz, 2001; Huber et al., 2005). In humans, its role in social cognition 
(Adolphs et al., 1998) and, notably, facial processing (Fusar-Poli et al., 2009) have 
established the amygdala as a very important region in oxytocin research. Although no 
oxytocin receptors have been detected in the amygdala in any human studies (Gimpl 
and Fahrenholz, 2001; Loup et al., 1991; Loup et al., 1989) its size in humans has been 
shown to vary in relation to the oxytocin gene (Furman et al., 2011; Inoue et al., 2010) 
and it is consistently implicated in studies involving oxytocin administration (Table 5.3).  
Studies using implicit processing of social stimuli consistently found attenuated 
activation within the amygdala after being administered oxytocin (Domes et al., 2007a; 
Kirsch et al., 2005; Petrovic et al., 2008; Riem et al., 2011). However, pairing implicit 
facial processing with a negative stimulus to condition for fear showed non-significant 
attenuation in the amygdala (Petrovic et al., 2008). In tasks using explicit processing of 
social stimuli, there were more mixed results for the direction of activation in the 
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amygdala resulting from oxytocin administration. However, when separating for 
gender, in studies involving all or mainly females, oxytocin administration increased 
activation in the amygdala (Domes et al., 2010; Pincus et al., 2010) but in males 
oxytocin administration attenuated activation in the amygdala (Gamer et al., 2010a). In 
a study involving a trust interaction, oxytocin administration increased activation in the 
amygdala when cooperation was reciprocated and this increase in activation was 
shown to be specific to when a subject was told they were playing another human 
versus a computer. These studies show that the type of study and gender play a large 
role in how oxytocin influences activity in the amygdala. It is also important to note 
that only three of these studies reported activation in the amygdala significant at a 
whole brain level (Domes et al., 2010; Rilling et al., 2012; Singer et al., 2008); the 
majority of these studies used region of interest (ROI) analysis or small volume 
correction (SVC) to extract significant activation within the amygdala. Two other 
studies used ROI analysis and reported insignificant findings bilaterally (Baumgartner 
et al., 2008; Labuschagne et al., 2010). Furthermore, our meta-analysis of all studies 
reporting whole brain fMRI findings did not show any hypo- or hyperactivation of the 
amygdala in response to oxytocin administration during tasks using emotional stimuli 
(Figure 5.2, Table 5.4).  
5.3.3.5 THALAMUS 
The thalamus has been implicated in various studies involving oxytocin administration. 
Its involvement may be due to its connections with other regions of the brain which 
help mediate and control social interactions and behaviour. In addition to serving as 
the brain’s relay board, the thalamus has been associated with selective attention and 
levels of arousal (Baumgartner et al., 2008; Portas et al., 1998) as well as consciousness 
183 
 
(Posner, 1994) and may be utilised to relay and modulate important emotional and 
cognitive information (Shane et al., 2008). During a trust game, oxytocin 
administration increased the amount of activity in the right thalamus before being 
given feedback on the outcome of the game (Baumgartner et al., 2008). However, in 
an implicit emotion processing task where subjects viewed faces of varying facial 
valence at varying intensities, oxytocin administration attenuated activation in the left 
thalamus in response to angry faces (Domes et al., 2007a) and in another study using 
explicit emotional processing, where subjects had to match faces with the same facial 
valence, there was a main effect of oxytocin administration in the left thalamus for sad 
facial valence (Labuschagne et al., 2010) and angry facial valence (Domes et al., 2010). 
Together, these findings may reflect differential mediation and relaying of signals from 
emotional stimuli to corresponding areas connected to the thalamus which varies with 
task design. 
5.3.3.6 PREFRONTAL AND ANTERIOR CINGULATE CORTEX 
One area associated with the limbic system is the prefrontal cortex (PFC) and the 
anterior cingulate cortex (ACC). Most of the imaging studies using males have shown 
that oxytocin administration attenuates activation within both of these regions during 
the processing of social stimuli (Baumgartner et al., 2008; Labuschagne et al., 2011; 
Petrovic et al., 2008; Singer et al., 2008). Overall, the studies show that, at least in 
men, the involvement of the OFC and ACC are minimised after oxytocin administration. 
Furthermore, attenuated activity in the dorso and ventrolateral PFC after oxytocin 
administration may be indicative of an attenuated need for emotion regulation and 
cognitive control.  
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The PFC is important for social interactions due to its role in aiding action selection and 
evaluation (Kennerley et al., 2011) as well as facial processing (Fusar-Poli et al., 2009) 
and mentalising, or interpreting the actions of others (Frith and Frith, 2005). 
Specifically, the roles of the ACC and orbitofrontal cortex (OFC) are important in 
helping to compute the value of various choices (Kennerley et al., 2011). More 
specifically, the OFC is important for evaluating current choices while the ACC encodes 
choice predictions (Kennerley et al., 2011). Most of the imaging studies using males 
have shown that oxytocin administration attenuates both of these regions during the 
processing of social stimuli(Baumgartner et al., 2008; Labuschagne et al., 2011; 
Petrovic et al., 2008; Singer et al., 2008). However, one study in mainly females, 
showed an increase in activation within the ACC after being administered oxytocin and 
performing a reading of the minds eyes task (Pincus et al., 2010). This may reflect a 
gender difference in how social stimuli are evaluated after being administered 
oxytocin but there are not enough studies to reach a strong conclusion. Overall, the 
studies show that, at least in men, the involvement of the OFC and ACC are minimised 
after oxytocin administration and may indicate a greater efficiency in evaluating social 
stimuli. 
Other areas of the prefrontal cortex (PFC) such as the dorsolateral PFC (dlPFC), which is 
involved in cognitive control (Rilling and Sanfey, 2011; Wood and Grafman, 2003), and 
ventrolateral PFC (vlPFC), which is implicated in emotion regulation (Ochsner and 
Gross, 2005), also play a role in encoding and processing value and activation within 
these regions are also shown to be attenuated by oxytocin administration in response 
to explicit and implicit facial processing (Domes et al., 2007a; Domes et al., 2010; 
Petrovic et al., 2008; Rilling et al., 2012). This effect is stable across genders and 
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different task types except in part of one study where females explicitly processing an 
angry face over the neutral face showed increased activation in the bilateral vlPFC and 
right dlPFC after oxytocin administration (Domes et al., 2010). However, in this same 
study, they also found that activation in the dlPFC was attenuated for fearful and 
happy faces after oxytocin administration. There is evidence that females process 
angry faces differently than men in the PFC (Fusar-Poli et al., 2009; McClure et al., 
2004). Females show greater activation in the PFC while explicitly processing angry 
faces as opposed to neutral faces with no difference in happy or sad faces (McClure et 
al., 2004) which may be why females exhibit this difference in activation with regard to 
facial valance after oxytocin administration. Thus attenuated activation in these areas 
after oxytocin administration may be indicative of an attenuated need for emotion 
regulation and cognitive control.  
5.3.4 EEG STUDIES IN HUMANS 
Studies using EEG have demonstrated how oxytocin administration can attenuate 
cortical activity and its relationship to social tasks (Fehm-Wolfsdorf et al., 1988; 
Huffmeijer et al., 2012a; Perry et al., 2010). To date, only five studies have used EEG 
and oxytocin in humans and only two have explored the social implications of altered 
cortical activity due to oxytocin administration while performing a task with social 
stimuli (Born, 1987; Fehm-Wolfsdorf et al., 1988; Huffmeijer et al., 2012a; Huffmeijer 
et al., 2012b; Perry et al., 2010) (Table 5.1).  
A few studies have been done using EEG and oxytocin administration without 
incorporating any social elements. Unsurprisingly, these studies did not find any effect 
of oxytocin administration. A study by Fehm-Wolfsdorf et al. (1988) explored the 
potential for oxytocin administration to facilitate non-social learning and long-term 
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recall of 25 unrelated nouns and the effect on auditory evoked potentials using a series 
of tone pips. Another study by Born (1987) administered oxytocin in a task while 
subjects performed an auditory mismatch task, no difference was found in cortical 
activity after oxytocin administration. Both of these experiments highlight that 
oxytocin administration did not appear to have any systematic effect on brain activity 
in tasks lacking social elements.  
To demonstrate that oxytocin administration can have an effect over cortical activity 
during social tasks, Perry et al. (2010) used EEG and oxytocin along with stimuli that 
demonstrated biological motion. Subjects were presented with a series of point-lights 
that reflected either biological or non-biological movements. After being administered 
oxytocin, subjects demonstrated improved performance between trials associated 
with biological movement versus those with random movement, and also elicited 
wide-spread mu and alpha suppression compared to being administered a placebo. 
This change in mu/alpha activity may be indicative of potential processing of higher 
social information as well as activation of the mirror neuron system (Oberman et al., 
2007). Another study with social stimuli explored the cognitive effects of charitable 
donations and their modulations by oxytocin administration. Huffmeijer et al. (2012a) 
measured frontal alpha asymmetry and parental love withdrawal, a measure of how 
often their parents would withhold love and affection to discipline their children for 
misbehaving or failing to attend to an instruction, after oxytocin and placebo 
administration and then gave participants a chance to donate to a charitable 
organisation. They found that in subjects with lower love withdrawal and relative 
lower right to left frontal alpha activity, oxytocin administration increased charitable 
donations. Additionally, subjects that showed higher relative left frontal activity gave 
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larger donations than those with higher relative right frontal activity. No differences in 
frontal alpha asymmetry were found after oxytocin administration; however, EEGs 
were only recorded at rest, with no social or cognitive probes which may be why no 
changes were observed. Huffmeijer et al. (2012b) went on to use faces as a social 
probe in women. They used the Eriksen flanker task (Eriksen, 1974) in which each trial 
was followed by either a happy or disgusted face and an indicator as to whether or not 
they were correct. They found that oxytocin administration increased the amplitudes 
of the vertex positive potential (VPP) and late positive potential (LPP) which indicated 
greater attention to the feedback stimuli (from the LPP) and an increased ability to 
process faces (from the VPP) regardless of the facial valence or feedback. This finding 
supports fMRI data showing that oxytocin administration has an effect over facial 
valence perception as well as showing that perception of facial valence is altered 
across both early (VPP) and later (LPP) stages of processing. Overall, these studies 
show how using EEG can increase our understanding of how oxytocin administration 
exerts its influence over cortical activity in addition to haemodynamic findings and 
how these changes in neural activity may influence social cognition. 
These studies show altered EEG activity after oxytocin administration corresponding 
with changes in performance on social tasks. No effects were found in experiments 
without a social aspect, highlighting that oxytocin does not appear to have any 
systematic effect on brain activity in tasks lacking social elements. The study by Perry 
et al. (2010) is particularly important as it highlights the specificity of cortical activity 
elicited by oxytocin administration in a social context. This study also highlights the 
importance of oxytocin administration in manipulating widespread cortical activity and 
provides a possible translation to the importance of mirror neurons and their 
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association with oxytocin administration. Collectively, these studies show how using 
EEG can increase our understanding of how oxytocin administration exerts its 
influence over cortical activity in addition to haemodynamic findings and give a more 
complete picture of how oxytocin administration may influence social cognition. 
5.3.5 EFFECT SIZES 
The magnitude of the effect of oxytocin administration described above here is 
provided for each ROI in the Table 5.3. For the human fMRI studies, we observed a 
Cohen’s d ranging from 0.39 to 2.12 for the emotional tasks, 0.47 to 1.03 for the social 
cognition tasks involving trust. 
The largest effect size was observed in the temporal lobes (1.56 ± 0.21). This reflects 
the large number of studies that showed activity in the temporal lobes, mainly during 
tasks incorporating facial processing. 
The smallest effect size was observed in the amygdala (0.82 ± 0.24). This smaller effect 
may be due to the large number of studies that used a region of interest approach to 
show that the amygdala was significant in their study. 
5.3.6 VOXEL BASED META-ANALYSIS  
We performed a meta-analysis using all studies which reported whole-brain findings 
using emotional stimuli. A total of 11 studies fit all the criteria and were included in the 
meta-analysis (Domes et al., 2007a; Domes et al., 2010; Gimpl and Fahrenholz, 2001; 
Labuschagne et al., 2011; Lischke et al., 2012; Petrovic et al., 2008; Pincus et al., 2010; 
Riem et al., 2011; Singer et al., 2008; Striepens et al., 2012; Wittfoth-Schardt et al., 
2012). Taking into account one and two sample studies, we found that the left insula 
was the only area that reliably showed greater activation after oxytocin administration 
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across all studies (Figure 5.2 and Table 5.4). These findings were found across all task 
types and genders, and thus may have important implications for the role of oxytocin 
research by showing that oxytocin administration augments neural responses to social 
tasks in the left insula independent of task type and gender.  
a     b 
 
FIGURE 5.2 - Results for voxel based SDM meta-analysis of placebo controlled fMRI 
studies employing acute oxytocin challenge in humans 
  
TABLE 5.4 - Results for voxel based SDM meta-analysis of placebo controlled fMRI 
studies employing acute oxytocin challenge in humans 
 Peak    Cluster  
 Talairach Z P  Voxels Breakdown 
Oxytocin > Placebo       
Left insula (extending to superior 
temporal gyrus and precentral 
frontal gyrus) 
-46,-6,-6 2.451 0.0000003  1182 Left BA 13 (222) 
Left BA 22 (219) 
Left BA 38 (174) 
Left BA 6 (165) 
Left BA 21 (120) 
Left BA 43 (70) 
Left BA 44 (39) 
Left BA 4 (37) 
Left BA 47 (31) 
Left BA 42 (26) 
Left BA 9 (19) 
Left BA 20 (12) 
       
Oxytocin < Placebo       
(none)       
 
Results were thresholded with voxel p ≤ 0.005 uncorrected, peak z ≥ 2, and cluster extent ≥ 10 voxels. 
Breakdown regions with an extent < 10 voxels extent are not reported. 
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5.4 DISCUSSION  
In the present study, we have addressed the acute effect of oxytocin administration on 
neural activity within the brain. Firstly, we have conducted a systematic review of the 
neurophysiological and electrophysiological placebo-controlled studies administering 
oxytocin. Secondly, we have measured the magnitude of change in activation of 
various brain regions as a result of oxytocin administration versus a placebo in specific 
key areas relevant to the behavioural effects of oxytocin. Lastly, we have provided the 
first fMRI voxel-based meta-analysis of the effects of oxytocin administration. We 
found that gender and task type seem to significantly impact the neurophysiological 
effects of oxytocin administration. The biggest effect sizes from oxytocin 
administration were observed in the temporal lobes and the smallest were observed in 
the amygdala. The fMRI voxel-based meta-analysis revealed significant insular 
hyperactivation during the oxytocin administration vs placebo contrasts. 
Our systematic review indicates that oxytocin administration appears to influence 
different brain regions in varying ways. In the reward system, oxytocin administration 
acts to increase activity related to social reward while decreasing learning social 
contingencies, this is the most evident during the evaluation of tasks involving trust 
and reciprocity (Baumgartner et al., 2008; Rilling et al., 2012). In the temporal lobes, 
the modulation of neural activity after oxytocin administration varies according to task 
type and gender. fMRI studies in women have shown that oxytocin exerts an almost 
opposite effect to that seen in men. However, most of the tasks in women used 
explicit emotional processing while most of those in men used implicit emotional 
processing (for a meta- analysis of brain activation during explicit vs implicit emotional 
processing see (Fusar-Poli et al., 2009)). Explicit emotional processing tasks in females 
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tended to augment activity in the temporal lobes after oxytocin administration (Domes 
et al., 2010; Lischke et al., 2012; Pincus et al., 2010) while implicit emotional 
processing in males tended to attenuate activity after oxytocin administration (Domes 
et al., 2007a; Petrovic et al., 2008; Wittfoth-Schardt et al., 2012).  
This may show that the manner in which each gender attends to social information 
varies but it may also reflect the differences in how oxytocin administration modulates 
activity based on task type. This shows the importance of the temporal lobes in 
processing social stimuli and shows how oxytocin administration influences how social 
stimuli are perceived and how socially salient information is attended to. 
There is a consistent association with oxytocin administration and amygdala function 
in human oxytocin studies with widespread region of interest and small volume 
correction around the amygdala. Our systematic review supports this view by showing 
consistent attenuation of amygdala activity in implicit emotion judgement in men. 
However, the negative results in our voxel-wise meta-analysis uncovers relevant 
heterogeneity among the surveyed studies, most notably between men and women, 
and between implicit and explicit tasks. It is still unclear whether or not the amygdala 
has any oxytocin receptors. So far, only one group has unsuccessfully attempted to 
localise oxytocin receptors in the amygdala, using a relatively nonspecific approach 
(autoradiography) (Loup et al., 1991; Loup et al., 1989). More studies are necessary to 
clearly show or exclude oxytocin receptor presence and abundance in human brain. 
However, magnocellular oxytocin neurons project to areas such as the central 
amygdala (Sofroniew et al., 1981) which may indicate one way in which oxytocin 
influences the amygdala. Recent PET imaging in rats has identified a potential ligand to 
look at oxytocin receptor density (Smith et al., 2013a) which may give better insight 
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into the receptor densities in humans in the future, although recent research by the 
same group has also shown this particular radiotracer may have limited brain 
penetration in primates (Smith et al., 2013b).  
There is evidence linking midbrain and mesolimbic dopamine with the effects of 
oxytocin on the processing of social stimuli. Some evidence suggests that dopamine is 
involved in mediating some of the same maternal behaviours that are exhibited under 
the influence of oxytocin (Douglas, 2010; Shahrokh et al., 2010) as well as pair bonding 
(Smeltzer et al., 2005, 2006b; Strathearn, 2011; Wang and Aragona, 2004). 
Furthermore, oxytocin has been implicated in helping to mediate addiction and 
withdrawal in the mesolimbic dopaminergic pathways (Baskerville and Douglas, 2010b) 
and differences in peripheral and central levels of oxytocin have been found in patients 
with disorders with potential dopamine abnormalities such as autism (Al-Ayadhi, 2005; 
Anderson et al., 2008; Hamilton et al., 2013; Previc, 2007), schizophrenia (Howes et al., 
2012; Howes and Kapur, 2009; Laruelle and Abi-Dargham, 1999; Sasayama et al., 
2012a; Winton-Brown et al., 2014) and social anxiety disorder (Bell et al., 2013; Fink et 
al., 2009; Hoge et al., 2008; Schneier et al., 2009). Additionally, preclinical studies have 
shown that dopaminergic fibres may regulate oxytocin release (Lindvall et al., 1984; 
Melis and Argiolas, 2011) and that the receptor binding sites and neuronal fibres of 
both of these neurochemicals reside in the same regions of the CNS and are often next 
to each other (Baskerville and Douglas, 2010b; Schwartz et al., 1994; Smeltzer et al., 
2006a). Further evidence suggests that, at least in the ventral and dorsal striatum, D2 
dopamine receptors and oxytocin are heteromers with facilitatory receptor to receptor 
interactions (Romero-Fernandez et al., 2012). Although most studies providing links 
between dopamine and oxytocin have been done in a preclinical population and most 
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evidence for a relation between dopamine and oxytocin in humans is speculative, a 
few recent studies in humans have also shown these two systems to be more directly 
related. Sauer et al. (2013) found a relationship between oxytocin genes, dopamine 
and oxytocin administration during responses to social stimuli. They postulated that 
the availability of dopamine may regulate oxytocin secretion within the amygdala. 
Furthermore, Love et al. (2012) found that dopaminergic responses to stress could be 
explained by variability within the oxytocin gene. Evidence from these studies above 
lead to the proposal that dopamine and oxytocin may work together to regulate 
behavioural responses to social stimuli, such that dopamine affects the assignment of 
emotional salience (Fett et al., 2012; Winton-Brown et al., 2014) while oxytocin 
modulates amygdala tone (Rosenfeld et al., 2011). However, further review of the 
relationship between dopamine and oxytocin is outside the scope of this paper and we 
would encourage those interested to look at reviews already available on this subject 
(Abi-Dargham, 2012; Baskerville and Douglas, 2010a; Love, 2014; Rosenfeld et al., 
2011; Skuse and Gallagher, 2009). 
Finally, our fMRI voxel-based meta-analysis clearly showed the insula is consistently 
modulated by oxytocin administration across all task types and genders. The insula is 
known for its role in emotion regulation by aiding in the recall and self-induction of 
emotion (Phan et al., 2002b) as well as facilitating a sense of empathy under 
uncertainty (Singer et al., 2009). In the context of processing emotional stimuli after 
oxytocin administration, the role of the insula may be one of increased recall of 
emotional information by self-induction of these emotions. Connectivity analyses have 
shown that, after oxytocin administration, connectivity between the insula and other 
areas important to social cognition, such as the amygdala, increases (Rilling et al., 
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2012; Striepens et al., 2012). Despite this intriguing result, there are many potential 
confounding factors which were hard to account for and may have biased the voxel-
based analysis. It is important to note that this meta-analysis was only done with 
relatively few studies (n = 11) therefore it was difficult to conduct moderator analysis 
to take into account different study design characteristics that may have affected 
effect sizes. Thus our work represents a more preliminary analysis of the general 
effects of oxytocin administration without taking into account factors such as gender, 
past experiences, and in-group versus out-group. For example, in some areas of the 
brain, such as the temporal lobes, there is a strong indication that females and males 
have opposite patterns of activity as a result of oxytocin administration. This may have 
caused some areas to appear as null which in a gender specific analysis may have been 
significant. However, we did not have enough studies in each gender to test this 
hypothesis. Additionally, the type of task varied between studies but no specific type 
of task had enough power to create its own meta-analysis, so results may have been 
biased in this regard too. As discussed above, it appears that implicit processing of 
social stimuli decreases activity while processing explicit stimuli increases activity, for 
example, in the amygdala. The significant activation of the insula in our meta-analysis 
highlights it as an important area to potentially include in further studies for further 
exploration.  
5.5 CONCLUSIONS 
Oxytocin is a complex molecule with many facets which have yet to be understood. 
Although it is clear that oxytocin administration has an effect on neural activity of 
cortical and subcortical areas over a range of social tasks, it is not clear yet precisely 
how oxytocin administration influences neural activity across these domains. We have 
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shown evidence that oxytocin may play differential roles across genders. The 
neurophysiological effects of oxytocin on subcortical areas such as the amygdala could 
also be influenced by task type. Indeed, our systematic review indicates small effect 
sizes in the amygdala, while our voxel-based meta-analysis indicates no effect in this 
region. Conversely, we found a significant effect of oxytocin administration in the left 
insula, which survived across all task types and genders. The temporal lobes were also 
shown to be influenced by oxytocin administration by our systematic review as these 
demonstrate the largest effect sizes across genders and task type.  
5.6 FUTURE PERSPECTIVES 
Further research into oxytocin and the areas it modulates are necessary to elucidate 
more on this neuropeptide. More studies looking at social tasks using oxytocin 
administration which incorporate differing neural domains will help clarify why 
oxytocin administration appears to attenuate activity in some tasks and genders and 
augment it in others. Looking at tasks which also implicate the reward system may also 
help elucidate the role of dopamine and its ties to oxytocin. oxytocin’s current links to 
dopamine and its pronounced effects over tasks in the social domain mean that 
oxytocin is of particular interest to clinical groups (Ferris, 2008). Preliminary studies 
have shown its potential efficacy in schizophrenia (Feifel et al., 2012a; Feifel et al., 
2010b; Pedersen et al., 2011b), autism (Hollander et al., 2003) and have shown 
behavioural effects in patients with schizophrenia (Averbeck et al., 2011; Evans et al., 
2011b), depression (Pincus et al., 2010), generalised anxiety disorder (Labuschagne et 
al., 2010, 2011) and autism (Guastella et al., 2010). Importantly, the prosocial effects 
of oxytocin may offer potential for synergistic pharmacotherapeutic and 
psychotherapeutic treatments of these severe disorders (Meyer-Lindenberg and Tost, 
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2012). One study demonstrating such potential benefits is a recent meta-analysis done 
in behavioural studies of clinical populations (Bakermans-Kranenburg and van, 2013). 
One advantage of oxytocin is that it is an endogenous hormone that has been used 
therapeutically in other areas of medicine, so its properties as a drug are fairly well 
known. In disorders such as psychosis, there is an increasing recognition that non-
dopaminergic drugs are needed to advance care, and there exists great interest in 
alternative therapeutic targets to dopamine. There are currently no drug treatments 
available for social dysfunction, so the concept of a treatment for social ailments is 
very novel. Further studies are warranted to examine how oxytocin administration 
instantiates these behavioural changes in these groups and whether or not oxytocin 




CHAPTER 6 -  THE NEURAL CORRELATES OF DECISION-
MAKING DURING AN ASSOCIATIVE LEARNING TASK WITH A 
SOCIAL COMPONENT - THE EFFECTS OF OXYTOCIN 
ADMINISTRATION IN PATIENTS WITH SCHIZOPHRENIA  
 BACKGROUND 6.1
In addition to the standard diagnostic criteria of positive and negative symptoms, 
schizophrenia is generally accompanied by deficits in social cognition which are not 
currently treated by standard anti-psychotics (Penn et al., 2009; Sergi et al., 2007) 
despite being an important determinant of poor functional outcome (Couture et al., 
2006; Fett et al., 2011). Deficits in social cognitive functioning in schizophrenia extend 
across multiple domains of social competence from difficulties in mental state 
attribution, and theory of mind (Bora et al., 2009; Brune, 2005b; Fett and Maat, 2011; 
Green, 1996), empathy (Shamay-Tsoory et al., 2007; Sparks et al., 2010), identifying 
emotional expressions (Huang et al., 2011; Kohler et al., 2003) to difficulties in 
maintaining eye gaze (Morris et al., 2009; Williams et al., 1999). Deficits in these social 
cognitive functions are particularly disabling as they have been shown to hinder the 
ability of patients with schizophrenia to interact with others and to integrate within 
society (Fett et al., 2011; Penn et al., 2000). Additionally, current treatment methods 
have little effect on improving social cognition. While psychosocial interventions have 
shown limited promise, these benefits have been narrow in their scope mainly 
improving isolated functions such as facial affect recognition and only showing limited 
improvements in theory of mind tasks (for a meta-analysis of studies see Kurtz and 
Richardson, 2011). Furthermore, current pharmacological interventions for the 
treatment of schizophrenia have no significant effect on improving social cognition 
(Gray and Roth, 2007). However, a promising new treatment, oxytocin has emerged 
which may help in alleviating these social cognition deficits in schizophrenia. Oxytocin 
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was originally known for its role in parturition and parental bonding (Insel and Young, 
2001b). It has now been applied to exploring wider social benefits from looking at how 
oxytocin administration can improve levels of trust, without influencing risk-taking 
(Baumgartner et al., 2008; Kosfeld et al., 2005) to increasing the amount of time spent 
gazing at socially relevant regions of the face (Guastella et al., 2008) or even increasing 
ethnocentrism, or the cooperation between in-group members at the expense of out-
group members (De Dreu, 2012; De Dreu et al., 2011).  
The potential importance of oxytocin for the treatment of social cognitive impairment 
in patients comes from different lines of research. As the research is currently limited 
in scope, all known studies exploring the relationship between schizophrenia and its 
symptoms to oxytocin will be briefly overviewed. To start, research has shown that in 
patients with schizophrenia there is a relationship between oxytocin levels in both the 
plasma and cerebrospinal fluid (CSF) and social cognitive abilities as well with 
symptomatology measures such as positive and negative symptom scores. 
Additionally, a few studies have even shown that similar clinical traits to those found in 
schizophrenia which were observed in the healthy population also correlated with 
oxytocin measures (Tseng et al., 2014; Walss-Bass et al., 2013).  
First, when looking at exogenous levels of oxytocin – measured in the CSF – conflicting 
results have been found when assessing whether or not oxytocin levels were lower in 
patients with schizophrenia than healthy controls (Beckmann et al., 1985; Glovinsky et 
al., 1994). However, in patients with schizophrenia, oxytocin levels in the CSF have 
been found to negatively correlate with the negative symptoms of the PANSS as well 
as second generation antipsychotic doses even when overall oxytocin levels did not 
differ from healthy controls (Sasayama et al., 2012b). It may be that differentiation 
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between healthy controls and patients with schizophrenia in terms of oxytocin levels in 
the CSF can only be quantified when other neurochemicals within the CSF are 
accounted for or if the symptoms in all patients assessed were significantly high. For 
example, it was only when oxytocin levels are entered into a model along with other 
substances in the CSF, multidimensional scaling modelling was able to correctly classify 
the CSF of patients with schizophrenia and healthy controls (Gattaz et al., 1985). Given 
that only one study, to the author’s knowledge, has found general differences in 
oxytocin levels within the CSF between patients with schizophrenia and healthy 
controls (Beckmann et al., 1985), it appears that oxytocin levels may vary more closely 
with deficits in social cognition and other symptoms which are generally associated 
with schizophrenia. 
Secondly, studies exploring endogenous, or peripheral/plasma levels, of oxytocin in 
patients with schizophrenia have found that oxytocin plasma levels correlated with 
various symptomatology measures in both schizophrenia and healthy controls. One 
study found that the avoidance of negatively valenced emotional faces positively 
correlated oxytocin levels and with positive and general symptoms as well as paranoia 
(Brown et al., 2014). Other research has also found that higher oxytocin plasma levels 
positively correlated with greater prosocial behaviours and, in females with 
schizophrenia, higher plasma levels of oxytocin also positively correlated with less 
severe positive symptoms and overall psychopathology (Rubin et al., 2010). A follow-
up study by this group also found that oxytocin plasma levels in females (both controls 
and patients with schizophrenia), but not males, led them to perceive faces as happier 
(Rubin et al., 2011). These findings also extend to subgroups of schizophrenia patients 
and show that oxytocin may influence brain volume and endocrine production through 
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hypothalamic pituitary axis (HPA) functioning. One study looking at patients with 
schizophrenia with polydipsic hyponatremia, where increased fluid intake leads to an 
excess of fluid in the body causing dilution of sodium levels, showed that plasma 
oxytocin levels were lower in these patients as well as being inversely correlated with 
anterior hippocampal volume but not posterior hippocampal or amygdalar volume. 
Further correlations were also found between plasma oxytocin levels and 
hippocampal-mediated HPA functioning following stress responses as well as 
predicting the ability for patients to correctly identify facial expressions (Goldman et 
al., 2008) suggesting that, in some patients with schizophrenia, oxytocin also can be 
linked to functional and structural deficits. Further to this, a study using post mortem 
analysis of brains of patients with schizophrenia before medication, also found wide 
variation in morphometric values for structures which were assessed for oxytocin 
receptor distributions (Mai et al., 1993). Additionally, correlations have been observed 
when measuring behavioural interactions. A study done by Kéri et al. (2009) showed 
that oxytocin plasma levels were increased in healthy controls after a trust-related 
interaction but showed no difference in patients with schizophrenia. Further 
examination of the oxytocin plasma levels after the trust-based interaction revealed 
that low levels of oxytocin were related to negative symptoms but not positive 
symptoms, depression, anxiety and neuropsychological functions. These findings can 
be extended to apply toward explaining clinical characteristics within the healthy 
population as well. In both healthy controls and patients with schizophrenia, social 
cognitive capacity and social cognition bias, including attributional bias and jumping to 
conclusions, negatively correlated with plasma levels of oxytocin across genders who 
showed evidence for delusions based on the “unusual thought content” item of the 
brief psychiatric rating scale (Walss-Bass et al., 2013). Moreover, in healthy controls, 
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plasma levels of oxytocin were found to negatively correlate with schizoptypal 
personality scores in females but not males (Tseng et al., 2014). Overall, these studies 
show that oxytocin levels are more general indicators of symptoms severity in patients 
with schizophrenia and social cognitive ability such as facial affect recognition which 
extends to exploring variations in clinical features in the healthy population as well. 
In addition to studies looking at oxytocin levels within the CSF and plasma, research 
has also shown that genetic variants in oxytocin receptor genes may be associated 
with schizophrenia and the symptoms associated with the illness. One study found that 
outcome specific to clozapine treatment response was predicted by oxytocin receptor 
gene expression as well as nominally correlating with negative symptoms (Souza et al., 
2010). These findings have been supported by a study showing that, oxytocin receptor 
gene expression also correlated with PANSS negative and general symptom scores and 
age of onset as a predictor for empathic concern (Montag et al., 2012). Furthermore, a 
group of oxytocin receptor genes were found to predict the risk for schizophrenia 
(Montag et al., 2013). Together, these findings from exogenous and endogenous 
oxytocin levels, or plasma and CSF levels, as well as variations in oxytocin receptor 
gene expression suggest that lower levels of oxytocin are predictive of higher 
symptomatology associated with schizophrenia and deficits in social cognitive 
functioning such as facial affect identification. This supports the notion that altering 
oxytocin levels may have a positive effect on improving social cognitive abilities and 
symptomatology in patients with schizophrenia.  
In light of these findings, a number of studies have currently been conducted to 
explore how oxytocin administration affects patients with schizophrenia. These studies 
investigated how both acute and longitudinal oxytocin administration affected a range 
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of behaviours in regard to improving symptomatology (Feifel et al., 2010a; 
Modabbernia et al., 2013; Pedersen et al., 2011a), social cognition (Davis et al., 2013; 
Woolley et al., 2014), verbal memory (Feifel et al., 2012b) and even improving 
olfactory discrimination (Lee et al., 2013).  
Several studies to date have focussed on the long term effects of oxytocin treatment 
with respect to the reduction of symptomatology and improvement in social cognitive 
functioning (Davis et al., 2013; Feifel et al., 2012b; Feifel et al., 2010a; Gibson et al., 
2014; Lee et al., 2013; Modabbernia et al., 2013; Pedersen et al., 2011a). All studies 
but one have found a significant reduction in various symptom scores in patients with 
schizophrenia after two to eight weeks of oxytocin administration compared to a 
placebo (Feifel et al., 2010a; Gibson et al., 2014; Modabbernia et al., 2013; Pedersen et 
al., 2011a). However, the results differed with respect to the symptom domains, some 
studies found reductions in positive symptoms but not negative symptoms and others 
found reductions in negative symptoms but not positive symptoms. Only one study, 
which used half the dose as the other studies (20 IU), found that oxytocin treatment 
improved olfactory discrimination but only had an effect on symptom scores in a 
particular subgroup of inpatients but not outpatients in reducing negative symptoms 
(Lee et al., 2013). The lack of other significant findings across all groups in this study 
may be attributable a number of factors including the low dosage and that the study 
may not have looked at treatment effects far enough out as other studies suggested 
periods of up to 6 weeks to reach an effect (Modabbernia et al., 2013). It may also 
show that inpatients are more sensitive to treatment effects. However, a meta-
analysis of studies on the effect of oxytocin treatment on symptoms (with the 
exception of (Gibson et al., 2014)) found a modest effect size of treatment across 
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positive, negative and general symptoms (d = 0.52) (Gumley et al., 2014). Furthermore, 
one study also found that longitudinal oxytocin treatment over three weeks helped 
improve some theory of mind processing in patients with schizophrenia in addition to 
improving symptom scores (Pedersen et al., 2011a). This suggests that long term 
oxytocin administration may offer potential benefits for patients with schizophrenia 
for improving symptomatology as well as some aspects of social cognitive ability. 
While these studies suggest that, over time, oxytocin may have an effect on 
symptomatology in schizophrenia, other studies have also explored the acute effects 
of oxytocin administration on general social cognition. Given that studies in healthy 
controls have shown changes in behavioural and neural activity after oxytocin 
administration (Wigton et al.), ranging from tasks looking at trust (Baumgartner et al., 
2008) to exploring ingroup outgroup dynamics (De Dreu, 2012; De Dreu et al., 2011). 
These findings inspired similar studies in patients with schizophrenia. These studies 
have shown that oxytocin administration increases the ability of patients with 
schizophrenia to accurately identify emotions (Averbeck et al., 2012) as well as 
elevating the degree of empathy that patients with schizophrenia show toward an in-
group (Abu-Akel et al., 2014). Although a few studies have shown that oxytocin 
administration is capable of improving emotion perception, this finding has not always 
been replicated. In one study, acute oxytocin administration was found to significantly 
improve “controlled social cognition,” or how indirectly expressed social stimuli such 
as emotions, thoughts, intentions and complex deliberations are understood over 
longer periods of time, similar to theory of mind tasks, but not “automatic social 
cognition,” or how social cues from the voice, face and body are interpreted, for 
example, explicit emotion recognition (Woolley et al., 2014). However, together, these 
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studies suggest that, even after an acute dose, oxytocin administration may help 
improve both basic and complex social cognitive processed in patients with 
schizophrenia. 
To date, the working mechanisms of oxytocin and its effects on neural activity are not 
entirely clear. Imaging studies done in healthy controls tentatively suggests that it 
elicits a general attenuation of neural activity in social processing regions such as the 
amygdala. However, it is important to note that there may be a gender difference 
where oxytocin generally attenuates neural activity within the amygdala in male 
subjects (Wigton et al.; Zink and Meyer-Lindenberg, 2012), and augments neural 
activity in the amygdala in females (Domes et al., 2010). Unfortunately, gender 
differences in how oxytocin administration affects both behaviour and neural activity 
are currently underexplored. To date, no published studies have explored the effect of 
oxytocin administration on neural activity in patients with schizophrenia. However, 
previous work done in our group has shown that both patients with schizophrenia and 
healthy controls show a heightened aversion toward angry faces in an associative 
learning decision-making task incorporating social faces (Averbeck and Duchaine, 
2009; Evans et al., 2011a; Evans et al., 2011b; Furl et al., 2012), chapter 3 (page 73), 4 
(page 119). In healthy controls, this bias was mitigated by oxytocin administration so 
that they were less averse toward choosing the angry face (Evans et al., 2010). One 
suggestion for the initial heightened aversion toward angry faces is that it is driven by 
amygdala hyperactivity, possibly due to an aberrant mesolimbic dopaminergic 
pathway (Rosenfeld et al., 2011). Given dopamine’s role in the manifestation and 
treatment of schizophrenia which was explored in further detail in the earlier chapters, 
exploring the ties between oxytocin and dopamine and their combined effect on 
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patients with schizophrenia’s social cognition and symptomatology would be beneficial 
in elucidating its treatment potential. As both dopamine and oxytocin have 
demonstrated relationships with the symptomatology of schizophrenia, a model of 
oxytocin, dopamine was proposed by Rosenfeld et al. (2011). Their model suggests 
that the amygdala plays a crucial role in facilitating social cognition in schizophrenia by 
modulating social salience through oxytocinergic and dopaminergic signalling. Imaging 
studies to date have shown, that at least in male healthy controls, oxytocin appears to 
attenuate neural activity in the amygdala which is believed to result in the facilitation 
of prosocial behaviours such as increased trust (Baumgartner et al., 2008) or emotion 
recognition (Gamer et al., 2010b). These studies suggest that using oxytocin to 
modulate neural activity within the amygdala could have a beneficial role in facilitating 
these same prosocial behaviours in patients with schizophrenia. 
This chapter describes a study that utilised the same task described in the previous 
chapters to assess how acute oxytocin administration influences how subjects make 
decisions on value and facial valence. During this task, subjects were required to 
determine through trial and error which of two emotional faces (e.g. a happy and an 
angry face) is rewarded more often and select the optimal choice. Previously, the 
emotional information contained in the face stimuli has been found to influence task 
performance, with subjects demonstrating a bias towards the selection of happy faces 
over angry faces (Averbeck and Duchaine, 2009; Evans et al., 2011a; Evans et al., 
2011b; Furl et al., 2012) (Chapter 3 (page 73) and Chapter 4 (page 119)), and oxytocin 
administration has been found to mitigate this bias in healthy controls (Evans et al., 
2010). 
Given these findings, I hypothesise that: 
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1. Patients with schizophrenia will show the previously demonstrated bias toward 
picking the happy face even when the evidence supports the angry face as the 
best choice and they will not be biased toward picking either of the neutral 
faces. Furthermore, I hypothesise that the administration of oxytocin will act to 
attenuate the bias toward the happy face in the emotionally valenced 
condition. 
 
2. Attenuation of bias when deciding between two emotionally valenced faces 
after oxytocin administration will be accompanied by a reduction of neural 
activity in regions associated with social processing such as the amygdala. This 
attenuation in neural activity will not be seen when patients are deciding 
between two neutral faces.  
 
3. When processing reward prediction error, due to oxytocin’s potential ties to 
the dopaminergic system and as oxytocin is believed to reduce the social 
salience of stimuli, neural activation correlating with RPE will be attenuated in 
response to oxytocin administration within areas rich in dopaminergic 
receptors such as the ventral striatum.  
 METHODS 6.2
6.2.1 PARTICIPANTS 
Twenty right handed male patients with schizophrenia or schizoaffective disorder, 
diagnosed according to the ICD-10 (ICD-10, 1992) were included in this study. Patients 
were recruited as a subsample from those who had already taken part in the study 
from Chapter 4. Diagnoses were further confirmed through the independent 
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assessment of case notes. Intelligence quotient (IQ) was measured using the two-item 
Wechsler Abbreviated Scale of Intelligence (WASI) consisting of the vocabulary and 
matrix reasoning subtests (Wechsler, 1999). Demographic information can be found 
below in Table 6.1. All participants signed informed consent and were compensated 
for their participation in the study on completion of the testing. Ethical approval was 
obtained from the Camberwell and St. Giles Research Ethics Committee. Further 
details of recruitment and inclusion and exclusion criteria can be found in Chapter 2 
(page 35). 
TABLE 6.1 - Demographic and clinical sample characteristics 
Patients with schizophrenia 
(N=20) (mean (SD)) 
Age (years) 37.90 (7.43) 
WASI IQ 98.85 (13.24) 
NS-SeC 2.80 (1.70) 
Gender 20M 
Age at onset (years) 24.50 (6.48) 
Duration of illness (years) 13.40 (6.53) 
CPZ equivalents 430.05 (236.27) 
PANSS 
 Positive Symptoms 14.95 (4.97) 
Negative Symptoms 18.30 (4.99) 
General Symptoms 30.70 (7.10) 
Total 63.95(14.65) 
IQ = Intelligence quotient; M = Male; F = Female; SD = Standard deviation 
WASI = Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999) 
NS - SeC = National Statistics Socio-economic Classification (Rose, 2001) 
CPZ = Chlorpromazine equivalent (Woods, 2003) 
PANSS = Positive and Negative Symptom Scale (Kay et al., 1987) 
6.2.2 TASK 
The task used was a forced-choice, stochastically rewarded decision-making task 
incorporating faces of varying social valence. In each trial two faces were presented to 
the left and the right of the screen. Pairs consisted of either: a happy face and an angry 
face of the same identity, or of two neutral faces of differing identities. Each visit 
consisted of two scanning sessions comprised of four counterbalanced blocks of 30 
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trials each (Figure 2.5, page 47). Pairs of emotionally valenced stimuli (i.e. happy and 
angry faces) were alternated with pairs of neutrally valenced stimuli (i.e. neutral faces). 
Within each emotionally valenced block, the identities of each face were kept 
consistent but the order of presentation of each identity was counterbalanced across 
sessions. Each block consisted of 30 trials with the presentation of each face 
counterbalanced across the left and right sides. Probability estimates were assigned to 
the faces at the beginning of each trial such that on 60% of the trials one face would 
win and 40% of trials the other face would win. The probability distribution of each 
face winning was counterbalanced across blocks such that the angry face won more in 
half of the blocks and the happy face won more in the other half, and that identity one 
won more over identity two for half of the blocks and vice versa for both the 
emotionally valenced and neutral faces. The order of these wins was counterbalanced 
across the participants and visits. In each trial, participants were instructed to pick the 
face which, at that time, they believed was the most likely to win. They were told that 
after making this decision they would be told whether or not they had won where a 
win would show that they had won 10 pence along with their current winnings total 
and a loss was associated with no change in winnings and only the message “You lose.” 
The presentation of stimuli is shown below in Figure 6.1. Further details, including the 




FIGURE 6.1 - Presentation of stimuli in the scanner for each trial 
6.2.3 PHARMACOLOGICAL MANIPULATION 
This study was a double blind crossover study administering oxytocin and placebo. 
Both the oxytocin (40 IU) and placebo nasal sprays were self-administered by our 
participants. First each spray was primed so that each spray delivered a full 4IU per 
nostril. Each participant was told to tilt their head back at a slight angle and insert the 
nasal spray into one of their nostrils while trying to keep the spray bottle as upright as 
possible. They were then told to push down on the pump action while simultaneously 
inhaling through their nostrils as deep as possible. They were then asked to switch 
nostrils and repeat this administration. A break of 45 seconds was given between each 
administration to allow for the nasal spray to be absorbed by the nostrils as 
recommended by (Guastella et al., 2013). Proper administration was demonstrated to 
each participant before self-administration albeit without physical insertion into the 
nostril and spraying of the agent. Each spray was acquired on the day of administration 
from the South London and Maudsley pharmacy, approximately one hour before being 
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administered to ensure an adequate storage temperature was not been breached 
before administration. 
The timing of the oxytocin/placebo administration was designed to be given 45 
minutes before the start of the first task within the fMRI scanner. This was set to be in 
line with previous fMRI studies which have shown significant changes in neural activity 
after oxytocin administration using this same time frame (Domes et al., 2007b; Kirsch 
et al., 2005; Kosfeld et al., 2005; Wittfoth-Schardt et al., 2012). However, the first task 
administered in the scanner was a trust-related decision-making task which does not 
form part of this thesis. The task used here was performed second after approximately 
45 minutes of the trust-based task beginning approximately 90 minutes post- 
oxytocin/placebo administration. 
6.2.4 FMRI DATA ACQUISITION 
Functional magnetic resonance imaging (fMRI) data were acquired on a Discovery 
MR750 3T scanner at the Centre for Neuroimaging Sciences, London (T2* weighted 
gradient-echo echo-planar images (EPIs), repetition time (TR) = 2000 ms, echo time 
(TE) = 35 ms, flip angle = 75°, 64 x 64 matrix, 24cm field of view). A 12-phase head coil 
array was used over the whole head for RF transmission and reception. Each whole-
brain image contained 38 3-mm axial slices separated by a distance of 0.3 mm with in-
plane isotropic voxel resolution of 3.75 x 3.75 mm. For each block, 430 scans were 
acquired and two sessions were recorded for each participant.  
Before the experimental portion of the experiment, a T1-weighted structural scan 
using a fast-spoiled gradient-echo pulse sequence (TR = 9.356 ms, TE = 3.828 ms, flip 
angle = 12°, time to inversion = 450 ms) was acquired for reference purposes. The first 
four volumes were discarded to allow for transient effects.  
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Participants made their responses using a two buttons on a two button-box with their 
index and middle fingers of their right hand. Head movement was minimised using 
headphones and additional padding around the head and ears as well as around the 
arms and legs. 
6.2.5 ANALYSIS 
All data were preprocessed and analysed using Statistical Parametric Mapping 12 
(SPM12) (Wellcome Department of Imaging Neuroscience, London, 
UK. www.fil.ion.ucl.ac.uk/spm) and MATLAB R2014a (MathWorks Inc. Sherbon, MA, 
USA). Further details of these steps can be found in Chapter 2 (page 53). 
A general linear model (GLM) was constructed in SPM12 to analyse the images with 
each event modelled as a delta (stick) function. Each block, consisting of 30 trials, was 
modelled independently and was defined as being either a block using emotionally 
valenced faces (e.g. happy and angry faces) or neutral faces (e.g. two faces of different 
identities). Events of interest within each block included the presentation of the faces, 
a decision-making regressor indicating when the decision was made for which face the 
subject believed would be rewarded (determined by a button press), and the feedback 
presentation within each trial. Also modelled were regressors to represent the motion 
parameters as well as parametric modulators on the decision-making regressor for the 
probability of each face chosen being associated with a win and feedback regressors. 
The probability that the face they picked would win was calculated using an ideal 
observer. The calculations used to determine this probability are outlined in depth in 
Chapter 2 (page 47). The feedback regressor, associated with when they were given 
feedback about whether or not the face they had chosen was associated with a 
reward, was parametrically modulated by the reward prediction error (RPE) 
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determined by subtracting the actual reward (i.e. 1 for a win and 0 for a loss) from the 
predicted probability that the chosen face would win as detailed in Chapter 2 (page 
49). Each regressor, except for the motion parameters, was convolved with a canonical 
hemodynamic response function and its temporal derivative. Missed trials were not 
modelled as events. Blocks where subjects failed to respond for greater than 50% of 
the trials were excluded from analysis as they were deemed to be insufficiently 
attending to the task. Furthermore, without feedback from all trials, it would have 
been more difficult for subjects to accurately assess which face was winning more 
often throughout the block. These excluded blocks accounted for one block across one 
subject after taking oxytocin when making decisions between two emotionally 
valenced faces. 
Performance estimates were calculated across all trials by comparing the face the 
subject picked to the face the ideal observer assigned the highest probability of 
winning. In the case that both faces had equal probability of winning (i.e. at 50% 
probability) either face picked was deemed optimal. Overall performance estimates 
were calculated across all trials as the number of times the participant picked the face 
deemed optimal over the number of valid trials (i.e. 30 – any misses). These estimates 
were then averaged across all blocks which were not excluded to get an overall 
performance estimate for all blocks using emotionally valenced and neutral faces. 
To assess how facial expression biased decision-making, all trials were separated into 
when participants agreed with the ideal observer and when they disagreed with the 
ideal observer for each facial valence as well as for the two neutral face identities. A 
2x2 contingency table was calculated for each block type (i.e. emotionally valenced 
and neutral) representing choices by the ideal observer and choices by the participant. 
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When the probability for each face winning was ambiguous (i.e. equal probabilities for 
both faces), the contingency count for each face was increased by 0.5. Using this table 
it was possible to calculate the conditional probability of each participant choosing the 
happy face when they should have chosen the angry face given the current evidence 
for the angry face p(happy|angry) as well as when they chose the angry face when 
they should have chosen the happy face given the current evidence for the happy face 
p(angry|happy). The difference between these two measures was calculated to 
represent the degree of bias toward picking the happy face (p(happy|angry) – 
p(angry|happy)). This measure indicates how often participants ignore the evidence 
that has accumulated for the negatively valenced face and chose the positively 
valenced face compared to how often they ignored evidence that had accrued for the 
positively valenced face and chose the negatively valenced face. This bias distribution 
was examined across all participants and entered into a one sample t-test to see if it 
significantly differed from 0. It is important to note these conditional probabilities 
were calculated separately to the probability that each face would win. A more 
comprehensive overview with equations is provided in Chapter 2 (page 49). This 
process has been replicated in multiple studies to represent the degree of bias 
(Averbeck and Duchaine, 2009; Evans et al., 2011a; Evans et al., 2010; Evans et al., 
2011b; Furl et al., 2012). 
The main focus of this study was to look at how decision-making and RPE affected 
neural activity so contrasts were looked at representing neural activity when a button 
was pressed to indicate which face the participant had chosen on a given trial, here 
after referred to as the decision-making condition as well as contrasts representing 
neural activity correlating with RPE given by the parametric modulator on reward 
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feedback. Second-level contrasts between drug conditions were assessed using paired 
sample t-tests. Within each drug comparison (i.e. oxytocin versus placebo), the main 
effect of task was analysed looking at by combining the blocks for emotionally 
valenced and neutral faces. Then contrasts were also created for blocks looking at only 
decision-making between the emotionally valenced faces to assess differences in 
decision-making with emotionally salient stimuli as well as within only the blocks 
looking at decision-making between neutral faces to assess differences in decision-
making between general social stimuli with no emotional salience. Interaction effects 
between the emotion and drug were also analysed to see if there was any interaction 
between the emotionally valenced face condition and the neutral face condition and 
the drug they were administered.  
To look at interaction effects between drugs and emotion an overall examination of 
blocks looking at the effects of drug (i.e. oxytocin versus placebo) and emotion (i.e. 
emotionally valenced versus neutral faces) were entered into 2x2 full factorial in 
SPM12 with drug and emotion as conditions. 
Contrasts were whole brain cluster-level family wise error (FWE) corrected at p<.05 
with a height threshold of p < .005, uncorrected, and an extent threshold of 100 
contiguous voxels. Voxels which survived peak level FWE correction at p<.05 are also 
reported. Reported voxel coordinates were converted from Montreal Neurological 
Institute (mni) coordinates into Talairach coordinates using the function icbm_spm2tal 
(Laird et al., 2010; Lancaster et al., 2007a) and were entered into Talairach Daemon to 
confirm their location in gray matter (Lancaster et al., 1997; Lancaster et al., 2000). 
Questionable results were further visualised by entering the original mni coordinates 
into xjview (http://www.alivelearn.net/xjview). Results are reported as their original 
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mni coordinates as output by SPM12. If more than one voxel was found to be 
significant within a region without a priori interest, only the peak voxel is reported. 
Additionally, the contrast estimates from each image were analysed at the peak voxels 
to determine the direction of change between each condition analysed as significant 
decreases within one condition could still appear as increases in another condition 
even if no change in neural activity was present. 
Region of interest analyses were also carried out within regions with an a priori 
interest to our study using small volume correction (SVC) within SPM12. Volumes of 
interest were defined using WFU PickAtlas Tool (Maldjian et al., 2003) for the 
amygdala and striatum and the ventral striatum was taken from Mawlawi et al. (2001). 
Only voxels which survived FWE correction at a peak level of p <.05 are reported. 
Correlation analyses were carried out to compare the degree of mean neural 
activation within the ventral striatum mask defined above when looking at RPE 
compared with all PANSS scores as well as medication equivalents. A secondary 
analysis also looked to see if any correlations could be accounted for by the 
performance measures or the degree of bias in each patient. For correlation measures, 
all parameters were assessed for appropriate skew and kurtosis. For any variables 
which were not normally distributed, non-parametric measurements are reported as 
Spearman’s rho. All other correlation measures are reported as Pearson r correlations. 







6.3.1 BEHAVIOURAL ANALYSIS 
6.3.1.1 PERFORMANCE 
To assess performance, in terms of the percentage accordance to an optimal observer, 
the face picked by the subject on each trial was compared to an ideal observer 
calculated based on the number of times a face won or would have won over the 
number of valid trials. Performance estimates across subjects were averaged 
separately across all neutral trials and emotional trials and are shown in Table 6.2. On 
average, patients with schizophrenia performed above chance levels (p>0.05). 
Furthermore, when choices were compared to an ideal observer, patients with 
schizophrenia did not significantly differ in their performance between the placebo 
and oxytocin conditions (p > 0.05).  
TABLE 6.2 - Performance estimates referenced to an ideal observer in terms of 
percentage agreement 
 
Emotional faces Neutral faces Difference from Chance (50%) 
  mean (SD) mean (SD) Emotional Neutral 
Placebo 58.7% (11.2%) 62.7% (13.6%) t(19) = 3.46, p = 0.003 t(19) = 4.19, p < 0.001 
Oxytocin 61.4% (12.0%) 62.8% (14.9%) t(19) = 4.22, p < 0.001 t(19) = 3.85, p = 0.001 
Total 60.1% (11.6%) 62.3% (14.3%)   
* = p < 0.05; † p < 0.1, SD = Standard deviation 
Performance was measured in terms of percentage accordance to an ideal observer (page 47). This was 
looked at separately across all blocks using emotionally valenced faces and neutral faces and t-values 




FIGURE 6.2 - Performance estimates for placebo and oxytocin when deciding between 
emotionally valenced faces where performance is compared to an ideal observer on a 
trial by trial basis. Each cross represents the performance of a single individual and 
the line represents the mean across all subjects. 
 
FIGURE 6.3 - Performance estimates for placebo and oxytocin when deciding between 
neutral faces where performance is compared to an ideal observer on a trial by trial 
basis. Each cross represents the performance of a single individual and the line 
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6.3.1.2 BIAS MEASURES 
In accordance with our findings in the previous chapter, the distribution of bias toward 
picking the happy face was found to be significantly different from zero in the patients 
with schizophrenia in the placebo condition. However, after oxytocin administration, 
this bias was completely attenuated. Also, in accordance with our findings in the 
previous chapter, there was no bias toward picking either of the neutral identities in 
patients with schizophrenia after being administered placebo or oxytocin (Table 6.3). 






faces Bias significance 
  mean (SD) mean (SD) Emotional faces Neutral faces 
Placebo 0.14 (0.22) 0.02 (0.12) t(19) = 2.82, p = 0.011* t(19) = 0.88, p = 0.388 
Oxytocin 0.06 (0.20) -0.02 (0.13) t(19) = 1.25, p = 0.225 t(19) = 0.85, p = 0.407 
* significant at p < 0.05;  SD = Standard deviation 
Bias estimates are estimated as the degree of bias toward picking one of the faces when the ideal 
observer supports the other face as the better option using a contingency table described on page 49.  
Bias significance was calculated as the difference from 0 
 
6.3.2 FMRI ANALYSIS 
6.3.2.1 NEURAL ACTIVITY DURING DECISION-MAKING 
6.3.2.1.1 DECISION-MAKING ACROSS EMOTIONALLY VALENCED AND NEUTRAL 
FACES 
6.3.2.1.1.1 WHOLE BRAIN ANALYSIS (MAIN EFFECT OF DRUG) 
When looking at decision-making across both the emotionally valenced and neutral 
faces condition, no differences were observed between the oxytocin and placebo 
condition at a whole brain level. 
6.3.2.1.1.2  REGION OF INTEREST ANALYSIS 
As the amygdala is an important region for emotional processing and it has been 
shown that oxytocin administration has an effect on this region (Wigton et al., in 
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press), a region of interest (ROI) analysis was performed using small volume correction 
(SVC) within a mask for the left and right amygdala. No differences were observed 
between the oxytocin and placebo condition using SVC. 
6.3.2.1.2 DECISION-MAKING BETWEEN EMOTIONALLY VALENCED FACES  
6.3.2.1.2.1 WHOLE BRAIN ANALYSIS (MAIN EFFECT OF DRUG) 
When looking at how decision-making affected neural activity in patients with 
schizophrenia after they had taken placebo versus oxytocin, whole brain analysis 
revealed significant clusters of neural activity in the bilateral precuneus extending into 
the right cuneus, posterior cingulate, left cingulate gyrus and bilateral temporal gyrus 
as well as the right insula. These regions also showed overlap with the temporoparietal 
junction (TPJ) bilaterally, whereby the cluster appeared to follow the borders of both 
the parietal and temporal lobes (Figure 6.4 and Table 6.4). Further analysis showed 
that this effect was driven by an attenuation of neural activity after oxytocin 
administration and an increase in neural activity after being administered placebo. 
 
FIGURE 6.4 - Neural activity for decision-making between emotionally valenced faces 










oxytocin, patients with schizophrenia demonstrated attenuated levels of neural 
activity from the bilateral precuneus along the bilateral TPJ than after taking a 
placebo. This image is shown at an uncorrected height threshold of p < 0.005 with an 
extent threshold of 100 and only clusters surviving FWE cluster-level correction of p < 
0.05 
6.3.2.1.2.2 REGION OF INTEREST ANALYSIS 
A region of interest (ROI) analysis was performed using small volume correction (SVC) 
within a mask for the left and right amygdala. The results showed significantly more 
neural activity in the placebo condition over the oxytocin condition in the left 
amygdala (x = -25, y = -4, z = -14, t(38) = 4.89, p = 0.002, k = 52, FWE peak level 
corrected for SVC) (Figure 6.5). The right amygdala was also found to be significantly 
more active in the placebo condition over the oxytocin condition (x = 27, y = -8, z = -14, 
t(38) = 3.74, p = 0.020, k = 11, FWE peak level corrected for SVC) (Figure 6.5). Further 
analysis of these effects showed that they were driven by a stronger attenuation of 
neural activity in the amygdala after oxytocin administration and a slight increase in 
activity after placebo administration. 
 
FIGURE 6.5 - Neural activity for decision-making between emotionally valenced faces 
for oxytocin administration versus placebo within the amygdala.This image shows 
that after taking oxytocin, patients with schizophrenia demonstrated attenuated 








This image is shown at an uncorrected height threshold of p < 0.005 with areas 
surviving FWE peak-level correction of p < 0.05 
6.3.2.1.3 DECISION-MAKING BETWEEN NEUTRAL FACES 
6.3.2.1.3.1 WHOLE BRAIN ANALYSIS (MAIN EFFECT OF DRUG) 
No differences in neural activity were found between the oxytocin and placebo 
condition when patients with schizophrenia were deciding between neutrally valenced 
faces. 
6.3.2.1.3.2 REGION OF INTEREST ANALYSIS 
Similarly, no differences in neural activity were found in the left or right amygdala 
between the oxytocin and placebo condition even after using SVC within this ROI. 
6.3.2.1.4 INTERACTION EFFECTS FOR DECISION-MAKING BETWEEN 
EMOTIONALLY VALENCED AND NEUTRAL FACES 
6.3.2.1.4.1 WHOLE BRAIN ANALYSIS (MAIN EFFECT OF DRUG) 
When looking across the whole brain for an interaction effect of drug (i.e. oxytocin or 
placebo) by emotion (i.e. emotionally valenced versus neutral faces), similar effects to 
those observed in the condition where patients were deciding between the two 
emotionally valenced faces were found in the bilateral cuneus, and precuneus 
extending into the bilateral superior and middle temporal gyri, posterior cingulate, left 





FIGURE 6.6 - Neural activity for interaction effects during decision-making between 
emotion and drug.This image shows that after taking oxytocin, patients with 
schizophrenia demonstrate greater levels of neural activity from the bilateral 
precuneus along the bilateral TPJ than after taking a placebo in the emotionally 
valenced condition but also that they show a slight increase in neural activity in these 
regions when deciding between two neutral faces after being administered oxytocin. 
This image is shown at an uncorrected height threshold of p < 0.005 with an extent 
threshold of 100 with only clusters surviving FWE cluster-level correction of p < 0.05 
 
FIGURE 6.7 - Contrast estimates left TPJ looking at interaction effects between drug 
and emotion showing how oxytocin attenuated neural activity in the left TPJ for 
emotionally valenced faces but slightly augments neural activity when deciding 










FIGURE 6.8 - Contrast estimates right TPJ looking at interaction effects between drug 
and emotion showing how oxytocin attenuated neural activity in the right TPJ for 
emotionally valenced faces but slightly augments neural activity when deciding 
between neutral faces. Contrast estimates and standard error estimates were taken 
from SPM. 
6.3.2.1.4.2 REGION OF INTEREST 
Using an ROI analysis, the left amygdala shows a trend toward significantly more 
neural activity in the placebo condition over the oxytocin condition (x = -21, y = -6, z = -
12, t(76) = 2.81, p = 0.051, k = 3, FWE peak level corrected for SVC) (Figure 6.5) 
 
FIGURE 6.9 - Neural activity for interaction effects at a trend level between drug and 
emotion during decision-making within the left amygdala.This image shows an 
interaction effect at a trend level between drug and emotion within the left 
amygdala. This image is shown at an uncorrected height threshold of p < 0.005 with 










FIGURE 6.10 - Contrast estimates within a region of interest analysis around the left 
amygdala looking at interaction effects between emotion and drug showing that 
neural activity appears to be driven by a strong attenuation of the left amygdala by 
oxytocin when deciding between two emotionally valenced faced but not two neutral 
faces. Contrast estimates and standard error estimates were taken from SPM. 
Left Amygdala ([-21 -6 12]) 
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TABLE 6.4 - Neural correlates for decision-making in patients with schizophrenia for oxytocin versus placebo 










size   
               Placebo > Oxytocin (Decision-making between Emotionally valenced faces) 
  
 
R Posterior Cingulate 29 
 
17 -48 22 
 
6.39 <.001 <.001 4360 2.07 
 
 
R Posterior Cingulate 31 
 
25 -66 22 
 
4.67 <.001 <.001 4360 1.52 
 
 
R Posterior Cingulate 23 
 
7 -34 20 
 
4.62 <.001 <.001 4360 1.50 
 
 
R Posterior Cingulate 31 
 
25 -60 24 
 
4.41 <.001 <.001 4360 1.43 
 
 
L Posterior Cingulate 31 
 
-23 -60 24 
 
4.73 <.001 <.001 4360 1.53 
 
 
L Posterior Cingulate 31 
 
-29 -66 26 
 
4.20 <.001 <.001 4360 1.36 
 
 
R Cingulate Gyrus 31 
 
21 -36 48 
 
4.42 <.001 <.001 4360 1.43 
 
 
L Precuneus 31 
 
-11 -62 24 
 
5.04 <.001 <.001 4360 1.64 
 
 
R Precuneus 7 
 
23 -52 44 
 
4.50 <.001 <.001 4360 1.46 
 
 
R Precuneus 31 
 
7 -70 24 
 
4.25 <.001 <.001 4360 1.38 
 
 
R Insula 13 
 
49 -40 20 
 
4.25 <.001 <.001 4360 1.38 
 
 
R Insula 13 
 
33 -36 20 
 
4.25 <.001 <.001 4360 1.38 
 
 
L Middle Temporal Gyrus (TPJ) 39 
 
-33 -66 28 
 
4.24 <.001 <.001 4360 1.38 
 
 
R Superior Temporal Gyrus (TPJ) 
 
 
59 -36 20 
 
























 11 1.21 
 





 Interaction effects (Drug (Oxytocin versus Placebo) x Emotion (Emotionally valenced faces versus Neutral faces)  
  
 
R Precuneus 7 
 
17 -60 40 
 
3.87 <.001 0.019 1051 1.26 
 
 
R Precuneus 19 
 
35 -64 40 
 
3.19 0.001 0.019 1051 1.03 
 
 
R Precuneus 31 
 
25 -50 38 
 














size   
 
R Precuneus 23 
 
9 -62 22 
 
2.77 0.004 0.019 1051 0.90 
 
 
R Precuneus 31 
 
37 -72 24 
 
2.70 0.004 0.019 1051 0.88 
 
 
L Precuneus 31 
 
-23 -68 26 
 
4.02 <.001 0.002 1660 1.30 
 
 
L Precuneus 31 
 
-19 -46 38 
 
3.19 0.001 0.002 1660 1.03 
 
 
R Cuneus 18 
 
7 -72 24 
 
3.15 0.001 0.019 1051 1.02 
 
 
R Middle Temporal Gyrus (TPJ) 19 
 
51 -60 18 
 
3.60 <.001 0.019 1051 1.17 
 
 
L Middle Temporal Gyrus 39 
 
-39 -62 32 
 
3.80 <.001 0.002 1660 1.23 
 
 
L Superior Temporal Gyrus 39 
 
-45 -54 34 
 
3.62 <.001 0.002 1660 1.17 
 
 
L Superior Temporal Gyrus (TPJ) 13 
 
-45 -44 30 
 
3.41 0.001 0.002 1660 1.11 
 
 
R Posterior Cingulate 23 
 
11 -58 22 
 
2.76 0.004 0.019 1051 0.90 
 
 
L Posterior Cingulate 30 
 
-17 -68 16 
 
3.05 0.002 0.002 1660 0.99 
 
 
L Cingulate Gyrus 31 
 
-19 -40 28 
 












 3 0.91 
                               
Corresponding coordinates for each brain region listed represent the peak voxels for each corresponding region within each 
significant cluster. All areas reported were found to be significant at a family wise error cluster level corrected threshold of <.05 
after running a whole brain analysis at an uncorrected threshold of p<.005.  
k = cluster size; BA  = Brodmann’s Area 
Effect size was calculated using Cohen’s d 
a Regions which were found to be significant using small volume correction. FWE values are reported at peak level significance after 
correction 
b Regions which were found to be significant at a trend level using small volume correction. FWE values are reported at peak level 




6.3.2.2 REWARD PREDICTION ERROR (RPE) 
6.3.2.2.1 RPE ACROSS EMOTIONALLY VALENCED AND NEUTRAL FACES  
6.3.2.2.1.1 WHOLE BRAIN ANALYSIS (MAIN EFFECT OF DRUG) 
When looking at how RPE correlated with neural activity in patients with schizophrenia after 
placebo versus oxytocin administration across the emotionally and neutral valenced faces, 
whole brain analysis showed no significant areas of activation. 
6.3.2.2.1.2 REGION OF INTEREST ANALYSIS 
Using an ROI analysis with SVC within the ventral striatum no voxels were found to be more 
significant after placebo or oxytocin administration for RPE correlating with neural activity in 
the emotionally valenced and neutral face condition. 
6.3.2.2.2 RPE FOR EMOTIONALLY VALENCED FACES 
6.3.2.2.2.1 WHOLE BRAIN ANALYSIS (MAIN EFFECT OF DRUG) 
When looking at how RPE correlated with neural activity in patients with schizophrenia 
across the emotionally valenced faces, whole brain analysis revealed a significant cluster of 
neural activity that was more active after patients with schizophrenia had taken placebo 
over oxytocin in the right superior parietal lobe, extending into the cuneus, inferior parietal 
lobe, supramarginal gyrus and superior temporal gyrus, with some voxels overlapping the 
right TPJ (Table 6.7 and Figure 6.11). It is important to note that similar neural activation was 
observed in the left hemisphere at this threshold; however, it did not survive the cluster 
extent criterion as not all the voxels were contiguous. Further analysis showed that the 
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significant neural activity observed was due to attenuation of neural activity after oxytocin 
administration and an increase in neural activity after placebo administration. 
 
FIGURE 6.11 - Neural activity correlating with RPE when deciding between two emotionally 
valenced faceswhere greater neural activity was observed after placebo administration 
than oxytocin administration in the right cuneus extending to the right TPJ. This image is 
shown at an uncorrected height threshold of p < 0.005 with an extent threshold of 100 
with only clusters surviving FWE cluster-level correction of p < 0.05 
6.3.2.2.2.2 REGION OF INTEREST ANALYSIS 
Using an ROI analysis with SVC within the ventral striatum no voxels were found to be more 
significant after placebo or oxytocin administration for RPE correlating with neural activity in 
the emotionally valenced face condition. 
6.3.2.2.2.3 CORRELATION ANALYSIS FOR RPE IN EMOTIONALLLY VALENCED FACES 
Mean neural activity for each subject was extracted from the ventral striatum and correlated 
with PANSS scores and chlorpromazine equivalents. No correlations were found between 










However, there was a significant positive correlation between neural activity in this region in 
response to oxytocin administration between all PANSS subscale and total scores (Table 6.5). 
Furthermore, when looking at the difference between neural activity after oxytocin 
administration over placebo administration, there was a positive correlation between 
positive and total PANSS scores as well as a negative correlation between CPZ equivalents 
and neural activation in the ventral striatum for RPE. These findings suggest that oxytocin 
has the largest effect on participants with high positive PANSS scores which may be slightly 
decreased by medication effects. 
TABLE 6.5 - Correlation measures between neural activity for RPE within the ventral 





(Oxytocin - Placebo) 
PANSS (Positive Symptoms)  0.701, p= 0.001** -0.046, p = 0.846 0.479, p= 0.033* 
PANSS (Negative Symptoms) 0.452, p = 0.045* -0.020, p = 0.934 0.301, p= 0.197 
PANSS (Total) 0.596, p= 0.006** -0.134, p = 0.572 0.483, p = 0.031* 
CPZ Equivalents -0.253, p= 0.281 0.359, p = 0.121 -0.448, p = 0.048* 
*significant at p < .05; **significant at p < .01 
Correlation measures are reported as Pearson r correlations. All values were assessed for skew and 
kurtosis. 
 
FIGURE 6.12 - Correlation measures between positive PANSS scores and contrast estimates 
for RPE within the ventral striatum after being administered oxytocin 
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6.3.2.2.3 RPE FOR NEUTRAL FACES 
6.3.2.2.3.1 WHOLE BRAIN AND REGION OF INTEREST ANALYSIS 
No differences were found in neural activity for RPE between oxytocin and placebo in the 
neutral condition at a whole brain level or after SVC. 
6.3.2.2.3.2 CORRELATION ANALYSIS FOR RPE IN NEUTRAL FACES 
Mean neural activity for each subject correlating with RPE in the neutral face condition was 
extracted from the ventral striatum and correlated with PANSS scores and CPZ equivalents. 
There was a significant positive correlation was found in response to the difference between 
oxytocin administration and placebo administration for total PANSS scores as well as CPZ 
equivalent measures. No other significant correlations were found between any other PANSS 
scores and neural activity after placebo and oxytocin administration separately (Table 6.6).   
TABLE 6.6 - Correlation measures between neural activity within the ventral striatum for 




(Oxytocin - Placebo) 
  Correlation measures (r) 
PANSS (Positive Symptoms) 0.397, p = 0.083† 0.029, p = 0.903 0.303, p= 0.193 
PANSS (Negative Symptoms) 0.067, p = 0.779 -0.036, p = 0.881 -0.396, p= 0.084† 
PANSS (Total) 0.214, p= 0.364 -0.357, p = 0.123 0.449, p = 0.047* 
CPZ Equivalents -0.368, p= 0.111 0.246, p = 0.296 -0.490, p = 0.028* 
*significant at p < .05; †trend level significance at p < .1 






TABLE 6.7 - Neural activity for reward prediction error for placebo versus oxytocin 










size   
               Placebo>Oxytocin (RPE for Emotionally valenced faces) 
 
 
R Superior Parietal Lobule 73 
 
35 -60 50 
 
5.99 <.001 0.004 1277 1.94 
 
 
R Superior Parietal Lobule 72 
 
35 -48 50 
 
2.89 0.005 0.004 1277 0.94 
 
 
R Inferior Parietal Lobule 40 
 
45 -56 46 
 
4.77 <.001 0.004 1277 1.55 
 
 
R Inferior Parietal Lobule 40 
 
55 -52 40 
 
3.70 0.001 0.004 1277 1.20 
 
 
R Cuneus 70 
 
11 -64 38 
 
5.76 <.001 0.004 1277 1.87 
 
 
R Precuneus 31 
 
21 -56 38 
 
4.16 <.001 0.004 1277 1.35 
 
 
R Precuneus 72 
 
17 -66 52 
 
3.04 0.003 0.004 1277 0.99 
 
 
R Supramarginal Gyrus (TPJ) 40 
 
61 -50 38 
 
3.71 0.001 0.004 1277 1.20 
 
 
R Superior Temporal Gyrus 39 
 
43 -52 36 
 
3.28 0.002 0.004 1277 1.06 
                               
Corresponding coordinates for each brain region listed represent the peak voxels for each corresponding region within each 
significant cluster. All areas reported were found to be significant at a family wise error cluster level corrected threshold of <.05 
after running a whole brain analysis at an uncorrected threshold of p<.005; k = cluster size; BA = Brodmann’s Area 




This study explored the effect of oxytocin on decision-making in an associative learning 
task in patients with schizophrenia using emotionally valenced and neutral faces as 
social variables in order to assess how oxytocin administration may affect neural 
activity and emotional bias in patients with schizophrenia. Schizophrenia is associated 
with profound difficulties in social decision-making which are not currently treated by 
standard antipsychotics. As oxytocin has been demonstrated to positively impact on 
facilitating social cognition and facial recognition, it was used here to determine if it 
could also influence decision-making where social variables were secondary to the 
main decision-making task. It was found that oxytocin administration exerted similar 
positive prosocial effects in the patients with schizophrenia by attenuating bias toward 
choosing a happy face - or attenuation of the aversion toward an angry face - which 
was accompanied by the attenuation of neural activity in social regions including the 
amygdala and TPJ. Furthermore, the effects of oxytocin on RPE were found to 
positively correlate with neural activity in the ventral striatum and positive symptom 
scores suggesting that symptomatology in schizophrenia may undermine the effects of 
oxytocin administration on reward related activity. These findings demonstrate that 
oxytocin administration is capable of inducing a robust effect on neural activity in 
patients with schizophrenia with potentially beneficial prosocial effects. 
After being administered a placebo, patients with schizophrenia demonstrated the 
same bias toward picking the happy face as shown in previous studies in both healthy 
participants and patients with schizophrenia (Averbeck and Duchaine, 2009; Evans et 
al., 2011a; Evans et al., 2010; Evans et al., 2011b; Furl et al., 2012) and in chapters 3 
and 4 (pages 73 and 119) despite performing the task significantly above chance. Thus, 
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when the evidence for being rewarded was greater for angry face, patients reliably 
chose the happy face more often resulting in a bias toward choosing the happy face. 
However, after being administered oxytocin, this bias toward the happy face was 
completely attenuated. This meant that patients with schizophrenia no longer showed 
an aversion toward picking the angry face nor did they show an affinity for choosing 
the happy face. As expected, no bias was found with respect to either of the neutral 
faces after being administered placebo or oxytocin. Furthermore, changes in bias 
attribution during decision-making were also accompanied by an attenuation of neural 
activity in the TPJ and amygdala after oxytocin administration compared to placebo 
administration. This attenuation was present in a cluster extending bilaterally from the 
precuneus into the bilateral TPJ. The TPJ is a brain region which has been found to 
show increased neural activation during social processing (Decety and Lamm, 2007) 
and generally shows diminished neural activity in schizophrenia compared to healthy 
controls during tasks involving mentalising (Das et al., 2012; Lee et al., 2011; Walter et 
al., 2009). The amygdala has been implicated in other oxytocin imaging studies as a 
region which generally is attenuated during tasks involving the processing of emotional 
faces in male subjects (Wigton et al.). A region of interest analysis using the amygdala 
also showed that oxytocin attenuated neural activity in the bilateral amygdala but that 
this effect was only significant during decision-making in the emotionally valenced 
condition and not during the neutral condition. Furthermore, although an interaction 
analysis of drug and emotion was significant suggesting that amygdala activity was also 
increased in the neutral face condition after oxytocin administration; further 
examination showed that these effects were driven by a greater difference in neural 
activity after oxytocin and placebo administration in the emotionally valenced 
condition than in the neutral condition suggesting that these effects are more specific 
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to oxytocin’s effect on processing emotionally salient information. Attenuation of 
these social regions alongside the attenuation of bias in patients with schizophrenia is 
in-line with data from healthy subjects showing that attenuation of social regions may 
facilitate prosocial behaviour. 
Previous studies exploring the effects of oxytocin administration on neural activity 
have shown that, in healthy males, relative to a placebo, oxytocin administration tends 
to attenuate neural activity in regions associated with social behaviour, such as the TPJ 
(Domes et al., 2007b; Frith and Frith, 2012; Wittfoth-Schardt et al., 2012) and 
amygdala (Domes et al., 2007b; Kirsch et al., 2005; Wigton et al.). Although mainly 
known for its role in mentalising, the TPJ has also been linked to other social processes 
including social attention (Asplund et al., 2010; Kucyi et al., 2012), detecting novel 
stimuli (Downar et al., 2000; McCarthy et al., 1997b) to increasing attention toward 
novel/salient stimuli (Castelli et al., 2002). Furthermore, the TPJ has also been 
associated with the severity of auditory hallucinations in schizophrenia (Gromann et 
al., 2012; Vercammen et al., 2010). The amygdala, moreover, also plays a role in 
emotional processing in the modulation of vigilance in the presence of stimuli 
signalling increased social novelty or threat (Phelps, 2006; Whalen et al., 1998) as well 
as in modulating neural activity in response to facial expressions (Anderson and Phelps, 
2000). Activation in both the TPJ and amygdala was also attenuated by the 
administration of oxytocin, relative to a placebo, in healthy males, when processing 
novel faces over familiar faces (Wittfoth-Schardt et al., 2012) as well as when implicitly 
processing emotionally valenced faces over neutral faces (Domes et al., 2007a; Kirsch 
et al., 2005). Our findings suggest that this attenuation in neural activity in social 
regions in healthy controls can also be extended to patients with schizophrenia. 
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Furthermore, the attenuation of neural activity was accompanied by attenuation in the 
degree of bias that patients with schizophrenia displayed for choosing the happy face 
when the angry face was more likely to be rewarded such that neither face was 
preferred by the patients with schizophrenia after they had taken oxytocin. This is 
similar to the previous behavioural finding shown in healthy controls during this task 
after oxytocin administration (Evans et al., 2010). Consistent with this, oxytocin has 
been shown to slow identification of negatively valenced stimuli while enhancing the 
recognition of positively valenced stimuli (Di Simplicio et al., 2009) suggesting that the 
observed reduction in neural activity may be indicative of oxytocin administration 
acting to dampen this enhancement toward positively valenced social stimuli by 
decreasing the aversive aspects of negatively valenced social stimuli (Averbeck, 2010). 
In accordance with previous studies, the amygdala, TPJ and precuneus did not show 
any significant changes in neural activity due to oxytocin administration in the neutral 
condition (Domes et al., 2007b; Labuschagne et al., 2010) demonstrating that oxytocin 
administration only had a significant effect on neural activity in the processing of 
emotionally valenced stimuli.  
Although patients with schizophrenia generally demonstrate hypoactivation of the TPJ 
during tasks involving mentalising (Das et al., 2012; Lee et al., 2011), it has been 
hypothesised that these decreases in neural activity may be due to the TPJ being more 
active while mentalising as patients may be attributing greater levels of intentionality 
to other parts of the task which are not social in lieu of only attributing social causality 
(Walter et al., 2009). Additionally, some studies have even shown hyperactivation in 
the TPJ during a mentalising task compared to healthy controls (Brüne et al., 2008). 
However, Chapter 4 (page 128) showed that patients with schizophrenia do not show 
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significant changes in neural activity than healthy controls during the task used in this 
thesis in the TPJ. Given that the group of patients analysed in the current chapter were 
a subset of patients from the previous experiment, this suggests that, during this task, 
neural activity within the TPJ for patients with schizophrenia is not significantly altered 
from that of healthy controls.  
With respect to RPE, or the difference between expected and actual reward, oxytocin 
administration was found to attenuate neural activity in a more superior region of the 
bilateral precuneus extending into more superior regions of the TPJ than the region 
which showed an attenuation of neural activity in the decision-making condition. 
These effects were also found to only be significant for RPE in the emotionally 
valenced face condition. This finding suggests that attenuation of neural activity in 
social regions after oxytocin administration may not be solely constrained to the 
observation, or implicit processing, of social stimuli but may also extend to the 
processing of social and financial reward in patients with schizophrenia. This has also 
been suggested in previous work in healthy controls showing that oxytocin 
administration was able to increase sensitivity to social feedback relative to non-social 
feedback when comparing the differences in processing the intrinsic value of faces 
compared to the processing of abstract, non-social stimuli (Hurlemann et al., 2010) as 
well as other work showing an increase in neural activity in the TPJ for RPE in social 
learning (Behrens et al., 2008; Frith and Frith, 2012).  
Although no significant differences between oxytocin and placebo were observed 
using SVC within the ventral striatum, an exploratory analysis was run to see if 
oxytocin had any general effects on neural activity within the ventral striatum and to 
see if these effects could be explained by symptomatology within the patients with 
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schizophrenia. When extracting for individual variance within the ventral striatum, the 
degree to which oxytocin increased neural activity positively correlated with all PANSS 
scores and RPE in the emotionally valenced faces, and when looking at correlations 
between the difference in neural activity from RPE in the emotionally valenced faces 
between oxytocin administration and placebo administration, this positive correlation 
is still significant for positive and total PANSS scores and also showed a negative 
correlation with chlorpromazine medication equivalents. These findings suggest that 
individuals with higher symptom profiles in schizophrenia, especially in regard to 
positive symptoms, show greater increases in neural activity after oxytocin 
administration in dopamine rich areas such as the ventral striatum and that 
antipsychotic medication may dampen the effects of oxytocin administration in the 
ventral striatum. Additionally, differences in neural activity correlating with RPE 
between oxytocin and placebo administration for neutral faces correlated with total 
PANSS scores and also negatively correlated with chlorpromazine medication 
equivalents, giving a potential indication of the general influence of oxytocin 
administration on RPE in relation to symptomatology scores. It is important to note 
that no high symptoms scores or medication equivalents, as measured under placebo 
administration, accounted for changes in neural activation in the ventral striatum. 
Correlations in these measures could have indicated that these correlations may have 
been a result of general extra striatal dopamine release due to symptom scores or an 
inhibition from medication effects (Abi-Dargham et al., 2000; Juckel et al., 2006). When 
taking into account the difference between neural activity after the oxytocin 
administration and placebo administration, these results demonstrate that oxytocin 
administration had the greatest effect on neural activity in participants with higher 
positive PANSS scores and that the effect of oxytocin administration may have been 
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diminished by medication effects. This is of clinical relevance as it suggests that 
patients who do not respond well to conventional treatments may respond to oxytocin 
administration. 
Potentially more interesting is the finding that these observed neural effects are 
present so late after oxytocin administration. The timings of this study were set to 
maximise the effects of oxytocin administration on neural activity in line with the 
timings from current studies on one of the other tasks used in the scanner (exploring 
trust based interactions) which is not analysed here. This other trust-based task was 
designed to begin at approximately 45 minutes post- oxytocin or placebo 
administration and lasted approximately 45 minutes. Thus the task explored in this 
chapter was designed to begin around an hour and a half past the administration of 
oxytocin or a placebo. Only one study to date has looked at how intranasal oxytocin 
administration affects CSF and plasma oxytocin levels over time in order to determine 
its maximum effects on CSF and plasma concentration (Striepens et al., 2013). They 
found that, although plasma levels of oxytocin increased after 15 minutes, no 
significant increases in CSF oxytocin levels were observed until 75 minutes post 
administration. However, the sample size was extremely small (1 on placebo and 3 on 
oxytocin) and no further time points were recorded so it is hard to draw any firm 
conclusions on whether these findings would extend to a larger population and how 
long oxytocin in the CSF would remain elevated after their last time point. However, a 
similar study in humans using a related neuropeptide, vasopressin, which has formed 
the basis for the current timings used in many oxytocin imaging studies, showed that 
oxytocin levels were increased in the CSF compared to a placebo up to at least 2 hours 
after administration, after which no more measurements were taken (Born et al., 
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2002). Even though plasma levels of oxytocin have not been found to correlate with 
levels in the CSF (Kagerbauer et al., 2013; Striepens et al., 2013), the literature 
suggests that oxytocin administration can result in elevated levels of plasma oxytocin 
for up to 7 hours, with oxytocin levels up to 10 times greater than in the placebo 
condition (van Ijzendoorn et al., 2012) and that, in rodents, CSF oxytocin levels are 
almost immediately elevated following intranasal administration and can remain 
elevated for up to 90 minutes in the amygdala and hippocampus (Neumann et al., 
2013). Given that plasma oxytocin levels have been found to correlate with social 
behaviour these findings may still show that the effects of oxytocin administration are 
more prolonged than currently thought. Together, these findings highlight our lack of 
understanding in the time course of oxytocin administration on increasing the levels of 
oxytocin within the CSF and suggest that it takes longer than previously thought to 
increase oxytocin within the CSF. Our study indicates that, at least in patients with 
schizophrenia, the behavioural and neural effects of oxytocin persist at least up until 
almost two hours after administration and suggests this task began closer to the actual 
peak for oxytocin concentration in the CSF than previous work. 
This current study only looked at patients with schizophrenia without examining a 
matched healthy control cohort therefore it is not currently possible to say how effects 
may compare to healthy controls and whether or not healthy controls would show 
attenuation in these regions to a greater or lesser degree, or not at all. However, as 
described in Chapter 4 (page 121), patients with schizophrenia did not show significant 
differences in neural activity to healthy controls in the same regions where oxytocin 
administration was found to attenuate neural activity, and given that oxytocin 
administration appears to attenuate neural activity in areas similar to those seen in 
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other studies with healthy controls, these findings are in line with what has been 
previously reported in a healthy population. This suggests that these findings were not 
due to general differences in neural activity between patients with schizophrenia and 
healthy controls but reflect a general attenuation of neural activity in social regions via 
oxytocin administration.  
This study was double blinded and took every care to prevent participants from being 
able to determine which drug, placebo or oxytocin, they had received, as subjective 
differences in their experiences may have influenced the current results. However, 
throughout the study, only two participants reported feeling a difference between the 
two sessions. Furthermore, any changes in perception would still not account for the 
significant attenuations seen in neural activation seen across all patients with 
schizophrenia in addition to the behavioural changes observed.  
Overall, these findings show that oxytocin is capable of attenuating neural activity in 
patients with schizophrenia in areas which are associated with social processing. These 
changes are accompanied by changes in bias attenuation indicative of increased 
prosocial behaviour. Furthermore, the effect of oxytocin administration on the reward 
processing during decision-making between two emotional faces positively correlated 
with positive symptoms in schizophrenia which suggests that patients with 
schizophrenia with higher positive symptoms may be more susceptible to the neural 
effects of oxytocin administration than others at least when processing social reward. 
Additionally, this indicates that oxytocin may not only influence the processing of 
social stimuli but the way in which social reward is processed. 
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CHAPTER 7 -  GENERAL DISCUSSION 
This thesis comprised two main experiments using functional Magnetic Resonance 
Imaging (fMRI) and the administration of different pharmacological probes to explore 
neural activity in healthy controls and patients with schizophrenia.  
The objective was to explore the role of dopamine and oxytocin in socially-focused 
associative learning by comparing neural activity after dopaminergic perturbation in 
healthy controls to patients with schizophrenia, as well as by studying how oxytocin 
affects neural activity during socially-focused associative learning in patients with 
schizophrenia.  
The main findings from this thesis showed that as demonstrated in previous studies, 
Chapters 3, 4 and 6 (pages 73, 119 and 218), when deciding between two emotionally 
valenced faces, healthy controls and patients with schizophrenia reliably favoured a 
happy face over an angry face even when the angry face was associated with a higher 
probability of being rewarded. This work replicated previous findings from research in 
healthy individuals and patients with schizophrenia without pharmacological 
manipulation or after taking a placebo (Averbeck and Duchaine, 2009; Evans et al., 
2011a; Evans et al., 2010; Furl et al., 2012). Additionally, the evidence showed that this 
bias was attenuated by the administration of ropinirole and amisulpride in healthy 
controls (Chapter 3, page 73) and oxytocin in patients with schizophrenia (Chapter 6, 
page 218) so that, after the administration of these drugs, participants no longer 
demonstrate a preference, or bias, for choosing either the happy or angry face.  
In healthy controls (Chapter 3) the attenuation of bias when deciding between two 
emotionally valenced faces after ropinirole administration was associated with an 
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increase in neural activity within the dACC and dmPFC, areas that are well-known to be 
involved in decision-making (Botvinick, 2007), social processing (Phan et al., 2002a) 
and where D2 dopaminergic binding occurs (Ko et al., 2009; Lumme et al., 2006). 
However, after amisulpride administration no significant changes in neural activity 
were observed when deciding between two emotionally valenced faces. These 
changes in neural activation patterns in response to dopaminergic manipulation that 
were present in healthy controls were absent in patients with schizophrenia when 
deciding between two emotionally valenced faces (Chapter 4). However, when 
compared to healthy controls who had received a placebo, patients with schizophrenia 
demonstrated attenuation of neural activity in the thalamus, primarily within the 
MDN, a region repeatedly shown to be abnormal in patients with schizophrenia, both 
structurally and functionally (Andrews et al., 2006; Byne et al., 2001; Mitelman et al., 
2005; Pakkenberg, 1990). Furthermore, when looking at decision-making in general 
(i.e. across emotionally-valenced and neutral blocks), patients with schizophrenia show 
decreased neural activity in a wider network of brain regions including the thalamus, 
cerebellum and mPFC. In patients with schizophrenia, deficits within this network have 
previously been shown by others using both MRI and positron emission tomography 
(PET) and have been posited to demonstrate “cognitive dysmetria” or poor mental 
coordination (Andreasen, 1997; Andreasen et al., 1996; Andreasen et al., 1998) 
possibly indicative of dysconnectivity within these regions (Friston, 2005; Stephan et 
al., 2006; Stephan et al., 2009). 
As predicted, directionally concordant effects were found between healthy controls 
who had taken amisulpride and patients with schizophrenia. Both groups exhibited 
attenuated neural activity within the cerebellum extending through the tentorium into 
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the fusiform gyrus - regions associated with social and facial processing (Anilkumar et 
al., 2008; Grill-Spector et al., 2004; Haxby et al., 2000; Van Overwalle et al., 2014) - 
when deciding between two neutral faces, compared to healthy controls who had 
taken a placebo. This suggests during facial identification, as opposed to emotional 
identification, both patients with schizophrenia and healthy controls who have taken 
amisulpride appear to recruit these regions associated with social and facial processing 
less despite performing the task at a similar level as the other groups. However, 
further analysis will need to be done to determine how these changes affected 
decision-making without altering performance. 
After being administered oxytocin (Chapter 6), attenuation of bias toward the happy 
face is accompanied by attenuation of neural activity in regions associated with social 
processing, such as the amygdala and TPJ, during decision-making involving 
emotionally valenced stimuli. This finding corresponded to the observations from 
Chapter 3, which showed that attenuation of bias during decision-making between two 
emotionally valenced faces after ropinirole administration was also accompanied by an 
attenuation of neural activity within the amygdala. The amygdala is viewed as a 
cardinal area for emotional processing (Costafreda et al., 2008; Pessoa and Adolphs, 
2010; Sergerie et al., 2008), and is part of the mesolimbic dopamine pathway (Koob 
and Swerdlow, 1988), suggesting a possible overlap between dopaminergic and 
oxytocinergic activity (Abi-Dargham, 2012; Rosenfeld et al., 2011). Attenuation of 
neural activity in the amygdala and TPJ may reflect that oxytocin may attenuate the 
aversion toward choosing the angry, in addition to decreasing the affinity toward 
choosing the happy face. 
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In addition to these main findings, exploratory analyses revealed further interesting 
findings. For example, in Chapter 4 it was found that patients with schizophrenia 
demonstrated greater neural activity correlating with RPE in the ventral striatum than 
healthy controls who had taken placebo. In most other studies exploring RPE in 
patients with schizophrenia the opposite pattern has been observed where patients 
with schizophrenia generally show less neural activity for RPE than healthy controls. 
The current finding may be attributable to the simplicity of the current model in 
comparison to the models, such as Q learning (Gradin et al., 2011; Murray et al., 2008). 
It is also possible that the patients in our study were more sensitive to reward 
feedback than the healthy controls or that they recruited more compensatory 
networks for processing reward than healthy controls within the striatum to be able to 
perform the task at a similar level as the healthy controls. Furthermore, the other 
studies outlined in this thesis looking at RPE, used greater monetary rewards than our 
study and one study even showed that, in addition to the modulatory effect of 
dopamine agonists and antagonists, in healthy participants, the degree of monetary 
reward also had a modulatory effect on neural activity such that higher monetary 
rewards were associated with higher neural activity (Pleger et al., 2009). When looking 
at the effects of dopamine on decision-making in trials investigating loss aversion or 
when deciding between two options associated with low reward probability, no effects 
of dopaminergic manipulation were seen (Jocham et al., 2011; Pessiglione et al., 2006), 
suggesting that the effects from these other papers may be specific to higher 
monetary reward. One way to assess this further would be to implement similar 
models as used in previous papers and compare the results in neural activity from 
these models and the model presented here.  
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Additionally, in Chapter 6, correlation measures were assessed when looking at neural 
activity correlating with RPE in the ventral striatum after oxytocin administration in 
patients with schizophrenia in the emotionally valenced face condition. The results 
showed strong (positive) correlations between positive and total illness symptoms with 
neural activity after oxytocin administration in patients with schizophrenia. 
Furthermore, when assessing correlations between symptom scores and the difference 
in neural activity in the ventral striatum between oxytocin and placebo administration, 
a positive correlation was also found between positive symptoms, but not total 
symptoms, and neural activity for RPE. This indicates that patients with schizophrenia 
who exhibit higher positive symptoms, despite being stable on their medication, 
appear to show the greatest changes in neural activity after oxytocin administration 
and suggests that, for these patients, oxytocin administration may be of particular 
clinical benefit.  
Previously it was also shown that bias toward choosing a happy face is attenuated in 
healthy controls through the administration of oxytocin (Evans et al., 2010). Chapter 3 
of this thesis shows that in healthy controls ropinirole and amisulpride also attenuate 
this bias such that neither face is favoured during decision-making. Furthermore, 
Chapter 6 demonstrates that oxytocin also attenuates this bias toward the happy face 
in patients with schizophrenia. Additionally, in healthy participants who received 
ropinirole and patients with schizophrenia who took oxytocin, attenuation of bias 
toward the happy face when deciding between two emotionally valenced faces was 
accompanied by an attenuation of neural activity within the amygdala. This finding is in 
line with studies showing that implicit processing of social stimuli after oxytocin 
administration was associated with attenuation of neural activity in the amygdala 
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(Domes et al., 2007b; Kirsch et al., 2005; Petrovic et al., 2008; Riem et al., 2011). As the 
amygdala has been suggested to be involved in the evaluation of biological significance 
(Pessoa and Adolphs, 2010) in terms of assigning personal or social value, and 
emotional arousal (McGaugh, 2005), attenuation of this region may signify that 
subjects are evaluating the faces more objectively without being as influenced by the 
emotional expressions. This is especially of clinical significance for patients with 
schizophrenia, as the attribution of aberrant salience to emotional faces could lead to 
patients believing that socially innocuous stimuli hold a more personal relevance to 
them. This process has specifically been suggested to underlie the formation and 
maintenance of paranoid delusions. This study shows that oxytocin and dopamine 
agonists attenuate neural activity relating to evaluation of emotional stimuli, as well as 
attenuating social bias without having a detrimental effect on task performance (i.e. 
choosing the face more associated with the higher probability of reward in lieu of the 
more biologically rewarding face). This implies that both ropinirole and oxytocin are 
capable of attenuating the attribution of biological significance to social stimuli that 
hold no personal relevance to the individuals viewing them; thus allowing for more 
objective and correct discrimination and classification of stimuli. 
In general, the lack of overlap between differences in neural activity after 
dopaminergic perturbation and differences in neural activity between healthy controls 
and patients with schizophrenia is interesting because it shows that differences in 
neural activity within patients with schizophrenia cannot necessarily be explained by 
changes in dopamine alone. This is in line with contemporary ideas on the role of 
glutamate in schizophrenia (Coyle, 2006; Laruelle et al., 2003; Stone et al., 2007). 
However, these findings using dopaminergic manipulation and patients with 
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schizophrenia are complicated by many other factors which may have impacted on the 
findings. The first of these potential confounders is the presence of autoreceptors, or 
receptors which are capable of providing their own negative feedback without further 
neurochemical perturbation along the neuron. These act to control the synthesis and 
release of neurotransmitters, such as dopamine, mainly in the nigrostriatal and 
mesolimbic systems (Meltzer, 1980). The second complication arises from inherent 
issues with the dosing and standardisation of medication. Although dopaminergic 
perturbation was initially addressed as if consistent timing and dosage would produce 
similar effects across participants, this is known not to be the case. Dopaminergic 
perturbation is known to have a differential response across individuals. The variability 
for these effects is thought to occur across an inverted-U-shaped curve where both too 
much and too little dopamine can lead to impairments in cognition (Cools and 
D'Esposito, 2011). Furthermore, depending on the size of the participant, using the 
same dose could have a higher or lower impact on changes in dopamine binding within 
the brain. Those with higher BMI or body fat ratios will tend to absorb the drug 
differently than those with a lower fat content and BMI so that not all of the drug may 
make the journey to the brain to cross the blood brain barrier. Therefore, although the 
doses administered were in line with standard clinical doses, it is hard to say for all 
those involved in the study if the dosage used would have elicited enough of change in 
dopaminergic binding to prompt changes in neural activity.  
This study was also limited by the fact that the concentration of dopamine was not 
standardised to each person. Fixed doses of dopamine agonists and antagonists were 
given to all individuals in the study and may have affected some more than others. 
Furthermore, dopamine levels within the bloodstream have also been shown to be 
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affected by fat content consumed throughout the day. Although care was taken to 
provide our subjects with qualitatively similar low-fat meals while they were at the 
Institute of Psychiatry for testing and instructions were given for appropriate meals on 
the testing day before their participation in the study, it was not possible to control 
what they had eaten before they attended the testing session. Therefore the peak 
dopamine concentrations may have differed between individuals. Plasma levels were 
not recorded, so it is impossible to tell how affected each individual was by the 
dopamine perturbation.  
Furthermore, although changes in neural activity during dopaminergic perturbation 
are assumed to be driven by changes in dopaminergic binding, without directly 
measuring this binding it is impossible to be sure. However, changes in neural activity 
from both amisulpride and ropinirole corresponded with areas that previously showed 
reliable changes in dopaminergic binding after the administration of dopamine 
agonists (Ko et al., 2009; Lumme et al., 2006) and antipsychotics (Ito et al., 2009). 
Although both drugs show some affinity for other neurochemicals such as serotonin 
(Abbas et al., 2009; Dhir and Kulkarni, 2007), they both demonstrate a strong affinity 
for D2 receptors (Alonso Cánovas et al., 2014; Green, 2002; Kaye and Nicholls, 2000). 
Thus, the effects observed in this study may also be due to each drug’s effects over 
other neurochemicals, however, this is less likely for the reasons listed above. 
Another possible confound is that all patients with schizophrenia, with the exception 
of two, were medicated. This makes it difficult to look at aberrant dopaminergic 
activity in an unbiased way. As all of our patients were clinically stable and 
antipsychotic efficacy has been found to correlate with D2 receptor binding (Kapur and 
Remington, 2001), it is highly likely that most patients with schizophrenia were within 
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the optimal therapeutic window of 65-78% D2 receptor blockade (Kapur and 
Remington, 2001). However, as this study was unable to ascertain specific binding 
measures within each participant, these numbers are purely speculative. Given that 
correlations were only found between changes in neural activity from amisulpride 
administration and patients with schizophrenia and none were found after ropinirole 
administration, it is probable these findings were due to similar dopaminergic receptor 
blockades. Furthermore, this study used mainly chronically ill patients with 
schizophrenia (average duration of illness 13.54 ± 8.76). It is therefore important to 
recognise that illness chronicity may have also affected the results. Given that most 
patients had been taking D2 antagonist medication for most years of their illness, this 
may account for why neural activity in the patients with schizophrenia resembled 
healthy controls who had taken amisulpride. 
In a similar vein, negative symptoms and cognitive deficits in schizophrenia are also 
thought to be brought about by decreases in dopamine D1 receptors, which would not 
have been affected by the drugs that were administered in this study. However, given 
that the majority of the differences that we found between patients with 
schizophrenia and healthy controls were not in regions that are high in D1 receptors, 
this is unlikely to be a substantial contributor to our results. More likely is the assertion 
that schizophrenia may be driven by other neurochemicals in addition to dopamine. An 
emerging theory is that schizophrenia is caused by aberrant glutamatergic levels 
(Coyle, 2006; Stephan et al., 2009; Stone et al., 2007). Although this may initially seem 
to conflict with the dopaminergic hypothesis of schizophrenia, it is possible that 
abnormalities in these neurotransmitter systems are interdependent (Laruelle et al., 
2003; Stone et al., 2007). Glutamate acts on N-methyl-d-asparate (NMDA) receptors, 
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which may have a downstream or potentially upstream effect on dopaminergic 
transmission. To this effect, studies have shown that while some glutamate projection 
neurons into the hippocampus and cortex are modulated by dopamine (David et al., 
2005; Hatzipetros and Yamamoto, 2006; Stone et al., 2007) some dopaminergic 
projections are also regulated by glutamate (Del Arco and Mora, 2008; Smith et al., 
1998; Surmeier et al., 2007). Ketamine, a glutamate antagonist, has also been found to 
reduce D2 receptor availability (Breier et al., 1998; Vollenweider et al., 2000), although 
the evidence with respect to this mechanism is not consistent (Aalto et al., 2002; 
Laruelle et al., 2003). Furthermore, one study has also shown that long-term 
administration of NMDA antagonists, acting on glutamate, disrupts dopaminergic 
transmission in a manner consistent with the deficits posited by the dopaminergic 
hypothesis of schizophrenia (Jentsch and Roth, 1999). Thus, while an initial aberrance 
in glutamate may give rise to schizophrenia, it appears symptoms associated with 
schizophrenia may still be driven by changes in dopamine. 
Interestingly, numerous studies have shown glutamatergic abnormalities in 
schizophrenia within the thalamus (for a review see (Watis et al., 2008)). Elevated 
levels of glutamate in this region have been shown in both untreated first episode 
patients with schizophrenia and patients with chronic schizophrenia (Théberge et al., 
2003; Théberge et al., 2002). Furthermore, an increase in glutamate in the thalamus 
was also found to positively correlate with the duration of illness (Théberge et al., 
2003). Given the illness chronicity of the patients with schizophrenia involved in this 
study and the lack of findings in the thalamus after dopaminergic perturbation, it can 
be speculated that the significant differences observed in neural activity between the 
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healthy controls and patients with schizophrenia within the thalamus were driven by 
these differences in glutamate.  
This thesis highlights the need for future research focussing on investigating 
neurochemical manipulations in schizophrenia to elucidate the neuropathology of this 
disorder. Current research strongly supports the role of dopamine in the instantiation 
and perseveration of symptomatology in schizophrenia, at least with regard to positive 
symptoms. However, it is also apparent that aberrant dopamine is not the only driving 
factor behind schizophrenia. In the future, it may be more conclusive to repeat this 
same task while using positron emission tomography (PET) in order to look at striatal 
D2 binding during the task to see how healthy controls compare with patients with 
schizophrenia. It may also be of use to use first-episode unmedicated patients in order 
to be able to investigate dopaminergic binding differences without the potentially 
confounding effects of (prolonged) medication. Also of interest would be to include a 
comparison of glutamatergic manipulation to see if any variance in neural activity 
could be accounted for by changes in glutamate levels. Using the data acquired, it may 
be useful to do further analyses looking at connectivity measures within the patients 
with schizophrenia compared to the healthy controls to further explore the potential 
contributions of “cognitive dysmetria” between the thalamus, cerebellum and mPFC 
and to see if measures of dysconnectivity contribute to differences in neural activity 
between these groups. As for future directions in research using oxytocin, it would be 
of interest to see if the findings presented in this thesis also translate to female 
subjects and to see if there are any gender specific effects of oxytocin in female 
patients with schizophrenia. It would also be useful to include a healthy control arm to 
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see if they respond to oxytocin in the same way as patients with schizophrenia during 
this task. 
I am currently preparing to do a network analysis of the data presented here using 
dynamic causal modelling to look at the effects of drug perturbation, as well as group 
effects on neural activation patterns. I am also preparing to use a more sophisticated 
behavioural model incorporating similar parameters to those explored in the papers 
explored in this thesis, particularly Q-learning, to further explore RPE differences 
between the patients with schizophrenia and healthy controls. 
In conclusion, although this thesis did not find clear associations between 
dopaminergic manipulation in healthy controls and patients with schizophrenia, some 
attenuation in neural activity within the patients with schizophrenia was similar to 
healthy controls who had taken amisulpride. This suggests that, due to medication 
effects, the group of patients used in this study more closely resembled healthy 
controls who had taken amisulpride. However, the extensive differences in neural 
activity between the healthy controls and patients with schizophrenia cannot be 
accounted for by differences in dopaminergic activity alone. These findings support the 
notion that schizophrenia arises from the perturbation of further neurochemicals such 
as glutamate (Coyle, 2006) and may also involve aberrant communication between 
areas of high integration such as the thalamus and cerebellum (Andreasen et al., 
1999).  
Additionally, these findings support the notion that oxytocin administration in patients 
with schizophrenia may facilitate prosocial interactions by attenuating neural activity 
in regions which in patients with schizophrenia may be normally hyperactive due to 
attributing elevated biological significance to certain social and non-social stimuli. Thus 
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attenuation of neural activity in these regions may allow patients with schizophrenia to 




Aalto, S., Hirvonen, J., Kajander, J., Scheinin, H., Nagren, K., Vilkman, H., et al., (2002). 
"Ketamine does not decrease striatal dopamine D2 receptor binding in man". 
Psychopharmacology (Berl.) 164(4), 401-406. 
Abbas, A.I., Hedlund, P.B., Huang, X.P., Tran, T.B., Meltzer, H.Y., Roth, B.L., (2009). 
"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo". 
Psychopharmacology (Berl.) 205(1), 119-128. 
Abi-Dargham, A., (2012). "Is It in Our Genes: Oxytocin, Dopamine, Stress, and Sex". Biol. 
Psychiatry 72(3), 171-172. 
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L.S., et al., (2000). 
"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia". Proceedings 
of the National Academy of Sciences 97(14), 8104-8109. 
Abu-Akel, A., Fischer-Shofty, M., Levkovitz, Y., Decety, J., Shamay-Tsoory, S., (2014). "The 
role of oxytocin in empathy to the pain of conflictual out-group members among patients 
with schizophrenia". Psychol Med FirstView, 1-10. 
Adolphs, R., (2001). "The neurobiology of social cognition". Current opinion in 
neurobiology 11(2), 231-239. 
Adolphs, R., (2003). "Cognitive neuroscience of human social behaviour". Nature reviews. 
Neuroscience 4(3), 165-178. 
Adolphs, R., (2010). "What does the amygdala contribute to social cognition?". Annals of the 
New York Academy of Sciences 1191, 42-61. 
Adolphs, R., Tranel, D., Damasio, A.R., (1998). "The human amygdala in social judgment". 
Nature 393(6684), 470-474. 
Al-Ayadhi, L.Y., (2005). "Altered oxytocin and vasopressin levels in autistic children in 
Central Saudi Arabia". Neurosciences (Riyadh) 10(1), 47-50. 
Allison, T., Puce, A., McCarthy, G., (2000). "Social perception from visual cues: role of the STS 
region". Trends in cognitive sciences 4(7), 267-278. 
Alonso Cánovas, A., Luquin Piudo, R., García Ruiz-Espiga, P., Burguera, J.A., Campos Arillo, 
V., Castro, A., et al., (2014). "Dopaminergic agonists in Parkinson's disease". Neurología 
(English Edition) 29(4), 230-241. 
Anderson, A.K., Phelps, E.A., (2000). "Expression Without Recognition: Contributions of the 
Human Amygdala to Emotional Communication". Psychol. Sci. 11(2), 106-111. 
Anderson, B.M., Schnetz-Boutaud, N., Bartlett, J., Wright, H.H., Abramson, R.K., Cuccaro, 
M.L., et al., (2008). "Examination of association to autism of common genetic variationin 
genes related to dopamine". Autism research : official journal of the International Society 
for Autism Research 1(6), 364-369. 
Andreasen, N.C., (1997). "The role of the thalamus in schizophrenia". Can. J. Psychiatry. 
42(1), 27-33. 
Andreasen, N.C., Calarge, C.A., O'Leary, D.S., (2008). "Theory of mind and schizophrenia: a 
positron emission tomography study of medication-free patients". Schizophrenia bulletin 
34(4), 708-719. 
Andreasen, N.C., Nopoulos, P., O'Leary, D.S., Miller, D.D., Wassink, T., Flaum, M., (1999). 
"Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms". 
Biological psychiatry 46(7), 908-920. 
Andreasen, N.C., O'Leary, D.S., Cizadlo, T., Arndt, S., Rezai, K., Ponto, L.L., et al., (1996). 
"Schizophrenia and cognitive dysmetria: a positron-emission tomography study of 
dysfunctional prefrontal-thalamic-cerebellar circuitry". Proceedings of the National 
Academy of Sciences of the United States of America 93(18), 9985-9990. 
Andreasen, N.C., Paradiso, S., O'Leary, D.S., (1998). ""Cognitive dysmetria" as an integrative 
theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?". 
Schizophrenia bulletin 24(2), 203-218. 
Andreasen, N.C., Pierson, R., (2008). "The Role of the Cerebellum in Schizophrenia". Biol. 
Psychiatry 64(2), 81-88. 
255 
 
Andrews, J., Wang, L., Csernansky, J.G., Gado, M.H., Barch, D.M., (2006). "Abnormalities of 
thalamic activation and cognition in schizophrenia". The American journal of psychiatry 
163(3), 463-469. 
Angrist, B.M., Gershon, S., (1970). "The phenomenology of experimentally induced 
amphetamine psychosis--preliminary observations". Biological psychiatry 2(2), 95-107. 
Anilkumar, A.P.P., Kumari, V., Mehrotra, R., Aasen, I., Mitterschiffthaler, M.T., Sharma, T., 
(2008). "An fMRI study of face encoding and recognition in first-episode schizophrenia". Acta 
Neuropsychiatrica 20(3), 129-138. 
Arias-Carrion, O., Stamelou, M., Murillo-Rodriguez, E., Menendez-Gonzalez, M., Poppel, E., 
(2010). "Dopaminergic reward system: a short integrative review". Int. Arch. Med. 3(1), 24. 
Asplund, C.L., Todd, J.J., Snyder, A.P., Marois, R., (2010). "A central role for the lateral 
prefrontal cortex in goal-directed and stimulus-driven attention". Nature neuroscience 
13(4), 507-512. 
Association, A.P., (2000). "Diagnostic and statistical manual of mental disorders (4th ed., 
text rev.)", Washington, DC. 
Averbeck, B.B., (2010). "Oxytocin and the salience of social cues". Proceedings of the 
National Academy of Sciences 107(20), 9033-9034. 
Averbeck, B.B., Bobin, T., Evans, S., Shergill, S.S., (2011). "Emotion recognition and oxytocin 
in patients with schizophrenia". Psychol Med, 1-8. 
Averbeck, B.B., Bobin, T., Evans, S., Shergill, S.S., (2012). "Emotion recognition and oxytocin 
in patients with schizophrenia". Psychol Med 42(02), 259-266. 
Averbeck, B.B., Duchaine, B., (2009). "Integration of social and utilitarian factors in decision 
making". Emotion 9(5), 599-608. 
Bacopoulos, N.C., Spokes, E.G., Bird, E.D., Roth, R.H., (1979). "Antipsychotic drug action in 
schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment". 
Science 205(4413), 1405-1407. 
Bakermans-Kranenburg, M.J., van, I.J.M.H., (2013). "Sniffing around oxytocin: review and 
meta-analyses of trials in healthy and clinical groups with implications for 
pharmacotherapy". Translational psychiatry 3, e258. 
Bardgett, M.E., Depenbrock, M., Downs, N., Points, M., Green, L., (2009). "Dopamine 
modulates effort-based decision making in rats". Behav. Neurosci. 123(2), 242-251. 
Bartels, A., Zeki, S., (2004). "The neural correlates of maternal and romantic love". 
NeuroImage 21(3), 1155-1166. 
Bartz, J.A., Zaki, J., Bolger, N., Ochsner, K.N., (2011). "Social effects of oxytocin in humans: 
context and person matter". Trends in cognitive sciences 15(7), 301-309. 
Baskerville, T.A., Douglas, A.J., (2010a). "Dopamine and Oxytocin Interactions Underlying 
Behaviors: Potential Contributions to Behavioral Disorders". CNS Neurosci. Ther. 16(3), e92-
e123. 
Baskerville, T.A., Douglas, A.J., (2010b). "Dopamine and oxytocin interactions underlying 
behaviors: potential contributions to behavioral disorders". CNS neuroscience & 
therapeutics 16(3), e92-123. 
Baumeister, A.A., Francis, J.L., (2002). "Historical development of the dopamine hypothesis 
of schizophrenia". Journal of the history of the neurosciences 11(3), 265-277. 
Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischbacher, U., Fehr, E., (2008). "Oxytocin 
shapes the neural circuitry of trust and trust adaptation in humans". Neuron 58(4), 639-
650. 
Beckmann, H., Lang, R.E., Gattaz, W.F., (1985). "Vasopressin-oxytocin in cerebrospinal fluid 
of schizophrenic patients and normal controls". Psychoneuroendocrinology 10(2), 187-191. 
Behrens, T.E.J., Hunt, L.T., Woolrich, M.W., Rushworth, M.F.S., (2008). "Associative learning 
of social value". Nature 456(7219), 245-249. 
Bell, C., Bhikha, S., Colhoun, H., Carter, F., Frampton, C., Porter, R., (2013). "The response to 
sulpiride in social anxiety disorder: D2 receptor function". J Psychopharmacol 27(2), 146-
151. 
Berger, M., Gray, J.A., Roth, B.L., (2009). "The Expanded Biology of Serotonin". Annu. Rev. 
Med. 60(1), 355-366. 
256 
 
Bernacer, J., Corlett, P.R., Ramachandra, P., McFarlane, B., Turner, D.C., Clark, L., et al., 
(2013). "Methamphetamine-induced disruption of frontostriatal reward learning signals: 
relation to psychotic symptoms". The American journal of psychiatry 170(11), 1326-1334. 
Berridge, K.C., (2007). "The debate over dopamine's role in reward: the case for incentive 
salience". Psychopharmacology (Berl.) 191(3), 391-431. 
Berridge, K.C., (2012). "From prediction error to incentive salience: mesolimbic computation 
of reward motivation". The European journal of neuroscience 35(7), 1124-1143. 
Berridge, K.C., Robinson, T.E., (1998). "What is the role of dopamine in reward: hedonic 
impact, reward learning, or incentive salience?". Brain Res. Brain Res. Rev. 28(3), 309-369. 
Bethopedia, (2012). "Neurotransmission of the Reticular System". 
Bird, E.D., Spokes, E.G., Barnes, J., MacKay, A.V., Iversen, L.L., Shepherd, M., (1977). 
"Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl 
transferase activity in schizophrenia and related psychoses". Lancet 2(8049), 1157-1158. 
Bleuler, E., (1908). "Die Prognose der Dementia Praecox -- Schizophreniegruppe". 
Allgemeine Zeitschrift fur Psychiatrie 65, 436-434. 
Bora, E., Yucel, M., Pantelis, C., (2009). "Theory of mind impairment in schizophrenia: meta-
analysis". Schizophrenia research 109(1-3), 1-9. 
Born, J., Lange, T., Kern, W., McGregor, G.P., Bickel, U., Fehm, H.L., (2002). "Sniffing 
neuropeptides: a transnasal approach to the human brain". Nature neuroscience 5(6), 514-
516. 
Born, J.B., R.; Pietrowsky, R.; Fehm-Wolfsdorf, G.; Pauschinger, P.; Fehm, H. L., (1987). 
"Influences of vasopressin and oxytocin on human event-related brain potentials in an 
attention task". Journal of Psychophysiology 4, 351-360. 
Botvinick, M.M., (2007). "Conflict monitoring and decision making: Reconciling two 
perspectives on anterior cingulate function". Cogn Affect Behav Ne 7(4), 356-366. 
Boyer, P., Lecrubier, Y., Stalla-Bourdillon, A., Fleurot, O., (1999). "Amisulpride versus 
Amineptine and Placebo for the Treatment of Dysthymia". Neuropsychobiology 39(1), 25-
32. 
Brefel, C., Thalamas, C., Rayet, S., Lopez-Gil, A., Fitzpatrick, K., Bullman, S., et al., (1998). 
"Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients". Br. J. Clin. 
Pharmacol. 45(4), 412-415. 
Breier, A., Adler, C.M., Weisenfeld, N., Su, T.P., Elman, I., Picken, L., et al., (1998). "Effects of 
NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel 
PET approach". Synapse 29(2), 142-147. 
Brown, E.C., Tas, C., Kuzu, D., Esen-Danaci, A., Roelofs, K., Brüne, M., (2014). "Social 
approach and avoidance behaviour for negative emotions is modulated by endogenous 
oxytocin and paranoia in schizophrenia". Psychiatry Res. 219(3), 436-442. 
Brune, M., (2005a). "Emotion recognition, 'theory of mind,' and social behavior in 
schizophrenia". Psychiatry Res. 133(2-3), 135-147. 
Brune, M., (2005b). ""Theory of mind" in schizophrenia: a review of the literature". 
Schizophrenia bulletin 31(1), 21-42. 
Brüne, M., Lissek, S., Fuchs, N., Witthaus, H., Peters, S., Nicolas, V., et al., (2008). "An fMRI 
study of theory of mind in schizophrenic patients with “passivity” symptoms". 
Neuropsychologia 46(7), 1992-2001. 
Buchsbaum, M.S., Christian, B.T., Lehrer, D.S., Narayanan, T.K., Shi, B., Mantil, J., et al., 
(2006). "D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of 
patients with schizophrenia". Schizophr. Res. 85(1–3), 232-244. 
Byne, W., Buchsbaum, M.S., Kemether, E., et al., (2001). "Magnetic resonance imaging of the 
thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality 
disorder". Arch. Gen. Psychiatry 58(2), 133-140. 
Carlsson, A., Lindqvist, M., (1963). "Effect of Chlorpromazine or Haloperidol on Formation of 
3-Methoxytyramine and Normetanephrine in Mouse Brain". Acta Pharmacol. Toxicol. 
(Copenh.) 20(2), 140-&. 
Carroll, R., (2000). "Cognitive impairment in schizophrenia". Advances in Psychiatric 
Treatment 6, 161-168. 
257 
 
Castelli, F., Frith, C., Happé, F., Frith, U., (2002). "Autism, Asperger syndrome and brain 
mechanisms for the attribution of mental states to animated shapes". Brain : a journal of 
neurology 125(8), 1839-1849. 
Cavanna, A.E., Trimble, M.R., (2006). "The precuneus: a review of its functional anatomy and 
behavioural correlates". Brain : a journal of neurology 129(3), 564-583. 
Chana, G., Landau, S., Everall, I., Cotter, D., (2008). "Glial cell number and nuclear size in the 
mediodorsal thalamic nucleus (MDNT) in schizophrenia". Schizophr. Res. 102(1–3), 344-
345. 
Chue, P., Eerdekens, M., Augustyns, I., Lachaux, B., Molcan, P., Eriksson, L., et al., (2005). 
"Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets". 
Eur. Neuropsychopharmacol. 15(1), 111-117. 
Cohen, J., (1992). "A power primer". Psychol. Bull. 112, 155-159. 
Cohen, M., (1988). "The Revised Conners Parent Rating Scale: factor structure replication 
with a diversified clinical sample". J. Abnorm. Child Psychol. 16(2), 187-196. 
Colombo, M., (2014). "Deep and beautiful. The reward prediction error hypothesis of 
dopamine". Studies in history and philosophy of biological and biomedical sciences 45, 57-
67. 
Cools, R., D'Esposito, M., (2011). "Inverted-U-Shaped Dopamine Actions on Human Working 
Memory and Cognitive Control". Biol. Psychiatry 69(12), E113-E125. 
Costafreda, S.G., Brammer, M.J., David, A.S., Fu, C.H.Y., (2008). "Predictors of amygdala 
activation during the processing of emotional stimuli: A meta-analysis of 385 PET and fMRI 
studies". Brain Res. Rev. 58(1), 57-70. 
Cotter, D., Pariante, C.M., (2002). "Stress and the progression of the developmental 
hypothesis of schizophrenia". Br. J. Psychiatry 181, 363-365. 
Couture, S.M., Penn, D.L., Roberts, D.L., (2006). "The functional significance of social 
cognition in schizophrenia: a review". Schizophrenia bulletin 32 Suppl 1, S44-63. 
Coyle, J., (2006). "Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis". Cell. 
Mol. Neurobiol. 26(4-6), 363-382. 
Creese, I., Burt, D.R., Snyder, S.H., (1976). "Dopamine receptor binding predicts clinical and 
pharmacological potencies of antischizophrenic drugs". Science 192(4238), 481-483. 
Crow, T.J., (1980). "Molecular pathology of schizophrenia: more than one disease process?". 
Br. Med. J. 280(6207), 66-68. 
Crow, T.J., Baker, H.F., Cross, A.J., Joseph, M.H., Lofthouse, R., Longden, A., et al., (1979). 
"Mono-Amine Mechanisms in Chronic-Schizophrenia - Postmortem Neurochemical Findings". 
Brit J Psychiat 134(Mar), 249-256. 
Cummings, J.L., (1993). "FRontal-subcortical circuits and human behavior". Arch. Neurol. 
50(8), 873-880. 
Das, P., Lagopoulos, J., Coulston, C.M., Henderson, A.F., Malhi, G.S., (2012). "Mentalizing 
impairment in schizophrenia: A functional MRI study". Schizophr. Res. 134(2–3), 158-164. 
David, H.N., Ansseau, M., Abraini, J.H., (2005). "Dopamine–glutamate reciprocal modulation 
of release and motor responses in the rat caudate–putamen and nucleus accumbens of 
“intact” animals". Brain Res. Rev. 50(2), 336-360. 
Davidson, M., Reichenberg, A., Rabinowitz, J., Weiser, M., Kaplan, Z., Mark, M., (1999). 
"Behavioral and intellectual markers for schizophrenia in apparently healthy male 
adolescents". The American journal of psychiatry 156(9), 1328-1335. 
Davis, K.L., Kahn, R.S., Ko, G., Davidson, M., (1991). "Dopamine in schizophrenia: a review 
and reconceptualization". The American journal of psychiatry 148(11), 1474-1486. 
Davis, M.C., Lee, J., Horan, W.P., Clarke, A.D., McGee, M.R., Green, M.F., et al., (2013). "Effects 
of single dose intranasal oxytocin on social cognition in schizophrenia". Schizophr. Res. 
147(2–3), 393-397. 
De Dreu, C.K., (2012). "Oxytocin modulates cooperation within and competition between 
groups: an integrative review and research agenda". Hormones and behavior 61(3), 419-
428. 
De Dreu, C.K., Greer, L.L., Van Kleef, G.A., Shalvi, S., Handgraaf, M.J., (2011). "Oxytocin 
promotes human ethnocentrism". Proceedings of the National Academy of Sciences of the 
United States of America 108(4), 1262-1266. 
258 
 
de la Fuente-Fernández, R., Ruth, T.J., Sossi, V., Schulzer, M., Calne, D.B., Stoessl, A.J., (2001). 
"Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's 
Disease". Science 293(5532), 1164-1166. 
Decety, J., Lamm, C., (2007). "The Role of the Right Temporoparietal Junction in Social 
Interaction: How Low-Level Computational Processes Contribute to Meta-Cognition". 
Neuroscientist. 
Del Arco, A., Mora, F., (2008). "Prefrontal cortex–nucleus accumbens interaction: In vivo 
modulation by dopamine and glutamate in the prefrontal cortex". Pharmacol. Biochem. 
Behav. 90(2), 226-235. 
Delgado, M.R., Frank, R.H., Phelps, E.A., (2005a). "Perceptions of moral character modulate 
the neural systems of reward during the trust game". Nature neuroscience 8(11), 1611-
1618. 
Delgado, M.R., Miller, M.M., Inati, S., Phelps, E.A., (2005b). "An fMRI study of reward-related 
probability learning". NeuroImage 24(3), 862-873. 
Devinsky, O., Morrell, M.J., Vogt, B.A., (1995). "Contributions of Anterior Cingulate Cortex to 
Behaviour". Brain : a journal of neurology 118, 279-306. 
Dhir, A., Kulkarni, S.K., (2007). "Involvement of dopamine (DA)/serotonin (5-HT)/sigma 
(sigma) receptor modulation in mediating the antidepressant action of ropinirole 
hydrochloride, a D2/D3 dopamine receptor agonist". Brain Res. Bull. 74(1-3), 58-65. 
Di Simplicio, M., Massey-Chase, R., Cowen, P.J., Harmer, C.J., (2009). "Oxytocin enhances 
processing of positive versus negative emotional information in healthy male volunteers". J 
Psychopharmacol 23(3), 241-248. 
Domes, G., Heinrichs, M., Glascher, J., Buchel, C., Braus, D.F., Herpertz, S.C., (2007a). 
"Oxytocin attenuates amygdala responses to emotional faces regardless of valence". 
Biological psychiatry 62(10), 1187-1190. 
Domes, G., Heinrichs, M., Gläscher, J., Büchel, C., Braus, D.F., Herpertz, S.C., (2007b). 
"Oxytocin Attenuates Amygdala Responses to Emotional Faces Regardless of Valence". Biol. 
Psychiatry 62(10), 1187-1190. 
Domes, G., Lischke, A., Berger, C., Grossmann, A., Hauenstein, K., Heinrichs, M., et al., 
(2010). "Effects of intranasal oxytocin on emotional face processing in women". 
Psychoneuroendocrinology 35(1), 83-93. 
Doran, A.R., Boronow, J., Weinberger, D.R., Wolkowitz, O.M., Breier, A., Pickar, D., (1987). 
"Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is 
inversely correlated with cerebrospinal fluid levels of homovanillic acid". 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 1(1), 25-32. 
Douglas, A.J., (2010). "Baby Love? Oxytocin-Dopamine Interactions in Mother-Infant 
Bonding". Endocrinology 151(5), 1978-1980. 
Downar, J., Crawley, A.P., Mikulis, D.J., Davis, K.D., (2000). "A multimodal cortical network 
for the detection of changes in the sensory environment". Nat. Neurosci. 3(3), 277-283. 
Dyck, M., Loughead, J., Gur, R.C., Schneider, F., Mathiak, K., (2014). "Hyperactivation 
balances sensory processing deficits during mood induction in schizophrenia". Soc. Cogn. 
Affect. Neurosci. 9(2), 167-175. 
Dyck, M., Loughead, J., Kellermann, T., Boers, F., Gur, R.C., Mathiak, K., (2011). "Cognitive 
versus automatic mechanisms of mood induction differentially activate left and right 
amygdala". NeuroImage 54(3), 2503-2513. 
Ekman, P., Friesen, W.V., (1971). "Constants across cultures in the face and emotion". 
Journal of personality and social psychology 17(2), 124-129. 
Eriksen, B.A.E.C.W., (1974). "Effects of noise letters upon the identification of target letters 
in a nonsearch task". Percept. Psychophys. 16(1), 143-149. 
Ernst, M., Paulus, M.P., (2005a). "Neurobiology of Decision Making: A Selective Review from 
a Neurocognitive and Clinical Perspective". Biol. Psychiatry 58(8), 597-604. 
Ernst, M., Paulus, M.P., (2005b). "Neurobiology of decision making: a selective review from a 
neurocognitive and clinical perspective". Biological psychiatry 58(8), 597-604. 
259 
 
Evans, S., Fleming, S.M., Dolan, R.J., Averbeck, B.B., (2011a). "Effects of emotional 
preferences on value-based decision-making are mediated by mentalizing and not reward 
networks". Journal of cognitive neuroscience 23(9), 2197-2210. 
Evans, S., Shergill, S.S., Averbeck, B.B., (2010). "Oxytocin Decreases Aversion to Angry Faces 
in an Associative Learning Task". Neuropsychopharmacology : official publication of the 
American College of Neuropsychopharmacology 35(13), 2502-2509. 
Evans, S., Shergill, S.S., Chouhan, V., Bristow, E., Collier, T., Averbeck, B.B., (2011b). 
"Patients with schizophrenia show increased aversion to angry faces in an associative 
learning task". Psychol Med 41(7), 1471-1479. 
Fairhall, S.L., Ishai, A., (2007). "Effective connectivity within the distributed cortical network 
for face perception". Cereb. Cortex 17(10), 2400-2406. 
Fasano, C., Kortleven, C., Trudeau, L.E., (2010). "Chronic activation of the D2 autoreceptor 
inhibits both glutamate and dopamine synapse formation and alters the intrinsic properties 
of mesencephalic dopamine neurons in vitro". Eur. J. Neurosci. 32(9), 1433-1441. 
Fehm-Wolfsdorf, G., Bachholz, G., Born, J., Voigt, K., Fehm, H.L., (1988). "Vasopressin but not 
oxytocin enhances cortical arousal: an integrative hypothesis on behavioral effects of 
neurohypophyseal hormones". Psychopharmacology (Berl.) 94(4), 496-500. 
Feifel, D., Macdonald, K., Cobb, P., Minassian, A., (2012a). "Adjunctive intranasal oxytocin 
improves verbal memory in people with schizophrenia". Schizophrenia research 139(1-3), 
207-210. 
Feifel, D., MacDonald, K., Cobb, P., Minassian, A., (2012b). "Adjunctive intranasal oxytocin 
improves verbal memory in people with schizophrenia". Schizophr. Res. 139(1–3), 207-210. 
Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., et al., (2010a). 
"Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients". Biol. 
Psychiatry 68(7), 678-680. 
Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., et al., (2010b). 
"Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients". Biological 
psychiatry 68(7), 678-680. 
Ferris, C.F., (2008). "Functional magnetic resonance imaging and the neurobiology of 
vasopressin and oxytocin". Prog. Brain Res. 170, 305-320. 
Fett, A.K., Gromann, P.M., Giampietro, V., Shergill, S.S., Krabbendam, L., (2013). "Default 
distrust? An fMRI investigation of the neural development of trust and cooperation". Social 
cognitive and affective neuroscience. 
Fett, A.K., Maat, A., (2011). "Social Cognitive Impairments and Psychotic Symptoms: What is 
the Nature of Their Association?". Schizophrenia bulletin. 
Fett, A.K., Shergill, S.S., Joyce, D.W., Riedl, A., Strobel, M., Gromann, P.M., et al., (2012). "To 
trust or not to trust: the dynamics of social interaction in psychosis". Brain : a journal of 
neurology 135(Pt 3), 976-984. 
Fett, A.K., Viechtbauer, W., Dominguez, M.D., Penn, D.L., van Os, J., Krabbendam, L., (2011). 
"The relationship between neurocognition and social cognition with functional outcomes in 
schizophrenia: a meta-analysis". Neuroscience and biobehavioral reviews 35(3), 573-588. 
Fink, M., Akimova, E., Spindelegger, C., Hahn, A., Lanzenberger, R., Kasper, S., (2009). 
"Social anxiety disorder: epidemiology, biology and treatment". Psychiatria Danubina 21(4), 
533-542. 
Franklin, K.B., McCoy, S.N., (1979). "Pimozide-induced extinction in rats: stimulus control of 
responding rules out motor deficit". Pharmacology, biochemistry, and behavior 11(1), 71-
75. 
Fried, I., Wilson, C.L., Morrow, J.W., Cameron, K.A., Behnke, E.D., Ackerson, L.C., et al., 
(2001). "Increased dopamine release in the human amygdala during performance of 
cognitive tasks". Nature neuroscience 4(2), 201-206. 
Friston, K., (2005). "Disconnection and cognitive dysmetria in schizophrenia". Am J Psychiat 
162(3), 429-432. 
Friston, K.J., (1998). "The disconnection hypothesis". Schizophr. Res. 30(2), 115-125. 
Friston, K.J., Frith, C.D., Frackowiak, R.S.J., Turner, R., (1995). "Characterizing Dynamic 
Brain Responses with fMRI: A Multivariate Approach". NeuroImage 2(2, Part A), 166-172. 
260 
 
Friston, K.J., Shiner, T., FitzGerald, T., Galea, J.M., Adams, R., Brown, H., et al., (2012). 
"Dopamine, Affordance and Active Inference". Plos Comput Biol 8(1). 
Frith, C., Frith, U., (2005). "Theory of mind". Curr. Biol. 15(17), R644-646. 
Frith, C.D., Frith, U., (2012). "Mechanisms of Social Cognition". Annu. Rev. Psychol. 63(1), 
287-313. 
Furl, N., Gallagher, S., Averbeck, B.B., (2012). "A selective emotional decision-making bias 
elicited by facial expressions". PloS one 7(3), e33461. 
Furman, D.J., Chen, M.C., Gotlib, I.H., (2011). "Variant in oxytocin receptor gene is associated 
with amygdala volume". Psychoneuroendocrinology 36(6), 891-897. 
Fusar-Poli, P., Placentino, A., Carletti, F., Landi, P., Allen, P., Surguladze, S., et al., (2009). 
"Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 
functional magnetic resonance imaging studies". J. Psychiatry Neurosci. 34(6), 418-432. 
Fusar-Poli, P., Radua, J., McGuire, P., Borgwardt, S., (2012). "Neuroanatomical maps of 
psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies". 
Schizophrenia bulletin 38(6), 1297-1307. 
Galbally, M., Lewis, A.J., Van Ijzendoorn, M.H., Permezel, M., (2011). "The Role of Oxytocin in 
Mother-Infant Relations: A Systematic Review of Human Studies". Harvard Rev Psychiat 
19(1), 1-14. 
Gamer, M., Zurowski, B., Buchel, C., (2010a). "Different amygdala subregions mediate 
valence-related and attentional effects of oxytocin in humans". Proceedings of the National 
Academy of Sciences of the United States of America 107(20), 9400-9405. 
Gamer, M., Zurowski, B., Büchel, C., (2010b). "Different amygdala subregions mediate 
valence-related and attentional effects of oxytocin in humans". Proceedings of the National 
Academy of Sciences 107(20), 9400-9405. 
Gattaz, W.F., Gasser, T., Beckmann, H., (1985). "Multidimensional analysis of the 
concentrations of 17 substances in the CSF of schizophrenics and controls". Biol. Psychiatry 
20(4), 360-366. 
Gibson, C.M., Penn, D.L., Smedley, K.L., Leserman, J., Elliott, T., Pedersen, C.A., (2014). "A 
pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in 
schizophrenia". Schizophr. Res. 156(2–3), 261-265. 
Gimpl, G., Fahrenholz, F., (2001). "The oxytocin receptor system: structure, function, and 
regulation". Physiol. Rev. 81(2), 629-683. 
Ginovart, N., Kapur, S., (2012). "Role of Dopamine D2 Receptors for Antipsychotic Activity", 
in: Gross, G., Geyer, M.A. (Eds.), Current Antipsychotics. Springer Berlin Heidelberg, pp. 27-
52. 
Gjedde, A., Kumakura, Y., Cumming, P., Linnet, J., Moller, A., (2010). "Inverted-U-shaped 
correlation between dopamine receptor availability in striatum and sensation seeking". Proc. 
Natl. Acad. Sci. U. S. A. 107(8), 3870-3875. 
Glatt, S.J., Stone, W.S., Faraone, S.V., Seidman, L.J., Tsuang, M.T., (2006). "Psychopathology, 
personality traits and social development of young first-degree relatives of patients with 
schizophrenia". Br. J. Psychiatry 189, 337-345. 
Glimcher, P.W., (2011). "Understanding dopamine and reinforcement learning: the 
dopamine reward prediction error hypothesis". Proceedings of the National Academy of 
Sciences of the United States of America 108 Suppl 3, 15647-15654. 
Glovinsky, D., Kalogeras, K.T., Kirch, D.G., Suddath, R., Wyatt, R.J., (1994). "Cerebrospinal 
fluid oxytocin concentration in schizophrenic patients does not differ from control subjects 
and is not changed by neuroleptic medication". Schizophr. Res. 11(3), 273-276. 
Goldman, M., Marlow-O'Connor, M., Torres, I., Carter, C.S., (2008). "Diminished plasma 
oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits". 
Schizophrenia research 98(1-3), 247-255. 
Grace, A.A., (1991). "Phasic Versus Tonic Dopamine Release and the Modulation of 
Dopamine System Responsivity - a Hypothesis for the Etiology of Schizophrenia". 
Neuroscience 41(1), 1-24. 
Gradin, V.B., Kumar, P., Waiter, G., Ahearn, T., Stickle, C., Milders, M., et al., (2011). 
"Expected value and prediction error abnormalities in depression and schizophrenia". Brain : 
a journal of neurology 134(Pt 6), 1751-1764. 
261 
 
Gray, J.A., Roth, B.L., (2007). "The pipeline and future of drug development in schizophrenia". 
Molecular psychiatry 12(10), 904-922. 
Green, B., (2002). "Focus on amisulpride". Curr. Med. Res. Opin. 18(3), 113-117. 
Green, M.F., (1996). "What are the functional consequences of neurocognitive deficits in 
schizophrenia?". The American journal of psychiatry 153(3), 321-330. 
Green, M.F., Kern, R.S., Braff, D.L., Mintz, J., (2000). "Neurocognitive deficits and functional 
outcome in schizophrenia: are we measuring the "right stuff"?". Schizophrenia bulletin 
26(1), 119-136. 
Griffith, J.J., Oates, J., Cavanaugh, J., (1968). "Paranoid episodes induced by drugs". The 
Journal of American Medical Association 205, 39. 
Grill-Spector, K., Knouf, N., Kanwisher, N., (2004). "The fusiform face area subserves face 
perception, not generic within-category identification". Nature neuroscience 7(5), 555-562. 
Gromann, P.M., Heslenfeld, D.J., Fett, A.K., Joyce, D.W., Shergill, S.S., Krabbendam, L., (2013). 
"Trust versus paranoia: abnormal response to social reward in psychotic illness". Brain : a 
journal of neurology. 
Gromann, P.M., Tracy, D.K., Giampietro, V., Brammer, M.J., Krabbendam, L., Shergill, S.S., 
(2012). "Examining frontotemporal connectivity and rTMS in healthy controls: implications 
for auditory hallucinations in schizophrenia". Neuropsychology 26(1), 127-132. 
Guastella, A.J., Carson, D.S., Dadds, M.R., Mitchell, P.B., Cox, R.E., (2009). "Does oxytocin 
influence the early detection of angry and happy faces?". Psychoneuroendocrinology 34(2), 
220-225. 
Guastella, A.J., Einfeld, S.L., Gray, K.M., Rinehart, N.J., Tonge, B.J., Lambert, T.J., et al., (2010). 
"Intranasal oxytocin improves emotion recognition for youth with autism spectrum 
disorders". Biological psychiatry 67(7), 692-694. 
Guastella, A.J., Hickie, I.B., McGuinness, M.M., Otis, M., Woods, E.A., Disinger, H.M., et al., 
(2013). "Recommendations for the standardisation of oxytocin nasal administration and 
guidelines for its reporting in human research". Psychoneuroendocrinology 38(5), 612-625. 
Guastella, A.J., MacLeod, C., (2012). "A critical review of the influence of oxytocin nasal spray 
on social cognition in humans: evidence and future directions". Hormones and behavior 
61(3), 410-418. 
Guastella, A.J., Mitchell, P.B., Dadds, M.R., (2008). "Oxytocin Increases Gaze to the Eye Region 
of Human Faces". Biol. Psychiatry 63(1), 3-5. 
Gumley, A., Braehler, C., Macbeth, A., (2014). "A meta-analysis and theoretical critique of 
oxytocin and psychosis: Prospects for attachment and compassion in promoting recovery". 
Br. J. Clin. Psychol. 53(1), 42-61. 
Gur, R.E., McGrath, C., Chan, R.M., Schroeder, L., Turner, T., Turetsky, B.I., et al., (2002). "An 
fMRI study of facial emotion processing in patients with schizophrenia". Am J Psychiat 
159(12), 1992-1999. 
Haber, S.N., Calzavara, R., (2009). "The cortico-basal ganglia integrative network: The role 
of the thalamus". Brain Res. Bull. 78(2–3), 69-74. 
Hamilton, P.J., Campbell, N.G., Sharma, S., Erreger, K., Herborg Hansen, F., Saunders, C., et 
al., (2013). "De novo mutation in the dopamine transporter gene associates dopamine 
dysfunction with autism spectrum disorder". Molecular psychiatry 18(12), 1315-1323. 
Hampton, A.N., Bossaerts, P., O'Doherty, J.P., (2008). "Neural correlates of mentalizing-
related computations during strategic interactions in humans". Proceedings of the National 
Academy of Sciences of the United States of America 105(18), 6741-6746. 
Harrison, P.J., (1999). "The neuropathology of schizophrenia. A critical review of the data 
and their interpretation". Brain : a journal of neurology 122 ( Pt 4), 593-624. 
Hart, A.S., Rutledge, R.B., Glimcher, P.W., Phillips, P.E., (2014). "Phasic dopamine release in 
the rat nucleus accumbens symmetrically encodes a reward prediction error term". The 
Journal of neuroscience : the official journal of the Society for Neuroscience 34(3), 698-
704. 
Hart, H., Radua, J., Nakao, T., Mataix-Cols, D., Rubia, K., (2013). "Meta-analysis of Functional 
Magnetic Resonance Imaging Studies of Inhibition and Attention in Attention-
deficit/Hyperactivity Disorder: Exploring Task-Specific, Stimulant Medication, and Age 
Effects". JAMA Psychiatry 70(2), 185-198. 
262 
 
Haruno, M., Kawato, M., (2006). "Different neural correlates of reward expectation and 
reward expectation error in the putamen and caudate nucleus during stimulus-action-
reward association learning". Journal of neurophysiology 95(2), 948-959. 
Hatzipetros, T., Yamamoto, B.K., (2006). "Dopaminergic and GABAergic modulation of 
glutamate release from rat subthalamic nucleus efferents to the substantia nigra". Brain Res. 
1076(1), 60-67. 
Haxby, J.V., Hoffman, E.A., Gobbini, M.I., (2000). "The distributed human neural system for 
face perception". Trends in cognitive sciences 4(6), 223-233. 
Heerey, E.A., Bell-Warren, K.R., Gold, J.M., (2008). "Decision-making impairments in the 
context of intact reward sensitivity in schizophrenia". Biological psychiatry 64(1), 62-69. 
Hikosaka, O., Nakamura, K., Sakai, K., Nakahara, H., (2002). "Central mechanisms of motor 
skill learning". Current opinion in neurobiology 12(2), 217-222. 
Hoge, E.A., Pollack, M.H., Kaufman, R.E., Zak, P.J., Simon, N.M., (2008). "Oxytocin levels in 
social anxiety disorder". CNS Neurosci. Ther. 14(3), 165-170. 
Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., et al., (2007). 
"Oxytocin increases retention of social cognition in autism". Biological psychiatry 61(4), 
498-503. 
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C.M., Aronowitz, B.R., et al., 
(2003). "Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's 
disorders". Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 28(1), 193-198. 
Hollerman, J.R., Schultz, W., (1998). "Dopamine neurons report an error in the temporal 
prediction of reward during learning". Nature neuroscience 1(4), 304-309. 
Holroyd, C.B., Coles, M.G.H., (2002). "The neural basis. of human error processing: 
Reinforcement learning, dopamine, and the error-related negativity". Psychol Rev 109(4), 
679-709. 
Hong, S., Hikosaka, O., (2008). "The globus pallidus sends reward-related signals to the 
lateral habenula". Neuron 60(4), 720-729. 
Howes, O.D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., et al., (2012). "The 
nature of dopamine dysfunction in schizophrenia and what this means for treatment". 
Archives of general psychiatry 69(8), 776-786. 
Howes, O.D., Kapur, S., (2009). "The dopamine hypothesis of schizophrenia: version III--the 
final common pathway". Schizophrenia bulletin 35(3), 549-562. 
Huang, J., Chan, R.C.K., Gollan, J.K., Liu, W., Ma, Z., Li, Z., et al., (2011). "Perceptual bias of 
patients with schizophrenia in morphed facial expression". Psychiatry Res. 185(1–2), 60-65. 
Huber, D., Veinante, P., Stoop, R., (2005). "Vasopressin and oxytocin excite distinct neuronal 
populations in the central amygdala". Science 308(5719), 245-248. 
Huffmeijer, R., Alink, L.R., Tops, M., Bakermans-Kranenburg, M.J., van, I.M.H., (2012a). 
"Asymmetric frontal brain activity and parental rejection predict altruistic behavior: 
moderation of oxytocin effects". Cognitive, affective & behavioral neuroscience 12(2), 382-
392. 
Huffmeijer, R., Alink, L.R., Tops, M., Grewen, K.M., Light, K.C., Bakermans-Kranenburg, M.J., 
et al., (2012b). "The impact of oxytocin administration and maternal love withdrawal on 
event-related potential (ERP) responses to emotional faces with performance feedback". 
Hormones and behavior. 
Hunter, J., Schmidt, F., (1990). "Methods of meta-analysis". Sage Publications, Newbury 
Park, CA. 
Hurlemann, R., Patin, A., Onur, O.A., Cohen, M.X., Baumgartner, T., Metzler, S., et al., (2010). 
"Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional 
empathy in humans". The Journal of neuroscience : the official journal of the Society for 
Neuroscience 30(14), 4999-5007. 
Hurley, M.J., Mash, D.C., Jenner, P., (2003). "Markers for dopaminergic neurotransmission in 
the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-
PCR". The European journal of neuroscience 18(9), 2668-2672. 
263 
 
Hutton, S.B., Murphy, F.C., Joyce, E.M., Rogers, R.D., Cuthbert, I., Barnes, T.R., et al., (2002). 
"Decision making deficits in patients with first-episode and chronic schizophrenia". 
Schizophrenia research 55(3), 249-257. 
Inoue, H., Yamasue, H., Tochigi, M., Abe, O., Liu, X., Kawamura, Y., et al., (2010). "Association 
between the oxytocin receptor gene and amygdalar volume in healthy adults". Biological 
psychiatry 68(11), 1066-1072. 
Insel, T.R., Young, L.J., (2001a). "The neurobiology of attachment". Nature reviews. 
Neuroscience 2(2), 129-136. 
Insel, T.R., Young, L.J., (2001b). "The neurobiology of attachment". Nature reviews. 
Neuroscience 2(2), 129-136. 
Ito, H., Arakawa, R., Takahashi, H., Takano, H., Okumura, M., Otsuka, T., et al., (2009). "No 
regional difference in dopamine D2 receptor occupancy by the second-generation 
antipsychotic drug risperidone in humans: a positron emission tomography study". The 
International Journal of Neuropsychopharmacology 12(05), 667-675. 
Jentsch, J.D., Roth, R.H., (1999). "The neuropsychopharmacology of phencyclidine: from 
NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia". 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 20(3), 201-225. 
Jocham, G., Klein, T.A., Ullsperger, M., (2011). "Dopamine-mediated reinforcement learning 
signals in the striatum and ventromedial prefrontal cortex underlie value-based choices". 
The Journal of neuroscience : the official journal of the Society for Neuroscience 31(5), 
1606-1613. 
Juckel, G., Schlagenhauf, F., Koslowski, M., Wüstenberg, T., Villringer, A., Knutson, B., et al., 
(2006). "Dysfunction of ventral striatal reward prediction in schizophrenia". NeuroImage 
29(2), 409-416. 
Kagerbauer, S.M., Martin, J., Schuster, T., Blobner, M., Kochs, E.F., Landgraf, R., (2013). 
"Plasma Oxytocin and Vasopressin do not Predict Neuropeptide Concentrations in Human 
Cerebrospinal Fluid". J. Neuroendocrinol. 25(7), 668-673. 
Kapur, S., (2003). "Psychosis as a state of aberrant salience: A framework linking biology, 
phenomenology, and pharmacology in schizophrenia". Am J Psychiat 160(1), 13-23. 
Kapur, S., Mizrahi, R., Li, M., (2005). "From dopamine to salience to psychosis--linking 
biology, pharmacology and phenomenology of psychosis". Schizophrenia research 79(1), 59-
68. 
Kapur, S., Remington, G., (2001). "ATYPICAL ANTIPSYCHOTICS: New Directions and New 
Challenges in the Treatment of Schizophrenia". Annu. Rev. Med. 52(1), 503-517. 
Kay, S.R., Fiszbein, A., Opler, L.A., (1987). "The Positive and Negative Syndrome Scale 
(Panss) for Schizophrenia". Schizophr. Bull. 13(2), 261-276. 
Kaye, C.M., Nicholls, B., (2000). "Clinical pharmacokinetics of ropinirole". Clinical 
pharmacokinetics 39(4), 243-254. 
Kennerley, S.W., Behrens, T.E., Wallis, J.D., (2011). "Double dissociation of value 
computations in orbitofrontal and anterior cingulate neurons". Nature neuroscience 14(12), 
1581-1589. 
Keri, S., Kiss, I., Kelemen, O., (2009). "Sharing secrets: oxytocin and trust in schizophrenia". 
Soc. Neurosci. 4(4), 287-293. 
Kéri, S., Kiss, I., Kelemen, O., (2009). "Sharing secrets: Oxytocin and trust in schizophrenia". 
Soc. Neurosci. 4(4), 287-293. 
Khandaker, G.M., Zimbron, J., Dalman, C., Lewis, G., Jones, P.B., (2012). "Childhood infection 
and adult schizophrenia: a meta-analysis of population-based studies". Schizophrenia 
research 139(1-3), 161-168. 
Kiebel, S.J., Garrido, M.I., Moran, R.J., Friston, K.J., (2008). "Dynamic causal modelling for 
EEG and MEG". Cogn. Neurodyn. 2(2), 121-136. 
King-Casas, B., Tomlin, D., Anen, C., Camerer, C.F., Quartz, S.R., Montague, P.R., (2005). 




Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., et al., (2005). "Oxytocin 
modulates neural circuitry for social cognition and fear in humans". The Journal of 
neuroscience : the official journal of the Society for Neuroscience 25(49), 11489-11493. 
Knapp, M., Mangalore, R., Simon, J., (2004). "The Global Costs of Schizophrenia". Schizophr. 
Bull. 30(2), 279-293. 
Ko, J.H., Ptito, A., Monchi, O., Cho, S.S., Van Eimeren, T., Pellecchia, G., et al., (2009). 
"Increased dopamine release in the right anterior cingulate cortex during the performance of 
a sorting task: A [11C]FLB 457 PET study". NeuroImage 46(2), 516-521. 
Kohler, C.G., Turner, T.H., Bilker, W.B., Brensinger, C.M., Siegel, S.J., Kanes, S.J., et al., (2003). 
"Facial emotion recognition in schizophrenia: Intensity effects and error pattern". Am J 
Psychiat 160(10), 1768-1774. 
Koob, G.F., Swerdlow, N.R., (1988). "The Functional Output of the Mesolimbic Dopamine 
System". Ann. N. Y. Acad. Sci. 537(1), 216-227. 
Kosfeld, M., Heinrichs, M., Zak, P.J., Fischbacher, U., Fehr, E., (2005). "Oxytocin increases 
trust in humans". Nature 435(7042), 673-676. 
Kraus, M.S., Keefe, R.S.E., (2007). "Cognition as an outcome measure in schizophrenia". Brit J 
Psychiat 191, S46-S51. 
Kucyi, A., Hodaie, M., Davis, K.D., (2012). "Lateralization in intrinsic functional connectivity 
of the temporoparietal junction with salience- and attention-related brain networks". J. 
Neurophysiol. 108(12), 3382-3392. 
Kudris, I., Skakun, N., Orlova, I., Libina, V., Kulikov, A., (2011). "Analysis of Amisulpride in 
Human Plasma by SPE and LC with Fluorescence Detection". Chromatographia 73(1-2), 67-
74. 
Kurtz, M.M., Richardson, C.L., (2011). "Social Cognitive Training for Schizophrenia: A Meta-
Analytic Investigation of Controlled Research". Schizophr. Bull. 
Labuschagne, I., Phan, K.L., Wood, A., Angstadt, M., Chua, P., Heinrichs, M., et al., (2010). 
"Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder". 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 35(12), 2403-2413. 
Labuschagne, I., Phan, K.L., Wood, A., Angstadt, M., Chua, P., Heinrichs, M., et al., (2011). 
"Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and 
modulation by oxytocin". Int. J. Neuropsychopharmacol., 1-14. 
Laird, A.R., Robinson, J.L., McMillan, K.M., Tordesillas-Gutierrez, D., Moran, S.T., Gonzales, 
S.M., et al., (2010). "Comparison of the disparity between Talairach and MNI coordinates in 
functional neuroimaging data: Validation of the Lancaster transform". NeuroImage 51(2), 
677-683. 
Lak, A., Stauffer, W.R., Schultz, W., (2014). "Dopamine prediction error responses integrate 
subjective value from different reward dimensions". Proceedings of the National Academy of 
Sciences of the United States of America 111(6), 2343-2348. 
Lancaster, J.L., Rainey, L.H., Summerlin, J.L., Freitas, C.S., Fox, P.T., Evans, A.C., et al., (1997). 
"Automated labeling of the human brain: a preliminary report on the development and 
evaluation of a forward-transform method". Human brain mapping 5(4), 238-242. 
Lancaster, J.L., Tordesillas-Gutierrez, D., Martinez, M., Salinas, F., Evans, A., ZilleS, K., et al., 
(2007a). "Bias between MNI and talairach coordinates analyzed using the ICBM-152 brain 
template". Hum. Brain Mapp. 28(11), 1194-1205. 
Lancaster, J.L., Tordesillas-Gutierrez, D., Martinez, M., Salinas, F., Evans, A., Zilles, K., et al., 
(2007b). "Bias between MNI and Talairach coordinates analyzed using the ICBM-152 brain 
template". Human brain mapping 28(11), 1194-1205. 
Lancaster, J.L., Woldorff, M.G., Parsons, L.M., Liotti, M., Freitas, C.S., Rainey, L., et al., (2000). 
"Automated Talairach atlas labels for functional brain mapping". Human brain mapping 
10(3), 120-131. 
Larquet, M., Coricelli, G., Opolczynski, G., Thibaut, F., (2010). "Impaired decision making in 
schizophrenia and orbitofrontal cortex lesion patients". Schizophrenia research 116(2-3), 
266-273. 
Laruelle, M., Abi-Dargham, P., (1999). "Dopamine as the wind of the psychotic fire: new 
evidence from brain imaging studies". J. Psychopharm. 13(4), 358-371. 
265 
 
Laruelle, M., Kegeles, L.S., Abi-Dargham, A., (2003). "Glutamate, Dopamine, and 
Schizophrenia". Ann. N. Y. Acad. Sci. 1003(1), 138-158. 
Laviolette, S.R., (2007). "Dopamine modulation of emotional processing in cortical and 
subcortical neural circuits: evidence for a final common pathway in schizophrenia?". 
Schizophrenia bulletin 33(4), 971-981. 
Lee, J., Quintana, J., Nori, P., Green, M.F., (2011). "Theory of mind in schizophrenia: Exploring 
neural mechanisms of belief attribution". Soc. Neurosci. 6(5-6), 569-581. 
Lee, K.H., Farrow, T.F., Spence, S.A., Woodruff, P.W., (2004). "Social cognition, brain 
networks and schizophrenia". Psychol Med 34(3), 391-400. 
Lee, M.R., Wehring, H.J., McMahon, R.P., Linthicum, J., Cascella, N., Liu, F., et al., (2013). 
"Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in 
schizophrenia: Results from a randomized double blind placebo controlled pilot study". 
Schizophr. Res. 145(1–3), 110-115. 
Leeson, V.C., Barnes, T.R., Hutton, S.B., Ron, M.A., Joyce, E.M., (2009). "IQ as a predictor of 
functional outcome in schizophrenia: a longitudinal, four-year study of first-episode 
psychosis". Schizophrenia research 107(1), 55-60. 
Lehman, A.F., Lieberman, J.A., Dixon, L.B., McGlashan, T.H., Miller, A.L., Perkins, D.O., et al., 
(2004). "Practice guideline for the treatment of patients with schizophrenia, second edition". 
Am J Psychiat 161(2), 1-56. 
Leibenluft, E., Gobbini, M.I., Harrison, T., Haxby, J.V., (2004). "Mothers' neural activation in 
response to pictures of their children and other children". Biological psychiatry 56(4), 225-
232. 
Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., et al., (2009). 
"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that 
evaluate health care interventions: explanation and elaboration". PLoS Med. 6(7), 
e1000100. 
Lieberman, J.A., Kane, J.M., Sarantakos, S., Gadaleta, D., Woerner, M., Alvir, J., et al., (1987). 
"Prediction of relapse in schizophrenia". Archives of general psychiatry 44(7), 597-603. 
Lindvall, O., Bjorklund, A., Skagerberg, G., (1984). "Selective histochemical demonstration of 
dopamine terminal systems in rat di- and telencephalon: new evidence for dopaminergic 
innervation of hypothalamic neurosecretory nuclei". Brain research 306(1-2), 19-30. 
Lischke, A., Gamer, M., Berger, C., Grossmann, A., Hauenstein, K., Heinrichs, M., et al., 
(2012). "Oxytocin increases amygdala reactivity to threatening scenes in females". 
Psychoneuroendocrinology 37(9), 1431-1438. 
Logothetis, N.K., (2008). "What we can do and what we cannot do with fMRI". Nature 
453(7197), 869-878. 
Loup, F., Tribollet, E., Dubois-Dauphin, M., Dreifuss, J.J., (1991). "Localization of high-
affinity binding sites for oxytocin and vasopressin in the human brain. An autoradiographic 
study". Brain research 555(2), 220-232. 
Loup, F., Tribollet, E., Dubois-Dauphin, M., Pizzolato, G., Dreifuss, J.J., (1989). "Localization 
of oxytocin binding sites in the human brainstem and upper spinal cord: an autoradiographic 
study". Brain research 500(1-2), 223-230. 
Love, T.M., (2014). "Oxytocin, motivation and the role of dopamine". Pharmacol Biochem Be 
119, 49-60. 
Love, T.M., Enoch, M.A., Hodgkinson, C.A., Pecina, M., Mickey, B., Koeppe, R.A., et al., (2012). 
"Oxytocin gene polymorphisms influence human dopaminergic function in a sex-dependent 
manner". Biological psychiatry 72(3), 198-206. 
Lumme, V., Aalto, S., Ilonen, T., Någren, K., Hietala, J., (2006). "Dopamine D2/D3 receptor 
binding in the anterior cingulate cortex and executive functioning". Psychiatry Research: 
Neuroimaging 156(1), 69-74. 
Mai, J.K., Berger, K., Sofroniew, M.V., (1993). "Morphometric evaluation of neurophysin-
immunoreactivity in the human brain: pronounced inter-individual variability and evidence 
for altered staining patterns in schizophrenia". J. Hirnforsch. 34(2), 133-154. 
Maier, S., Szalkowski, A., Kamphausen, S., Perlov, E., Feige, B., Blechert, J., et al., (2012). 
"Clarifying the Role of the Rostral dmPFC/dACC in Fear/Anxiety: Learning, Appraisal or 
Expression?". PloS one 7(11), e50120. 
266 
 
Marjoram, D., Job, D.E., Whalley, H.C., Gountouna, V.E., McIntosh, A.M., Simonotto, E., et al., 
(2006). "A visual joke fMRI investigation into Theory of Mind and enhanced risk of 
schizophrenia". NeuroImage 31(4), 1850-1858. 
Matsumoto, M., Matsumoto, K., Abe, H., Tanaka, K., (2007). "Medial prefrontal cell activity 
signaling prediction errors of action values". Nat. Neurosci. 10(5), 647-656. 
Maurelli, M., Marchioni, E., Tartara, A., (1988). "Central extra-endocrine effects of 
vasopressin and oxytocin in the rabbit". Il Farmaco; edizione scientifica 43(2), 161-168. 
Mawlawi, O., Martinez, D., Slifstein, M., Broft, A., Chatterjee, R., Hwang, D.-R., et al., (2001). 
"Imaging Human Mesolimbic Dopamine Transmission With Positron Emission 
Tomography[colon] I. Accuracy and Precision of D2 Receptor Parameter Measurements in 
Ventral Striatum". J. Cereb. Blood Flow Metab. 21(9), 1034-1057. 
McCall, C., Singer, T., (2012). "The animal and human neuroendocrinology of social 
cognition, motivation and behavior". Nature neuroscience 15(5), 681-688. 
McCarthy, G., Luby, M., Gore, J., Goldman-Rakic, P., (1997a). "Infrequent events transiently 
activate human prefrontal and parietal cortex as measured by functional MRI". Journal of 
neurophysiology 77(3), 1630-1634. 
McCarthy, G., Luby, M., Gore, J., Goldman-Rakic, P., (1997b). "Infrequent Events Transiently 
Activate Human Prefrontal and Parietal Cortex as Measured by Functional MRI". 
McCarthy, G., Puce, A., Gore, J.C., Allison, T., (1997c). "Face-specific processing in the human 
fusiform gyrus". Journal of cognitive neuroscience 9(5), 605-610. 
McClure, E.B., Monk, C.S., Nelson, E.E., Zarahn, E., Leibenluft, E., Bilder, R.M., et al., (2004). 
"A developmental examination of gender differences in brain engagement during evaluation 
of threat". Biological psychiatry 55(11), 1047-1055. 
McGaugh, J.L., (2005). "Emotional arousal and enhanced amygdala activity: New evidence 
for the old perseveration-consolidation hypothesis". Learn. Memory 12(2), 77-79. 
McGrath, J., Saha, S., Chant, D., Welham, J., (2008). "Schizophrenia: A Concise Overview of 
Incidence, Prevalence, and Mortality". Epidemiol. Rev. 30(1), 67-76. 
McGrath, J.J., Féron, F.P., Burne, T.H., Mackay-Sim, A., Eyles, D.W., (2003). "The 
neurodevelopmental hypothesis of schizophrenia: a review of recent developments". Ann. 
Med. 35(2), 86-93. 
Melchitzky, D.S., Lewis, D.A., (2000). "Tyrosine Hydroxylase- and Dopamine Transporter-
Immunoreactive Axons in the Primate Cerebellum". Neuropsychopharmacology : official 
publication of the American College of Neuropsychopharmacology 22(5), 466-472. 
Melis, M.R., Argiolas, A., (2011). "Central control of penile erection: a re-visitation of the role 
of oxytocin and its interaction with dopamine and glutamic acid in male rats". Neuroscience 
and biobehavioral reviews 35(3), 939-955. 
Meltzer, H.Y., (1980). "Relevance of Dopamine Autoreceptors for Psychiatry: Preclinical and 
Clinical Studies". Schizophr. Bull. 6(3), 456-475. 
Meyer-Lindenberg, A., Domes, G., Kirsch, P., Heinrichs, M., (2011). "Oxytocin and 
vasopressin in the human brain: social neuropeptides for translational medicine". Nature 
reviews. Neuroscience 12(9), 524-538. 
Meyer-Lindenberg, A., Tost, H., (2012). "Neural mechanisms of social risk for psychiatric 
disorders". Nature neuroscience 15(5), 663-668. 
Middleton, F.A., Strick, P.L., (1996). "The temporal lobe is a target of output from the basal 
ganglia". Proceedings of the National Academy of Sciences of the United States of America 
93(16), 8683-8687. 
Minzenberg, M.J., Laird, A.R., Thelen, S., Carter, C.S., Glahn, D.C., (2009). "Meta-analysis of 41 
Functional Neuroimaging Studies of Executive Function in Schizophrenia". Arch. Gen. 
Psychiatry 66(8), 811-822. 
Mitelman, S.A., Byne, W., Kemether, E.M., Hazlett, E.A., Buchsbaum, M.S., (2005). "Metabolic 
disconnection between the mediodorsal nucleus of the thalamus and cortical Brodmann's 
areas of the left hemisphere in schizophrenia". Am J Psychiat 162(9), 1733-1735. 
Modabbernia, A., Rezaei, F., Salehi, B., Jafarinia, M., Ashrafi, M., Tabrizi, M., et al., (2013). 
"Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia". CNS 
Drugs 27(1), 57-65. 
267 
 
Moerman, D.E., Jonas, W.B., (2002). "Deconstructing the Placebo Effect and Finding the 
Meaning Response". Ann. Intern. Med. 136(6), 471-476. 
Moghaddam, B., Javitt, D., (2012). "From Revolution to Evolution: The Glutamate Hypothesis 
of Schizophrenia and its Implication for Treatment". Neuropsychopharmacology : official 
publication of the American College of Neuropsychopharmacology 37(1), 4-15. 
Montag, C., Brockmann, E.-M., Bayerl, M., Rujescu, D., Müller, D.J., Gallinat, J., (2013). 
"Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: A case–
control study". The World Journal of Biological Psychiatry 14(7), 500-508. 
Montag, C., Brockmann, E.-M., Lehmann, A., Müller, D.J., Rujescu, D., Gallinat, J., (2012). 
"Association between Oxytocin Receptor Gene Polymorphisms and Self-Rated ‘Empathic 
Concern’ in Schizophrenia". PloS one 7(12), e51882. 
Montague, P.R., Berns, G.S., (2002). "Neural economics and the biological substrates of 
valuation". Neuron 36(2), 265-284. 
Montague, P.R., King-Casas, B., Cohen, J.D., (2006). "Imaging valuation models in human 
choice". Annu. Rev. Neurosci. 29, 417-448. 
Monte-Silva, K., Kuo, M.F., Thirugnanasambandam, N., Liebetanz, D., Paulus, W., Nitsche, 
M.A., (2009). "Dose-Dependent Inverted U-Shaped Effect of Dopamine (D-2-Like) Receptor 
Activation on Focal and Nonfocal Plasticity in Humans". J. Neurosci. 29(19), 6124-6131. 
Morris, R.W., Vercammen, A., Lenroot, R., Moore, L., Langton, J.M., Short, B., et al., (2012). 
"Disambiguating ventral striatum fMRI-related bold signal during reward prediction in 
schizophrenia". Molecular psychiatry 17(3), 280-289. 
Morris, R.W., Weickert, C.S., Loughland, C.M., (2009). "Emotional face processing in 
schizophrenia". Current Opinion in Psychiatry 22(2), 140-146 
110.1097/YCO.1090b1013e328324f328895. 
Murphy, S.T., Zajonc, R.B., (1993). "Affect, cognition, and awareness: affective priming with 
optimal and suboptimal stimulus exposures". Journal of personality and social psychology 
64(5), 723-739. 
Murray, G.K., Corlett, P.R., Clark, L., Pessiglione, M., Blackwell, A.D., Honey, G., et al., (2008). 
"Substantia nigra/ventral tegmental reward prediction error disruption in psychosis". 
Molecular psychiatry 13(3), 239, 267-276. 
Murray, G.K., Corlett, P.R., Fletcher, P.C., (2010). "The Neural Underpinnings of Associative 
Learning in Health and Psychosis: How Can Performance Be Preserved When Brain 
Responses Are Abnormal?". Schizophr. Bull. 36(3), 465-471. 
Mussel, P., Goritz, A.S., Hewig, J., (2013). "The value of a smile: Facial expression affects 
ultimatum-game responses". Judgm Decis Mak 8(3), 381-385. 
Narendran, R., Mason, N.S., Chen, C.M., Himes, M., Keating, P., May, M.A., et al., (2011). 
"Evaluation of dopamine D(2)/(3) specific binding in the cerebellum for the positron 
emission tomography radiotracer [(1)(1)C]FLB 457: implications for measuring cortical 
dopamine release". Synapse 65(10), 991-997. 
Nayak, R.K., Doose, D.R., Nair, N.P.V., (1987). "The Bioavailability and Pharmacokinetics of 
Oral and Depot Intramuscular Haloperidol in Schizophrenic-Patients". J. Clin. Pharmacol. 
27(2), 144-150. 
Nemeroff, C.B., (2004). "The biochemical basis of neuropharmacology, 8th ed.". Am J 
Psychiat 161(2), 379-379. 
Neumann, I.D., Landgraf, R., (2008). "Advances in vasopressin and oxytocin--from genes to 
behaviour to disease. Preface". Prog. Brain Res. 170, xi-xiii. 
Neumann, I.D., Maloumby, R., Beiderbeck, D.I., Lukas, M., Landgraf, R., (2013). "Increased 
brain and plasma oxytocin after nasal and peripheral administration in rats and mice". 
Psychoneuroendocrinology 38(10), 1985-1993. 
Nielsen, M.Ø., Rostrup, E., Wulff, S., Bak, N., Lublin, H., Kapur, S., et al., (2012). "Alterations 
of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients". Biol. Psychiatry 
71(10), 898-905. 
O'Doherty, J.P., (2004). "Reward representations and reward-related learning in the human 
brain: insights from neuroimaging". Current opinion in neurobiology 14(6), 769-776. 
O'Doherty, J.P., Dayan, P., Friston, K., Critchley, H., Dolan, R.J., (2003). "Temporal difference 
models and reward-related learning in the human brain". Neuron 38(2), 329-337. 
268 
 
Oberman, L.M., Pineda, J.A., Ramachandran, V.S., (2007). "The human mirror neuron system: 
a link between action observation and social skills". Social cognitive and affective 
neuroscience 2(1), 62-66. 
Ochsner, K.N., Gross, J.J., (2005). "The cognitive control of emotion". Trends in cognitive 
sciences 9(5), 242-249. 
Oei, N.Y.L., Rombouts, S.A.R.B., Soeter, R.P., van Gerven, J.M., Both, S., (2012). "Dopamine 
Modulates Reward System Activity During Subconscious Processing of Sexual Stimuli". 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 37(7), 1729-1737. 
Ogawa, S., Lee, T., Kay, A., Tank, D., (1990). "Brain magnetic resonance imaging with 
contrast dependent on blood oxygenation". Proceedings of the National Academy of 
Sciences 87(24), 9868-9872. 
Organization, W.H., (1992). "The ICD-10 classification of mental and behavioural disorders : 
clinical descriptions and diagnostic guidelines". World Health Organization, Geneva ; [Great 
Britain]. 
Owen, M.J., O’Donovan, M.C., Thapar, A., Craddock, N., (2011). "Neurodevelopmental 
hypothesis of schizophrenia". The British Journal of Psychiatry 198(3), 173-175. 
Pakkenberg, B., (1990). "Pronounced reduction of total neuron number in mediodorsal 
thalamic nucleus and nucleus accumbens in schizophrenics". Arch. Gen. Psychiatry 47(11), 
1023-1028. 
Parkinson, J.A., Dalley, J.W., Cardinal, R.N., Bamford, A., Fehnert, B., Lachenal, G., et al., 
(2002). "Nucleus accumbens dopamine depletion impairs both acquisition and performance 
of appetitive Pavlovian approach behaviour: implications for mesoaccumbens dopamine 
function". Behav Brain Res 137(1-2), 149-163. 
Paulus, M.P., Hozack, N.E., Zauscher, B.E., Frank, L., Brown, G.G., McDowell, J., et al., (2002). 
"Parietal dysfunction is associated with increased outcome-related decision-making in 
schizophrenia patients". Biol. Psychiatry 51(12), 995-1004. 
Paus, T., (2001). "Primate anterior cingulate cortex: Where motor control, drive and 
cognition interface". Nature Reviews Neuroscience 2(6), 417-424. 
Pedersen, C.A., Gibson, C.M., Rau, S.W., Salimi, K., Smedley, K.L., Casey, R.L., et al., (2011a). 
"Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social 
perception in schizophrenia". Schizophr. Res. 132(1), 50-53. 
Pedersen, C.A., Gibson, C.M., Rau, S.W., Salimi, K., Smedley, K.L., Casey, R.L., et al., (2011b). 
"Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social 
perception in schizophrenia". Schizophrenia research 132(1), 50-53. 
Penn, D.L., Corrigan, P.W., Bentall, R.P., Racenstein, J.M., Newman, L., (1997). "Social 
cognition in schizophrenia". Psychol. Bull. 121(1), 114-132. 
Penn, D.L., Keefe, R.S., Davis, S.M., Meyer, P.S., Perkins, D.O., Losardo, D., et al., (2009). "The 
effects of antipsychotic medications on emotion perception in patients with chronic 
schizophrenia in the CATIE trial". Schizophrenia research 115(1), 17-23. 
Penn, D.L., Kohlmaier, J.R., Corrigan, P.W., (2000). "Interpersonal factors contributing to the 
stigma of schizophrenia: social skills, perceived attractiveness, and symptoms". Schizophr. 
Res. 45(1–2), 37-45. 
Perry, A., Bentin, S., Shalev, I., Israel, S., Uzefovsky, F., Bar-On, D., et al., (2010). "Intranasal 
oxytocin modulates EEG mu/alpha and beta rhythms during perception of biological 
motion". Psychoneuroendocrinology 35(10), 1446-1453. 
Pessiglione, M., Seymour, B., Flandin, G., Dolan, R.J., Frith, C.D., (2006). "Dopamine-
dependent prediction errors underpin reward-seeking behaviour in humans". Nature 
442(7106), 1042-1045. 
Pessoa, L., Adolphs, R., (2010). "Emotion processing and the amygdala: from a 'low road' to 
'many roads' of evaluating biological significance". Nature reviews. Neuroscience 11(11), 
773-783. 
Peters, B.D., Szeszko, P.R., Radua, J., Ikuta, T., Gruner, P., DeRosse, P., et al., (2012). "White 
matter development in adolescence: diffusion tensor imaging and meta-analytic results". 
Schizophrenia bulletin 38(6), 1308-1317. 
269 
 
Petrovic, P., Kalisch, R., Singer, T., Dolan, R.J., (2008). "Oxytocin attenuates affective 
evaluations of conditioned faces and amygdala activity". The Journal of neuroscience : the 
official journal of the Society for Neuroscience 28(26), 6607-6615. 
Pettersson-Yeo, W., Allen, P., Benetti, S., McGuire, P., Mechelli, A., (2011). "Dysconnectivity 
in schizophrenia: Where are we now?". Neurosci. Biobehav. Rev. 35(5), 1110-1124. 
Phan, K.L., Wager, T., Taylor, S.F., Liberzon, I., (2002a). "Functional Neuroanatomy of 
Emotion: A Meta-Analysis of Emotion Activation Studies in PET and fMRI". NeuroImage 
16(2), 331-348. 
Phan, K.L., Wager, T., Taylor, S.F., Liberzon, I., (2002b). "Functional neuroanatomy of 
emotion: a meta-analysis of emotion activation studies in PET and fMRI". NeuroImage 16(2), 
331-348. 
Phelps, E.A., (2006). "Emotion and Cognition: Insights from Studies of the Human 
Amygdala". Annu. Rev. Psychol. 57(1), 27-53. 
Philiastides, M.G., Biele, G., Vavatzanidis, N., Kazzer, P., Heekeren, H.R., (2010). "Temporal 
dynamics of prediction error processing during reward-based decision making". NeuroImage 
53(1), 221-232. 
Pincus, D., Kose, S., Arana, A., Johnson, K., Morgan, P.S., Borckardt, J., et al., (2010). "Inverse 
effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: 
a double-blind placebo controlled FMRI study". Frontiers in psychiatry 1, 134. 
Pizzagalli, D.A., Evins, A.E., Schetter, E.C., Frank, M.J., Pajtas, P.E., Santesso, D.L., et al., 
(2008). "Single dose of a dopamine agonist impairs reinforcement learning in humans: 
Behavioral evidence from a laboratory-based measure of reward responsiveness". 
Psychopharmacology 196(2), 221-232. 
Pleger, B., Ruff, C.C., Blankenburg, F., Kloppel, S., Driver, J., Dolan, R.J., (2009). "Influence of 
dopaminergically mediated reward on somatosensory decision-making". PLoS biology 7(7), 
e1000164. 
Poore, J.C., Pfeifer, J.H., Berkman, E.T., Inagaki, T.K., Welborn, B.L., Lieberman, M.D., (2012). 
"Prediction-error in the context of real social relationships modulates reward system 
activity". Frontiers in human neuroscience 6, 218. 
Portas, C.M., Rees, G., Howseman, A.M., Josephs, O., Turner, R., Frith, C.D., (1998). "A specific 
role for the thalamus in mediating the interaction of attention and arousal in humans". The 
Journal of neuroscience : the official journal of the Society for Neuroscience 18(21), 8979-
8989. 
Posner, M.I., (1994). "Attention: the mechanisms of consciousness". Proceedings of the 
National Academy of Sciences of the United States of America 91(16), 7398-7403. 
Preuschoff, K., Quartz, S.R., Bossaerts, P., (2008). "Human insula activation reflects risk 
prediction errors as well as risk". The Journal of neuroscience : the official journal of the 
Society for Neuroscience 28(11), 2745-2752. 
Previc, F.H., (2007). "Prenatal influences on brain dopamine and their relevance to the rising 
incidence of autism". Med. Hypotheses 68(1), 46-60. 
Pujol, J., Harrison, B.J., Ortiz, H., Deus, J., Soriano-Mas, C., Lopez-Sola, M., et al., (2009). 
"Influence of the fusiform gyrus on amygdala response to emotional faces in the non-clinical 
range of social anxiety". Psychol Med 39(7), 1177-1187. 
Radua, J., Borgwardt, S., Crescini, A., Mataix-Cols, D., Meyer-Lindenberg, A., McGuire, P.K., et 
al., (2012a). "Multimodal meta-analysis of structural and functional brain changes in first 
episode psychosis and the effects of antipsychotic medication". Neuroscience and 
biobehavioral reviews 36(10), 2325-2333. 
Radua, J., Mataix-Cols, D., (2012). "Meta-analytic methods for neuroimaging data 
explained". Biology of mood & anxiety disorders 2(1), 6. 
Radua, J., Mataix-Cols, D., Phillips, M.L., El-Hage, W., Kronhaus, D.M., Cardoner, N., et al., 
(2012b). "A new meta-analytic method for neuroimaging studies that combines reported 
peak coordinates and statistical parametric maps". Eur. Psychiatry 27(8), 605-611. 
Radua, J., van den Heuvel, O.A., Surguladze, S., Mataix-Cols, D., (2010). "Meta-analytical 
comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other 
anxiety disorders". Archives of general psychiatry 67(7), 701-711. 
270 
 
Radua, J., Via, E., Catani, M., Mataix-Cols, D., (2011). "Voxel-based meta-analysis of regional 
white-matter volume differences in autism spectrum disorder versus healthy controls". 
Psychol Med 41(7), 1539-1550. 
Rausch, F., Mier, D., Eifler, S., Esslinger, C., Schilling, C., Schirmbeck, F., et al., (2014). 
"Reduced activation in ventral striatum and ventral tegmental area during probabilistic 
decision-making in schizophrenia". Schizophr. Res. 156(2–3), 143-149. 
Reynolds, G.P., (1983). "Increased concentrations and lateral asymmetry of amygdala 
dopamine in schizophrenia". Nature 305(5934), 527-529. 
Riem, M.M., Bakermans-Kranenburg, M.J., Pieper, S., Tops, M., Boksem, M.A., Vermeiren, 
R.R., et al., (2011). "Oxytocin modulates amygdala, insula, and inferior frontal gyrus 
responses to infant crying: a randomized controlled trial". Biological psychiatry 70(3), 291-
297. 
Rilling, J.K., DeMarco, A.C., Hackett, P.D., Thompson, R., Ditzen, B., Patel, R., et al., (2012). 
"Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain 
activity in men". Psychoneuroendocrinology 37(4), 447-461. 
Rilling, J.K., Sanfey, A.G., (2011). "The neuroscience of social decision-making". Annual 
review of psychology 62, 23-48. 
Roiser, J.P., Wigton, R., Kilner, J.M., Mendez, M.A., Hon, N., Friston, K.J., et al., (2013). 
"Dysconnectivity in the frontoparietal attention network in schizophrenia". Frontiers in 
psychiatry 4, 176. 
Rolls, E.T., Loh, M., Deco, G., Winterer, G., (2008). "Computational models of schizophrenia 
and dopamine modulation in the prefrontal cortex". Nature reviews. Neuroscience 9(9), 
696-709. 
Romero-Fernandez, W., Borroto-Escuela, D.O., Agnati, L.F., Fuxe, K., (2012). "Evidence for 
the existence of dopamine d2-oxytocin receptor heteromers in the ventral and dorsal 
striatum with facilitatory receptor-receptor interactions". Molecular psychiatry. 
Rose, D., Pevalin, D.J., (2001). "The national statistics socio-economic classification: unifying 
official and sociological approaches". Colchester: University of Essex, Institute of Social 
Economic Research Working Papers. 
Rosenfeld, A.J., Lieberman, J.A., Jarskog, L.F., (2011). "Oxytocin, dopamine, and the 
amygdala: a neurofunctional model of social cognitive deficits in schizophrenia". 
Schizophrenia bulletin 37(5), 1077-1087. 
Rubin, L.H., Carter, C.S., Drogos, L., Pournajafi-Nazarloo, H., Sweeney, J.A., Maki, P.M., 
(2010). "Peripheral oxytocin is associated with reduced symptom severity in schizophrenia". 
Schizophr. Res. 124(1–3), 13-21. 
Rubin, L.H., Carter, S., Drogos, L., Pournajafi-Nazarloo, H., Savarese, A., Sweeney, J., et al., 
(2011). "Sex-Specific Associations between Peripheral Oxytocin and Positive Emotion 
Perception in Schizophrenia". Schizophr. Bull. 37, 251-252. 
Sanfey, A.G., (2007). "Social decision-making: insights from game theory and neuroscience". 
Science 318(5850), 598-602. 
Santesso, D.L., Evins, A.E., Frank, M.J., Schetter, E.C., Bogdan, R., Pizzagalli, D.A., (2009). 
"Single Dose of a Dopamine Agonist Impairs Reinforcement Learning in Humans: Evidence 
From Event-Related Potentials and Computational Modeling of Striatal-Cortical Function". 
Hum. Brain Mapp. 30(7), 1963-1976. 
Sasayama, D., Hattori, K., Teraishi, T., Hori, H., Ota, M., Yoshida, S., et al., (2012a). "Negative 
correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male 
patients with schizophrenia". Schizophrenia research 139(1-3), 201-206. 
Sasayama, D., Hattori, K., Teraishi, T., Hori, H., Ota, M., Yoshida, S., et al., (2012b). "Negative 
correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male 
patients with schizophrenia". Schizophr. Res. 139(1–3), 201-206. 
Sauer, C., Montag, C., Reuter, M., Kirsch, P., (2013). "Imaging oxytocin x dopamine 
interactions: an epistasis effect of CD38 and COMT gene variants influences the impact of 
oxytocin on amygdala activation to social stimuli". Frontiers in neuroscience 7, 45. 
Scharlemann, J.P.W., Eckel, C.C., Kacelnik, A., Wilson, R.K., (2001). "The value of a smile: 
Game theory with a human face". J Econ Psychol 22(5), 617-640. 
271 
 
Schmitz, Y., Benoit-Marand, M., Gonon, F., Sulzer, D., (2003). "Presynaptic regulation of 
dopaminergic neurotransmission". J. Neurochem. 87(2), 273-289. 
Schneier, F.R., Abi-Dargham, A., Martinez, D., Slifstein, M., Hwang, D.R., Liebowitz, M.R., et 
al., (2009). "Dopamine transporters, D2 receptors, and dopamine release in generalized 
social anxiety disorder". Depress. Anxiety 26(5), 411-418. 
Schooler, N.R., Levine, J., (1976). "Initiation of Long-Term Pharmacotherapy in 
Schizophrenia - Dosage and Side-Effect Comparisons between Oral and Depot Fluphenazine". 
Pharmakopsychiatr. Neuropsychopharmakol. 9(4), 159-&. 
Schultz, W., (1998). "Predictive reward signal of dopamine neurons". Journal of 
neurophysiology 80(1), 1-27. 
Schultz, W., (2006). "Behavioral theories and the neurophysiology of reward". Annual 
review of psychology 57, 87-115. 
Schultz, W., (2007). "Behavioral dopamine signals". Trends in neurosciences 30(5), 203-
210. 
Schultz, W., (2013). "Updating dopamine reward signals". Current opinion in neurobiology 
23(2), 229-238. 
Schultz, W., Dayan, P., Montague, P.R., (1997). "A neural substrate of prediction and 
reward". Science 275(5306), 1593-1599. 
Schwartz, J.C., Diaz, J., Griffon, N., Levesque, D., Martres, M.P., Sokoloff, P., (1994). "Multiple 
dopamine receptors: the D3 receptor and actions of substances of abuse". EXS 71, 81-92. 
Seeman, P., Lee, T., (1975). "Antipsychotic drugs: direct correlation between clinical potency 
and presynaptic action on dopamine neurons". Science 188(4194), 1217-1219. 
Sergerie, K., Chochol, C., Armony, J.L., (2008). "The role of the amygdala in emotional 
processing: A quantitative meta-analysis of functional neuroimaging studies". Neurosci. 
Biobehav. Rev. 32(4), 811-830. 
Sergi, M.J., Green, M.F., Widmark, C., Reist, C., Erhart, S., Braff, D.L., et al., (2007). "Social 
cognition and neurocognition: Effects of risperidone, olanzapine, and haloperidol". 
Schizophr. Bull. 33(2), 478-478. 
Shahrokh, D.K., Zhang, T.Y., Diorio, J., Gratton, A., Meaney, M.J., (2010). "Oxytocin-Dopamine 
Interactions Mediate Variations in Maternal Behavior in the Rat". Endocrinology 151(5), 
2276-2286. 
Shamay-Tsoory, S.G., Shur, S., Harari, H., Levkovitz, Y., (2007). "Neurocognitive basis of 
impaired empathy in schizophrenia". Neuropsychology 21(4), 431-438. 
Shane, M.S., Stevens, M., Harenski, C.L., Kiehl, K.A., (2008). "Neural correlates of the 
processing of another's mistakes: a possible underpinning for social and observational 
learning". NeuroImage 42(1), 450-459. 
Shore, D.M., Heerey, E.A., (2011). "The Value of Genuine and Polite Smiles". Emotion 11(1), 
169-174. 
Simons, C.J., Tracy, D.K., Sanghera, K.K., O'Daly, O., Gilleen, J., Dominguez, M.D., et al., 
(2010). "Functional magnetic resonance imaging of inner speech in schizophrenia". 
Biological psychiatry 67(3), 232-237. 
Singer, T., Critchley, H.D., Preuschoff, K., (2009). "A common role of insula in feelings, 
empathy and uncertainty". Trends in cognitive sciences 13(8), 334-340. 
Singer, T., Kiebel, S.J., Winston, J.S., Dolan, R.J., Frith, C.D., (2004). "Brain responses to the 
acquired moral status of faces". Neuron 41(4), 653-662. 
Singer, T., Snozzi, R., Bird, G., Petrovic, P., Silani, G., Heinrichs, M., et al., (2008). "Effects of 
oxytocin and prosocial behavior on brain responses to direct and vicariously experienced 
pain". Emotion 8(6), 781-791. 
Skuse, D.H., Gallagher, L., (2009). "Dopaminergic-neuropeptide interactions in the social 
brain". Trends in cognitive sciences 13(1), 27-35. 
Smeltzer, M.D., Curtis, J.T., Aragona, B.J., Wang, Z., (2006a). "Dopamine, oxytocin, and 
vasopressin receptor binding in the medial prefrontal cortex of monogamous and 
promiscuous voles". Neurosci. Lett. 394(2), 146-151. 
Smeltzer, M.D., Curtis, J.T., Aragona, B.J., Wang, Z.X., (2005). "Oxytocin and dopamine 
receptor differences in the medial prefrontal cortex of monogamous and promiscuous voles". 
Horm. Behav. 48(1), 128-129. 
272 
 
Smeltzer, M.D., Curtis, J.T., Aragona, B.J., Wang, Z.X., (2006b). "Dopamine, oxytocin, and 
vasopressin receptor binding in the medial prefrontal cortex of monogamous and 
promiscuous voles". Neurosci. Lett. 394(2), 146-151. 
Smith, A.L., Freeman, S.M., Voll, R.J., Young, L.J., Goodman, M.M., (2013a). "Carbon-11 N-
methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin 
receptors". Bioorg. Med. Chem. Lett. 23(3), 902-906. 
Smith, A.L., Freeman, S.M., Voll, R.J., Young, L.J., Goodman, M.M., (2013b). "Investigation of 
an F-18 oxytocin receptor selective ligand via PET imaging". Bioorg. Med. Chem. Lett. 
23(19), 5415-5420. 
Smith, D.V., Huettel, S.A., (2010). "Decision Neuroscience: Neuroeconomics". Wiley 
interdisciplinary reviews. Cognitive science 1(6), 854-871. 
Smith, G.S., Schloesser, R., Brodie, J.D., Dewey, S.L., Logan, J., Vitkun, S.A., et al., (1998). 
"Glutamate modulation of dopamine measured in vivo with positron emission tomography 
(PET) and C-11-raclopride in normal human subjects". Neuropsychopharmacology : official 
publication of the American College of Neuropsychopharmacology 18(1), 18-25. 
Smith, J.K., Neill, J.C., Costall, B., (1997). "Bidirectional effects of dopamine D2 receptor 
antagonists on responding for a conditioned reinforcer". Pharmacology, biochemistry, and 
behavior 57(4), 843-849. 
Smith, Y., Raju, D.V., Pare, J.F., Sidibe, M., (2004). "The thalamostriatal system: a highly 
specific network of the basal ganglia circuitry". Trends in neurosciences 27(9), 520-527. 
Sofroniew, M.V., Weindl, A., Schrell, U., Wetzstein, R., (1981). "Immunohistochemistry of 
vasopressin, oxytocin and neurophysin in the hypothalamus and extrahypothalamic regions 
of the human and primate brain". Acta Histochem. Suppl. 24, 79-95. 
Souza, R.P., de Luca, V., Meltzer, H.Y., Lieberman, J.A., Kennedy, J.L., (2010). "Schizophrenia 
severity and clozapine treatment outcome association with oxytocinergic genes". The 
International Journal of Neuropsychopharmacology 13(06), 793-798. 
Sparks, A., McDonald, S., Lino, B., O'Donnell, M., Green, M.J., (2010). "Social cognition, 
empathy and functional outcome in schizophrenia". Schizophr. Res. 122(1–3), 172-178. 
Sripada, C.S., Phan, K.L., Labuschagne, I., Welsh, R., Nathan, P.J., Wood, A.G., (2012). 
"Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex". 
Int. J. Neuropsychopharmacol., 1-6. 
Stephan, K.E., Baldeweg, T., Friston, K.J., (2006). "Synaptic plasticity and dysconnection in 
schizophrenia". Biol. Psychiatry 59(10), 929-939. 
Stephan, K.E., Friston, K.J., Frith, C.D., (2009). "Dysconnection in Schizophrenia: From 
Abnormal Synaptic Plasticity to Failures of Self-monitoring". Schizophr. Bull. 35(3), 509-
527. 
Stone, J.M., Morrison, P.D., Pilowsky, L.S., (2007). "Review: Glutamate and dopamine 
dysregulation in schizophrenia — a synthesis and selective review". J. Psychopharm. 21(4), 
440-452. 
Strathearn, L., (2011). "Maternal Neglect: Oxytocin, Dopamine and the Neurobiology of 
Attachment". J. Neuroendocrinol. 23(11), 1054-1065. 
Striepens, N., Kendrick, K.M., Hanking, V., Landgraf, R., Wullner, U., Maier, W., et al., (2013). 
"Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal 
administration in humans". Sci. Rep. 3. 
Striepens, N., Scheele, D., Kendrick, K.M., Becker, B., Schafer, L., Schwalba, K., et al., (2012). 
"Oxytocin facilitates protective responses to aversive social stimuli in males". Proceedings of 
the National Academy of Sciences of the United States of America 109(44), 18144-18149. 
Sugranyes, G., Kyriakopoulos, M., Corrigall, R., Taylor, E., Frangou, S., (2011). "Autism 
Spectrum Disorders and Schizophrenia: Meta-Analysis of the Neural Correlates of Social 
Cognition". PloS one 6(10), e25322. 
Surmeier, D.J., Ding, J., Day, M., Wang, Z., Shen, W., (2007). "D1 and D2 dopamine-receptor 
modulation of striatal glutamatergic signaling in striatal medium spiny neurons". Trends 
Neurosci. 30(5), 228-235. 
Taber, K.H., Wen, C., Khan, A., Hurley, R.A., (2004). "The limbic thalamus". J. 
Neuropsychiatry Clin. Neurosci. 16(2), 127-132. 
273 
 
Takahashi, H., Koeda, M., Oda, K., Matsuda, T., Matsushima, E., Matsuura, M., et al., (2004). 
"An fMRI study of differential neural response to affective pictures in schizophrenia". 
NeuroImage 22(3), 1247-1254. 
Thalheimer, W., Cook, S., (2002). "How to calculate effect sizes from published research: A 
simplified methodology". Work-Learning Research. 
Théberge, J., Al-Semaan, Y., Williamson, P.C., Menon, R.S., Neufeld, R.W.J., Rajakumar, N., et 
al., (2003). "Glutamate and Glutamine in the Anterior Cingulate and Thalamus of Medicated 
Patients With Chronic Schizophrenia and Healthy Comparison Subjects Measured With 4.0-T 
Proton MRS". Am J Psychiat 160(12), 2231-2233. 
Théberge, J., Bartha, R., Drost, D.J., Menon, R.S., Malla, A., Takhar, J., et al., (2002). 
"Glutamate and Glutamine Measured With 4.0 T Proton MRS in Never-Treated Patients With 
Schizophrenia and Healthy Volunteers". Am J Psychiat 159(11), 1944-1946. 
Thormodsen, R., Jensen, J., Holmèn, A., Juuhl-Langseth, M., Emblem, K.E., Andreassen, O.A., 
et al., (2011). "Prefrontal hyperactivation during a working memory task in early-onset 
schizophrenia spectrum disorders: An fMRI study". Psychiatry Research: Neuroimaging 
194(3), 257-262. 
Tissari, A.H., Rossetti, Z.L., Meloni, M., Frau, M.I., Gessa, G.L., (1983). "Autoreceptors mediate 
the inhibition of dopamine synthesis by bromocriptine and lisuride in rats". Eur. J. 
Pharmacol. 91(4), 463-468. 
Toru, M., Nishikawa, T., Mataga, N., Takashima, M., (1982). "Dopamine metabolism 
increases in post-mortem schizophrenic basal ganglia". Journal of neural transmission 54(3-
4), 181-191. 
Tricomi, E.M., Delgado, M.R., Fiez, J.A., (2004). "Modulation of caudate activity by action 
contingency". Neuron 41(2), 281-292. 
Tseng, H.C., Chi, M.H., Lee, L.-T., Tsai, H.C., Lee, I.H., Chen, K.C., et al., (2014). "Sex-specific 
associations between plasma oxytocin levels and schizotypal personality features in healthy 
individuals". J. Psychiatr. Res. 51(0), 37-41. 
Ujike, H., (2002). "Stimulant-induced psychosis and schizophrenia: The role of sensitization". 
Curr Psychiat Rep 4(3), 177-184. 
van Gaalen, M.M., van Koten, R., Schoffelmeer, A.N., Vanderschuren, L.J., (2006). "Critical 
involvement of dopaminergic neurotransmission in impulsive decision making". Biological 
psychiatry 60(1), 66-73. 
van Ijzendoorn, M.H., Bhandari, R., van der Veen, R., Grewen, K.M., Bakermans-Kranenburg, 
M.J., (2012). "Elevated Salivary Levels of Oxytocin Persist More than 7 h after Intranasal 
Administration". Frontiers in neuroscience 6, 174. 
Van Overwalle, F., Baetens, K., Marien, P., Vandekerckhove, M., (2014). "Social cognition 
and the cerebellum: a meta-analysis of over 350 fMRI studies". NeuroImage 86, 554-572. 
van Rossum, J.M., (1966). "The significance of dopamine-receptor blockade for the 
mechanism of action of neuroleptic drugs". Arch. Int. Pharmacodyn. Ther. 160(2), 492-494. 
Vercammen, A., Knegtering, H., den Boer, J.A., Liemburg, E.J., Aleman, A., (2010). "Auditory 
hallucinations in schizophrenia are associated with reduced functional connectivity of the 
temporo-parietal area". Biological psychiatry 67(10), 912-918. 
Villafuerte, S., Heitzeg, M.M., Foley, S., Yau, W.Y., Majczenko, K., Zubieta, J.K., et al., (2012). 
"Impulsiveness and insula activation during reward anticipation are associated with genetic 
variants in GABRA2 in a family sample enriched for alcoholism". Molecular psychiatry 17(5), 
511-519. 
Vogt, B.A., Gabriel, M., (1993). "Neurobiology of cingulate cortex and limbic thalamus : a 
comprehensive handbook". Birkhäuser, Boston. 
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